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Non-melanoma skin cancers (NMSC) are very common skin tumours that develop 
slowly on the upper layers of the skin and are usually removed by surgery but this can 
lead to disfiguring scars. Better treatments are needed for NMSC to minimise scarring 
and prevent the cancer from returning. Bleomycin is a drug used to treat different types 
of cancer in both people and animals, including NMSC. It is currently injected into 
patients but this leads to the drug also being distributed to other healthy tissues, and 
can cause severe side-effects that, in few cases, can lead to fatal lung damage. Ideally, 
we would like to apply bleomycin directly on to the skin tumour but bleomycin is a 
big molecule and cannot pass through the skin or directly enter into cancer cells to kill 
them. Therefore, we need to find new ways of packaging the drug to get it inside cancer 
cells. Once inside cancer cells bleomycin can kill them by damaging their DNA. 
However, we currently do not understand how bleomycin causes DNA damage. 
Liposomes are small artificial bubbles of spherical shape that can be filled with 
pharmaceutical drugs. Liposomes are made up from the same building blocks, 
cholesterol and phospholipids, which make up our skin and cell membranes and are 
proposed to be able to pass through our skin and into our cells, to directly deliver the 
drugs into the cancer cells. In this study, we propose that liposomes can assist the drug 
delivery of bleomycin by improving absorption and penetration through the skin. We 
are using a new compound called Bleosome, which contains liposomes packed with 
bleomycin. Bleosome is a cream that can be applied directly to the surface of the skin 
and may be used in the management of NMSC in human and veterinary medicine. The 
main goal of this project was to evaluate the effect of Bleosome as a non-invasive and 
innovative therapy. Hence, we aimed to assess if Bleosome was able to penetrate 
through the skin and reach the target tumour, to evaluate how cancer cells respond to 
the treatment and what happens when we use Bleosome on real patients such as horses 
with sarcoids, a form of skin tumour. We found that: (1) Bleosome penetrated further 
through healthy skin, reaching a much deeper level than bleomycin. We repeated this 
experiment on skin removed from dogs, horses and humans and obtained similar 
results; (2) we confirmed using a number of different cancer cell lines, cancer cells 
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grown on plastic dishes in the laboratory, that Bleosome can kill cancer cells and that 
the amount of cancer cell death increases with increasing doses of the drug; (3) to 
better understand how Bleosome works we used a special technology called RNA-Seq 
to reveal changes in the activity of lots of genes at the same time after treatment with 
Bleosome. We observed that cells were not able to repair their DNA and eventually 
died by a process called autophagy; and (4) we treated a cohort of horses bearing 
cutaneous sarcoids, a type of skin cancer, with Bleosome after the bulk of the tumour 
was removed by surgery and showed that Bleosome was tolerated by the patients and 
lacked painful and harmful side-effects. In conclusion, Bleosome can effectively 
penetrate through the skin, kill cancer cells and is well-tolerated by horses with skin 
cancer. These are promising results indicating that Bleosome may be an effective 
treatment, with easy application and limited side-effects, to treat skin cancer that 






Bleomycin is a potent anticancer agent that is able to induce single and double stranded 
breaks in DNA. It is effective against several types of cancer, including cutaneous skin 
tumours, in both human and veterinary medicine. However, due to its molecular 
characteristics, including polar charge and high molecular weight, it is unable to 
effectively penetrate the skin barrier and freely cross the plasma membrane. 
Bleomycin can be administered systemically but is known to carry severe side effects 
such as fatal pulmonary fibrosis, which is the most concerning one and represents the 
main limiting factor to its potential use in clinical applications. Furthermore, several 
studies claim that bleomycin causes cell death in a cell-type dependent manner, 
although to date, the actual mechanism of action is not fully elucidated. 
Advances in cancer therapy aim to minimise the side effects of treatments and improve 
the quality of life of patients. Within the context of developing minimally invasive 
treatments, liposomes have become highly valued for their ability to deliver payload 
drugs to the target tumour tissues and to be applied topically therefore decreasing 
systemic toxicity. Bleosome is a novel formulation of bleomycin where the cytotoxic 
agent bleomycin has been encapsulated in ultra-deformable (UD) liposomes. In this 
study, we evaluated Bleosome as a topical, non-invasive treatment for non-melanoma 
skin cancer (NMSC).  
This PhD project also aimed to evaluate the mechanism of action and efficacy of 
Bleosome ex vivo, in vitro and in vivo. We hypothesised that encapsulation of 
bleomycin within nanoparticles, namely UD liposomes, enhances the penetration of 
the drug through the skin, and we tested this in three model systems: canine, equine, 
and human skin explants.  Firstly, we optimised an imaging technique that allowed us 
to directly visualise the liposomes using the transmission electron microscope, and 
effectively fluorescently labelled bleomycin, prior to encapsulation within liposomes, 
to visualise penetration through skin and equine patient-derived sarcoids, using 
multiphoton microscopy. We concluded that lipid nanoparticles could act as 
penetration enhancers, carrying the entrapped bleomycin through the channels of the 
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outermost stratum corneum and subsequently releasing the drug and allowing it to 
penetrate deeper in the skin. At the cellular level, we determined the effect of 
Bleosome on cell viability on a panel of canine, feline and human cancer cell lines in 
vitro. Using live cell imaging, we showed that Bleosome is taken up by cancer cells 
more efficiently than free bleomycin. We also compared the variation in protein and 
gene expression in two canine cancer cell lines after 8 and 24 hours post-Bleosome 
treatment. Preliminary data showed that the response to Bleosome is cell type 
dependent, and the transcriptomic profiling of a canine cancer cell line treated with a 
time course of Bleosome revealed that these specific cells are unable to repair the DNA 
lesions, produced by Bleosome treatment. Lastly, we administered Bleosome to equine 
patients bearing cutaneous sarcoids, in an adjuvant setting, following laser excision. 
After surgical excision of the sarcoids, Bleosome was applied topically on the site of 
the scar in 12 horses, twice a day, for a mean length of 4 weeks. To date, after an 
overall follow-up of 12 months, 5 patients were in complete remission (41.6%), 4 
experienced recurrences (33.3%), and 3 failed to follow up (25%). The treatment was 
overall very well tolerated and the study was still on going at the time of writing. 
Overall, the findings of my PhD provide compelling evidence of the mechanism of 









Non-melanoma skin cancers (NMSC) are the most common skin tumours currently 
diagnosed in Caucasian people (Simonetti et al. 2009). In veterinary species, within 
this cathegory of neoplasms, basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC) are the most frequently encountered in the canine and feline oncology cases 
(Amadori and Marconato 2012); while in horses, cutaneous sarcoids are the most 
common diagnosed cutaneous malignancies (Bergvall 2013). In both human and 
veterinary medicine, these tumours share similar features and outcomes. Although 
overall mortality from this cathegory of skin cancer is generally low in both humans 
and pets, NMSC causes considerable morbidity, particularly on the face in men, and 
can cause severe discomfort and impaired performance in dogs, cats and horses 
(Amadori and Marconato 2012; Knottenbelt 2019). Conventional therapies for NMSC 
include surgery, electrochemotherapy (ECT), radiotherapy, topical formulation of 
different cathegories of compounds alone or in combination (Galiczynski and Vidimos 
2011; Amadori and Marconato 2012). However, all these standard therapies currently 
available can cause potential functional impairments and/or undesirable cosmetic 
outcomes (Burns and Brown 2005). Moreover, all these treatments are highly invasive, 
painful and, in some cases, require general anaesthesia. To address this unmet clinical 
need, our research focused on the evaluation of a novel compound called Bleosome. 
Bleosome consists of the anticancer agent bleomycin encapsulated within ultra 
deformable (UD) liposomes.  
 
1.2 Overview of the key characteristics of bleomycin and 




Bleomycin is an anticancer agent belonging to the family of glycopeptide antibiotics. 
It was originally isolated from Streptomyces verticillus in 1966, by Umezawa and 
colleagues (Umezawa et al. 1966). Bleomycin is a phase-specific agent, exerting its 
maximum toxicity during M and G2 phases of the cell cycle, and hampering cell cycle 
progression during S to G2 transition (Riviere and Papich 2009). The principal target 
of bleomycin is the DNA, carrying out single (SSB) and double strand (DSB) breaks 
(Chen and Stubbe 2005).   
Bleomycin is used as a first-line agent in human medicine, directed against malignant 
lymphomas and embryonal testicular tumours; bleomycin has also led to good results 
in the treatment of head and neck malignancies, cervical and skin tumours, including 
squamous cell carcinomas (Chen and Stubbe 2005). Despite its proved efficacy in 
human oncology patients, the use of bleomycin in veterinary medicine is still poorly 
established (Marconato 2009). It is highly valued in multidrug regimens because its 
toxicity does not overlap that of other anticancer drugs (Riviere and Papich 2009). 
However, bleomycin toxicity is dose-dependent and includes pulmonary 
inflammation, which has been reported to develop into fatal lung fibrosis in 1% to 3% 
of patients (Sleijfer 2001). This led to the development of new therapeutic strategies 
aimed to overcome this issue, therefore bleomycin started to be used in topical 
therapeutic regimens against skin tumours. The most exploited method in both animal 
and human patients is ECT, a topical treatment that employs the use of short electric 
pulses coupled with the administration of bleomycin. It has been successful in the 
management of skin tumours in humans (Zygogianni et al. 2016) and in pets 
(Impellizeri et al. 2016). Although, this method reduces the major systemic side 
effects of bleomycin, it also carries some adverse reactions and requires veterinary 
patients to undergo general anaesthesia.   
Recently, the trend in cancer treatment is towards the development of more targeted 
and non-invasive therapies. To this purpose, particular attention has been focused on 
liposomes, which are nanocarriers able to deliver a wide range of drugs with reduced 
side effects and enhancing their therapeutic power. Given that bleomycin delivered by 
ECT enhanced the clinical outcome against skin tumours, a novel formulation of 
bleomycin was created by encapsulating bleomycin inside UD liposomes, a new 
generation of liposomes specifically designed to penetrate into the skin. This new 
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product is called Bleosome and is proposed to be a topical, non-invasive formulation 
of bleomycin, active in the management of cutaneous malignancies. 
To date, few studies have been performed with bleomycin liposomal formulation (Lau 
et al. 2005; Arndt et al. 2001; Alomrani et al. 2011; Chiani et al. 2017). Although they 
have demonstrated that this type of bleomycin can be effective against different types 
of cancer cell lines there is a need to prove its therapeutic power and its benefit in 
reducing the severe toxicity in vivo. This may lead to the clinical use of Bleosome in 
the management of cutaneous tumours in veterinary and in human patients, and 
successful clinical trials in veterinary medicine may be an optimal basis for translating 
this therapy into human medicine. The innovative potential of the Bleosome resides 
in its lack of side effects as a non- or low-invasive treatment of skin tumours, resulting 
in the increased well-being of the patients and improved quality of life.   
  
1.3 Bleomycin chemical structure    
   
The molecular structure of bleomycin is composed of three functional domains: the 
N-terminal metal-binding domain, the C-terminal DNA-binding domain 
(encompassing the bithiazole tail), and the carbohydrate moiety. The linker region, 
situated between metal and DNA binding domains, has a key role in inducing DNA 
DSBs (figure 1.1) (Ramotar and Wang 2003). The N-terminal domain is flexible and 
can bind both redox-active and non-redox-active metal ions, such as iron and cobalt, 
respectively (Ehrenfeld et al. 1985). Among the metal ions, iron is predominantly used 
in clinical preparations of bleomycin, as it enhances the production of DNA lesions 
(Winkler et al. 1986). The metal ion is required to enable contact between bleomycin 
and DNA, and is able to produce radical species by activation of oxygen (Ramotar and 
Wang 2003). The pyrimidine moiety and the C-terminus domain of bleomycin are 
involved in selective DNA cleavage, by binding to N3- and N2- amino groups of the 
guanine 5’ to the pyrimidine cleavage site (5’-GC-3’) (Abraham, Zhou, and Hecht 
2001; Hecht 2000; Chen and Stubbe 2004).   Many studies have been conducted to 
evaluate the role of bleomycin domains showing that the whole molecule is bigger 
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than the sum of its parts, and that one single molecule of the drug is able to produce 
efficient lesions on both strands of DNA. Moreover, modifications of either the metal-
binding domain, the linker region or the bithiazole group lead to reduced effects on 
the DNA cleavage ability of bleomycin (Chen and Stubbe 2005). Conversely, the role 
of the carbohydrate moiety still remains unclear. Recent studies demonstrated that 
removal of the carbohydrate moiety from bleomycin (creating deglycobleomycin) has 
little effect on its ability to cleave DNA in vitro (Leitheiser et al. 2000). However, a 
study demonstrated that deglycobleomycin appears to be about 100 times less toxic to 
Chinese hamster fibroblasts than the unmodified bleomycin (Tounekti et al. 2001) and 
there is evidence that it has a higher uptake in some cancer cells (Schroeder et al. 
2014). Thus, a better understanding of the transport mechanism of bleomycin into the 
cells and developing strategies to increase its uptake are likely ways to enhance the 
anti-tumour effects of this drug.   
  
 
Figure 1.1 Molecular structure of bleomycin. (a) The metal-binding region is in green, arrows show 
the pyrimidine moiety responsible DNA guanine; the linker region in red is connected to the bithiazole 
tail in blue.(b) The disaccharide moiety, in orange, may be involved in cellular uptake. (c) Three 
different positively charged tails are shown and they are responsible for the slight difference among 
pharmaceutical preparations of bleomycin, which are most commonly employed for clinical purposes. 
(Chen and Stubbe 2005). 
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1.4 Bleomycin induced lesions in DNA and RNA    
 
1.4.1 Single Strand DNA cleavage   
 
The basis of bleomycin sequence specificity and its specific binding to DNA is 
attributed to the H-bonds between the pyrimidine (N3 and N4 amino group) in the 
metal-binding domain of bleomycin and the guanine, that is 5’ to the cleavage site (2-
amino group and the 3-N). The pyrimidine moiety is planar and aromatic, binds to the 
nucleic bases and intercalates between bases. Positively charged moieties distal to the 
bithiazole group penetrate the major groove and may provide ionic interactions with 
DNA phosphates (Chen and Stubbe 2005).  
To be able to effectively cleave nucleic acids, bleomycin needs to be in its activated 
form (metallobleomycin) by binding transition metals (Fe(II) or CU(II)) and oxygen, 
in the presence of a one-electron reductant. This leads to the formation of the activated 
bleomycin, (BlmFe (III)-OH) (figure 1.2 (a)). The generated DNA damage is similar 
to that caused by ionising radiation (Chen and Stubbe 2005).   
The activated bleomycin has a half-life of minutes and is responsible for commencing 
DNA damage. (Chen and Stubbe 2005; Richard M. Burger 1998 (B)). Depending on 
the presence of oxygen, this generated radical intermediate can be rearranged to 
produce different types of DNA lesions which are closely related to the ones produced 
by ionising radiation (Ramotar and Wang 2003). One of these products includes an 
apurinic\ apyrimidinic (AP) site, where the entire base is lost. The unstable sugar is 
also able to perform a DNA SSB where 3’ end is terminated with a portion of the 
deoxyribose ring to form a 3’ phosphoglycolate (3’-PG). It has been shown that this 
lesion is able to block DNA synthesis by DNA polymerase. The remaining portion of 
the fragmented sugar exists in the free base propenal form, which has the ability to 





Figure 1.2 Mechanism of DNA damage generated by bleomcyin. (a) bleomycin bond to transitional 
metal (Fe), forming the activated metallobleomycin. Depending on the availability of O2, this 4’-
radical intermediate (blue box) can partition between two pathways (b). In the pathway on the left, the 
4’ radical intermediate is oxidized to a 4’-carbocation to which H2O is added, generating the 
4’oxyidised abasic site. In the pathway on the right, the 4’-radical intermediate reacts with O2 to form 
a 4’peroxy radical. The resulting 4’-hydroperoxide then undergoes a complex series of chemical 
transformation, ultimately generating a gapped DNA 3’ phosphoglycolate/ 5’ phosphate (3’PG/5’P) 




1.4.2 DNA Double Strand breaks 
 
Bleomycin also produces bi-stranded DNA lesions at certain specific sequences, such 
as CGCC, which are generated when the Fe-bleomycin complex creates an AP site on 
one strand and a directly opposed SSB on the complementary strand (Absalon et al. 
1995). The spontaneous cleavage of the AP site by primary amines (e.g., histone 
amine) in vivo converts the bi-stranded lesion into a DSB (figure 1.3) (Absalon et al. 
1995). However, DSB of DNA is affected by a single bleomycin molecule and 
consequently requires reactivation of bleomycin (figure 1.2 (b) right-hand side 
pathway) and bleomycin reorganisation during or after the cleavage of the first strand 
of DNA (figure 1.3) (Chen and Stubbe 2005).   
   
 
Figure 1.3 Rearrangement of the bleomycin molecule during DSB. Stubbe et al, have proposed a model 
for reorganisation of bleomycin from one strand to the cleavage site in the second strand, based on 
structural information from bleomycin-CO(III)-OOH bound to a hot spot for DNA DSB. The key to the 
reorganisation is proposed to be the linker region and the flexibility of the bithazole tail that is bound 
by partial intercalation. The rotation around the bond between the two thiazole rings in the tail of 
bleomycin, together with the other motions, make the peroxide of the activated drug available for 
interaction with the second DNA strand (Chen and Stubbe 2005).   
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In general, bleomycin-induced DNA lesions are mutagenic (Bennett, Swerdlow, and 
Povirk 1993) and some factors, rather than oxygen, may affect the nature of the 
bleomycin induced lesions, including the structure of the DNA (Kane et al. 1995). 
Moreover, when bleomycin is used in a clinical protocol including other DNA-
damaging agents, it may cause irreparable DNA lesions (Chen and Stubbe 2005).  
Treatment of isolated nuclei from normal and cancer cell lines with bleomycin and 
analysis of DNA cleavage demonstrated that bleomycin preferentially damages 
internucleosome linker regions rather than nucleosome structure themselves ( Kuo and 
Yang 2008).  
   
1.4.3 RNA damage   
 
Bleomycin also has the ability to cleave ribonucleic acids, including mRNA, tRNA 
and rRNA, with similar mechanisms to those targeting DNA (Hecht 1994). The 
cleavage of RNA is likely to occur at 5’-GU-3’ sequences. However, despite the fact 
that in vitro, all the main classes of RNA can be cleaved by metallobleomycins (Burger 
et al.1981(A)), the extent of RNA lesions is significantly less than that of DNA (Chen 
and Stubbe 2004). Moreover, Abraham et al. (2001) have demonstrated that 
bleomycin can lead to the inhibition of protein synthesis in a rabbit reticulocyte cell-
free system and in Xenopus oocytes. This may be due to the RNA damage promoted 
by bleomcyin. However, to effectively maintain a blockage of protein synthesis, high 
concentrations of bleomycin is needed. In summary, evidence that RNA is a 
therapeutic target in biological systems in vivo has received limited support (Hecht 






1.5 Resistance to bleomycin  
 
The extent of the response of cancer cells to bleomycin is dependent on the tumour 
type. The reason why this drug seems to be more efficient against some malignancies 
rather than other is not well understood. A possible explanation for this could reside 
in the mechanism of drug resistance and in the different mechanisms of cellular uptake 
(Chen and Stubbe 2005; Pron et al. 1999). Bleomycin causes mutational lesions and 
it is likely that the normal cells of a cancer patient exposed to bleomycin rely on 
mechanisms that lead to repair the drug-induced lesions (Ramotar and Wang 2003). 
Several studies have identified repair pathways involved in repair of bleomycin 
induced lesions; among these, Xu et al. (1998) claimed that the SSB of DNA could be 
rescued by the base excision repair pathway using apurinic/apyrimidinic endonuclease 
1 (APE1) and polymerase-β (POLβ). APE1 has an important role in processing the 
oxidised abasic sites. Furthermore, increased levels of APE1 in germ cell lines have 
been shown to correlate with bleomycin resistance (Chen and Stubbe 2005). In the 
case of POLβ, studies on cultured mouse macrophage cells (P388D1) showed that the 
inhibition of POLβ sensitised the cells to bleomycin damage, supporting a role of 
POLβ in the base excision repair pathway (Chen and Stubbe 2005). Moreover, as 
bleomycin is also capable of producing DNA DSB, it is likely that specific DS-lesion 
repair pathways are involved, such as non-homologous end joining (NHEJ) and 
homologous recombination repair (HRR) (Chen and Stubbe 2005). Other DNA 
protective factors include Hap1, a DNA repair enzyme (Robertson et al. 2001)  and 
the integrin protein receptor family. This is consistent with a study that showed that 
yeasts are protected from the lethal effect of bleomycin by their cell walls. In animal 
cells, the family integrin proteins exert functions analogous to the yeast cell wall and 
can trigger signal transduction pathways similar to the one generated during yeast cell 
wall maintenance, and may activate a defence mechanism against bleomycin 
(Ramotar and Wang 2003). However, despite these insights, the mechanism of celluar 




1.5.1 Bleomycin hydrolase  
 
Several studies identified bleomycin hydrolase (BLMH), a neutral cysteine protease, 
as another key factor in the bleomycin resistance. It is proposed to metabolically 
inactivate bleomycin in normal and cancer tissues (Umezawa et al. 1974). It plays an 
important role in antigen presentation, hydrolysis of homocysteine-thiolactone, 
breakdown of deaminated filaggrin into amino acids N-terminal proteolysis of 
huntingtin, and it is involved in other pathological processes such as atopic dermatitis, 
keratinization disorders and Alzheimer's disease (Wang et al. 2013). To better 
understand the role of BLMH the enzyme was shown to be able to hydrolyse the 
amino-alanine amide moiety at the C-terminus of bleomycin, generating the inactive 
de-amino metabolite (Sebti et al. 1991). Using a specific thiol protease inhibitor (E64) 
that blocks BLMH activity, it was shown that mammalian cells exposed to E64 
become more sensitive to bleomycin (Sebti et al. 1991). However, recent studies in 
the yeast orthologue gene, BLH1, showed that it does not affect cytotoxicity of 
bleomycin in the organisms when deleted or overexpressed. Thus, the role of BLMH 
in producing tumour resistance is controversial (Ramotar and Wang 2003). On the 
basis of the ongoing studies, it would appear that BLMH has a more general role in 
cells to degrade proteins, and to indirectly regulate gene expression by degrading 
specific transcription factors (Koldamova et al. 1999). If this is the case, the bleomycin 
resistance observed by expression of yeast BLH1 protein in mammalian cells may be 
explained, for example, by the degradation of pro-apoptotic factors thus preventing 
cell death (Ramotar and Wang 2003).   
  
1.6 Bleomycin transport 
   
Bleomycin is a large hydrophilic molecule (MW 1.5 kDa), which is unable to 
passively diffuse through the cell plasma membrane effectively (Pron et al. 1999). It 
has been hypothesised that bleomycin cellular uptake may involve a specific receptor-
mediated endocytosis mechanism.  Based on models derived from Chinese hamster 
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fibroblasts and human head and neck carcinoma cell lines, the internalisation process 
depends on the number of “bleomycin receptors” on the cell surface and on the 
endocytic activity of the cells. After its uptake, bleomycin is internalised into vesicles 
but it is still unknown how bleomycin is released from the intracellular vesicles into 
the cytoplasm, and why only a few molecules of bleomycin reach the DNA under 
standard use of the drug (Pron et al. 1999). No further characterisation of this putative 
receptor or the endocytosis pathway has been reported. Identification of the plasma 
membrane receptor and its expression in different tissue could be the key to 
determining why there is differential toxicity of bleomycin between tumour cells and 
cells of the lung (Chen and Stubbe 2005). Other studies revealed that altered transport 
may be the general mechanism conferring bleomycin resistance, and bleomycin 
uptake might require de novo protein synthesis. A study claimed that bleomycin might 
share a pathway with spermidine uptake, which is blocked by the PTK2 kinase mutant, 
and that the drug was ultimately sequestered in the vacuoles (Aouida et al. 2004). The 
authors argued that sequestering bleomycin into vacuoles is a possible detoxification 
pathway and the observed cytotoxicity of bleomycin comes from non-sequestered 
drug, which diffuses from the cytosol into the nucleus.  Schroeder et al. (2014) claimed 
that the uptake mechanism involves one or more cell surface receptors involved in 
glucose transport in tumour cells, which are upregulated in tumour cells to support 
their enhanced use of glycolysis. Recent studies suggest that the selective tumour cell 
targeting of the bleomycin is due to the disaccharide moiety of the drug (Yu et al. 
2013; Madathil et al. 2014). At the present, there is no general consensus on either the 
efficiency of uptake into the cells or into the nucleus of cells. Furthermore, there is no 
consensus about the mechanism of uptake and about which part of the bleomycin 
molecule is essential for this process (Chen and Stubbe 2005). Given the importance 
of uptake and cellular distribution to differential cytotoxicity of bleomycin, further 
studies to elucidate these mechanisms are required.  
  
1.7 Cellular response to bleomycin-induced DNA damage   
 
Bleomycin is proposed to induce two distinct types of tumour cell death, which are 
dependent on the concentration of bleomycin within cells and, consequently, the 
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degree of DNA damage caused by DSBs. At low therapeutic doses of bleomycin, cells 
accumulate in G2/M phase, generating a mitotic cell pathway. At high doses, 
bleomycin causes extensive DNA damage by DSBs, leading to an apoptosis-like 
process (Tounekti et al. 2001; Chen and Stubbe 2005). However, the specific cell-
death pathway induced by bleomycin is proposed to be cell-type dependent (Fulda et 
al. 2001). Studies in cell culture support a role for ATM in bleomycin-induced DNA 
damage. ATM is a phosphatidylinositol- 3-kinase-like kinase proposed to function as 
both a damage sensor and signal transducer.  ATM is proposed to be required for the 
efficient activation of the DNA-repair pathway in response to bleomycin-induced 
DNA damage in mammalian cells. ATM activates the tumour suppressor protein p53, 
which has been heralded as the guardian of the genome for its role in mediating cell 
cycle inhibition, DNA repair, and apoptosis (Lu et al. 2017).Lee et al. (2010) found 
that bleomycin induces necrosis and apoptosis in wild-type p53 human non-small cell 
lung and colon cancer cells, and that p53 expression affected the sensitivity of these 
tumours to bleomycin.  
Bugaut et al. (2013) also showed that bleomycin has an immunogenic effect by 
triggering the “immunogenic cell death” (ICD) whereby the DNA damage and the 
oxidative stress induced by bleomycin may trigger an event cascade that leads IFN 
gamma and CD8+ T cells to mount a response against the tumour cells. Furthermore, 
bleomycin may have a dual effect, as it also induces the production of TGF-beta by 
tumour cells leading to regulatory T cells (T-regs) accumulation, which limits anti-
tumuor efficacy (Bugaut et al. 2013). In summary, preferential activation of these 
different cell-death pathways in different tumour cells lines could potentially account 
for differential cytotoxicity and cell-type dependent differences (Chen and Stubbe 
2005).  
  
1.8 Pharmacokinetic and clinical use  
  




The main components of bleomycin sulphate, the form of the drug used for injection, 
are bleomycins A2 and B2, which differ in the terminal amine substituent of the 




Figure 1.4 Chemical structure of Bleomycin sulphate, including the A2 and B2 terminal amine 
substituents (He et al. 2016) 
 
In human medicine, bleomycin is commonly designed to be delivered as systemic 
drug. It can conventionally be administered by intramuscular, intravenous or 
subcutaneous injection (Hospira 2013). In veterinary medicine, it is essentially 
administered by subcutaneous, intralesional, and rarely, by intracavitary injection 
(Marconato 2009). However, its use is restricted by its intrinsic pulmonary toxicity 
(Froudarakis et al. 2013). After injection, bleomycin reaches a peak of plasma 
concentration in 30 to 60 minutes and it is homogeneously delivered in the body. 
However, it does not cross the blood–brain barrier, but it does pass through the 
placenta (Froudarakis et al. 2013).  The primary route of elimination is via the kidneys. 
About 65% of the administered intravenous dose is excreted in urine within 24 hours 
with a mean terminal half-life of 2 hours following intravenous bolus administration 
(Hospira 2013). Indeed, renal dysfunction leads to significantly increased drug 
exposure (Froudarakis et al. 2013). At a cellular level, the inactivation of bleomycin 
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may involve BLMH. This enzyme is widely distributed in normal tissues with the 
exception of the skin and lungs, and this may explain the severe toxicity of bleomycin 
in these two tissues (Chen and Stubbe 2005).  
Systemic use of bleomycin has been shown to be useful in the management of several 
neoplasms either as a single agent or in combination with other chemotherapy drugs. 
In human medicine, the tumours treated include lymphomas (Hodgkin’s disease, non-
Hodgkin’s lymphoma), testicular carcinoma (embryonal cell, choriocarcinoma, and 
teratocarcinoma), SCC of head and neck (including mouth, tongue, tonsil, 
nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, 
and larynx), penis, cervix, and vulva (Hospira, 2013). Bleomycin has also been shown 
to be successful in the management of malignant pleural effusion as it has been proven 
to be an effective sclerosing agent for this disorder and in the prevention of recurrent 
pleural effusions (Hospira 2013). Although it has marked anticancer potential, 
bleomycin also causes severe side effects when administered systemically (Marconato 
2009): skin adverse reactions have been reported in approximately 50% of treated 
patients consisting of erythema, rash, striae, vesiculation, hyperpigmentation, and 
tenderness of the skin. Hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis 
have also been reported. It was necessary to discontinue bleomycin therapy in about 
3% of treated patients because of these toxicities (Hospira 2013). The most serious 
side effects are pulmonary adverse reactions, occurring in approximately 10% of 
treated patients. The most frequent presentation is pneumonia, occasionally 
progressing to pulmonary fibrosis and approximately 3% of treated patients died of 
pulmonary fibrosis (Hospira 2013). This represents the main limiting factor to its 
clinical use, especially for veterinary patients. The molecular basis of bleomycin-
induced lung injury (BILI) involves cytokines and free radicals as key effectors, and 
they are related also to low levels of BLMH in the lung, particularly in type II 
pneumocytes. This feature makes lung cells vulnerable to toxic effects of bleomycin 
during mitosis. Acute inflammation is central to development of BILI. Inflammatory 
exudate consists mainly of mononuclear macrophages, lymphocytes and neutrophils 
(Froudarakis et al. 2013). Continued exposure of lungs to bleomycin can lead to 
increase collagen synthesis and deposition of various matrix proteins including 
collagens, elastin, and proteoglycans. Moreover, bleomycin-activated alveolar 
15 
 
macrophages stimulate the synthesis of hyaluronic acid, a connective tissue molecule 
that is seen in fibrotic lungs (Froudarakis et al. 2013). Other side effects rarely seen in 
human patients and, to a lesser extent in animals include idiosyncratic reactions, 
vascular abnormalities (such as Raynaud’s phenomenon), gastrointestinal disorders 
and pain at the local tumour injection site (Hospira 2013). In veterinary medicine, the 
use of bleomycin as systemic agent is poorly described, and its main utilisation is in 
the treatment of feline SCC (Marconato 2009).  
  
1.8.2 Topical treatment   
  
Bleomycin is an extremely toxic agent once inside the cell, but its high intrinsic 
cytotoxicity is restricted by the inability of bleomycin to freely diffuse through the 
plasma membrane (Gothelf, Mir, and Gehl 2003). This limiting factor along with its 
systemic toxicity, has highlighted the need for a new route of administration, aimed 
to potentiate its anti-cancer activities, enhance cellular penetration and reduce side-
effects. Previously, several attempts to develop topical administration of this antibiotic 
were made in both human and veterinary medicine, including intralesional 
administration, photochemical internalization and the most efficient and well-studied 
ECT (Mir and Orlowski 1999; Glass et al. 1996; Rodrıguez-Cuevas et al. 2001; 





ECT is based on coupling electroporation with chemotherapy agents (Impellizeri et al. 
2016). The structure of the cell membrane prevents the influx of hydrophilic drugs, 
macromolecules and peptides. By applying an electric current, it is possible to 
overcome this barrier by allowing the cells to become permeable to these molecules, 
which normally would not be able to cross the cell membrane. This method is called 
electroporation (Impellizeri et al. 2016). When electroporation is combined with 
certain chemotherapy drugs, the cytotoxicity of these drugs is increased by several-
fold, leading to a dramatic improvement in the response of the treated tumour 
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(Impellizeri et al. 2016). Ideal drugs for ECT use are lipophilic, non-permeant or 
poorly permeant molecules with a high intrinsic toxicity (Mir and Orlowski 1999). 
Bleomycin is a non-permeant molecule, which cannot diffuse across the cell 
membrane because of its size, physical and chemical properties. When administered 
via parenteral route, cellular uptakes of bleomycin is dependent on transmembrane 
proteins, this mechanism is restricted by the number of proteins involved and by the 
speed at which these proteins can withdraw from the cell membrane. Electroporation 
enables almost free diffusion of bleomycin into the cells for as long as the cells remain 
permeable (up to 60 minutes). The cytotoxic effect of bleomycin can be increased by 
up to 700-fold when used in ECT (Mir and Orlowski 1999; Impellizeri et al. 2016). 
Bleomycin can be applied intralesionally or systemically before the electroporation 
(Impellizeri et al. 2016).  
  
1.8.3.1 Human clinical applications  
  
Substantial amounts of clinical data are published on the application of electroporation 
in human patients. The European Standard Operating Procedures for Electro-
Chemotherapy (ESOPE) achieved an objective response rate of ~85% with a single 
treatment in a wide variety of skin tumours (melanoma, head and neck cancer, SCC, 
breast cancer skin metastases, cutaneous Kaposi’s sarcoma) of 3 cm in diameter or 
smaller (Bertino et al. 2016; Dolinsek et al. 2016; Campana et al. 2016). Clinically, 
the application of ECT has been mainly focused on the treatment of cutaneous or semi-
cutaneous tumours with palliative intent including melanoma, head and neck cancer, 
SCC, BCC, breast cancer skin metastases, cutaneous Kaposi’s sarcoma. Among these, 
several studies have demonstrated that BCCs are one of the most responsive 
malignancies to ECT treatment using bleomycin (Glass et al. 1996; Rodriguez-Cuevas 
et al. 2001). However, ECT has been proved to be a useful palliative therapy in 
melanoma, breast cancer skin metastasis, and SCCs (Rodriguez-Cuevas et al. 2001).  
Moreover, ECT is one of the treatments of choice for tumours refractory to 
conventional treatment and can be used as cyto-reductive therapy before standard 
therapy.  Finally, ECT can be adopted to treat haemorrhagic or painful nodules and it 
can be applied in previously irradiated areas (Giardino et al. 2006).  
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1.8.3.2 ECT in veterinary medicine  
  
Several studies support the veterinary use of ECT coupled with bleomycin in the 
treatment of tumour types traditionally known to have limited or no treatment options, 
or to be poorly responsive to standard therapy (Spugnini, Citro, and Baldi 2009 (A); 
Tozon, Tamzali, and Cemažar 2017). Furthermore, Impellizeri et al (2016) achieved 
a good outcome in the management of unresectable tumours or those in inaccessible 
anatomical areas.  
  
1.8.3.2.1 Canine studies  
 
In canine patients, a wide range of neoplasms such as lymphosarcoma, 
hemangiopericytoma, neurofibrosarcoma, liposarcoma, acanthomatous epulis, 
melanoma, were responsive to ECT and bleomycin (Spugnini and Porrello 2003). One 
study, conducted on 9 dogs bearing different types of cutaneous tumours, achieved 
38% of complete response for more than 5 months and 50% of partial response up to 
19 months  (Spugnini and Porrello 2003). Moreover, ECT and bleomycin has been a 
beneficial treatment for mast cell tumours (MCTs) when combined with surgery 
(Spugnini et al. 2006). Even with recurrence and re-treatment with ECT, survival 
ranged from 6 to more than 28 months. Coupling surgery with bleomycin delivered 
by ECT, there has been success in the treatment of a canine perianal gland adenoma, 
achieving a complete response after treatment, which lasted for more than 18 months 
(Tozon et al. 2005). This method of treatment could be ideal against tumours with 
behaviour limited to local recurrence (Impellizzeri et al. 2016). Furthermore, Reed et 
al. (2010) achieved a complete remission, treating an oral SCC and an acanthomatous 





1.8.3.2.2 Feline studies 
  
The main target of ECT in feline patients is SCC. In one study, ECT has elicited 
favourable responses against cutaneous SCC in cats treated with bleomycin 
administrated intravenously before electroporation (Tozon, Tamzali, and Cemažar 
2017). Furthermore, Spugnini et al. (2015) conducted a non-randomised prospective 
study to evaluate the efficacy of bleomycin with electroporation compared to 
bleomycin alone in the treatment of 21 feline cases of periocular carcinoma, 
comprising 17 SCC and 4 anaplastic carcinomas, as well as to 26 cases with advanced 
SCC of the head. In the periocular cohort, 12 were treated with bleomycin and 
electroporation, and 9 received bleomycin alone. In the advanced SCC group, 14 
received ECT, while 12 had bleomycin only. Of the 26 ECT treated cases, there were 
21 complete responses and 2 partial responses, with the treatment being well tolerated 
and reported to have minimal toxicity. In contrast, the bleomycin only group (21 
cases) had four complete responders and three partial responses. This finding is 
significant and supportive of the central role that cellular uptake may play in the 
efficacy of bleomycin treatment. 
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1.8.3.3 Side effects of ECT 
 
ECT with bleomycin has shown to be a promising and efficient therapeutic option in 
the management of skin tumours. However, it produces some side effects, although 
milder compared to the systemic use of the drug, including painful underlying muscle 
contractions (Campana et al. 2016). In human patients, commonly local analgesia is 
sufficient to treat the pain, although in the treatment of multiple nodules, general 
anaesthetic is also described (Campana et al. 2016). In animal patients general 
anaesthetic is always mandatory, and for some patients classified in a critical ASA 
class, it can be a restricting factor for the use of ECT (Impellizzeri et al. 2016). Local 
side effects after ECT are erythema and slight oedema at the site of the treated lesions, 
which occurred in most of the patients and disappeared in a few days (Spugnini et al. 
2009 (B)).  In the study of Spugnini et al (2015), when ECT was performed in cats 
bearing periocular carcinoma and advanced SCC, they found that two cats in the 
advanced head SCC ECT group had local inflammation involving the deep 
subcutaneous connective tissues, which led to compulsive scratching. All of the cats 
that underwent ECT experienced transient muscular contractions at the time of 
treatment. Haematological toxicity was not observed in the 26 cats of the ECT study, 
except for mild neutropenia on day 7 in two cats (grade I according to VCOG-CTAE 
guidelines) (Spugnini, Pizzuto et al, 2015). Cardiac arrhythmias and respiratory 
dysfunction treatment-induced are also rare side-effects (Chaudhary and Rajuria 
1995). 
  
1.9 Novel therapeutic approach  
  
Advancement in the management of cancer is focusing more on precise medicine and 
on delivering therapies specifically targeted against cancer cells, and diminishing the 
cytotoxicity to healthy cells. These attempts in reducing systemic side-effects have 
resulted in the development of less invasive treatments and major patient compliance. 
In 1906, Paul Ehrlich coined the phrase “magic bullet” to describe the liposomes as 
novel tools that are able to deliver the chemotherapy payload directly to the cancer 
cells (Utku 2011). The theoretical benefits of carrier-mediated drugs include greater 
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solubility, longer duration of exposure, selective delivery of entrapped drug to the site 
of action, superior therapeutic index and the potential to overcome resistance 
associated with the regular anti-cancer agent (Zamboni 2008). Early evidences in 
veterinary medicine on the efficacy of liposomes as novel selective carriers for 
chemotherapy were obtained in 1989, when MacEwen and colleagues assessed that 
the systemic treatment with muramyl tripeptide-     
phosphatidylethanolamine encapsulated in liposomes resulted in delayed metastatic 
disease in dogs bearing osteosarcoma following surgical amputation, and in 
significantly prolonged median survival times compared to patients receiving 
liposomes alone; authors reported also the lack of severe side effects following the 
liposomal chemotherapy treatment (MacEwen et al. 1989).  
For these reasons, entrapping bleomycin in liposomes may improve the efficacy of 
this drug, allowing a targeted therapeutic approach and reducing systemic 
toxicological risks.  
Bleomycin delivered by ECT has shown to be effective against skin tumours in both 
animals and human beings. Therefore, the compelling idea was to develop a new non-
invasive treatment for this class of neoplasms, such as a topical skin treatment, using 
bleomycin encapsulated inside liposomes: the Bleosome. The hypothesis behind 
Bleosome’s manufacture was to highlight the anti-cancer properties of bleomycin and 
to avoid the drawbacks of electroporation. Moreover, Bleosome could be formulated 
as cutaneous cream, which would have far-reaching applications as a completely non-
invasive tool for both human and for animal patients. This PhD study is focused on 
testing the efficacy of this new formulation against NMSC.  
  
1.9.1 Liposomes   
  
Liposomes are valued for their biological and technological advantages as they are 
able to encapsulate ions and molecules inside their membranes (Bozzuto and Molinari 
2015). Several types of liposomes are in clinical use and, to date, notable progress has 
been made in their formulation. Furthermore, new biomedical applications of 
liposomes are either in clinical trials or about to be put on the market (Bozzuto and 
Molinari 2015).     
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Liposomes are mainly composed of phospholipids, amphiphilic molecules that have a 
hydrophilic head and two apolar hydrophobic chains. Thanks to their amphipathic 
nature, when phospholipids are dispersed in aqueous solutions, they have a strong 
tendency to form membranes: the polar heads interact with the aqueous environment, 
whereas, their long apolar aliphatic chains promote interaction with one another 
forming two lipid layers (figure 1.5) (Papahadjopoulos, Cowden, and Kimelberg 
1973). The hydrophobic chains of each layer face each other forming a lipophilic inner 
compartment that avoids the loss of the entrapped molecules, acting as a permeability 
barrier, both inward and outward. (Bozzuto and Molinari 2015). These lipid bilayers, 
indeed, are kept together by hydrophobic interactions, and the van der Waals forces 
are responsible for the interaction between long hydrocarbon tails, thus strengthening 
this architecture. Furthermore, hydrogen bonds and polar interactions between the 
water molecules of the aqueous environment and the polar heads of lipids stabilise this 
organisation. The final architecture of lipids relies on their nature, concentration, 




Figure 1.5 Structure of a liposome (left), and a lipid bilayer (right). Liposomes are composed of a lipid 
bilayer, forming a membrane, with hydrophilic heads facing outward and hydrophobic chains 
interacting inward. From Bozzuto and Molinari 2015  
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Liposomes can be classified on the basis of the preparation method (reverse-phase 
evaporation vesicles or vesicle extruded technique), size (small, intermediate, or 
large), and lamellarity (uni-, oligo-, and multilamellar vesicles) (Alavi et al. 2013). 
All liposomes have in common a structure that renders them capable of encapsulating 
both hydrophilic and hydrophobic drugs.  The entrapment efficiency of a molecule in 
a liposome depends on its polarity and partition coefficient, which also determines its 
localisation in the liposomal membrane. If a drug is hydrophobic in nature, it resides 
in the acyl hydrocarbon chain of the liposome, whereas if a drug is polar or 
hydrophilic, it tends to localise in the aqueous central core or adjacent, near the polar 
head groups of the liposome (Noonan et al. 2014). Liposomes act like a protecting 
environment for the encapsulated drug, and, thanks to their properties, they avoid 
enzymatic degradation and immunologic and chemical inactivation of the carried 
molecule. Therefore, liposomes prevent a drug from being metabolised prior to 
reaching the target tissue and they minimise the exposure of healthy tissue to the 
encapsulated drug during its circulation in the blood. Both these effects contribute to 
an increase in the therapeutic index. In fact, high levels of the active form of a drug 
are delivered to the tumour site, enabling the expected cytotoxic effect to be achieved 
(Bozzuto and Molinari 2015). A characteristic of solid tumour tissues is the formation 
of a new vascular network with an increased vascular permeability. The enhanced 
permeation and retention (EPR) effect is a phenomenon characterising malignant 
tissues by which nanocarriers of an appropriate size can pass through tumour-vessel 
walls and enter the neoplastic lesion. In particular, the new vasculature, created by 
solid tumours, consists of a discontinuous endothelium with wide fenestrations, which 
enable large molecules (of about 4,000 kDa or 500 nm) to enter the interstitial space 
(Torchilin 2011).  Liposomes can satisfy the size conditions needed to pass through 
tumour vessels and concentrate in the target site. This mechanism represents the major 
targeting principle for intravenously administered liposomes (Bozzuto and Molinari 
2015). Another encouraging feature of liposomes is that they diminish systemic 
toxicity of the chemotherapy drugs. Therefore, when a therapeutic agent is 
encapsulated into these nanocarriers, it adopts the carrier’s pharmacokinetics until the 
drug is released. As a consequence, liposomes modify both the tissue distribution and 
the rate of clearance of the loaded drug, thus any undesirable side-effects of the loaded 
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drug are dramatically reduced compared to the free form (Bozzuto and Molinari 
2015). Despite this knowledge, the exact mechanism undergoing the pharmacokinetic 
and pharmacodynamics variability of these agents remains unclear, but most likely 
includes the mononuclear phagocyte system (Zamboni 2008). Elimination of 
liposomes takes place in different ways. The first involves absorption of plasma 
proteins on the surface of liposomes and then their recognition by the mononuclear 
phagocyte system. This event results in the excretion of the cargo at the hepatic level 
and its subsequent metabolism by Kupffer cells. Furthermore, liposomes are 
metabolised by splenic macrophages (Ishida, Harashima, and Kiwada 2002).  
Physicochemical characteristics of the liposomes, however, influence the 
pharmacokinetics of the loaded drug; they can differ in lipid composition, size, 
membrane lipid packing, steric stabilisation, surface charge, dose, and route of 
administration. This confers to these carriers the advantage to well suit with the final 
therapeutic goal (Bozzuto and Molinari 2015). For this reason, a broad range of 
liposomes differing in formulation have been designed including: PEG-coated (or 
stealth) liposomes, which are able to better escape from mononuclear phagocyte 
system uptake and to circulate in bloodstream for a longer time compared to the non-
PEG coated ones (Alavi et al. 2013); immunoliposomes, generated by coupling  
antibodies to the liposomal surface and allowing an active tissue targeting through the 
bond to tumour cell-specific receptors (Paszko and Senge 2012); dual function 
liposomes; and thermosensitive liposomes (Bozzuto and Molinari 2015). However, 
there are some drawbacks that inevitably affect the efficacy of liposomes; the most 
relevant ones include short half-life, instability, and the possibility of phospholipids 
undergoing oxidation and hydrolysis-like reactions, the leakage and fusion of 
encapsulated drug, and high production costs (Alavi et al. 2013).  
 
1.9.2 Challenges to applicability of liposomes 
 
An optimal delivery system for active drug needs to satisfy several necessary 
conditions including high encapsulation efficiency, long-term stability, small particle 
size with narrow size distribution. Although it has been assumed that liposomes have 
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a great potential for delivery of active principles, their applicability in clinics has faced 
many challenges  (Van Tran, Moon, and Lee 2019). 
Two of the major problems limiting liposomes utilisation in practical applications are 
their low physical and chemical stabilities (Takeuchi et al. 2001). The physical 
instability of liposomes can be explained by two parameters: changed particle size and 
size distribution due to the aggregation and fusion of vesicles and leakage of the 
entrapped drug (Grit and Crommelin 1993). Such destabilisations will happen at a 
faster rate when the surface charges of liposomes are decreased by pH or the presence 
of strong ions. It has been reported that liposomes with no or weak surface charges 
will tend to aggregate more readily than strongly charged ones (Van Tran, Moon, and 
Lee 2019). 
The leakage of encapsulated drug strongly depends on the particle size and structural 
compositions of the liposomes. To ensure the physical stability of liposomes, 
therefore, increasing the surface charge and optimising the structural compositions and 
particle size will be necessary approaches (Van Tran, Moon, and Lee 2019). As for the 
chemical instability of liposomes, it has been suggested that oxidation and hydrolysis 
of the phospholipids may be one of the main pathways causing this problem (Grit and 
Crommelin 1993). Also, temperature and pH are the two major parameters that can 
significantly influence the chemical stability of liposomes, and it recommended that 
for long-term stability, liposomes should be stored at a low temperature (4-6 °C) and 
neutral pH (6.5) (Van Tran, Moon, and Lee 2019). 
Another problem limiting the clinical application of liposomes is the low encapsulation 
efficiency of some molecules, especially hydrophilic ones such as vitamin C. It has 
been shown that by using conventional methods (thin-film, ethanol-injection methods) 
to prepare liposomes, hydrophilic substances may be easily dissolved in the external 
aqueous phase of liposomes, and as they are encapsulated in the aqueous cores of 
liposomes, this leads to low efficiency (Eloy et al. 2014). In addition, the conventional 
methods are based on the self-assembly of phospholipids in an aqueous environment 
and thus, because of the random nature of bilayer folding, these techniques will 
produce vesicles non-uniform in size and shape (Van Tran, Moon, and Lee 2019). 
Large-scale production is also a major challenge. It has been reported that liposomes 
used for drug delivery can be fabricated by various techniques including mechanical 
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methods, such as thin-film, sonication, microfluidisation, extrusion; and techniques 
using aqueous solution to replace organic solvents, such as ethanol injection and 
reverse-phase evaporation (Van Tran, Moon, and Lee 2019). For large-scale 
production, however, it seems that majority of the methods are unsuitable, due to 
difficulties in scaling-up and limitated cost-effectiveness. Therefore, novel techniques 
that improve industrial production of nanoparticles for medical purposes are sought-
after (Van Tran, Moon, and Lee 2019). 
 
1.9.3 Skin cancers and liposomes as carrier for topical treatment  
  
Liposomes have been utilised to encapsulate several types of drugs and designed to 
successfully deliver anticancer, antibacterial, antifungal, immunomodulation, 
diagnostics, ophthalmic, vaccines, enzymes and genetic elements. This enhances the 
therapeutic power and reduces the side effects of the encapsulated agents (Alavi, 
Karimi, and Safaei 2017). Focusing on cancer therapy, successful outcomes have been 
achieved by encapsulating very harmful drugs such as doxorubicin, oxaliplatin, 
cytarabine and paclitaxel (Zamboni 2008). Bleosome was designed to deliver the 
therapeutic benefit of bleomycin with reduced systemic toxicity. Based on the 
excellent results that ECT using bleomycin has achieved in the management of skin 
tumours, the primary aim of this study is to prove the efficacy of bleomycin 





1.10.1 Human patients 
  
In human medicine, NMSC are the most common type of cancer affecting Caucasian 
populations (Simonetti et al. 2009). They include, among others, BCC, the most 
commonly diagnosed skin tumour with 75% of incidence, and SCC (Anthony 2000). 
They both derive from epidermal keratinocytes. The major predisposing factor for the 
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development of these types of tumours is chronic sunshine exposure, followed by fair 
skin, other forms of ionising radiations, immunosuppression, previous skin 
malignancy and premalignant states, such as multiple actinic keratosis (Newlands et 
al. 2016). BCCs have several clinical presentations: the nodular lesions are the most 
frequently diagnosed and may have cystic or pigmented variants. Morphoeic BCCs 
are typically found on the skin of the head and neck, while superficial forms are 
predominantly located on the trunk (Newlands et al. 2016). BCCs are unlikely to 
rapidly grow and rarely disseminate (Daphu et al. 2014). However the Royal College 
of Pathology dataset, in 2014, established the term ‘infiltrative BCC’ for all high-risk 
histological variants and noted that many BCCs contain both high and low risk 
subtypes (Newlands et al, 2016).  
The first clinical evidence of SCC is skin induration. The affected area may be plaque-
like, verrucous, tumid or ulcerated, sometimes even without evidence of keratinisation 
(Daphu et al. 2016). Cutaneous SCC of the nasal vestibule or of the ear canal is often 
diagnosed late, resulting in poor prognosis. Conventional surgical excision, curettage 
and cautery, cryosurgery, Mohs micrographic surgery and radiotherapy are the most 
common invasive treatments for NMSC (Daphu et al. 2016).  
Current topical treatments for NMSC include semi-solid formulations of 5-
fluorouracil (5-FU), imiquimod and photodynamic therapy (PDT) (Barrera and 
Herrera 2007). 5-FU is a chemotherapeutic agent that blocks DNA synthesis and 
prevents cell proliferation (Galiczynski and Vidimos 2011). This medication has some 
side-effects, including an intense local inflammatory reaction that results in a lack of 
patient compliance. Other disadvantages are the relative long treatment period and 
partial inefficacy of the treatment to penetrate into the deep layers of skin (Barrera and 
Herrera 2007). Imiquimod is an immune response modifier that directly and indirectly 
interacts with the immune system (Perrotta, Giordano, and Malaguarnera 2011). 
Studies have revealed that almost all patients treated with imiquimod exhibit some 
degree of local inflammation at the application site. In FDA studies, patients presented 
some degree of erythema, oedema, ulceration or erosion (Burns and Brown 2005). 
PDT involves the administration of a photosensitising drug. Subsequent activation by 
light of a specific wavelength leads to the formation of highly reactive singlet oxygen 
(1O2), destroying the cells via chemical, biological and physiological reactions 
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(Araujo, Thomazine, and Lopez 2010). However, a 5-year follow up, multicentre 
study, demonstrated that PDT was less efficacy in the treatment of skin tumours 
compared to surgery (Rhodes et al. 2007).  
   
1.10.2 Veterinary patients  
  
BCCs are rarely observed in dogs and cats, with an incidence of 4-12% and 15-26% 
of the overall cutaneous tumours, respectively. BCCs are a low grade type of tumour. 
In animal patients, the aetiology is unknown and these malignancies can be found on 
the skin of head, neck, trunk and, occasionally on the nasal planum of cats. Clinically, 
BCC can be found in the solid, cheratinic and, in cats, clear cell form. Usually, the 
lesion is a single, hyperpigmented, cystic and sometimes ulcerated nodule (Amadori 
and Marconato 2012). The standard treatment for BCC involves mainly surgical 
excision, coupled with chemotherapy and radiotherapy for metastatic disease 
(Amadori and Marconato 2012). 
SCC is more frequent, with an incidence of 5-15% of all cutaneous tumours in 
veterinary patients. It arises from keratinocytes and the aetiology is not well 
understood, although, like in humans, it is likely to be dependent from the action of 
sun exposure and from immunological disorders. In canine patients, the clinical 
presentation is a cauliflower-like lesion on the anatomical areas that are more exposed 
to the sun (ear, nose, ventral abdomen) and it is commonly a single lesion. It is well 
known that white haired cats are the most predisposed to develop this kind of 
malignancies, and the most commonly affected areas of the body are nasal planum, 
pinna, eyelids and lips. In this species, SCC is sometimes presented as multiple lesions 
(Amadori and Marconato 2012). SCCs are locally invasive with a low metastatic rate 
(Amadori and Marconato 2012). SCC are commonly treated with surgery, cryosurgery 
and in some cases, radiotherapy. Topical treatment for feline patients, like for humans, 
includes PDT and imiquimod, although they are not yet established treatment option 
for pets. It has been shown that they can carry side-effects similar to human medicine 
(Marconato et al. 2013). After PDT, hyperaemia, oedema, cyanosis and pruritus are 
reported. Moreover, for patients undergoing this treatment, general anaesthetic is 
needed (Marconato et al. 2013).  In one study, 12 cats treated with imiquimod 
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manifested adverse reactions suspected to be associated with the  use of the cream, 
including local erythema (25%), increased liver enzymes and neutropenia (8%), and 
partial anorexia and vomiting (Gill et al. 2008).  
Sarcoids are the most common skin tumours in horses worldwide. The pathogenesis 
of this neoplasm is multifactorial, and the tumour is associated with bovine 
papillomavirus types 1 and 2 (Bergvall 2013). Clinical presentation varies and 
includes 6 types of lesions: occult, verrucous, nodular, fibroblastic, mixed, and 
malignant (malevolent) types (Knottenbelt 2019). This tumour does not normally 
spread to distant areas of the body, but can become very aggressive locally. Multiple 
tumours are common and all clinical types can be present in the same horse (Bergvall 
2013). The tumour has a high risk of recurrence. Large, recurrent lesions carry a worse 
prognosis (Bergvall 2013). To date, there is no consensus on the optimal treatment for 
equine sarcoids ( Knottenbelt 2019). The most common techniques involve the use of 
surgery, chemotherapy, immunotherapy, gene therapy, radiotherapy, photodynamic 
and phytotherapy. All of these therapeutic options are invasive or locally aggressive 
and painful for the patients, and several studies have concluded that none of them, 
even in combination, achieves a durable remission in a high proportion of patients 
(Knottenbelt 2019).  
NMSC in both veterinary and human medicine share similar features in terms of 
biological behaviour and response to treatment; of note, despite the different nature of 
sarcoids, arising from mesenchymal cells compared to BCCs and SCCs that are 
epithelial tumours, this class of malignancies tends to have low rate of distance 
metastasis but is characterised by locally aggressiveness and by the tendency of 
relapsing after the treatment. 
The limitations of the standard treatments of NMSC highlight the clinical need of 
developing new less invasive formulations, which are able to ensure optimal drug 
penetration through the skin and effective anticancer activity. Semi-solid conventional 
formulations, such as creams, ointments and gels, have been used for topical 
administration of drugs for many years (Fleury and Vianna Lopez 2011). Simple 
application of the formulations on the surface of the skin, however, is not sufficient to 
allow the drug to reach the site of action. This means that it is important for the 
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formulation to be capable to penetrate through the different skin layers to reach the 
tumour site (Schmid and Korting 1996). Nanocarriers, such as liposomes, could 
improve NMSC targeting, by enhancing the ability of the drug to reach and penetrate 
through the skin and into the tumour. Moreover, nanocarriers can improve drug 
stability and reduce skin irritation by avoiding direct contact of the drug with the skin 
surface (Schimid and Korting 1996). UD liposomes have been developed to efficiently 
traverse the stratum corneum and be effective drug carriers through skin layers (Jain 
et al. 2003).  
  
1.11 Skin structure  
  
The skin is the largest organ of the body and is composed of three main layers: the 
epidermis, dermis and hypodermis. The epidermis plays an important role in the 
defence against external environment and in the penetration of substances into the 
skin. It is the outer, avascular layer of the skin, primarily composed of keratinocytes. 
Due to cellular differentiation, the epidermis is divided into different layers, which are 
formed by the division of basal cells in the stratum basale, from the lower part of the 
skin toward the surface. Thus, basal cells undergo progressive maturation, giving rise 
to the spinous layer composed of squamous cells. From this stage, cells differentiate 
again, creating the granular layer and finally the stratum corneum, which is the 
outermost layer of the skin (Fleury and Vianna Lopez 2011). 
The stratum corneum is the major barrier for the penetration of substances through the 
skin because of its heterogeneous composition, packed organisation of corneocytes 
and intercellular lipid matrix. The corneocytes are flat anucleated squamous cells, 
made essentially of keratin and encircled by a lipid matrix composed primarily of 
ceramides, cholesterol, and free fatty acids (Bouwstra et al. 2003).  
In the stratum basale, there are two other cell types that are important in the context 
of skin tumour composition, melanocytes and Langerhans cells. Melanocytes are 
dendritic cells capable of melanin production, and Langerhans cells are antigen-
presenting cells that are responsible for the immune response in the skin (figure 1.6) 





Figure 1.6 Layers of the epidermis. The epidermis is the outermost part of the skin and consists of five 
layers of keratinocytes that start from the basal layer, mature and differ first in the keratinocytes of the 
spinous layer then in those of the granular layer to eventually become anucleated cells (corneocytes) 
in the stratum lucidum and finally in the stratum corneum. This maturative keratinization of the 
epidermis in a healthy subject takes about 3 weeks to occur. Corneocytes are the largest layer 
(approximately 85%) of keratinocytes and are securely held together by secretion of intercellular lipids 
from the same keratinocytes and, in the least, by sebaceous glands (Betts et al. 2013)  
  
The skin is a heterogeneous organ and contains a wide variety of cell types that can 
generate several types of benign and malignant tumours. For instance, SCC and BCC 
originate from keratinocytes (Fleury and Vianna Lopez 2011).   
Over the past two decades, significant attention has been paid to understanding the 
mechanisms by which drugs penetrate through the skin. It is well known that 
substances usually penetrate the skin by three different routes: through the stratum 
corneum between the corneocytes (intercellular route); through these cells and the 
intervening lipids (intracellular route); or through the skin appendages, such as hair 
follicles and sweat glands (Moser et al. 2001). Molecules with adequate solubility in 
water and oil, with a log of oil/water partition coefficients between 1 and 3 (Mitragotri 
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et al. 2011) and a molecular weight lower than 0.6 kDa (Alnasif et al. 2014; El 
Maghraby, Williams, and Barry 2001 (B)) may penetrate through the skin. Therefore, 
topical administration is limited to hydrophobic and low-molecular weight drugs. 
Because most anticancer drugs are hydrophilic (like bleomycin), have low oil/water 
partition coefficients, high molecular weights and ionic characters, they do not easily 
penetrate the stratum corneum (Simonetti et al. 2009).  
  
1.12 UD liposomes for skin penetration  
 
Conventional liposomes are composed mainly of phospholipids (section 1.9.1). 
Liposomes formed with different components have been developed in an attempt to 
ameliorate the stability of the vesicles and their ability to penetrate through different 
membranes, especially the stratum corneum. Thus, elastic liposomes, also called UD 
or flexible liposomes were developed (Fleury and Vianna Lopez 2011). Conventional 
liposomes have limited ability to pass through skin layers and are deposited in the 
outermost cutaneous layer, whereas UD liposomes can penetrate intact skin, carrying 
therapeutic concentrations of drugs through the skin but only when applied under non-
occluded conditions(Cevc and Blume 1992). Elastic liposomes were the first 
generation of elastic vesicles introduced by Cevc and Blume (1992) with an average 
particle size of 140.6 ± 19 nm. Their novel composition includes an edge activator 
added to phospholipid bilayers. An edge activator is often a single chain surfactant, 
having a high radius of curvature, that destabilizes lipid bilayers, increasing the 
deformability of the vesicle (Cevc et al. 1998; Cevc and Blume 2001; Honeywell-
Nguyen and Bouwstra 2003(A)). Edge activators include sodium cholate, sodium 
deoxycholate, Span 60, Span 65, Span 80, Tween 20, Tween 60, Tween 80 and 
dipotassium glycyrrhizinate (Cevc et al. 1998; El Maghraby, Williams, and Barry 
2001 (B)). Several studies investigated the likely mechanism by which flexible 
vesicles could improve delivery of drugs through the skin. Two mechanisms were 
proposed (Honeywell-Nguyen and Bouwstra 2003 (B)). First, vesicles can act as drug 
carrier systems, whereby intact vesicles enter the stratum corneum carrying vesicle-
bound drug molecules into the skin (mechanism 1). Second, vesicles can act as 
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penetration enhancers, whereby vesicle bilayers enter the stratum corneum and 
subsequently modify the intercellular lipid lamellae. This will enable the penetration 
of free drug molecules into and across the stratum corneum (mechanism 2) (figure 
1.7).  
In more detail, the first mechanism was put forward by Cevc and colleagues for UD 
liposomes (Cevc, Schätzlein, and Richardsen 2002). They claimed that intact UD 
liposomes penetrated through the stratum corneum, under the influence of the 
naturally occurring transcutaneous hydration gradient (Cevc and Blume 2001). The 
driving force for UD liposomes penetration into the skin is xerophobia: the tendency 
of phospholipids to avoid dry surroundings (Cevc and Blume 2001). To remain fully 
swollen, UD liposomes need to move into the more hydrated layers of skin (epidermis 
and dermis), and this movement is driven by the hydration gradient across the layers 
of the skin, therefore UD liposomes can penetrate the intact skin because of their high 
deformability (Romero and Morilla 2013). In contrast, conventional liposomes 
become dehydrated and fuse to the dry surface of the stratum corneum and are able to 
only lie on the upper layers of this external surface, and do not pass beyond the first 
micron of the skin. UD liposomes are sensitive to the transdermal hydration gradient 
and can also exploit virtual channels in the skin barrier to enhance their penetration. 
These channels are also known as hydrophilic pores through which water can 
evaporate (Cevc, Schätzlein, and Richardsen 2002).  
Mechanism 2 suggests that UD liposomes can enhance general penetration of 
encapsulated drugs through the skin. Verma et al (2003) found that these vesicles were 
able to carry both the entrapped and the non-entrapped hydrophilic fluorescent 
compound, carboxyfluorescein, into the stratum corneum and possibly to deeper 
layers of the skin, suggesting a penetration enhancing effect (Verma et al. 2003). 
However, in this study, the authors treated skin with carboxyfluorescein encapsulated 
in UD liposomes and with UD liposomes and free carboxyfluorescein outside of the 
vescicles. They observed that, when entrapped in UD liposomes, carboxyfluorescein 
penetrated into deeper skin layers than did when it was applied in its free form, 
separated by the UD liposomes. This might confirm the hypothesis of intact vesicle 
permeation, although the total amount of encapsulated carboxyfluorescein that 
penetrated into deeper skin layers and into the receiver compartment did not exceed 
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0.2% of the applied dose (Verma et al. 2003). In another study, flexible liposomes 
with ketotifen only on the outside of the vesicles significantly improved ketotifen skin 
permeation and deposition over deformable liposomes with ketotifen entrapped inside 
the vesicles, suggesting that the penetration enhancing effect may be of greater 
importance in the enhanced skin delivery of ketotifen by deformable liposomes 
(Elsayed et al. 2006).  
  





Figure 1.7  Schematic representation of the two mechanisms of action of UD liposomes through the 
skins layers. On the right, the representation of the mechanism number 1 and on the left the mechanism 




Overall, the current experimental evidence suggests that both mechanisms may play a 
role in the enhanced skin penetration of drugs delivered using UDs. Closely related to 
this subject is the mechanism of drug release from vesicles. Entrapment might result 
in slow transdermal flux and suboptimum permeation. Once released, drug diffusion 
in skin must occur; thus, the fate of the released drug is dependent on its solubility in 
the tissue (Romero and Morilla 2013).  
In summary, liposomes have been shown to be an innovative method to carry the 
entrapped drug to the target tissue and it appears that UD liposomes may enable their 
cargo to penetrate through the skin. However, the exact mechanism of improved skin 
penetration of entrapped drugs is still poorly elucidated and some reports describe 
liposome instability and drug leakage during the storage period (Fleury and Vianna 
Lopez 2011). In vivo experiments on patients should be performed to demonstrate the 
potential of flexible liposomes loaded with different anticancer drugs for topical skin 
cancer treatment (Fleury and Vianna Lopez 2011). 
 
1.13  Preliminary evidence on the efficacy of Bleosome in 
vitro 
 
Despite the potential clinical benefits of encapsulating bleomycin in UD liposomes, 
only a few studies have been conducted to test the efficacy of this novel formulation 
in vitro. 
Arndt et al (2001) found that the encapsulation of bleomycin into liposomes strongly 
enhanced its antitumor activity against P388 leukemia and the Lewis lung carcinoma 
cell lines in vitro, and that its activity was comparable for liposomal and free drug in 
the B16 melanoma cells (Arndt et al. 2001). Another study investigated the effect of 
liposome composition on the cytotoxic efficacy of bleomycin against Daudi cell line 
from Burkitt’s lymphoma, and showed that the efficacy of this formulation relied on 
the composition of liposomes, comparing fusogenic, flexible and pegylated vesicles 
(Alomrani et al. 2011). Furthermore, Chiani et al (2017) demonstrated that the 
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bleomycin encapsulated in PEG liposomes had lower toxicity compared to the free 
drug against TC-1 (mouse lung) and HFLF-P15 (human fetal lung fibroblasts) cells, 
but the cytotoxicity against LLC1 cells was significantly higher than that of 
unencapsulated bleomycin (Chiani et al. 2017). Furthermore, bleomycin entrapped in 
UD liposomes can effectively target SCC cell line in vitro (Lau et al. 2005). 
These studies confirm the retained efficacy in killing cancer cell lines of liposomal  
bleomycin, compared to the free form, however they also highlight that there is still a 
the lack of consensus in literature about the different mechanism of action of free and 
encapsulated bleomycin. Moreover, they valide, the hypothesis of a cell-type 
dependent response to the treatment, and of the importance of the type of nanocarriers 
used for the delivery of bleomycin, according to the lesion to target. Further efforts are 
required to elucidate the molecular mechanisms triggered by Bleosome in particular 
cell lines, in order to improve the formulation of the compound and to potentially target 
mechanisms of resistance to bleomycin treatment. 
 
1.14 Preliminary evidence on the clinical efficacy of 
Bleosome  
 
Pilot studies have been conducted to determine the efficacy of Bleosome as topical, 
non-invasive therapy for NMSC. Firstly, Chopra and colleagues encapsulated the 
bleomycin in a film of UD liposomes and they checked the particle size and the 
entrapment efficiency of the novel composition over a time course (S. Chopra, 
personal communication).  The size of the nanoparticles were stable up to 40 days, and 
thereafter began to slightly increase in size, going from initial 200 nm to 230 nm; 
however, this increase was low compared to the placebo formulation of liposomes, 
used as control, whose dimension increased up to 500 nm. When the entrapment 
efficacy was checked, the liposomal bleomycin relative entrapment curve indicated a 
loss of 50% of the original concentration of bleomycin (1mg/ml at day 0) within the 
liposomes at day 15. Following day 15, the curve continued downwards, showing a 
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gradual decrease to almost a fifth of the original concentration (0.53mg/ml to 
0.11mg/ml) and the amount of the bleomycin outside the liposomes increased from 
0.52 mg/ml to 0.65 mg/ml. In percentage, the amount of bleomycin in the liposome on 
day 13 was 45.5%, which subsequently decreased to 16.7% on day 69, resulting in a 
loss of 38.8% of active principle over 56 days (S. Chopra, personal communication). 
Chopra et al (in preparation) performed a pilot study on the clinical application of 
Bleosome, treating 60 named patients bearing NMSC including large BCCs, facial 
keratoachantoma and multiple actinic keratosis and reported 100% positive response 
to the treatment, with 97% of clearance rate, and concluded that Bleosome was well 
tolerated, painless, cost-effective and easy to apply (S. Chopra, unpublished data).  
Furthermore, a study on the efficacy of Bleosome on equine sarcoids compared the 
efficacy of 5-FU or tazarotene alone and in combination with the topical application 
of Bleosome, and found that, the combination of treatments resulted in a much-
improved outcome, and demonstrated the lack of side-effects of the liposome-
encapsulated bleomycin, when administered topically to equine patients (Knottenbelt 




Skin cancer is the most common type of cancer affecting Caucasian populations. It 
has a very high rate of incidence, exceeding the sum of all other cancers combined  
(Simonetti et al. 2009). NMSC are not fatal but can destroy facial sensory organs such 
as the nose, ear and lips (Alam et al. 2011). Ideally, these lesions should be treated 
using non-invasive techniques.  
There are some well-established treatments for NMSC, such as curettage, surgery, 
cryotherapy and chemotherapy. However, these conventional treatments lead to 
severe inflammation, pain and unappealing scars in human medicine (Lopez et al. 
2004). Whereas in veterinary medicine the most common treatments involve 
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sometimes destructive surgical techniques. Moreover, pets must undergo general 
anaesthetic in the majority of the cases (Amadori and Marconato 2012). 
To increase patient compliance and to reduce surgical costs and undesirable scars, the 
topical administration of anticancer drugs has been investigated. The topical 
administration of anticancer drugs is an interesting alternative for reducing side effects 
and for increasing drug targeting and therapeutic benefits (Fleury and Vianna Lopez 
2011). Bleomycin is a potent anticancer agent that is able to induce SSB and DSB in 
DNA. It has proved to be effective against several types of tumours, including 
cutaneous ones. Because of its molecular characteristics (polar charge, high molecular 
weight, and system of cellular uptake) it is unable to freely cross the plasma membrane 
and efficiently reach the site of action. Treatment with high dose of bleomycin, also 
leads to severe side-effects, limiting its clinical application.  
To address these issues, in the recent years, there has been an increasing interest in the 
development of new topical administration of bleomycin. Bleomycin administered 
through ECT regimen carried excellent outcome in the management of skin tumours, 
and the common target tumours in both veterinary and human medicine were NMSC. 
However, this technique can be invasive and may require a general anaesthetic.  
For this reason, this study is focused on exploring the potential of Bleosome, a novel 
topical compound composed of bleomycin encapsulated in UD liposomes, as 
innovative non-invasive treatment for NMSC in veterinary and human medicine.  
UD liposomes have the power to effectively ameliorate the drugs cellular uptake, to 
carry polar molecules through the skin, and to diminish the negative side effects of 
systemic chemotherapy. Moreover, it is likely that they act selectively in the tumour 
site. Despite this therapeutic potential there are few studies on the effectiveness of 
bleomycin encapsulated into liposomes in vitro.   
We hypothesise that coupling UD liposomes with the potent anticancer agent 
bleomycin, it may improve the tumour targeting, lessen adverse reactions and create 
a non-invasive method to cure skin tumours in both humans and animals. 
Experimental skin penetration study in vitro, ex vivo and in vivo will enable a mutli-
layer understanding of the effective power of this new bleomycin formulation, the 
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extent of skin penetration and the efficacy against NMSC. This study may potentially 
impact veterinary and human medicine. Furthermore, NMSC as first class of target 
tumours may be the starting point in the effective management of skin cancers, as 
bleomycin had proven to be efficient against a wide type of tumours, including 
lymphoproliferative disorders and MCTs.  
 
1.16 Rationale of the study: hypotheses and objectives 
 
NMSC are very common tumours in humans and companion animals. Clinical 
challenges are often associated with definitive treatment of NMSC in veterinary 
species, and the management of this class of tumours often involves destructive and 
painful therapeutic interventions. Bleomycin encapsulated within UD liposomes is a 
promising novel minimally invasive anti-cancer therapy. Considering the similar 
clinical and pathological features of human and animal NMSC, veterinary patients 
could not only benefit from this easy and safe treatment, but also represent a 
comparable model for translating the application of the Bleosome into human 
medicine. 
 
This PhD study aimed to test the following hypotheses:  
1. Bleomycin is a large and hydrophilic molecule, which is not able to freely pass 
through cellular membrane and skin barrier. Hence, we propose that UD 
liposomes will facilitate and highly improve the penetration of the entrapped 
bleomycin through plasma membrane and through several layers of the skin. 
2. Bleosome is comparable to the efficacy of bleomycin against several types of 
tumour.   
3. Bleomycin acts in a tumour-type dependent manner and that is due to cell-type 
dependent response to bleomycin treatment.  
4. Bleosome will enable the penetration of the active principle into the target 
cutaneous cancer lesion and avoid the systemic toxicity. 
 
The objectives to be addressed in this PhD are: 
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1. To investigate the ability of Bleosome to penetrate through human, canine and    
equine skin and cellular membrane, and to determine the underlying mechanism 
driving penetration of Bleosome through the skin.  
2. To determine the efficacy of Bleosome in inhibiting the cell viability in a panel of 
canine, feline and human cancer cell lines in vitro.   
3. To investigate the signalling pathways and mechanisms activated at the molecular 
level in cancer cells in response to Bleosome treatment. 
4. To clinically evaluate the efficacy and safety of Bleosome as topical therapy in 
















Chapter 2 Materials and methods 
 
2.1 General materials and methods 
 
General reagents, solutions and buffers are listed in Appendix 1 Buffers and Solutions. 
Phosphate buffered saline (PBS) was prepared by the Central Service Unit at the 
Roslin Institute (Midlothian, UK). Unless stated otherwise, cells were grown in T25, 
75 and T175 cell culture flasks for adherent cells (Thermo Scientific, Paisley, UK). 
Falcon tubes (15 and 50 ml) were from Greiner Small 0.5 and 1.5 ml tubes were from 
Eppendorf (Loughborough, UK). Pipette tips were form Starlab. Centrifugations of 0.5 
and 1.5 ml tubes were completed using the centrifuge 5415R (Eppendorf, 
Loughborough, UK) and 15 and 50 ml tubes using the 5810R (Eppendorf, 
Loughborough, UK). Reagents were weighed using a L2200S+ or BP210D balance 
(Sartorius, Goettingen, DE). 
 
2.1.1 Cell lines 
 
Six cell lines were used for this study. CML10 is a canine melanoma cell line, 
characterised and kindly provided by Lauren Wolfe (Auburn University, USA). 
REM134 and MCF7 are canine and human mammary carcinoma respectively, the first 
was characterised by Else et al (1982) (Edinburgh, UK) and the second was purchased 
from European Collection of Authenticated Cell Cultures (ECACC) (UK). C2 is a 
canine mastocytoma cell line with KIT tandem duplication of a 48bp sequence 
variation (reference: RRID:CVCL_1R44) (CA, USA). SSCF1 and SMG cell lines are 
both derived from feline squamous cell carcinoma (SCC), the first was characterised 
from a laryngeal lesion by T.J. Rosol (Ohio State University, USA) and the latter from 
an oral SCC carcinoma, by Erika Abbondati (The University of Edinburgh, UK). 
REM134 and MCF7 cells were grown in in Dulbecco’s modified Eagle’s medium 
(DMEM) (high glucose (HG) (ThermoFisher Scientific, Paisley, UK ), while CML10 
was grown in DMEM low glucose (LG), both supplemented with 10% foetal bovine 
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serum (FBS) and 1% penicillin/streptomycin (ThermoFisher Scientific, Paisley, UK). 
SMG and SSCF1 cells were grown in DMEM –HG (ThermoFisher Scientific), 
supplemented with 10 ng/ml EGF.                                                                                                                                         
C2 cells were grown is Eagle DMEM (ThermoFisher Scientific) supplemented with 
5% FBS,1% Non-essential amino acid, 1% Glutamax and 25 mg of Gentamicin. All 
cell cultures were maintained at 37°C in a humidified 5% CO2 incubator. 
 
2.1.2 Thawing cells 
 
Cells were revived from frozen vials kept at -180°C. Cells were quickly defrosted in a 
37°C water bath, transferred into a falcon tube containing 4 ml of warmed cell culture 
media and centrifuged at 5000 g for 5 minutes. The supernatant was discarded and the 
cell pellet re-suspended in 6 ml of warmed cell culture media before transfer into a 
T25 cell culture flask. Cells were incubated until ~ 80% confluence in a humidified 
37°C, 5% CO2 incubator and transferred to a T75 flask for further culture as described 
above. 
 
2.1.3 Passaging cells 
 
Cells were routinely passaged at 70 - 100% confluency every 4-5 days (REM134, 
MCF7, C2, CML10, SMG, SCCF1). To passage cells, cell culture media was removed 
and cells were washed twice with 5 ml of PBS. Cells were then incubated with 1-3 ml 
of 0.25% Trypsin-EDTA (ThermoFisher Scientific, Paisley, UK) at 37°C 5% CO2 for 
5-15 minutes until detached. Trypsinization was terminated by adding at least twice 
the trypsin volume of cell culture media containing FBS to the cells and washing well 
to ensure efficient cell collection. Cells were seeded at the required cell number into 




2.1.4 Counting cells 
 
A haemocytometer was used to manually count cells. Following trypsinization as 
described in section 2.1.3, the cell suspension was centrifuged at 500 g for 5 minutes 
and the pellet resuspended in 1 ml of PBS. The cell suspension was mixed in a 1:1 
ratio with Trypan Blue stain (ThermoFisher Scientific, Paisley, UK) and added to the 
counting chamber of the haemocytometer. Live cells (not stained blue by Trypan stain) 
were counted in the 5 x 5 square counting chamber and the total cell number was 
calculated by the following formula: 
 
Cells / ml = (Number of cells in 5 x 5 counting chamber ✕ 2 (dilution factor)) ✕ 104 
 
2.1.5 Freezing cells 
 
Cells were grown to near confluency (~ 90%), trypsinised, and the total number of 
cells calculated as above. Each cell line was frozen down at approximately 3 x 106 
cells in 0.5 ml of freezing media per cryogenic vial. The cell suspension was 
centrifuged at 500 g for 5 minutes and re-suspended in the appropriate volume of 
freezing media. The cell suspension was then aliquoted into cryogenic vials, placed 
into a Mr Frosty™ freezing container (ThermoFisher Scientific, Paisley, UK) (which 
contains 100% isopropyl alcohol for a steady freezing rate of 1°C per minute) and 
frozen in a -80°C freezer for at least 12 hours. Vials were then transferred to a -180°C 
freezer for long-term storage. 
 
2.1.6 Harvesting cells 
 
To harvest adherent cells, cell culture media was removed and cells were washed twice 
with chilled PBS. Depending on the size of the cell culture vessel, cells were then 
scraped with a cell scraper in 200 μl to 1 ml of ice-cold PBS (6 well plate to T75 flask) 
and collected in 1.5 ml Eppendorf tubes. The cell suspension was centrifuged at 1500 
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g for 3 minutes at 4°C. The supernatant was discarded and the cell pellet was snap 
frozen on dry ice and stored at -80°C. 
 
2.1.7 Cell lysis 
 
To lyse harvested cell pellets, 2-3 times the volume of urea lysis buffer (Appendix 1, 
Buffers and Solutions) was added to the frozen cell pellet (no more than 100 μl per 
pellet). The mixture was pipetted up and down until all particles of the cell pellet were 
dissolved, and the lysate solution was incubated on ice for 30 minutes. The solution 
was centrifuged at 13000 g for 10 minutes at 4°C. The supernatant (cell lysate) was 
transferred to a new tube, snap frozen on dry ice and stored at -80°C.  
 
2.2 Cytotoxic drug treatment 
 
Bleosome 0.2% is a compound containing bleomycin encapsulated in Ultra-
Deformable (UD) liposomes designed to be delivered topically. Bleomycin aqueous 
solution (cream) 0.2% is made by bleomycin dissolved in aqueous solvent in the form 
of cream. Bleovet 0.2% is made by bleomycin dissolved in aqueous solvent in the form 
of gel. All the formulation were manufactured and provided by Ascot Laboratories 
LTD, London, UK. Bleosome and bleomycin aqueous solution were supplied in a 
cream, and Bleovet in a gel form containing 1.32221 mM (2mg/ml) of active principle 
(bleomycin). All compounds were stored at 4°C (fridge temperature) before and after 
use.  
 
2.2.1 Cell viability assay 
 
The CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega, Madison, USA) 
was used to determine the viability of cells after treatment with indicated titrations of 
Bleosome and bleomycin aqueous solution. The kit determines the number of viable 
cells in culture based on the quantity of ATP present. A luminescent signal is produced 
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proportional to the amount of ATP present, which is directly proportional to the 
number of viable cells. Experimentally, cells were trypsinised and seeded as single 
cells in opaque 96-well plates (Corning, CA, USA) at 500 cells per well and incubated 
for 24 hours. Then, either serial dilutions of Bleosome and aqueous cream bleomycin 
were added in triplicate wells. Cell viability was measured 72 hours post-treatment. 
According to the manufacturer’s instructions, the CellTiter-Glo® Substrate and 
CellTiter-Glo® Buffer were thawed at room temperature and mixed in a 1:1 ratio into 
a homogenous solution by inverting to form the CellTiter-Glo® Reagent. The 96–well 
cell culture plate was allowed to equilibrate to room temperature for 30 minutes prior 
to the addition of 100 μl of CellTiter-Glo® Reagent to each well. An ATP standard 
curve was produced in the same 96-well cell culture plate. ATP concentrations used to 
form the standard curve were 10 μM, 1 μM, 100 nM and 10 nM. CellTiter-Glo® 
Reagent is also added to the ATP standard wells. The cell culture plate was mixed for 
2 minutes on an orbital shaker and incubated at room temperature for 10 minutes. 
Luminescence was recorded for 1 second per well by a spectrophotometer (WPA 
Biowave, Biochrom, Massachusetts, USA) using the Viktor3 software. Data was 
averaged and normalized against the average signal of vehicle control treated samples 
and a dose-response curve was produced. 
 
2.2.2 Colony formation assay 
 
To determine colony forming ability, cells were trypsinised into single cells and seeded 
at 1000 cells / 10 cm plate (CML10) or at 500 cells / 10 cm plate (REM134). Three 
concentrations of Bleosome and aqueous cream bleomycin were added to media 
immediately after cell seeding. Plates were incubated at 37°C in humidified 5% CO2 
incubator for 10-14 days. When colonies were visible, media were removed, and the 
cells were washed twice in PBS. Five ml of cold methanol were then added to each 
plate and incubated at RT for 5 minutes. The methanol was removed, and 10 ml of 
10% Giemsa stain (Sigma-Aldrich, USA) was used to stain the colonies for 20 
minutes. The plates were rinsed thoroughly in tap water and air-dried. For each 
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concentration tested, plates were set up in triplicate. The total number of colonies was 
manually counted and the average number of colonies for each condition calculated.  
 
2.3 Protein analysis 
 
2.3.1 Protein quantification – Bradford assay 
 
A Bradford Assay was used to quantify total protein concentration of samples. Briefly, 
a 1:5 dilution is made of each cell lysate sample at the point of lysing. In a 96-well 
plate, 5 μl of the 1:5 cell lysate sample is transferred to a well, with each sample tested 
in triplicate. As a control 1 μl of each BSA standard solution (0.125, 0.25, 0.5, 1, 2 and 
4 mg/ ml) was assayed, also in triplicate at the same time. To each well containing a 
sample, standard and to three blank wells, 250 μl of Quick Start™ Bradford 1x Dye 
Reagent (Bio-Rad, Watford, UK) was added and mixed well. After 5 minutes, the plate 
was read for absorbance (optical density at 560 nm) using a spectrophotometer (WPA 
Biowave, Biochrom) using the Viktor3 software (PerkinElmer). A standard curve was 
produced by plotting the standards (a linear relationship was determined). The 
equation of the line was used to calculate the concentration of the samples.  
 
2.3.2 Western blotting by SDS page 
 
Proteins were resolved based on their molecular weight by SDS polyacrylamide gel 
electrophoresis (SDS PAGE) (Laemmli 1970), transferred to Amersham™ Hybond-
C™ nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK) 
and hybridised to an appropriate primary antibody and HRP-conjugated secondary 
antibody for subsequent detection by enhanced chemiluminescence (Amersham™ 





2.3.3 Gel preparation 
 
The polyacrylamide gels were prepared and assembled using the Biorad Protean II 
mini-gel system. Cover slips and 1 mm spacer plates were cleaned with 70% ethanol 
and the casting frame was assembled. The plates were checked for leaking by 
incubating with water for 5 minutes and emptying. The resolving gel was prepared by 
combining 6 or 12% acrylamide (depending on the size of the protein of interest), 
along with 5% stacking gels, Resolving gel was made up using 30% acrylamide/ 0.8% 
bisacrylamide solution (National Diagnostics, USA), 1.5 M Tris-HCl pH 8.8 and 10% 
SDS at 10 ml per gel and the stacking gel by combining 30% acrylamide, 1.5 M Tris-
HCl pH 6.8 and 10% SDS at 5 ml per gel (refer to table 2.1 for recipes). When ready 
to pour the resolving gel, 10% ammonium peroxidisulphate (APS) and TEMED 
(tetramethylethylenediamine, Signma-Aldrich, Gillingham, UK) were added to the 
resolving gel, which initiates polymerisation. Approximately 7 ml of resolving 
solution was poured to 2/3 of the height of Mini-Protean glass plates and isopropanol 
was added on top to remove air bubbles. The gel was allowed to set at room 
temperature for approximately 20 minutes. The isopropanol was then removed and the 
stacking gel preparation was completed by adding 10% APS and TEMED. The 
stacking gel was then dispensed on top of the resolving gel (approximately 3 ml) and 
a comb was immediately inserted. The gel was allowed to set at room temperature for 
approximately 20 minutes. Once set, the gel was removed from the casting frame and 
the comb was gently removed. The wells were washed gently with dH2O from a water 
bottle, placed into a running module and immersed in SDS-PAGE running buffer prior 










For 10 ml resolving gel: 
Solution component Volume for 6% 
gel (ml) 
Volume for 12% 
gel (ml) 
H2O 5.3 3.2 
30% acrylamide 2.0 4.0 
1.5 M Tris-HCl pH 8.8 2.5 2.6 
10% SDS 0.1 0.1 
10% APS 0.1 0.1 
TEMED 0.008 0.004 
        
For 5 ml stacking gel 
Solution component Volume for 5% 
gel (ml) 
H2O 3.4 
30% acrylamide 0.83 
1.5 M Tris-HCl pH 6.8 0.63 
10% SDS 0.05 
10% APS 0.05 
TEMED 0.005 
 
Table 2.1 SDS-PAGE resolving and stacking gel recipes. Recipes for producing 10 ml resolving gels 
and 5 ml stacking gels for SDS-PAGE western blotting. The percentage of the resolving gel was chosen 
based on the size of the protein of interest; for small proteins, a higher percentage gel was used and 
vice versa. Stacking gels were always produced as 5%. 
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2.3.4 Protein sample loading 
 
The concentration of protein in each sample had been previously determined by a 
Bradford assay (see above). The protein samples were prepared by adding the 
appropriate volume of 4 x SDS sample buffer (see Buffers and Solutions appendix for 
recipe. 1 M DTT is added to 4 x SDS sample buffer prior to mixing with samples in a 
1:4 ratio) to cell lysates (volumes calculated from the Bradford assay). Prior to loading, 
each sample was heated to 100°C for 2 minutes to denature the proteins. Each sample 
was loaded into wells in the stacking gel at 10 μl of sample per well. The size standard 
used was Precision Plus Protein Dual Colour (5 μl, Bio-Rad, Watford, UK) was loaded 
into 1 well at 10 μl. The gel was subject to electrophoresis at 120 V for approximately 
75-90 minutes. 
 
2.3.5 Protein transfer to nitrocellulose membrane 
 
One piece of 10 cm x 5 cm Amersham™ Hybond-C™ nitrocellulose membrane 
(Amersham Pharmacia Biotech) was prepared per gel, along with 2 pieces of blotting 
paper at 10 cm x 6 cm per blot. A shallow dish was half filled with 1 x transfer buffer 
and 2 sponges are soaked along with the blotting paper. A transfer cassette was placed 
into the shallow dish black side down and assembled as follows: 1 sponge, 1 piece of 
blotting paper, the gel, the nitrocellulose membrane, 1 piece of blotting paper and 1 
sponge. The gel was removed from the electrophoresis module when the run was 
completed and the glass plates separated to remove the gel by inserting a wedge and 
lifting gently. The stacking gel was discarded and the resolving gel was removed from 
the glass plate and placed gently on the blotting paper soaking in transfer buffer. The 
remaining layers of membrane, blotting paper and sponge were added on top and the 
bubbles between the layers were removed by rolling a 15 ml falcon tube over the top 
sponge. The cassette was closed and inserted into a transfer holder, ensuring the black 
side of the cassette faces the black side (cathode) of the holder. An ice block was 
inserted into the holder and the module was filled with 1 x transfer buffer. The transfer 





The nitrocellulose membrane was removed from the transfer cassette and checked for 
protein marker transfer. The membrane was placed into a square petri dish and stained 
using Ponceau red (Ponceau S Sigma-Aldrich, CA, USA), 0.5 g dissolved in 1 ml 
glacial acetic acid) for 30 seconds with rotation. The membrane was washed with 
distilled water until the bands were visible, then, washed with PBS Tween (0.1%) 2 x 
5 minutes.  Subsequently, the membrane was blocked for non-specific antibody 
binding by incubating with 5% milk for 1 hour at RT. After blocking, the membrane 
was probed with primary antibody diluted in blocking agent (3 ml per membrane) 
overnight at 4°C and washed for 3 x 5 minutes in PBS Tween. After washing, the 
secondary antibody conjugated to horseradish peroxidase (HRP) was diluted in 
blocking agent at 10 ml per membrane and incubated at room temperature for 1 hour 
on an orbital shaker. Finally, the blot was washed 3 x 15 minutes in PBS Tween. See 
Table 2.2 for antibody dilutions. 
 
2.3.7 Chemiluminescent protein detection 
 
After washing, the membrane was subject to chemiluminescent protein detection. The 
Amersham™ ECL™ reagents (GE Healthcare) were combined in a 1:1 ratio at 2 ml 
per blot and incubated on the membrane for 1 minute at room temperature. The excess 
reagent was removed and the membrane covered with clingfilm (Saran), ensuring no 
bubbles. In the dark room, the membrane was exposed to a radiograph film (GE 
Healthcare) for 30 seconds to 30 minutes (depending on the protein being detected) 
inside a closed cassette. The film is then developed using the X-Ograph SRX-101A 
developer and the resultant film shows bands of protein that can be aligned with the 








2.3.8.1 Primary antibodies 
 
All primary antibodies are listed in table 2.2, including the final dilution used for 
immunoblotting and the suppliers. 
Target protein Clonality Supplier Dilution 
ATM (D2E2) Rabbit monoclonal Cell Signaling 1:500 
BLMH (ab188371) Rabbit polyclonal Abcam 1:500 
BRCA1 C-terminal (ab191042) Rabbit polyclonal Abcam 1:500 
DNA PKs [Y393] (ab 32566) Rabbit monoclonal Abcam 1:1000 
Gamma H2A.X (phosphoS139) 
antibody [9F3] (ab26350) 
Mouse monoclonal Abcam 1:500 
Ku70 + Ku80 C-terminal  
(ab 166822) 
Rabbit polyclonal Abcam 1:250 
P21 (R.229.6) Rabbit monoclonal ThermoFisher 1:500 
P53 Rabbit monoclonal ThermoFisher 1:1000 
Rad51 [EPR4030(3)] 
(ab133534) 
Rabbit monoclonal Abcam 1:500 
Phospho ATM (Ser1981) 
(D6H9) 
Rabbit monoclonal Cell Signaling 1:500 
Phospho-p53 (Ser15) (16G8) Mouse monoclonal Cell Signaling 1:500 
Beta Actin [AC-15] (ab6276) Mouse monoclonal Abcam 1:5000 
Table 2.2 Table of antibodies. List of primary antibodies used in this study. The clonality, supplier 
and dilution of each primary antibody are listed.  
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2.3.8.2 Secondary antibodies 
 
Secondary antibodies were HRP-conjugated swine anti-rabbit IgG and rabbit anti-
mouse IgG (Dako, Agilent Technologies, CA, USA). Both of them were diluted 
1:1000. 
 
2.4 Quantitative real-time polymerase chain reaction 
(RT-qPCR) 
 
2.4.1 Primer design 
 
Primers were designed against BLMH, ATM, RAD51, BRCA1, PRKDC, XRCC4.  
GAPDH was used as a reference gene (see Table 2.3 for details of primers). All DNA 
oligonucleotides were purchased from Eurofins MWG Operon. Canine specific 
primers were designed based on the canine specific gene sequences obtained from the 
Ensembl genome browser (http://www.ensembl.org/Canis_familiaris/Info/Index/). 
The entire transcript was uploaded to Primer3Plus online program 
(https://primer3plus.com/cgi-bin/dev/primer3plus.cgi), with introns annotated. Primer 
sequences were selected based on: proximity to 3’ end of sequence, spanning large 
introns, avoiding multiple G and C nucleotide repeats, low GC% and a Tm near 60°C. 
The parameters mentioned were quantified using the “general settings” tool of the 
program. To ensure the specificity of selected sequences for the genes of interests, 
forward and reverse primers were then uploaded in the “BLAST/BLAT” command of 
the Ensembl genome browser, searching against canine genome. All primers were 
delivered as lyophilised powders and were resuspended in nuclease free water to a 






Table 2.3. Primer sequences. The primers utilised in this study for each gene are described above. 




2.4.2 Primer efficiency testing 
 
Serial dilutions of cDNA were mixed from stock to 1:1000 and reactions were 
performed in technical triplicate with each primer set. The efficiency was calculated 
according to the Pfaffl method, where cycling threshold values were plotted against 
the cDNA dilution, and the slope of the graph calculated. Efficiency (E) was calculated 
by: 
 
E = 10 -1/slope 
 
Efficiency values of approximately 2.00 are required as the comparative ΔΔCt method 
of data analysis utilised here assumes efficiency of 100% (i.e. a single doubling of the 
template for each reaction cycle). 
Gene For 
 primer sequence Reverse primer sequence 
2.4.3 RNA extraction 
 
RNA was extracted from C2 and CML10 cell lines treated with Bleosome according 
to chapter 4. Lysates were prepared as described in 2.1.7. The supernatant was 
removed from the harvested cell pellet, the pellet was loosened by flicking the tube 
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and the cells were resuspended in Buffer RLT (350 μl for < 5x106 cells or 600 μl for 
5x106 – 1x107 cells). The cell lysate was mixed by pipetting or vortexing and 
homogenised by processing through a QIAshredder spin column (Qiagen, CA, USA) 
and centrifuged for 2 minutes at 16,100 g One times volume of 70% ethanol was added 
to the homogenised lysate and mixed by pipetting. Up to 700 μl of sample was 
transferred to an RNeasy spin column in a 2 ml collection tube and centrifuged for 15 
seconds at ≥ 11,200 g. The flow through was discarded. DNase digestion was 
completed by adding 350 μl of Buffer RW1 to the RNeasy spin column and 
centrifuging for 15 seconds at ≥ 11.200 g to wash the membrane. DNase 1 stock 
solution (Qiagen, CA, USA) was diluted in Buffer RDD (10 μl: 70 μl respectively) 
and the DNase mixture was added to the RNeasy spin column and incubated for 15 
minutes at RT. Buffer RW1 (350 μl) was added to the RNeasy spin column and 
centrifuged for 15 seconds at ≥ 11,200 g.  Buffer RPE (500 μl) was added to the 
RNeasy spin column and centrifuged for 15 seconds at ≥ 11, 200 g, then repeated for 
a longer spin (2 minutes at ≥ 11,200 g). The RNeasy spin column was placed into a 
new 2 ml collection tube and centrifuged for 1 minute at 16,100 g. To elute the RNA, 
30-50 μl of RNase free water was dispensed onto the RNease spin column and 
centrifuged for 1 minutes at ≥ 11,200 g into a new 1.5 ml RNase free collection tube. 
A Nanodrop (NanoDrop™ 2000/2000c Spectrophotometer Thermofisher Scientific, 
Paisley, UK) was used to measure the yield of RNA from each extraction, and the 
A260:A280 ratio as a measure of contamination in the samples. Ratios of 
approximately 2.0 were considered optimal. RNA was stored at -80°C until use. 
 
 
2.4.4 Reverse transcription 
 
RNA extracted from cells was reversed transcribed to cDNA using Omniscript 
Reverse Transcriptase (Qiagen, CA, USA). For each RNA sample, 7 μl of RNA was 
mixed with 10x Buffer RT (2 μl), 5mM dNTP mix (2 μl), 1 μM Oligo-dT primer (0.2 
μl), 5 units/μl RNase inhibitor (0.25 μl), Omniscript Reverse Transcriptase (1 μl), 
100μM dTT (2 μl) and RNase free water (5.55 μl) to give a total volume of 20 μl. The 
cDNA mixture was gently vortexed for no longer than 5 seconds, centrifuged briefly 
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to collect contents at the bottom of the tube and incubated for 60 minutes at 37°C. 
cDNA was stored at -20°C until use. 
 
2.4.5 RT-qPCR set up and analysis 
 
All RT-qPCR were performed using the Roche LightCycler® 480 instrument with 
LightCycler® 480 Multiwell Plate 96 according to the manufacturers protocol. The 
reactions were performed with QuantiNova™ Sybr® Green (Qiagen, CA, USA) 
master mix. Briefly, 20 μl reaction volumes were used; 12.5 μl of mastermix, 1 μl of 
primer mix (containing forward and reverse primers) 0.05 μl of ROX (for 
normalisation of fluorescent signals) and 6.45 μl of nuclease free water. The cycling 
conditions are summarised in Table 2.4. 
 
PCR step Temperature (◦C) Time Number of cycles 
PCR initial 
activation step 
95 2 seconds 1 
 95 5 seconds  
Amplification 60 11 seconds 40 
 72 5 seconds  
Melting curve 
analysis 
As machine As machine As machine 
Table 2.4 RT-qPCR cycling conditions. The cycling parameters for the Roche LightCycler® 480 that 
were used for RT-qPCR analysis are described. The temperature and length of time for each cycling 
step is stated, as is the number of cycles run per condition. 
 
All data analysis was performed by exporting .txt files of crossing point data from the 
Roche LightCycler® 480 software to Microsoft Office Excel 2011 (Microsoft 
Corporation). Statistical analysis was performed using Minitab© 16 Statistical 
Software (Minitab Ltd). Changes in gene expression between experimental samples 
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were analysed through relative quantitation using the Livak 2-ΔΔCt method. To 
measure the relative quantitation, reference gene was assayed alongside every reaction 
(GAPDH). This method assumes that the target and reference genes are amplified with 
efficiencies approaching 100% and within 5% of each other. The following steps were 
taken to calculate fold changes in gene expression: 
 
1. The ΔCt was calculated by subtracting the geometric mean of all reference gene 
crossing point values to the mean of the experimental crossing point values. This is 
performed for both the experimental samples and the reference control samples 
therefore x2 ΔCt values are obtained. 
2. The ΔΔCt values were calculated by normalising the ΔCt of the experimental 
sample to the reference sample. 
3. The gene expression ratios were calculated by raising the negative of the ΔΔCt 
above the power of 2 (2-ΔΔCt). 
4. The result is the fold change value of the target gene expression normalised to the 
internal calibrator provided by the reference gene. By using the internal calibrator 
variation in the amount of cDNA tested can be overcome. 
 
2.5 RNA sequencing using Next Generation Sequencing 
(NGS) 
 
2.5.1 RNA quality control 
 
All sequencing was performed by The University of Edinburgh sequencing service 
(Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, Edinburgh). 
Samples were prepared in labelled RNase free tubes. Samples were checked for quality 
by the Agilent 2200 Tapestation with the RNA analysis screen tape (Agilent) 
(Stockport, UK). This method provides an accurate and objective assessment of total 
RNA degradation as indicated by the RNA integrity number (RIN). The RIN is a 
software output that estimates the integrity of total RNA samples based on the entire 
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electrophoretic trace of the RNA sample rather than just the ratio of the ribosomal 
bands, 28S and 18S. This includes the presence or absence of degradation products. 
The assigned RIN is independent of sample concentration, instrument and analyst, and 
therefore it is considered a de facto standard for RNA integrity (Griffin et al. 2012). 
Concentrations of RNA within the samples were also assessed by fluorometric 
quantitation, using Qubit 4 Fluorometer (ThermoFisher Scientific, Paisley, UK ). 
Samples sent for sequencing fulfilled all the following requirements: RIN > 7; 
concentration >37 ng/ul; A260:280 >2, amount > 2200 ng, volume >60 ul (figure 2.1). 
Good quality and quantity of RNA is critical for obtaining optimal sequencing results. 
 
 
Figure 2.1  RNA-sequencing data quality analysis using RNA Integrity Number of some of the samples 




2.5.2 Library preparation for RNA sequencing 
 
Library preparation from mRNA before sequencing is necessary to obtain a clear view 
of the coding transcriptome with strand-specific information (Corney 2013). The 
mRNA library was prepared by The University of Edinburgh sequencing service 
(Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, Edinburgh) using 
Tru Seq Stranded mRNA Library Prep Kit (Illumina, CA, USA). Library preparation 
consists of the following steps: 
 
1. RNA fragmentation: mRNAs are typically fragmented to smaller pieces of RNA to 
enable sequencing. 
2. Reverse transcription: first and second strand cDNA is reverse transcribed from 
fragmented RNA using random hexamers or oligo(dT) primers. 
3. Adapter ligation: the 5' and 3' ends of cDNA are repaired, and adapters (containing 
sequences to allow hybridization to a flow cell) are ligated. 
4. Library clean-up and amplification: libraries are enriched for correctly ligated 
cDNA fragments and amplified by PCR to add any remaining sequencing primer 
sequences. 
5. Library quantification, quality control and sequencing: library concentration is 




Illumina RNA-sequencing uses a “sequencing by synthesis” (SBS) approach (Metzer 
et al., 2010). Libraries are denatured and undergo a process known as "bridge 
amplification" to create clonal clusters of single-stranded DNA molecules. Briefly, 
once the fragments attach on the flow cell, DNA is sequenced by adding polymerase 
resulting in a covalently bound full-length complementary copy of the cDNA 
fragment. The cDNA fragment obtained is subjected to several rounds of PCR 
amplification to produce clones that can be optically resolved during sequencing. 
Obtaining optimal cluster density is critical since it will determine the number of reads 
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obtained. Therefore, the cDNA is labelled with dNTPs (nucleoside triphosphate). Each 
of the dNTPs is labelled with a specific fluorescent colour. After laser excitation, 
different emitted fluorescent waves are recorded for each cluster. Based on the 
fluorescence emission the base of each cluster is identified and because the clusters 
contain identical DNA sequences the entire cluster is read as one base. A camera 
records these base reads across the entire flow cell. This takes place between 50 and 
100 cycles to create about 150-200 million 50 bp to 100 bp reads. When two separate 
read cycles occur in both directions, it is called paired-end reads. This kind of read will 
provide data about both sides of the fragment of interest (Metzker 2010). In this study, 
we sequenced fragments of 75 bp to a yield of at least 290 milion paired-end reads 
using an Illumina HiSeq 4000 machine. 
 
2.5.4 Bioinformatic NGS analysis 
 
Bioinformatic analyses were performed by The University of Edinburgh sequencing 
service (Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, Edinburgh). 
The process of analysis is described as follows: 
 
1. Trimming: reads were trimmed using Cutadapt  (version cutadapt-1.9.dev2). Reads 
were trimmed for quality at the 3’ end using a quality threshold of 30 and for adapter 
sequences of the TruSeq stranded mRNA kit (AGATCGGAAGAGC). Reads after 
trimming were required to have a minimum length of 50. 
2. Reference: the reference used for mapping was the Canis familiaris (CanFam3.1) 
genome from Ensembl. The annotation used for counting was the standard GTF-format 
annotation for that reference (annotation version 84). 
3. Reads were aligned to the reference genome using STAR (version 2.5.2b) specifying 
paired-end reads and the option --outSAMtype BAM Unsorted. All other parameters 
were set at the standard option. 
4. Read counting by feature: reads were assigned to features of type ‘exon’ in the input 
annotation grouped by gene_id in the reference genome using featureCount (version 
1.5.1). featureCounts assigns counts on a ‘fragment’ basis as opposed to individual 
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reads such that a fragment is counted where one or both of its reads are aligned and 
associated with the specified features. Strandedness was set to ‘reverse’ and a 
minimum alignment quality of 10 was specified. In addition to the counts matrix used 
in downstream differential analysis, a matrix of Fragments Per Kilobase of transcript 
per Million mapped reads (FPKM) values was generated, using the rpkm() function of 
edgeR (Robinson et al, 2010) (version 3.20.9) and normalized effective library sizes. 
Gene lengths for the FPKM calculation were the number of bases in the exons of each 
gene (only counting bases once where they occur in multiple exon annotations). FPKM 
values may be useful in analyses requiring accurate gene-gene (as opposed to sample-
sample) comparisons. Gene names and other fields were derived from input annotation 
and added to the count/expression matrices. 
5. Count processing:   
5.1 Filtering:  The raw counts table was filtered to remove genes consisting 
predominantly of near-zero counts, filtering on counts per million (CPM) to avoid 
artefacts due to library depth. Specifically, a row of the expression matrix was required 
to have values greater than 0.1 in at least 3 samples, corresponding to the smallest 
sample group as defined by Group, once any samples were removed (where 
applicable).  
5.2 Normalisation: Reads were normalised using the weighted trimmed mean of M-
values method5, passing ‘TMM’ as the method to the calcNormFactors method of 
edgeR. 
6. Differential gene set analysis: Differential gene set analysis was carried out with the 
ROAST method  from the Limma package (version 3.34.9) of Bioconductor, using the 
same models and contrasts as used in differential expression. The following gene sets 
were used:  
 Gene Ontology Biological Process, downloaded from Ensembl version 98  
 Reactome Pathways, downloaded from Ensembl version 98  
 
ROAST was executed using 9,999 rotations (randomisations). Each gene set was 
annotated with those genes individually differential (in the same direction as 




2.6 Immunohistochemistry (IHC) 
 
Equine sarcoids and skin were treated and fixed as detailed in chapter 4. Once ready, 
samples were sent to the Pathology Unit of the Royal (Dick) Veterinary School of the 
University of Edinburgh, where immunohistochesmistry (IHC) was performed by Dr 
Scott Maxwell. Briefly, the procedure was performed as follow: 
1.Processing: samples were processed on an Excelsior AS processors 
(ThermoScientific, Paisley, UK) according to the following program: 1X (1hour and 
30 minutes) 10% NBF; 6X (3 hours each) absolute alcohol; 3X ( 3 hours each) 
Histoplast IM wax (ThermoScientific, Paisley, UK); 
2.Embedding: samples were embedded on the HistoStar (ThermoScientific, Paisley, 
UK) using Histoplast IM wax; 
3.Cutting/Microtomy: all blocks were cut at 4µ on a Finesse microtome 
(ThermoScientific, Paisley, UK). All sections were floated onto Thermo Plus Slides 
and placed in a low temperature drier overnight. An hematoxylin and eosin (H&E) 
staining was initially performed on each block. H&E staining was carried out on the 
Varistain Gemini (ThermoScientific, Paisley, UK)  using the in-house staining 
program; 
4.Antigen retrieval: the Autostainer 360 (Thermo Scientific, Paisley, UK) was used 
and the antigen retrieval was carried out offline using a microwave- Histos 5 
(Milestone, Sorisole, IT). The fluid used was Antigen Unmasking Solution by Vector 
(H-3301). Retrieval was carried out at 110°C for 5 minutes (with an overall time 
including getting up to temperature of 12 minutes); 
5. IHC Staining: Anti-BLMH antibody (ab204584, abcam, Cambridge, UK) was the 
antibody anti bleomycin hydrolase used, and it was also stained using a Vector Red 
(Immpact Nova Red Vector SK-4805, Novus Biologicals, CO, USA) chromagen. 
The staining was carried out on the Thermo Autostainer 360 according to the 




2.7 Fluorescence-activated cell sorting (FACS) 
 
Fluorochrome-conjugated probes have been used to label and then sort CML10 and 
C2 cell lines using BD Fortessa cell analyser (BD Biosciences, USA). Specific 
fluorophores are detailed in table 2.5. Following a general protocol, cells were 
harvested, washed and adjusted to a concentration of 0.5-1x 106cells per condition in 
ice cold PBS. Cells were strained using 70 μm cell strainers to avoid clumps that could 
block the flow cytometer. Cells were then stained in polystyrene round-bottom 12x75 
mm tubes. Control samples (cells incubated with equivalent concentration of nuclear 
marker, dead cell marker, fluorescent drugs ) were evaluated for each experiment. At 
least 100,000 events were acquired for analysis.  
All the procedures were performed at 4°C protected from light, according to the 
relative manufacturer’s protocol. Cells were then analysed in the flow cytometer by a 
laser at different wavelengths depending on the conjugated fluorochrome. Cells were 
gated by adjusting the size (forward scatter (FSC)) and granularity or complexity (side 
scatter (SSC)) of the cells to the middle of an FSC × SSC graph.  Post-acquisition 
analysis was performed using FlowJo (Treestar, USA). Results were analysed after 
setting the gate on the cellular population, eliminating debris. The percentage of 
positive cells was determined by comparison to the control cells (unstained) and 










Zombie Yellow BioLegend 396 572 
LysoTracker 
Deep red 
LifeTechnology 647 668 






LifeTechnology 555 584 
Bodipy-FL  503 512 
 
Table 2.5  List of fluorescent probes with relative emission and excitation spectra 
 
2.8 Bleomycin fluorescent labelling process assessed by 
High-Performance Liquid Chromatography/ Mass 
Spectrometry (HPLC/MS) 
 
In order to visualise Bleosome and bleomycin activity within cells and skin tissues by 
microscopy, 120 mg of bleomycin sulphate (A2-B2) were coupled with a green 
fluorophore, the Bodipy-FL. Monitoring of the reaction and characterization of the 
final product were achieved by means of High-Performance Liquid Chromatography/ 
Mass Spectrometry (HPLC/MS). The whole process was conducted in collaboration 
with the the group of Dr. Marc Vendrell at The Queen’s Medical Research Institute 
(QMRI), the University of Edinburgh. 
 
2.8.1 High-Performance Liquid Chromatography/ Mass 
Spectrometry - HPLC/MS 
 
High-Performance Liquid Chromatography (HPLC) is a highly improved form of 
column chromatography. Instead of a solvent being allowed to flow through a column 
under gravity, it is pushed through under high pressures of up to 400 atmospheres. This 
increases the speed of the process (Clark and Frank 2016). Reverse phase HPLC is the 
most commonly used form of HPLC and it was used in this study.   
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2.8.2 Solubility tests to establish the process for the purification of 
the labelled compound 
 
Bodipy-FL (Edinburgh, UK) might bind the amine groups of bleomycin, releasing N-
hydroxisuccinimide (succinimide-OH). In order to obtain a pure fluorescent labelled 
compound, free from other fluorescent impurities and succinimide-OH, different trials 
were conducted to find a solvent in which succinimide-OH, but not bleomycin, could 
be dissolved: this enabled to separate the undissolved fluorescently labelled bleomycin 
by mechanically removing the solution containing succinimide-HO. Solubility tests 
showed dimethyl sulfoxide (DMSO) to be the only solvent in which bleomycin 
sulphate was dissolved, while succinimide-OH was found to be very soluble in 
dichloromethane (DCM), which was thus chosen for the purification of the final 
compound. 
 
2.8.3 Coupling bleomycin sulphate with Bodipy-FL  
 
The mass and absorbance profiles of bleomycin sulphate and Bodipy-FL were 
evaluated by HPLC in order to achieve references for the two starting materials, prior 
to commencing the coupling process. 
Bodipy-FL is supposed to bind to the amine groups of the metal binding domain of the 
bleomycin sulphate, releasing the succinimide-OH leaving group. The main concern 
about the coupling process was that the fluorophore could have tagged all of the three 
amine groups of bleomycin. Therefore, the labelling could have potentially affected 
the ability of bleomycin to bind and intercalate the DNA of cancer cells, thus affording 
a final compound with reduced overall efficacy. Hence, the first aim was to establish 
the right amount of fluorophore to use in order to obtain the highest possible amount 
of mono-labelled bleomycin (bleomycin sulphate bound to one amine group), by 
minimizing double and triple labelling of the drug. Initially, a small-scale trial using 
0.9 equivalents of fluorophore was conducted to evaluate reaction conditions. 
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Subsequently, according to the findings of this preliminary experiment (images shown 
in section 3.4.3), a larger batch of drug was coupled using less Bodipy (0.7 
equivalents), i.e. a 8.1 mg amount was reacted with 45 mg of bleomycin sulphate, 
according to the following equation: 
 
mmol of bleomycin sulphate:    45 mg / 1512.62 bleomycin MW= 0.03 mmol 
bleomycin 
mmol of Bodipy-FL:      1 e.g, bleomycin : 0.03mmol bleomycin = 0.7 e.g. :x = 0.021 
mmol Bodipy-FL 







BODIPY-FL 389.16 0.7 0.021 8.1 
BLEOMYCIN 1512.62 1 0.03 45 
Table 2.6 Molecular weight (MW), equivalents (e.g.), millimoles (mmol) and milligrams (mg) of Bodipy-
FL and bleomycin sulphate (bleomycin) employed in the first coupling reaction with 45 mg bleomycin 
sulphate (corresponding to roughly half of the total amount of drug to be labelled). 
 
45 mg of bleomycin sulphate were dissolved in DMSO, and put in an Eppendorf 
equipped with a stirring bar; subsequently, Bodipy-FL dissolved in DMSO, was added 
to the bleomycin solution dropwise over 20 minutes. The addition process was 
conducted slowly to prevent multiple tagging of the drug. 
The reaction was checked by HPLC after 30 minutes, 1.5 hours and 3 hours; the 
reaction was then left running overnight (images are shown in section 3.4.3). 
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The remaining 81 mg of bleomycin sulphate were coupled with 0,8 equivalents of 








BODIPY-FL 389.16 0.8 0.0376 14.6 
BLEOMYCIN 1512.62 1 0.047 71 
Table 2.7 Molecular weight (MW), equivalents (e.g.), millimoles (mmol) and milligrams (mg) of Bodipy-
FL and bleomycin sulphate (bleomycin) put in the second coupling reaction with 71 mg bleomycin 
sulphate (corresponding to roughly half of the total amount of drug to be labelled). 
 
2.8.4. Lyophilisation and purification 
  
Both batches of Bodipy-tagged bleomycin were lyophilised to remove the DMSO: the 
reaction mixture was diluted with water, snap-frozen in dry ice, and the solvents were 
removed overnight by means of a freeze dryer.  
In order to remove impurities and succinimide-OH, 5ml of DCM (according to section 
2.8.2) were added and the resulting suspension was allowed to sit for 15 minutes, until 
undissolved solid settled. Subsequently, the supernatant (succinimide-OH and DCM) 
was removed using a syringe. This process was performed five times until the removed 
supernatant resulted colourless (meaning that no residues of fluorescent impurities 
were left). After drying under vacuum, the final compound resulted in a fine, red 




2.8.5 Fluorescently labelled Bleosome and bleomycin (F-Bleosome 
and F-bleomycin) 
 
The final powder was sent, refrigerated and protected from light, to the Ascot 
Laboratories Ltd (London, UK), to be encapsulated into ultra-deformable liposomes 
and to have a final fluorescent Bleosome (F-Bleosome) in the form of a 0.2% cream. 
A small amount (20 mg) was saved to create the aqueous form of non-encapsulated 
fluorescent bleomycin (F-bleomycin), used as comparison with F-Bleosome in 
penetration and cellular up-take experiments. Briefly, 0.02 g of fluorescent bleomycin 
powder were dissolved in 9.98 ml of PBS, vortexed and stored at 4◦C protected from 
light. 
 
2.9 Skin and equine sarcoid samples used for penetration 
studies. 
 
2.9.1 Skin samples 
 
2.9.1.1 Canine and equine skin 
 
2.9.1.1.1 Sample collection 
 
Skin samples were collected from animal cadavers donated from The Edinburgh Cat 
and Dog Home to the Royal (Dick) Veterinary School of the University of Edinburgh. 
Specimens were withdrawn from flank and abdomen of cadavers, previously shaved 
with an electric clipper. As soon as the euthanasia was performed, cadavers were 
brought to the post-mortem and the skin was immediately removed from each animal 
using a knife, the section was attached to a square cork block and kept tense by pins, 
subcutaneous fat was subsequently removed by a scalpel. Immediately after the 
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procedure, each sample was wrapped in aluminium foil, stored in a sealed plastic bag, 
snap frozen in dry-ice, and stored at -70◦C or -20◦C. 
 
2.9.1.1.2. Skin sample processing for Bleosome penetration study performed with 
Confocal Laser Scanning Microscopy (CLMS) 
 
Skin samples were thawed by washing 3x in PBS at RT. They were cut by a scalpel 
into 2x2 square centimetres. Thickness of sections were measured using an electronic 
calliper. Sections staining and treatments are detailed in relative chapters. 
 
2.9.1.1.3 Skin sample processing for Bleosome penetration study performed with 
fluorescent microscopy 
 
Skin samples were treated as in  2.9.1.1.2. Samples were then treated with indicated 
dose of Bleosome at the indicated time points. To obtaining cryosectioned slides to be 
visualised with the fluorescent microscope, samples were processed as follow: 
1. Snap-freezing:: at the relative time point, each skin section was cut in four equally 
sized slices using a scalpel. Each slice was positioned, oriented on the edge, in a 
20x20x5 metal cryomold, with the longer side parallel to the longer side of the 
cryomold and the epidermis facing the right side. The cryomold was filled with Tissue-
Tek® O.C.T.™ Compound (Sakura, USA) in a sufficient amount to embed the whole 
tissue. Subsequently, the slice was snap-frozen using a metal beaker filled for 2/3 with 
isopentane and placed in a box containing liquid nitrogen. The cryomold was 
positioned, but not fully submerged, in the isopentane using forceps, until frozen and 
then wrapped in aluminium foils, sealed in plastic bags, positioned in dry-ice and 
subsequently stored at -70 ◦C. This protocol was modified by Peters 2010.  
2. Cryosectioning: samples were transferred into the cryostat (Cryostat CMI900, 
Leica, Stantonbury, UK) and mounted on the chuck with O.C.T. compound. 
Temperature in the cryostat was set at -20◦C and thickness of sections was set at 10 
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µm. The blade used was MB35 Premier, microtome blade 340/80 mm 
(ThermoScientific, Paisley, UK) and the sample was oriented with the epidermis 
perpendicular to the blade (figure 2.2). 
 
 
Figure 2.2 Orientation of the sample for cryosectioning.(Peters 2010)  
 
Once cut, sections were impressed on a slide (Superfrost Plus Microscope Slide, 
ThermoScientific, Paisley, UK), dried at RT for 3 hours covered by aluminium foil, to 
avoid light exposure. Samples were stored at -20◦C. This protocol was modified by 
Fisher et al, 2006. 
3. Fixation and mounting: slides were exposed at RT for 30 minutes and then fixed 
with neutral buffered formalin (NFB) 10%, for 10 minutes; subsequently slides 
were rinsed in PBS for 5 minutes, this procedure was performed twice. Half of the 
slides were pre-treated with TrueBlackTM  Lipofuscin Autofluorescence Quencer 
(Biotinum, CA, USA) as per manufacturer instruction. All the slides were stained 
with DAPI nuclear counterstaining (ThermoFisher, Paisley, UK) following the 
manufacturer protocol; subsequently, they were rinsed in PBS, dried and 
coverslipped with ProLong™ Gold Antifade Mountant (ThermoFisher, Paisley, 





2.9.1.1.4 Skin sample processing for Bleosome penetration study performed with 
Transmission Electron Microscopy (TEM) 
 
Skin samples were thawed X3 in PBS at RT. They were cut by a scalpel in 2x2 square 
centimetres as in 2.9.1.1.2., and, treated with Bleosome according to chapter 3. 
At the indicated time point, each sample was cut in to 1 centimetre thick slices that 
were fixed in 3% glutaraldehydein 0.1 M Sodium Cacodylate buffer, pH 7.3, for 2 
hours, then washed in 0.1M Sodium Cacodylate 3x 10 minutes. Samples were 
subsequently sent to the microscopy unit at the King’s Buildings Institute, The 
University of Edinburgh, where they were processed, in order to be visualised with the 
TEM. Briefly, Specimens were post-fixed in 1% Osmium Tetroxide in 0.1M Sodium 
Cacodylate for 45 minutes, then washed 3x 10 minutes in 0.1 M Sodium Cacodylate 
buffer. These samples were then dehydrated in 50%, 70%, 90% and 100% ethanol 
(X3) for 15 minutes each, then in two 10-minute changes in Propylene Oxide. Samples 
were then embedded in TAAB 812 resin.  Sections 1 μm thick were cut on a Leica 
Ultracut ultramicrotome, stained with Toluidine Blue, and viewed in a light 
microscope to select suitable areas for investigation. Ultra-thin sections 60 nm thick 
were cut from selected areas, stained in Uranyl Acetate and Lead Citrate then viewed 
in a JEOL JEM-1400 Plus TEM.    
 
2.9.1.2 Human skin 
 
2.9.1.2.1 Sample collection 
 
Human skin was collected from patients undergoing reductive plastic surgery. Patients 
were presented with an informative leaflet and agreed, by signing a consent form, to 
donate the surplus skin removed by surgery to this study (supplementary data 8.2.2 
and 8.2.3). After the surgical excision, a surgeon removed the subcutaneous fat from 
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the skin tissue with a scalpel and the samples were snap frozen in dry-ice and 
subsequently stored at -70◦C. 
 
2.9.1.2.2. Sample processing 
 
At the time of the experiment, skin samples were thawed and processed as 2.9.1.1.2. 
 
2.9.2 Equine sarcoids 
 
2.9.2.1 Sample collection   
 
All equine sarcoids included in this study were kindly provided by the equine 
veterinary surgeons of the Royal (Dick) Veterinary Equine Hospital at The University 
of Edinburgh. Owners consented to include their horses in this study signed a consent 
form, after being explained all the procedures and provided with a dedicated 
information leaflet (Supplementary data). This study entitled: “Evaluation of the 
efficacy of Bleosome as a topical treatment for equine sarcoids” received the approval 
of the Veterinary Ethical Review Committee (VERC) with the VERC reference 
number is 6.19. Sarcoids were surgically removed from patients, as part of their 
standard therapeutic protocols, by CO2 laser or excision. Immediately after the 
excision, sarcoids were wrapped in aluminium foils, stored in sealed plastic bags and 
snap frozen in dry-ice, to be stored at -70◦C or -20◦C.  
 
2.9.2.2 Sample processing 
 
Sarcoids were thawed by washing 3x in PBS at RT. They were treated, cut or treated 






2.10.1 Fluorescence microscopy 
 
In this study, Leica DMLB upright phase/fluorescent microscope (Strantonbury, UK) 
with quad pas emission filter/ Lumencor LED light engine with 6 bandpass excitation 
filters and Hamamatsu low light mono camera for quantification use was used. 
Objective lenses used were 20x (Green Ring) Type Fluotar Ph2, na 0.50 and 40x 
(Green/Blue Ring) Type Fluotar Ph3, na 0.75. For the bleomycin green fluorescence 
the Cyan Lumencor Exciter filter (202/324 band-pass) was used (configuration: 
485/20), with 200msec exposure time; for the visualisation of DAPI stained structures, 
the Violet Lumencor Exciter filter (201/401 band-pass) was used (configuration: 
390/18), with 30 msec exposure time. 
 
2.10.2 Transmission Electron Microscopy (TEM) 
 
In this study, TEM was used to visualize the liposomes through the skin, after the 
Bleosome treatment. Samples were prepared according to section 2.9.1.1.4; samples 
were viewed in a JEOL JEM-1400 Plus TEM (USA).   Representative images were 
collected on a GATAN OneView camera at different magnification. 
 
2.10.3 Confocal Laser Scanning Microscopy (CLSM) 
 
2.10.3.1 CLSM settings for the equine sarcoids penetration study 
 
Equine sarcoids (Bleosome treated and untreated) were cut in 2 mm slices using a 
coronal mouse brain matrix (rbma 600c acrylic brain matrix for rat 300g-600g coronal 
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slices, World Precision Instrument, USA). Slices were put on a glass slide and kept 
flat by positioning another glass on the top (see chapter 5). All images were collected 
using a Zeiss LSM 710 AxioObserver Confocal Microscope (Cambourne, UK) 
equipped with EC Plan-Neofluar 20x/0.50 M27 objective lens. Imaging was 
performed with a 20x 0.8 na oil lens using a 488 argon laser (4.0% laser power) for 
BODIPY-FL (493-598 nm band pass filter), with 716v detector gain; and a 405 nm 
diode laser (9.9% laser power) for Hoechst 33342 (410-492 nm band pass filter), with 
878.14v detector gain. Picture of the whole sample were acquired using the tile-scan 
tool. Fluorescence intensities and Bleosome particles position were assessed using Zen 
lite 3.0 (Blue edition, Zeiss, Cambourne, UK). 
 
2.10.3.2 CLSM settings for live-cell imaging study 
 
Cells were grown in 2-well chamber slides (Nunc Lab-Tek II Chambered Coverglass, 
1.5 borosilicate glass, ThermoFisher, Paisley, UK) according to chapter 4, and were 
placed under a Zeiss LSM 880 Confocal microscope Airyscan/Fastscan with 32 
sensitive GaAsP detectors, equipped with an incubation chamber, which is maintained 
at 37 °C with controlled CO2 flow. Images were acquired using a using a 488 argon 
laser (0.5% laser power) for BODIPY-FL (500-651 nm band pass filter), with 983.2v 
detector gain; and a 405 nm diode laser (1.1 laser power) for Hoechst 33342 (411-499 
nm band pass filter), with 681.86v detector gain. Cells were captured in single images, 
moreover, images were also acquired for 10 seconds, for 60 cycles creating a 10 
minutes time-course video for each time point and treatment. 
 
2.10.4 Multiphoton microscopy 
 
In this study, all images were collected with a Zeiss LSM7 MP intravital multiphoton 
microscope equipped with W Plan-Apochromat 20x/1.0 DIC D=0.17 M27 75mm 
objective lens and a Coherent chameleon ultraII pulsed laser with OPO (wavelength 
tunable 690 to 1400nm) (Cambourne, UK). Imaging was done with a 20x upright, 
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water dipping lens,  big detector (binary GASP detector) with the green (NDD R4) and 
blue (NDD R3) filters set up was used (figure 2.3). 
 
 
Figure 2.3 Green (NDD R4) and Blue (NDD R3) filters used in this study. 
 
780 nm laser line and 22% laser power were used. NDD R4 master gain was 541, NDD 
R3 master gain was 653; laser gain was 22.0 and 1.0 was set as digital gain. 
Multidimensional acquisition was performed with the Z-stack tool, setting 150 slices 
as average with an interval of approximately 3 µm.  
3-D images were visualised, processed and interpreted using Imaris Biplane (9.1.2 
version) (Zurich, CH) software. 
  
2.11 Statistical analysis 
 
Quantitative analysis was based on a minimum of three replicates. Data were analysed 
using Minitab® 17 Statistical Software (Minitab Ltd., Coventry, UK) and all graphs 
and diagrams were generated using Microsoft Office 2011 software (Microsoft 
Corporation). P-values <0.05 were considered statistically significant. Normality test 
was performed using Minitab® 17 Statistical Software. When data followed a normal 
distribution, two sample t-tests were used to compare differences between two 
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samples, or one-sample t-tests to determine whether the sample mean was statistically 
different from a known or hypothesised mean. General linear model (2-way ANOVA- 
analysis of variance) was used to understand if in two groups there was an interaction 
between two independent variables on the dependent variable.  
IC50 values were calculated using GraphPadPrism 6 (GraphPad Software, La Jolla, 























Chapter 3. A comparative study of the potentional of 
a novel formulation of bleomycin to penerate 




Advances in cancer therapy are focused on minimising the side-effects of treatments 
and improving the quality of life of patients. Minimally invasive treatments are sought 
after and liposomes are highly valued for their ability to topically deliver a payload of 
drugs to target tumour tissues, and decrease systemic toxicity. To this extent, we 
evaluated Bleosome (bleomycin encapsulated in ultra-deformable (UD) liposomes) as 
topical treatment for non-melanoma skin cancer (NMSC) in veterinary and human 
medicine. Although, liposomes have been extensively studied as a vehicle of drug 
delivery to the skin, the exact mechanism employed by UD lipid vesicles in penetrating 
the skin barrier remains controversial. In this study, we investigated the mechanism of 
penetration of Bleosome through the skin by developing and optimising a direct 
imaging technique. Initially, we attempted to utilise the autofluorescent property of 
Bleosome itself to estimate the rate and peak of penetration of Bleosome through 
animal skin using fluorescent microscopy, however, the intrinsic autofluorescence of 
the compound was comparable to the autofluorescence of skin, and we therefore 
concluded that this method was not suitable. We subsequently visualised both the 
liposomes and the entrapped bleomycin through the skin after topical application of 
Bleosome using two different methodologies: (1) we visualised the penetration of 
liposomal nanoparticles through the skin over a time course using the transmission 
electron microscope (TEM) and concluded that UD liposomes are able to penetrate the 
outermost stratum corneum of the skin only, without reaching deeper layers; and (2)  
we fluorescently labelled the entrapped bleomycin with Bodipy-FL, packaged into UD 
liposomes and visualised the penetration of the drug molecules within canine, equine 
and human skin, using multiphonon microscope (MP). Here, we found that, in all 
species tested the entrapped bleomycin, after several hours of Bleosome topical 
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application to the skin, crossed the stratum corneum and passed through deeper layers 
of the epidermis. Moreover, we found that length of treatment had a significant impact 
on the rate of penetration and that Bleosome penetrated significantly deeper through 
canine, equine and human skin, compared to free bleomycin. We concluded that, in 
the case of Bleosome, UD liposomes act as penetration enhancers: they cross the first 
layer of the skin, interact with intercellular lipid lamellae, and pass through tortous 
virtual channels between keratynocytes. We propose that this may cause damage to 
the lipidic bilayers of the liposomes enabling the release of bleomycin and deeper 




Non-melanoma skin cancers (NMSC) are a group of cutaneous tumours including 
basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) (Simonetti et al. 
2009).  
The incidence of NMSC has steadily increased in human medicine, making it a major 
challenge in terms of management of public health (Fleury and Vianna Lopez 2011). 
 
In veterinary medicine, SCC is more frequent in dogs and cats than in humans, with 
an incidence of 5-15% of all cutaneous tumours. SCCs are locally invasive with a low 
metastatic rate (Amadori and Marconato 2012). In horses, sarcoids are locally 
invasive, fibroblastic skin tumours and represent the most common tumour in equids 
worldwide (Taylor and Haldorson 2013). Treatment for NMSC in both human and 
veterinary medicine includes several standard treatments, such as curettage, surgery, 
cryotherapy, radiotherapy and chemotherapy (Amadori and Marconato 2012); Fleury 
and Vianna Lopez 2011). However, these conventional treatments lead to severe 
inflammation, pain and unappealing scars (Lopez et al. 2004). To increase patient 
compliance and to reduce surgical costs and undesirable scars, particularly in cases 
where the cancer has spread over large areas of the body, the topical administration of 
anti-cancer drugs has been investigated. This is an interesting alternative for reducing 
side effects and for increasing drug targeting and therapeutic benefits. The major 
challenge of this kind of treatment is to increase penetration of the anti-neoplastic drug 
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through the skin in sufficient quantity to kill tumour cells (Fleury and Vianna Lopez 
2011) 
Bleomycin is a potent anti-cancer agent that is able to induce single and double 
stranded breaks in DNA. It is effective against several types of tumours, including 
cutaneous ones. Because of its molecular characteristics, including polar charge, high 
molecular weight, hydrophilic molecule and system of cellular uptake, it is unable to 
efficiently cross the plasma membrane and lipophilic skin barriers and reach the site 
of action (J. Chen and Stubbe 2005a). Furthermore, systemic treatment with high dose 
of bleomycin, leads to severe side effects (1.8.1), limiting its clinical application 
(Sleijfer 2001). To address these issues, there has been an increasing interest in the 
development of a novel formulation of bleomycin for topical administration. 
Bleomcyin administered through electrochemotherpy (ECT) regimen produced 
excellent outcomes in the management of NMSCs. However, this technique is 
invasive (1.8.3). Furthermore, when administered to animals and, in some cases to 
human patients, general anaesthesia is required (Enrico P. Spugnini, Citro, and Baldi 
2009 (A)). For this reason, we focused our interest on liposomes as a potential carrier 
of bleomycin through the skin.  
Skin is an excellent barrier and has evolved to provide protection against the external 
environment, and to limit the absorption of exogenous molecules (Fleury and Vianna 
Lopez 2011). Nanotechnologies have been proposed to escape the defenses of the 
skin, taking advantage of some defects of the stratum corneum, which at the 
microscopic level is a poorly permeable nanoporous membrane (Gregor Cevc and 
Gebauer 2003). In fact, in some regions the corneocytes do not perfectly overlap and 
channels, like pores with a higher water content, are formed and contributes to the tiny 
hydrophilic furrows (0.4−36 nm large) present in the intercellular spaces between the 
polar heads of the stratum corneum lipids (Gregor Cevc and Gebauer 2003). Among 
nanocarriers, liposomes, owing to their particular composition, are considered as the 
most suitable means to enhance the skin penetration of drugs because of a number of 
intrinsic characteristics. However, it is now recognised that conventional liposomes, 
having a rigid bilayer, mostly disassemble on the skin surface and fail to enhance skin 
drug absorption (Elsayed et al. 2007). Thus, novel generations of lipid vesicles have 
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been proposed to solve this issue (Elsayed et al. 2007). Among them, flexible or ultra-
deformable (UD) liposomes are of increasing interest. These vesicles are composed 
mainly of amphiphilic molecules forming bilayers with the addition of non-ionic, 
single chain surfactants with high curvature radius, which have deformable properties. 
In contrast to conventional liposomes, flexible liposomes can adapt their structure to 
support relatively high stress because the surfactant relocates in the zones of 
maximum pressure allow shape changes at minimum energetic cost (G. Cevc and 
Blume 1992). However, their mechanism of penetration is still undefined (Perez et al. 
2016) and there is limited evidence of a correlation between the level of flexibility of 
the liposomes and their qualitative and quantitative penetration potential into human 
skin (Franzé et al. 2017). Two mechanisims have been proposed to explain how 
deformable vesicles improve delivery of drugs through the skin  (Honeywell-Nguyen 
and Bouwstra 2003 (B); Honeywell-Nguyen, Arenja, and Bouwstra 2003 (A)). Firstly, 
vesicles can act as drug carrier systems, passing through the virtual channels of the 
stratum corneum and carrying vesicle bound drug molecules into the skin (mechanism 
1). Alternatively, vesicles can act as penetration enhancers, where their lipidic bilayers 
interact with corneocytes and subsequently modify the intercellular lipid lamellae. 
This would cause the damage of the nanocarriers membrane and facilitate penetration 
of free drug molecules into and across the stratum corneum (mechanism 2). 
In support of mechanism 1, Cevc et al. (1998) suggested that there are two different 
penetration pathways: the intercluster pathway and the intercorneocyte pathway. The 
authors claimed that these regions contained structural irregularities within the 
intercellular lipid lamellae, and that these irregularities can function as ‘virtual 
channels’ through which elastic vesicles can penetrate, and that intact deformable 
liposomes penetrated through the stratum corneum and through the underlying viable 
skin into blood circulation (Gregor Cevc, Schätzlein, and Richardsen 2002). 
However, in another study, deformable liposomes were able to carry both the 
entrapped and the non-entrapped hydrophilic fluorescent compound, 
carboxyfluorescein, into the stratum corneum and possibly to deeper layers of the skin 
(Verma et al. 2003) suggesting also a possible penetration enhancing effect 
(mechanism 2). Another study also showed that deformable liposomes improved only 
the skin deposition of dipotassium glycyrrhizinate, as skin fluxes were below detection 
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limit, whereas skin deposition increased 4.5-fold in comparison to an aqueous control 
(Trotta et al. 2002). UD liposomes also improved only skin deposition of 5-fluorouracil 
with little or no effect on the drug permeation, according to El Maghraby et al. (2001 
(A)), and therefore only useful for dermal delivery of these drugs. The limited 
partitioning into the acceptor phase used in the experiment indicates that deformable 
vesicles are not carrying the associated drug into the acceptor phase. In addition, the 
percentage of 5-fluorouracil that penetrated the skin was higher than the drug 
entrapment efficiency which strongly suggested that liposome components may have 
altered skin structure, thus enhancing 5-fluorouracil transmission through human 
epidermis (mechanism 2) (El Maghraby et al. 2001 (A)). Hence, some studies showed 
improved transdermal permeation, while others showed little or no effect (El 
Maghraby et al. 2001 (A); Trotta et al. 2002) after encapsulating drugs into UDs. El 
Maghraby et al (2008)  suggested that the reasons for the variation in reported results, 
regarding improvement of skin permeation, may arise from different vesicle 
compositions, alternative methods of preparation, and the selection of skin membranes 
from different species (El Maghraby, Barry, and Williams 2008).  
The aim of the present study was to investigate if Bleosome could penetrate through 
the skin of dogs, horse and humans and to elucidate the  mechanism by which UD 
liposomes could improve delivery of the bleomycin through the skin, under non-
occlusive conditions. We hypothesised that, if able to penetrate through deep layers of 
the epidermis, Bleosome could be used as topical agent in the treatment of cutaneous 
tumours. To achieve these aims we labelled bleomycin with a fluorescent probe and 
then encapsulated the fluorescently labelled drug into UD liposomes to create 
fluorescently labelled Bleosome. Subsequently, we treated live canine, equine and 
human skin tissues with the fluorescently labelled Bleosome and visualised the 
position of the entrapped drug within the skin over a time course by multiphoton 
microscopy (MP). In parallel, we treated comparable canine skin sections with 
unlabelled Bleosome and analysed samples using the trasmission electron microscopy 
(TEM), with the aim of visualising the liposomal nanocarriers within the skin. Hence, 
we optimised a novel method of directly visualising both liposomes and entrapped 
bleomycin inside live skin tissues after the Bleosome treatment. We found that 
Bleosome penetrated through equine, canine and human skin significantly deeper than 
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free bleomycin and we speculated that UDs, when carry bleomycin for skin delivery, 
might act as penetration enhancers.  
 
3.3 Materials and methods 
 
3.3.1. Skin collection and storage 
 
3.3.1.1 Animal skin 
 
The skin was collected in the post mortem department of the Royal (Dick) School of 
Veterinary Study, The University of Edinburgh, from euthanised dogs and horses. Skin 
samples were withdrawn from the abdomen and flank area of the carcasses. Equine 
and canine penetration studies were performed at least twice using skin from different 
animals (different breed, age and sex). Before excision, the hair of the target areas was 
removed using electric clippers. Skin was collected by a knife and afterwards, the 
subcutaneous fat and muscles were removed with a scalpel. Subsequently, according 
to the OECD guidelines, skin samples were snap-frozen in dry ice and stored at -20°C 
or -70°C until ready for the experiment, as detailed in section 2.9.  
 
3.3.1.2 Human skin 
 
Human skin was collected from patients undergoing reductive plastic surgery who 
voluntarily agreed to take part to this study. Detailed information can be found in 
section 2.9.1.2.1 
 




3.3.2.1 Processing canine skin sections:  
 
The skin was cut by a scalpel in three sections sized 2 cm x 2 cm, at a thickness of 
approximately 1 mm, and orientated with the epidermis side facing upward in a sterile 
100 x 15 mm Petri Dish (Corning™ ) filled with DMEM to a level suitable to prevent 
the subcutaneous side of the skin section from drying out (figure 3.1). Two time points 
(2 hours (2h) and 4 hours (4h)) plus the control ((0h), untreated skin) were set-up, and 
the skin sections were treated with 0.1 ml of Bleosome, administered by insulin-
syringes without needle, in the middle of the top surface, within a rubber “O” ring. 
 
 
Figure 3.1 Skin sections (2 cm2) treated with Bleosome, moistened in cell medium. The two sections 
correspond to the 2h and 4h time points.  
 
At each time point, the Bleosome left on the surface was gently rinsed using a cotton 
swab and the respective sample was snap-frozen in isopentane cooled by liquid 
nitrogen. Each section was then cut into thin slices, placed in a cryomold to be 
cryosectioned at 10 µm thick sections and impressed on slides (detailed protocol in  
2.9.1.1.3). Several experiments were conducted to optimise the protocol:  
 
1) In the first experiment, samples were left drying overnight at RT and were then 
fixed with pre-cooled acetone and stained with DAPI (ThermoFisher 
Scientific) according to the manufacturer’s instruction. This experiment was 




2) For the second experiment, half of the samples were fixed with 10% neutral 
buffered formalin (NBF) and half with acetone, and stained with DAPI 
(ThermoFisher Scientific) according to the manufacturer’s instruction. This 
experiment was performed one time. 
 
3) In the third experiment, samples were fixed with 10% NBF, subsequently, half 
samples were pre-treated with TrueBlack® (a quencher agent), prior to staining 
with DAPI (for details refer to 2.9.1.1.3). This experiment was performed in 
duplicate. 
 
4) A further experiment was conducted by treating the skin sections for 2 and 4 h 
with either 0.1 ml of bleomycin aqueous cream (0.2 %), bleomycin ointment 
(Bleovet 0.2%), or Bleosome. All samples were pre-treated with TrueBlack. 
Bleomycin aqueous cream and Bleovet ointment contain non-encapsulated 
bleomycin, and they have different moisture contents (2.2) (figure 3.2). This 












3.3.2.2 Fluorescent Microscope visualisation 
 
             Bleosome                                   bleomycin aqueous cream                                 Bleovet  
Figure 3.2. Skin sections treated with either Bleosome, bleomycin aqueous cream or bleovet ointment for 0h, 





Slides were visualised at the Leica DMLB upright phase/fluorescent microscope, at 
20x and 40x magnification. To evaluate the inherent green fluorescence of bleomycin, 
the Cyan Lumencor Exciter filter (202/324 band-pass) was used. To visualise DAPI 
stained structures the Violet Lumencor Exciter filter (201/401 band-pass) was used 
(microscope settings and specification are detailed in 2.10.1). 
  
3.3.3 Transmission electron microscopy (TEM) 
 
 3.3.3.1 Treatment of canine skin sections 
 
Each experiment conducted with TEM was performed using the skin withdrawn from 
a single dog, randomly chosen from the frozen skin library, which was used in that 
study only; hence all the penetration studies were conducted using canine skin sections 
belonging to different animals (of different breeds, sex and ages).  
Canine skin samples were thawed in PBS, then cut in 2 x 2 x 0.1 cm sized sections, 
positioned in petri dishes filled with a sufficient amount of PBS to moisten the 
subcutaneous side (figure 3.3). 
 
 





Subsequently, skin sections were treated with Bleosome 0.2% and for each 
experiment, a control sample (untreated) was used. Residual Bleosome cream was 
gently removed with a cotton swab at the indicated time point. Skin samples were 
processed according to section 2.9.1.1.4.  
 
Four experimental settings were used in order to optimise the technique and validate 
the results: 
1) Skin sections were treated with 0.1 ml of Bleosome 0.2%, dosed using an 
insulin syringe without needle and spread evenly with a gloved fingertip all 
over the free surface of the epidermis side of the skin section, without allowing 
the compound to be absorbed. Skin explants were treated for: 0 h (control, 
section kept hydrated by adding PBS, without Bleosome), 30 minutes (min), 2 
h, 4 h, 6 h and 8 h. A variant of this experiment (including time points until 6 
h) was performed twice. 
 
2) Skin sections were treated with 0.1 ml of Bleosome 0.2% dosed using an 
insulin syringe without needle, positioning the drug on the top right corner of 
the skin section; from that corner, the compound was subsequently gently 
spread all over the free surface of the epidermis side. Time points used in this 
experiment were: 0h (untreated control), 30 min, 2h, 4h and 6h. This 
experiment was performed one time. 
 
3) Skin sections were treated with 0.1 ml of Bleosome 0.2%, dosed using an 
insulin syringe without needle and spread evenly with a finger on the free 
surface of the epidermis side of the skin section, without letting the compound 
being absorbed. Skin sections were treated in this manner repeatedly, every 60 
min. Time points for this experiment were set at: 0h (control, no Bleosome 
treatment, PBS only), 30 min (this section was treated one time), 2h (this 
section received two Bleosome treatments), and 4h (this section received four 




4) Skin sections used in this experiment were treated straight after the collection 
from the canine cadaver, without being frozen. Cutaneous explants were cut as 
in the previous experiments and treated with 0.1 ml of Bleosome 0.2%, dosed 
using an insulin syringe without needle and spread evenly with a finger all over 
the free surface of the epidermis side of the skin section, without letting the 
compound being absorbed. Lengths of treatment for this study were set at: 0h 
(control, no Bleosome treatment, but PBS), 30 min, 2h and 4h. This experiment 
was performed one time. 
 
3.3.3.2 TEM visualisation 
 
Skin samples were processed according to 2.9.1.1.4. Samples were visualised using a 
JEOL JEM-1400 Plus TEM. Representative images were collected on a GATAN 
OneView camera at a range of magnifications. 
 
3.3.4. Coupling 120 mg of bleomycin sulphate (A2-B2) with the 
fluorophore Bodipy-FL 
 
In order to visualise Bleosome and bleomycin activity within cells and skin tissues by 
microscopy, 120 mg of bleomycin sulphate (A2-B2) was coupled with a green 
fluorophore called Bodipy-FL. The efficiency of the reaction and the final product 
were assessed by High-Performance Liquid Chromatography/ Mass Spectrometry 
(HPLC/MS). The whole process was conducted in collaboration with the Division of 
Biochemistry at The Queen’s Medical Research Institute (QMRI), the University of 
Edinburgh. The protocol is detailed in 2.8. 
 




The CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega) was used to 
determine the viability of cells after treatment with several different doses of 
fluorescent Bleosome (F-Bleosome) and non-fluorescent Bleosome (Bleosome) as 
comparison. Detailed protocol can be found in 2.2.1. Briefly, 96-well plates were 
seeded with canine cancer cell lines: C2 (canine mast cell tumour) and CML10 (canine 
metastatic melanoma). Cells were treated with F-Bleosome 0.2% or Bleosome  0.2% 
using the flowing dose titration: 0, 0.1, 0.5, 1, 2, 3, 4, 5, 7, 10, 20 μM, to compare the 
efficacy of the fluorescent compound to the unlabelled one at 72 h post-treatment. The 
assay for each cell line was performed in duplicate. A prelinimanry experiment was 
performed treating cells with the concentrations of F-Bleosome indicated above and 
the luminometry was read after 10 min of treatment. 
 
3.3.5. Multiphoton Microscopy (MP) 
 
3.3.5.1 Processing canine and equine skin sections 
 
Each experiment conducted with MP was performed using the skin withdrawn from a 
single dog and horse chosen randomly from the frozen skin library; hence, all the 
different penetration studies were conducted using canine and equine skin sections 
from different animals (including a range of breeds, sex and ages). At least two 
experiments were performed using canine skin and two using equine skin.  
Equine and canine skin was processed in the same manner: skin was thawed in PBS 
and cut in 2 cm x 2 cm sections. The majority of the sections had a thickness of 1 mm 
(range from 0.5 to 1.5 mm), and was measured by an electronic caliper. Cutaneous 
explants were positioned in petri dishes (one for each sample) filled with enough PBS 
to prevent dehydration. 
Each skin section, oriented with the epidermis side facing upward, was stained with 
Hoechst 33342 (ThermoFisher Scientific, Paisley, Uk) diluted in PBS at concentration 
of 0.02 mg/ml, spread with a syringe without needle on the epidermis side of the skin 
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explants and allowed to stain for 30 min in the dark at RT. The skin was then washed 
in PBS. Subsequently, skin explants were positioned with the subcutaneous surface 
facing upward and 0.5 ml of diluted (0.02 mg/ml) Hoechst stain was spread on this 
side of the sections, and incubated for 30 min in the dark at RT, and then washed with 
PBS.  
For each experiment, 8 skin explants were used: 3 sections were treated with 0.1 ml of 
F-Bleosome 0.2% and the other 3 with 0.1 ml of aqueous F-bleomycin 0.2%. Both 
compounds were dosed and administered using an insulin syringe without a needle. 
One section was used as an untreated control and kept hydrated by adding PBS to the 
epidermal surface. The F-Bleosome cream was spread evenly over the epidermal 
surface, using a finger, preventing the compound from being absorbed. The F-
bleomycin was administered by the syringe evenly on the epidermal surface of each 
section (figure 3.4). Particular attention was given to avoiding dropping of F-Bleosome 
and F-bleomycin on the side of the section, if this occurred, the explant was removed 
from the experiment and replaced with another skin section.  Three time points for 
each treatment were set: 10 min, 4h and 6h. At the respective time point, the residual 
F-Bleosome cream was gently removed with a cotton swab, and the skin section rinsed 





Figure 3.4 Representative canine and equine skin sections treated with F-Bleosome and F-bleomycin. 
(a) is the untreated canine skin section (control), (b) and (d) are canine and equine skin explants treated 
with F-Bleosome respectively, (c) and (e) are canine and equine skin explants treated with F-bleomycin 
respectively. 
 
3.3.5.2 Processing human skin sections  
 
Human skin used was collected from the breast of a healthy donor undergoing plastic 
reductive surgery. Skin was processed and treated following the same protocol detailed 
in section 3.3.5.1. The penetration experiment was performed once and the dimension 
of the skin explants used was 2 cm x 2 cm, with an average thickness of 0.5 mm (from 
0.5 to 1 mm). 
 




All the samples were obsverved with a Zeiss LSM7 MP intravital. Skin explants were 
positioned in 35 x10 mm petri dishes, (gridded Nunclon™ Delta, Thermofisher) with 
the epidermis side anchored to the bottom of the dish by 4% agarose with the 
subcutaneous side facing upward, toward the microscope lens. The dish with the 
sample was filled with PBS and positioned in the visualising plate of the MP. The 20x 
upright lens was dipped in the PBS contained in the dish, avoiding the formation of air 
bubbles. Green (NDD R4  ET535/30) and blue (NDD R3  ET460/36) filters were used. 
Details of microscope settings are listed in 2.10.4.  
 
3.3.5.4  3-D Image analysis with Imaris software 
 
To analyse three-dimensional (3-D) images of skin, acquired using MP, we used Imaris 
9.1.2 (Bitplane) software (complete protocol in Supplementary Data 8.2.4). In this 
study, two channels were used to detect green and blue fluorescence. However, the 
Imaris software is not capable of distinguishing between structures emitting low and 
high-intensity of the same fluorophore, detected in a single channel (e.g. green – NDD 
R4); similarly, structures emitting both green and blue fluorescence (e.g. cellular 
nuclei) are not considered as separate entities by the software, but they are categorised 
according to the higher fluorescent signal detected. Hence, a method aimed to 
distinguish between F-Bleosome and F-bleomycin particles from autofluorescent skin 
structure, was optimised. Briefly, structures labelled with Hoechst staining that did not 
emit or emitted a low green fluorescent signal (the majority of autofluorescent skin 
appendages, e.g. connective tissue and cellular elements) were considered as 
“surfaces” (“surfaces” had NDD R3-blue source channel); while all the elements 
emitting high level of green signal, either labelled with Hoechst (such as cellular 
nuclei) or not (F-Bleosome and F-bleomycin), were marked as “spots” (“spots” had 
NDD R4-green source channel). After this distinction, the program was asked to 
distinguish between the “spots far from surfaces” (green particles emitting high-
intensity green fluorescence far from the particles emitting blue and low-intensity 
green fluorescence), from the “spots close to surfaces” (green particles emitting high-
intensity green fluorescence, and blue fluorescence very close to autofluorescent skin 
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and cellular structures, emitting low-intensity green fluorescence), using a specific 
threshold (0.5). The aim was to target the green particles that were far from the 
autofluorescent skin structures and that were not stained with Hoechst (cellular nuclei 
were always close to intracellular autofluorescent elements and thus recognised as 
“spots close to surfaces”). This system enabled us to identify F-bleomycin and F-
Bleosome particles within the examined skin section, recognised as green emitting 




3.4.1 Fluorescent microscopy is not a suitable tool to evaluate the 
penetration potential of Bleosome through the skin 
 
To assess the ability of Bleosome to penetrate through the skin we initially sought to 
take advantage of previously reported autofluorescence of the compound (Ranji et al. 
2016) and fluorescent microscopy, as used in a similar study conducted using human 
skin explants treated with Bleosome 0.2% (personnel Communication, S. Chopra). 
Canine skin sections were treated with 0.1 ml of Bleosome (0.2%) for 0 (control), 2 
and 4 h. We observed that the untreated skin section (0 h) is autofluresencent with hair 
follicles and glands within the outermost stratum corneum expressing the highest 
intensity (figures 3.5, 3.6 and 3.7). Nuclear staining with DAPI (blue) was successful, 
and all the underlying strata of the skin appeared with a bright green fluorescence 
signal. Furthermore, when compared to the treated sections, no significant differences 
were noted in the green intensity observed at 30 min, 2 h and 4 h time points. Initially, 
acetone was used as fixative for the cryosectioned slides (data not shown); however, 
this is a coagulative fixative that can cause the dissolution of lipidic particles. We then 
repeated the experiment fixing the slides with 10% NBF. Again, the background 
autofluorescence of canine skin was still too high to distinguish the autofluorescence 
of Bleosome and did not allow meaningful interpretation of the degree of skin 





Figure 3.5 Cryosectioned slides of canine skin explants fixed with 10% NBS. (a) is an image from a 
slide of the untreated section (0 h, control), (b)  represents image from a slide of skin treated with 
Bleosome for 2h, (c) is a representative image from a slide of skin treated with Bleosome for 4 4h. In 
all the images, the outermost stratum coreum is visible, and the first cellular layer (the stratum 
spinosum) is highlighted by the presence of blue stained nuclei.  
 
To overcome the effect of autofluorescence of the skin we trialled fixing the slides with 
10% NBS and using a quencher agent called TrueBlack®. TrueBlack® was added to 
half the examined slides, with the aim of extinguishing the inherent green fluorescent 
background signal of skin (figure 3.6). We found that the quencher agent had limited 
effect (figure 3.6).  





Figure 3.6 The autofluorescence of skin is not extinguished by the quencher agent. Images from slides 
of skin sections without pre-treatment with TrueBlack® (from (a) to (f)) and pre-treted with TrueBlack® 
(from (h) to (o)). (a), (c) and (e) are the epidermis of the sections corresponded respectively to control, 
2h and 4h of treatment, (b),(d) and (f) are details of hair follicles of  sections corresponded respectively 
to control, 2h and 4h of treatment. (h), (i) and (l) are the epidermis of the sections corresponded 
respectively to control, 2h and 4h of treatment with Bleosome on slides pre-treated with TrueBlack®, 
(m),(n) and (o) are details of hair follicles of  sections corresponded respectively to control, 2 h and 4 
h of treatment.in slides pretreated with  TrueBlack® 
 
All the images were captured using the same microscope settings and exposure time 
for the green and blue filter (section 2.10.1); they show how some cutaneous elements, 
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such as the stratum corneum and hair follicles, are intensely brightly fluorescent. 
Comparing the green intensity of the skin between each time points, some slight 
differences can be observed, however, this is not objectively quantifiable, and it can 
be due to a slight variation of the amount of autofluorescent skin structures rather than 
to the peak of penetration of the compound.  
In order to confirm that liposomes did not hamper the autofluorescence and 
visulisation of bleomycin during the sample processing, we treated the skin sections 
with Bleosome, aqueous cream bleomycin and Bleovet ointment.  Aqueous cream 
bleomycin and Bleovet ointment are two versions of non-encapsulated bleomycin 
(figure 3.7). We comfirmed that the inherent fluorescence of all of the compounds used 
did not exceed the autofluorescence emitted by skin (data not shown) and concluded 






Figure 3.7  Comparison of green fluorescence intensity of skin treated with encapsulated and free bleomycin. (a), (b) and (c) correspond to skin  untreated (control), treated for 2  
and 4 h respectively with Bleosome; (d), (e) and (f) correspond to skin  untreated (control), treated for 2  and 4 h respectively with aqueous cream bleomycin; and (g), (h) and (i) 
correspond to skin  untreated (control), treated for 2  and 4 h respectively with Bleovet
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3.4.2 Visualisation of liposome penetration through the skin by TEM 
 
We have established a protocol for the visualization of liposomes within skin sections 
after treatent with Bleosome, in collaboration with the imaging unit at the King’s 
Buildings (the University of Edinburgh). As a control, UD liposomes within Bleosome 
0.2% cream were directly visualised using the TEM. The cream was sonicated, 
imaged, and liposomal nanoparticles appeared as electron-dense (black) round-shaped 
structures, with size varying between 150 to 250 nm (figure 3.8).  
 
 
Figure 3.8 Direct visualisation of UD liposomes included in the Bleosome cream after sonication, with 
TEM. (a) x1200, a liposomes is cirled in red, (b) x1200, relevant liposomes are indicated by red arrows, 
(c) x500, a nanoparticle is indicated by red arrow. 
 
To visualise liposomes within the skin, canine skin explants were treated with 0.1 ml 
of Bleosome 0.2% for 0 (PBS control), 0.5, 2, 4, 6 and 8 h. All the epidermal strata 
can be visualised with the TEM, from the outermost stratum corneum, and its layers 
of keratynocytes, to the cellular and extracellular matrix components of the innermost 
strata spinosum and basale (Figure 3.9). Within the untreated control skin section (0 
h) liposomes were not observed in any of the epidermal structures visualised (figure 
3.9 (a), (b) and (c)); whereas liposomal particles can be recognised in all the skin 
explants treated with Bleosome over the time course (figure 3.9 from (d) to (r)). At 
different magnifications, it is possible to see that the nanoparticles have penetrated 
through the corneocytes of the stratum corneum. Interestingly, liposomes did not 
penetrate deeper over time and were not found beyond the external keratynocytes 
layer. We also found in almost all the skin sections examined, including the control, 
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that external layers of corneocytes had a tendency of detaching from the innermost 








Figure 3.9 Visualisation of liposomes through the skin at different time points after a single Bleosome 
administration at different magnifications. The line (0h) corresponds to the pictures of the untreated 
samples (control): (a) x500, (b) x1200, (c) x1200; the line (30’) corresponds to the images of samples 
treated for 30 min with Bleosome: (d) x1200, (e) x2500, (f) x10K; line (2h) shows images taken from 
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skin sections treated for 2 h: (g) x500, (h) x2500, (i) x5000, the line (4h) show images relative to skin 
sections treated for 4 h: (j) x 1200, (k) x2500K, (l) x10K. Line (6h) shows images relative to skin sections 
treated for 6 h: (m) x2500, (n) x1200, (o) x2500. Line (8h) includes pictures of the skin after 8 h of 
Bleosome treatment: (p) x500, (q) x1200), (r) x 2500. The (0h) line shows the whole epidermis layer 
without the precence of liposomes. Liposomal nanoparticles can be appreciated circled in red within 
the kerantynocyes of the stratum corneum only, in the pictures relative to every time points of treatmen. 
Detachemnt of the layers of corneocytes can be noted in all the pictures. 
 
To confirm the hypothesis that there was no connection between the length of 
treatment and the depth of penetration of Bleosome through the skin, Bleosome was 
concentrated in one particular area of the section (data not shown). Moreover, in a 
further experiment, skin explants were subjected to repeated treatments, according to 
experimental setting number 3 in section 3.3.1. Here, skin sections were evaluated for 
30 min, 2 and 4 h and the position of the liposomes within epidermal layers was found 
again within the keratynocytes of the stratum corneum only, and not deeper than this 
external stratum for each time point tested (figure 3.10). 
Subsequently, to establish if artefacts due to the freezing and thawing of skin could be 
responsible for the detachment of layers of keratynocytes, the skin explants collected 
from a canine cadaver was immediately processed and treated, with a single 
administration of Bleosome, for 30 min, 2 and 4 h. These results were comparable to 
our previous findings, where nanoparticles were limited to the stratum corneum (data 










Figure 3.10 Liposomes were found within the SC only after different time points and repeated Bleosome 
applications. The line (0h) corresponds to the pictures of the untreated samples (control): (a) x2500(b) 
x10K (c) x2500; the line (30’) corresponds to the images of samples treated for 30 min with Bleosome: 
(d) x1200, (e) x10K, (f) x2500; line (2h) shows images taken from skin sections treated for 2 h: (g) 
x1200, (h) x10K, (i) x2500, the line (4h) show images relatives to skin sections treated for 4 h: (j) x 
1200, (k) x10K, (l) x2500. (0h) line shows details of the whole epidermis (a), stratum conreum (b) and 
underlying cellular levels of the epidermis (c): liposomes are absent at every level of the examined 
skin.(b),(e),(h) and (k) show details of the keratynocytes of the outermost stratum corenum at high 
magnification: in the control (b) liposomes are absent, while in every other time points of treatment 
(30’,2 and 4 h) the liposomal nanoparticles are present and visible between the corneocytes, relevant 
nanocarriers are circled in red. The other images shows details of the epidermis at lower magnification 
and confirmed the presence of liposomes only within the stratum conreum, nanoparticles are never 




3.4.3 Labelling of bleomycin with BODIPY-FL flurophore 
 
To effectively observe Bleosome penentration though the skin we aimed to label 
bleomycin, prior to encapsulation into UD liposomes, with a fluorophore. In 
collaboration with Marc Vendrell’s group at the QMRI, optimisation of the fluorescent 
labelling process was undertaken by trialling a range of fluorophore/bleomycin ratios 
(details in 2.8). Our main aim was to identify the optimal amount of fluorophore to 
use to produce a final compound containing the highest possible amount of mono-
labelled bleomycin (bleomycin sulphate bound to one Bodipy unit), avoiding double 
and triple labelling of the drug (bleomycin sulphate bound to two or three Bodipy 
units).  We also wanted to avoid residual unbounded fluorophore, as this could affect 
the imaging studies and generate unreliable data, while a small percentage of free 
bleomycin (less than 15%) was not likely to alter the efficacy of the final compound. 
Once we optimized the methodology with a small-scale trial, the reaction was scaled 
up and carried out in two larger batches. During the coupling process, the reaction was 
checked regularly by HPLC. Figure 3.11 shows the HPLC profile of the reaction after 
30 min (Figure 3.11 (a) and (c)) of the first and the second batch respectively. The two 
reactions displayed a very similar HPLC profile at the end of the process (Figure 3.11 
(b) and (d)): the major component of the reaction mixture was represented by mono-
labelled bleomycin, while a small amount of free bleomycin and succinimide-OH were 
present before the purification process. Following the conjugation reaction between 
bleomycin and the fluorophore, the powders produced by the two experiments were 
combined, purified from succinimide-OH and other minor fluorescent impurities, and 
finally analysed by HPLC (Figure 3.11 (f) shows the components of the final 









Figure 3.11 Fluorescent labelling of bleomycin. (a) and (b) represent the HPLC profiles of the first 
coupling reaction between 45 mg of bleomycin and Bodipy-FL, after 30 min and overnight respectively; 
(c) and (d) represent the HPLC profiles of last coupling reaction between 81 mg of bleomycin and 
Bodipy-FL, after 30 min and overnight, respectively.(e) and (f) are the HPLC profiles of the combined 
labelled bleomycin batches before and after the final lyophilisation respectively. According to their 
absorbance profile and mass spectra: peak 1.83 (red circle)  corresponds to succinimide-OH; peak 
3.38 (black circle) to free bleomycin;  peak 4.22-4.12 (green circle) corresponds to the mono-labelled 
bleomycin (bleomycin bound to the dye onto one amine group); 5.20 (yellow circle) corresponds to 
double-labelled bleomycin (bleomycin bound to the dye onto two amine groups); peak 7.63  (blue circle) 
corresponds to  free (unbound) Bodipy-FL.; 8,05 (violet circle) corresponds to a minor impurity of the 
fluorophore.  (f) shows quantification in percentage of the components of the final compound: 87.55% 
monolabelled bleomycin and 12.45% free bleomycin. 
 
The final powder contained 87% of mono-labelled compound and 13% of free 
bleomycin. This compound was sent, refrigerated and protected against direct light, to 
the Ascot Laboratories Ltd to be encapsulated into UD liposomes. A small amount 
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was saved to create the aqueous form of unencapsulated fluorescently labelled 




Figure 3.12 Final labelled bleomycin. (a) appearance of the final bleomycin powder coupled with 
Bodipy-FL; (b) appearance of the final bleomycin powder coupled with Bodipy-FL dissolved in PBS. 
 
3.4.4 F-Bleosome retains the same efficacy as unlabelled Bleosome 
 
To determine if F-Bleosome retained comparable efficacy to unlabelled Bleosome, we 
utilised cell viability assays. A preliminary experiment confirmed that the 
fluorescence of the labelled compound did not affect the luminometer reading of the 
assay. Here, cells were treated with F-Bleosome for approximately 10 min before 
being analysed. The assumption was that these cells did not have time to be killed by 
the compound, and, for this reason, they would be detected as viable cells, and 
generate the same signal among different drug concentrations if the fluorescence did 
not interfere with the reading. We found that cells expressed approximately the same 
signal and level of viability, regardless of the concentration of the drug (Figure 3.13). 
For this reason, we concluded that this method was appropriate to assess the efficacy 





Figure 3.13 Fluorescent label of F-Bleosome does not effect the reliability of the cell viability assay. 
F-Bleosome was added to cells 10 min prior to reading the assay and had no effect on the luminescence 
read-out. 
 
Hence, we performed the viability assay on two different canine cancer cell lines, 
using equivalent concentrations of Bleosome and F-Bleosome. Figure 3.14 shows that 
the mortality curve generated by both compounds followed the same trend: the 
percentage of viable cells decreased with increasing concentrations of the drug, and 
this was consistent in both cell lines tested. Therefore, we showed that there was no 
significant difference between the killing effect of F-Bleosome and Bleosome and 
concluded that the fluorescent dye coupled to bleomycin did not affect the cytotoxicity 
of the drug.   
Confident that the biology of the drug was not impinged by the addition of the Bodipy-





Figure 3.14 Comparison of the viability of C2 (a) and CML10. (b) cells (y axis)  treated with different 
concentrations of Bleosome and F-Bleosome (x axis) after 72 h. 
 
3.4.5 F-Bleosome is able to penetrate through skin better than F-
bleomycin 
 
Canine, equine and human skin sections were harvested and processed as before 
(3.3.5). Samples were counterstained with nuclear staining and treated with 0.1 ml of 
F-Bleosome or F-bleomycin for 10 min, 4 h and 6 h. Images were captured using a 
Zeiss LSM7 MP intravital and analysed with Imaris 9.1.2 (Bitplane) (protocol in 
Supplementary Data 8.2.4).  
 
3.4.5.1. Canine skin  
 
Several experiments were performed to confirm that F-Bleosome can efficiently 
penetrate through canine skin, and the results generated were always concordant; 
hence, here, representative results are shown. 
The skin has several structures that are autofluorescent, including collagen, cellular 
nuclei and hair follicles. All images were compared to untreated control sections of 
skin to account for background fluorescence. The nuclear staining, performed by 
Hoechst, highlighted nuclei in all the sections examined. This was a novel finding, as 
this method for staining nuclei within the skin has not previously been reported. 
However, the intensity of the blue was very similar to the green of F-Bleosome (NDD 
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R4), and hence, we set the “blue” colour of Hoechst as “magenta” (NDD R3) during 
image acquisition, to have a better contrast in the image analysis. In merged pictures, 
when the two colours (magenta and green) are overlapping in one object, this object 
appears white (see cellular nuclei in figure 3.15 (c)). Hoechst does not stain liposomal 
particles or bleomycin, therefore objects appearing green in the merged pictures are 
considered as F-bleomycin and F-Bleosome. Control samples show structures that 
appear fluorescent in the untreated skin, by subtracting the fluorescence of these 
structures to the overall fluorescence of the treated samples (showed as white in the 
merged images), what appears as “green fluorescence” in merged may be considered 
as F-bleomycin and F-Bleosome (figure 3.15 (f)). 
 
To provide a better understanding of the method and the appearance of F-Bleosome 
molecule on MP images using this technique, as an example, representative images 
are shown as z-projections in figure 3.15. Z –projections are images in which data 
from three dimensions are collapsed into two, putting all the pixel into a two-
dimensional stack, that have the same x and y coordinate.  
 
Figure 3.15 Appearance of F-Bleosome particles with the MP images. Canine skin samples were 
treated with Blosome for 0h and 6h. (a - c) 0h line shows z-projections of the control (untreated skin 
section) in two different channels: the green channel (a); the magenta channel (Hoechst) (b) ; merged 
magenta + green channels (c). (d  - f) 6h line shows z-projections corresponding to 6 h of Bleosome 
treatment in two different channels: the green channel (d); the magenta channel (Hoechst)(e) ; merged 




Three different areas of each sample were captured. All the images were analysed 
using Imaris. This software allowed us to visualize the skin section in 3-D and to 
inspect it from all possible perspectives. In figures 3.16 and 3.17 two sides of the 3-D 







Figure 3.16 Side views of 3-D canine sections treated with F-Bleosome and F-bleomycin at each time 
point. (a) is the image of the control (untreated skin section); (b), (d) and (f) correspond to the 3-D 
images of the skin sections treated with F-Bleosome  after 10’, 4 h and 6 h. Representative F-Bleosome 
molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 3-D sections 




Figure 3.17 Top view of the same 3-D canine sections treated with F-Bleosome and F-bleomycin 
showed in figure 3.16. (a) is the image of the control (untreated skin section); (b), (d) and (e) correspond 
to the 3-D images of the skin sections treated with F-Bleosome  after 10’, 4 h and 6 h. Representative 
F-Bleosome molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 




The untreated skin section did not show any distinct green particles, but displayed a 
high level of autofluorescence due mainly to cutaneous structures, such as the collagen 
associated with the extracellular matrix and the vascular wall, cellular nuclei and the 
hair follicles. These structures were also stained to some extent by Hoechst, and in the 
merged channel are shown as white (figues 3.16 and 3.17 (a)), whereas F-Bleosome 
and F-bleomycin molecules appear green in the merged picture (figures 3.16 and 3.17 
(b); (d);(f)). Images in figures 3.16 and 3.17 show that the untreated section did not 
show any solid green fluorescent structures using this method, while in the skin 
sections treated with F- Bleosome, the presence of round green fluorescent particles is 
evident. These particles correspond to the fluorescently labelled bleomycin 
encapsulated in UD liposomes, and their presence can be detected at the earliest time 
point post-treatment. After 10 min, the F-Bleosome particles are located at a very 
superficial level through the skin explant, and have a defined small, round shape. 
However, over increasing time of treatment, F-Bleosome particles can be found at 
deeper levels through the skin section, at a higher overall number and also their 
dimensions appeared to increase compared to the early stage of the treatment with a 
less defined spheroid shape. As a comparison, we also treated additional skin sections 
in the same manner, with F-free bleomycin. Interestingly, F-bleomycin is rarely 
detected throughout the skin sections and when detected the particles are smaller in 
size compared to the same time-point of F-Bleosome treatment. Moreover, the number 
and the depth of F-bleomcyin particles does not seems to be affected by increasing the 
length of treatment. 
All the images were analysed with Imaris software to quantify the data. However, 
Imaris is limited as it does not automatically subtract the objects expressing both 
magenta (Hoechst) and green from those that are generating only the green signal; 
hence, we have used an alternative system to identify the fluorescent drugs within the 
skin as detailed in 3.3.5.4. Figures 3.18 and 3.19 represent images after the Imaris 
software analysis: “surfaces” are yellow objects; while “spots” are oval objects. “Spots 
far from surfaces” (green spots in figures 3.18 and 3.19) are considered as F-Bleosome 
and F-bleomycin particles, and the “spots close to surfaces” (pink spots in figures 3.18 
and figure 3.19) are recognised by the software as the cellular nuclei or other very 
bright skin structures. This system permitted us to identify a majority of F-bleomycin 
and F-Bleosome particles within the examined skin section. However, a limitation of 
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this method is that particles of drug located close to the autofluorescent skin structures 









Figure 3.18 Side view of the images shown in figure 3.16 following Imaris analysis. Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Side view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 






Figure 3.19 Top view of the images shown in figure 3.17 after the Imaris analysis. Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Top view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 





The images analysed with Imaris generated data that weresstatistically analysed.  
The untreated skin section did not show any particles expressing the green signal 
alone, thus not producing any “spots far from surfaces”; all skin sections treated with 
F-Bleosome contained particles of drug, and they were always present in a greater 
number compared to the sections treated with F-bleomycin, as shown in table 3.1. 
 
 
Table 3.1 Number of particles of drug detected within canine skin sections treated with F-Bleosome and 
F-bleomycin after 10’, 4h and 6h. Overall number of drug particles detected between the two treatments 
were significantly different according to Pearson Chi-Square test (p-value: 0.002). 
 
The Imaris software was able to accurately localise every detected particle within the 
3-D section examined. However, it was not possible to obtain the same accuracy in 
the measurement of the volume and of the area of the particles: the program estimated 
only an overall mean of the dimension of all the objects detected within an image. This 
threshold is applied in a pre-set mode to all the particles without the option to adjust 
for individual particles. For this reason, statistical analysis was focused on the position 
of the drug molecules, specifically on the depth (z-axis) of the particles within the skin 
section. Data were analysed using the general linear model (GLM): two-way ANOVA 
and Fisher’s post-hoc test. Considering the location of every single particle of drug 
detected at every time point, the F-Bleosome molecules were found overall in a deeper 
position than the F-bleomycin ones. Significantly, we found that the depth of F-
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bleomycin particles was unchanged over time (between 10 min and 6 h, p-value: 0.1) 
whereas the F-Bleosome particles penetrated deeper through the skin over time (p-
value <0.001). 
The two treatments were also compared at each time point, and F-Bleosome molecules 
were found at a significant deeper position within the skin than the free F-bleomycin 
after 4 and 6 h, while, after the 10 min of drug administration, both the entrapped and 
free bleomycin, were found at a similar superficial level within the skin (figure 3.20). 
Looking at the deepest position at which F-Bleosome molecule was found after 6 h, it 
was at approximately 800 µm and at more than 300 µm after 4 h of treatment, while 
the deepest particle of the free form of fluorescent bleomycin reached a depth of 




Figure 3.20 Box plots comparing the depth of the drug molecules through the canine skin sections 
treated with  F-Bleosome and F-bleomycin at each time point. (a) represents the different depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 10’. (b) Represents the different depth in µm of drug molecules in the skin sections treated 
with F-Bleosome (blue plot) and F-bleomycin (orange plot) after 4h and (c) represents the depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 6h. (d) compares the three time points. * indicates statistically significant difference ( p-




3.4.5.2 Equine skin 
 
The penetration study using equine skin sections was performed following the same 
procedure as used for the canine skin.  
Skin explants were treated as previously explained and visualised by MP using the 





Figure 3.21 Side view of 3-D equine sections treated with F-Bleosome and F-bleomycin at each time 
point. (a) is the image of the control (untreated skin section);(b), (d) and (f) correspond to the 3-D 
images of the skin sections treated with  F-Bleosome  after 10’, 4 h and 6 h. Representative F-Bleosome 
molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 3-D sections 




Figure 3.22 Top view of the same 3-D equine sections treated with F-Bleosome and F-bleomycin of 
figure 3.21. (a) is the image of the control (untreated skin section);(b), (d) and (f) correspond to the 3-
D images of the skin sections treated with  F-Bleosome  after 10’, 4 h and 6 h. Representative F-
Bleosome molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 3-





These images (figures 3.21 and 3.22) compare the penetration through equine skin F-
Bleosome and F-bleomycin, according to the length of time of treatment. The results 
obtained from the skin penetration study using equine skin are comparable to the 
canine skin: the overall number of F-Bleosome particles was higher than the F-
bleomycin at every time point, as well as their rate of penetration through the skin. 
Once again, in the F-bleomycin treatment, at 10 min, the drug particles are not as 
evident as the F-Bleosome ones. However, at the 6 h time point, the skin section 
treated with the free fluorescent drug here (figures 3.21 and 3.22(g)), showed a very 
high level of green background autofluorescence, and, without software analysis, F-
Bleosome particles are more clearly visible compared to the canine skin treated for the 
same amount of time with free F-bleomycin.  
Captured images were analysed by Imaris as previously described. An example of 
the distribution of green spots (F-Bleosome and F-bleomycin molecules) at indicated 




Figure 3.23 Side view of the images shown in figure 3.21 following Imaris analysis. Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Side view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 





Figure 3.24 Top view of the images shown in figure 3.22 after the Imaris analysis.  Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Side view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 






Data gained from the image analysis supported our previous results in canine skin 
and revealed that the overall number of drug molecules was higher at every time 
point in the F-Bleosome-treated skin sections compared to those treated with the free 
F-bleomycin (table 3.2). 
 
 
Table 3.2 Number of particles of drug detected within equine skin sections treated with F-Bleosome 
and F-bleomycin after 10’, 4h and 6h. Overall number of drug particles detected between the two 
treatments were significantly different according to Pearson Chi-Square test (p-value≤0.000). 
 
Statistical analysis was conducted on the z-position (depth) of particles of drug in all 
the skin sections (GLM: two-way ANOVA, Fisher’s post hoc test). Results were 
comparabe to the canine study. Position of F-Bleosome molecules was found to be 
significantly deeper and proportional to the length of treatment (10’ vs 4 h vs 6 h, p-
value ≤0.000) compared to the F-bleomycin. Furthermore, comparing the position of 
all the particles of the drug detected, there was a statistically significant difference 
between the two treatments: F-Bleosome penetrated significantly deeper the F-
bleomycin at 4h and 6h treament (p-value<0.001). However, there was no significant 
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difference after 10 min of treatment (figure 3.25). At 4 h, the deepest F-Bleosome 
particle was found at 271 µm of depth, and at 430 µm after 6 h of treatment, while the 
deepest molecule of the unencapsulated counterpart, was found at 108 and 222 µm 




Figure 3.25 Box plots comparing the depth of the drug molecules through the equine skin sections 
treated with  F-Bleosome and F-bleomycin at each time point. (a) represents the different depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 10’. (b) Represents the different depth in µm of drug molecules in the skin sections treated 
with F-Bleosome (blue plot) and F-bleomycin (orange plot) after 4h and (c) represents the depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 6h. (d) compares the three time points. * indicates statistically significant difference ( p-
value <0.05, two-way ANOVA). 
 
3.4.5.3 Human skin  
 
Human skin was kindly gifted to us by volunteers who agreed to take part in this study. 
To compare the penetration of Bleosome through human skin to our previous work in 
canine and equine skin we performed the skin penetration test on human samples 
following the same procedure and using same microscope settings as before. However, 




Figure 3.26 Side view of 3-D human sections treated with F-Bleosome and F-bleomycin at each time 
point. (a) is the image of the control (untreated skin section);(b), (d) and (f) correspond to the 3-D 
images of the skin sections treated with  F-Bleosome  after 10’, 4 h and 6 h. Representative F-Bleosome 
molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 3-D sections 




Figure 3.27 Top view of the same 3-D human sections treated with F-Bleosome and F-bleomycin of 
figure 3.26. (a) is the image of the control (untreated skin section);(b), (d) and (f) correspond to the 3-
D images of the skin sections treated with  F-Bleosome  after 10’, 4 h and 6 h. Representative F-
Bleosome molecules are indicated by red arrows. (c), (e) and (g) correspond to the side view of the 3-




As figures 3.26 and 3.27 show, after 10 min of treatment, particles of bleomycin from 
both compounds were not clearly detected, while, after 4 h, in the F-Bleosome treated 
section, several fluorescent molecules can be observed across the skin section (figures 
3.26 and 3.27 (d)). Interestingly, at the same time point, in the sample treated with F-
bleomycin, a stronger green background rather than proper fluorescent particles were 
observed (figures 3.26 and 3.27 (e)), and the intensity of the fluorescence was higher 
in the outermost layers of skin, without passing beyond the nuclear layer. After 6 h, 
fewer skin components were visible, resulting in ambigous images; this was probably 
due to photobleaching of the Hoechst staining over time. However, F-Bleosome 
particles can be still recognised in the deeper layers of the skin section (figures 3.26 





Figure 3.28 Side view of the images shown in figure 3.26 following Imaris analysis. Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Side view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 





Figure 3.29 Top view of the images shown in figure 3.27 after the Imaris analysis.  Yellow objects are 
“surfaces”, corresponding to skin appendages stained with Hoechst and/or expressing a low level of 
green signal, oval objects are “spots”, corresponding to the green-emitting structures (drug molecules) 
and the most autofluorescent skin structures stained also with Hoechst (cellular nuclei). After distance 
transformation, the pink spots are “spots close to surfaces” corresponding to cellular nuclei and green 
spots are “spots far from surfaces” corresponding to drug molecules. (a) Side view of the control, (b) 
analysis of skin section after 10’ of F-Bleosome treatment, (c) 10’ after F-bleomycin treatment, (d) the 




We compared the z-position of F-Bleosome and F-bleomycin at each time point and 
confirmed that F-Bleosome can penetrate deeper through human skin, after 4 and 6 h 
of treatment, than free F-bleomycin. As previously reported in dogs and horses, after 
10 min, both compounds appeared to be present at similar level in the outermost layers 
of the cutis (figure 3.30). Again, there was a significant difference in the rate of 
penetration of F-Bleosome through the skin compared to F-bleomycin (p-value 
≤0.000) (GLM: two-way ANOVA, Fisher’s post hoc test). In human skin, after 6 h, 
the deepest F-Bleosome particle was found at approximately 1 mm of depth, compared 




Figure 3.30 Box plots comparing the depth of the drug molecules through the human skin sections 
treated with  F-Bleosome and F-bleomycin at each time point. (a) represents the different depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 10’. (b) Represents the different depth in µm of drug molecules in the skin sections treated 
with F-Bleosome (blue plot) and F-bleomycin (orange plot) after 4h and (c) represents the depth in µm 
of drug molecules in the skin sections treated with F-Bleosome (blue plot) and F-bleomycin (orange 
plot) after 6h. (d) compares the three time points. * indicates statistically significant difference ( p-







In this study, we optimised an imaging technique that enabled us to visualise both the 
UD liposomes and the entrapped bleomycin within layers of human and animal skin, 
after the Bleosome treatment. To this purpose, we took advantage of the TEM and the 
MP and we coupled the bleomcyin with the fluorophore Bodipy-FL to create a 
fluorescently labelled Bleosome and unencapsulated bleomycin, to the aim of 
visualising the drugs with the MP. The TEM visualisation revealed that the UD 
nanocarriers reside only within the outermost stratum conreum of the skin, after 
several length and modality of Bleosome treatment; while we obsverved a 
significantly improved penetration of the bleomycin, when encapsulated in UDs, 
within human and animal skin, compared to its free form. These results led us to 
conclude that UD liposomes enhance the transport of bleomycin through deep layers 
of animal and human skin. Furthermore, the double visualisation of liposomes and the 
entrapped drug through the skin allowed us to speculate that the nanocarriers might 
act as skin penetration enhncers, following the mechanism number 2 proposed by 
Verma et al (2003), when they transport bleomycin. 
Several studies have reported that UD liposomes were able to penetrate through intact 
skin in vivo, transferring therapeutic amounts of drugs ( Cevc and Blume 2001; Cevc 
and Blume 2003(A);  Cevc and Blume 2004), including macromolecules, with 
efficiency comparable with subcutaneous administration (Paul, Cevc, and Bachhawat 
1995;  Cevc et al. 1998; Paul, Cevc, and Bachhawat 1995;  Cevc and Gebauer 2003 
(B)). Other in vitro skin permeation studies confirmed that deformable liposomes were 
able to improve skin delivery of various chemical entities. Although most of these 
results were indicative of improved transdermal delivery, in vitro transport rates were 
usually much lower than the exceptionally high transport rates reported in vivo 
(Elsayed et al. 2007). However, several comprehensive reviews suggest that there is 
still a scarcity of informative clinical data for the use of such carriers (Hussain et al. 
2017). There are still many controversies regarding the actual mechanism of cutaneous 
penetration improvement of UD liposomes. Previous studies have investigated how 
UD vesicles could improve skin delivery of drugs and there are two main mechanisms 
proposed (Honeywell-Nguyen and Bouwstra 2003 (B)): the transappendageal and 
transepidermal pathways. The transappendageal routes are also known as the shunt 
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routes and include permeation through the sweat glands and across the hair follicles 
with their associated sebaceous glands (Honeywell-Nguyen and Bouwstra 2003 (B)). 
The transepidermal pathway can be defined as the pathway where compounds 
permeate across the intact, unbroken stratum corneum. This pathway contains two 
micropathways with two different mechanisms of skin penetration: 
 Mechanism 1: The intercellular route, which is a continuous but tortuous way 
through the intercellular lipid domains (El Maghraby, Barry, and Williams 
2008). Vesicles can act as drug carrier systems, whereby intact vesicles enter 
the stratum corneum carrying vesicle-bound drug molecules into the skin, 
passing through these tiny channels (Cevc, Schätzlein, and Richardsen 2002).  
 
 Mechanism 2: The transcellular pathway through the keratinocytes, then 
across the intercellular lipids (Barry 1991). Here, vesicles can act as 
penetration enhancers, whereby vesicle bilayers enter the stratum corneum and 
subsequently modify the intercellular lipid lamellae. This will lead to the 
penetration of free drug molecules into and across the stratum corneum 
(Verma et al. 2003). 
 
The first mechanism was put forward by Cevc et al. for deformable liposomes (G. 
Cevc and Blume 1992; Cevc, Schätzlein, and Richardsen 2002;  Cevc and Blume 
2001). They proposed that the driving force for the vesicles entering the skin is 
xerophobia (the tendency to avoid dry surroundings) (Cevc and Blume 1992). The 
important difference between deformable liposomes and traditional liposomes is the 
high and stress-dependent adaptability of such deformable vesicles, which enables 
them alone to squeeze between the cells in the stratum corneum, despite the large 
average vesicle size (Cevc, Schätzlein, and Richardsen 2002). Thus, they can trespass 
the intact skin spontaneously, under the influence of the naturally occurring in vivo 
transcutaneous hydration gradient (Cevc and Blume 2001), intact without permanent 
disintegration (Cevc, Schätzlein, and Richardsen 2002). 
Several studies supported that deformable liposomes and surfactant-based elastic 
vesicles may act as carrier systems. In one study, pretreatment of skin membranes with 
empty deformable liposomes did not enhance oestradiol flux, while application of 
oestradiol entrapped in vesicles resulted in 14–17-fold increase in flux relative to 
control (El Maghraby, Williams, and Barry 1999). Interestingly, fluxes of oestradiol 
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from large and small vesicles were similar in this study, providing no evidence of 
intact vesicle penetration. Furthermore, (van den Bergh et al. 1999) showed that pre-
treatment of hairless mouse skin with surfactant-based elastic vesicles increased the 
diffusion of 3H2O compared to pre-treatment with a buffer control, indicating a 
possible penetration enhancing mechanism. Based on results of previous studies, some 
authors support that both the intact vesicular permeation into the stratum corneum and 
the penetration enhancing effect play a role in the enhanced skin delivery of drugs by 
deformable liposomes under non-occlusive conditions, and suggest that one of the two 
mechanisms might predominate according to the physico-chemical properties of the 
drug. However, the rate and amount of released drug is a balance between two factors: 
(1) drug affinity to vesicles, and (2) drug solubility in lipids of the stratum corneum 
(Honeywell-Nguyen and Bouwstra 2003 (A)). As reported in a recent study, poor drug 
release resulted in retention of the drug within vesicles in the stratum corneum and 
elastic vesicles served as a slow release depot system (Honeywell-Nguyen and 
Bouwstra 2003 (A)). For hydrophilic drugs, such as bleomycin, the penetration 
enhancing effect seems to play a more important role in the enhanced skin delivery 
than in case of lipophilic drugs (as for many penetration enhancers), since permeation 
of hydrophilic molecules tends to be relatively slower and hence more enhanceable 
(Williams and Barry 1991). The intact vesicle penetration mechanism will also have 
an important role especially in improving skin deposition. However, as previously 
mentioned, drug release from vesicles in the stratum corneum is an important step that 
affects transdermal flux (Honeywell-Nguyen and Bouwstra 2003 (A)). For those 
reasons, the synergistic activity of liposomes and loaded drugs needs to be explored. 
In addition, research needs to be conducted to determine the final localisation of the 
entrapped drug after the skin penetration (Hussain et al. 2017). To the best of our 
knowledge, this is the first study to explore the mechanism of skin penetration of UD 
liposomes by direct visualisation of both the liposomal molecules and the entrapped 
drug through the skin using explants from dogs, horses and humans.  
 
We initially attempted to visualise the penetration of Bleosome through the skin using 
fluorescent microscopy. Our collaborators (S. Chopra et al, unpublished) have 
previously shown in human skin explants the penetration of Bleosome over a time 
course (0 h – 6 h) using the intrinsic autofluorescence of Bleosome (Ranji et al. 2016). 
Their results showed a peak of overall fluorescence within the skin sections at 2 and 4 
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h, while the intensity of fluorescence decreased by 6 h, and they concluded that the 
peak of penetration of Bleosome is 2 - 4 h after the treatment. To reproduce these 
findings in animal skin, we conducted a similar experiment with canine skin excised 
from cadavers; however, the untreated (control) skin showed a high intrinsic 
autofluorescence (figure 3.5). Skin autofluorescence is a phenomenon likely due to 
flavoproteins (FAD) and NAD- related compounds, but also to elastin, collagen, and 
lipofuscin and redox state of the cells (Laiho et al. 2005). In our experiment, 
cryosectioned skin samples were evaluated, rather than formalin-fixed-paraffin-
embedded (FFPE) tissues, as the latter are known to typically 'autofluoresce' when 
viewed under a fluorescent microscope (Laiho et al. 2005). However, even utilising 
the cryosectioning technique, the level of autofluorescence of canine skin was very 
high. To quench the autofluorescence we trialled multiple fixing techniques including 
pre-cooled acetone and organic solvents, and a quenching agent (TrueBlack®). 
However, the high autofluorescence of the skin was still higher than the intrinsic 
fluorescence of the drug (data not shown) and no significant difference was shown 
over the time course of treatment (figure 3.6). Interestingly, hair follicles appeared to 
be the most autofluorescent structures within the skin. One route by which liposome-
encapsulated drugs are supposed to penetrate the skin is the transappendegeal 
mechanism (Scheuplein 1965), passing through the sweat glands and hair follicles. 
Thus, the high level of fluorescence emitted by those structure in the images of this 
study (figures 3.6), might be due to the passage of the Bleosome through these 
structures. However, it is important to note that in the untreated skin sections, hair 
follicles generated a level of green fluorescence, which is not significantly different 
from the green signal of the hair follicles in the treated skin.  
To obtain more meaningful data and confirm that liposomal nanoparticles did not 
hindered the green fluorescence of the entrapped bleomycin, we compared the 
Bleosome treatment with other compounds containing free bleomycin without 
liposomes. Again, the results did not show a significant difference in the final emitted 
fluorescence between the control and all the time points of treatment (figure 3.7).  
We therefore concluded that the penetration of the compound through the skin could 
not be observed by the intrinsic fluorescence of Bleosome. 
  
Therefore, we aimed to explore the mechanism of skin penetration of Bleosome by 
visualising directly both the liposomes and the entrapped bleomycin. In order to 
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perform this study, TEM and MP were both used as complimentary techniques: the 
former allowed the direct visualisation of liposomes, the latter, the direct visualisation 
of encapsulated bleomycin particles within skin samples. Using TEM to compare 
untreated skin sections and skin sections treated with Bleosome at different time 
points, we found the presence of the UD nanoparticles through the stratum corneum 
in the treated samples only. The appearance of liposomes within skin layers in our 
images was consistent with the nanoparticles themselves visualised with TEM after 
sonication of Bleosome (figure 3.8) and with representative images in the literature 
(Subongkot et al. 2014; Rangsimawong et al. 2015). However, the quality of skin 
sections was variable: in the majority of the images, the layers of corneocytes were 
found detached from the underlying layers of the stratum corneum even in the 
untreated skin samples, which was considered during the evaluation of the rate of 
penetration over several time points. Similarly, Subongkot et al (2014) conducted a 
similar study on porcine skin and found that after the treatment with UD liposomal 
nanoparticles there was a detachment of the stratum corneum, while it was normal in 
untreated samples. Moreover, they observed that the broad shape and the fewer 
electron-dense keratin filaments of the corneocytes in the treated stratum corneum 
resulted from denaturation of keratin inside the corneocytes. The intercellular spaces 
of porcine skin treated with ULs were wider than those of intact skin, because the 
corneodesmosomes, that connected the corneocytes between each stratum corneum 
layer, were degraded. As a result of the degradation of corneodesmosomes, the stratum 
corneum layers of treated skin were detached (Subongkot et al. 2014). Observing our 
images, we could not reach the same conclusion, as the layers of the stratum corneum 
were found detached, in both treated and untreated skin sections, suggesting that this 
phenomenom could be due to slight damage of this outermost and fragile layer of the 
epidermis, during the sample processing. However, we do show that nanoparticles are 
able to penetrate through the stratum corneum and reside between corneocytes, but 
they could not be found deeper than this outermost layer, even after several hours of 
application of the compound (from 30 min to 8 h of treatment). The penetration 
experiment, using these experimental settings, was performed several times, and the 
resulting images were consistent, showing the presence of the liposomes in the stratum 
corneum only at every time point analysed. To explore the possibility that freezing 
procedures could affect the integrity of the stratum corneum by the formation of 
freezing crystals, we used ‘fresh’ skin samples, treated immediately after the 
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collection from cadavers, omitting the freeze storage and thawing of samples.  The 
quality of ‘fresh’ skin sections was comparable to ‘frozen skin’ samples: all the layers 
of the skin could be visualised, there was still some degree of detachment of the 
keratinocyte layers, and the skin structures were recognisable. Moreover, UD 
liposomes within ‘fresh’ skin, after 2 and 4 h of treatment with Bleosome, resided in 
the outermost layers of the stratum corneum, and not deeper (data not shown), these 
results are in accordance with those  using ‘frozen’ skin samples.  
Our first penetration studies were based on a time course of administration of 
Bleosome, and demonstrated that the length of time of treatment did not affect the 
depth of penetration of liposomes through the skin. To explore the possibility that the 
quantity of compound played the main role in enhancing the penetration of liposomes 
deeper through the skin, we treated skin explants with repeated application of the 
compound every 60 min: applying from 0.1 ml to 0.4 ml of Bleosome per skin section. 
Again, we found that UDs were confined in the stratum corneum and were not in the 
deeper underlying cellular layers. This experiment was conducted multiple times, and 
we fully optimised the technique in terms of different length, quantity and modality of 
treatment; furthermore, each experiment was performed using skin explants derived 
from dogs of different breeds, sex and ages, and our results were always consistent. 
Therefore, we concluded that UD liposomes within Bleosome, are able to penetrate 
through the outermost layers of the skin, crossing and intercalating between the 
keratinocytes of the stratum corneum, but they cannot traverse beyond this layer.  This 
finding is in accordance with a recent in vivo electron microscopy study, which 
demonstrated a fast (within 1 h of application) partitioning of intact surfactant-based 
elastic vesicles into the human stratum corneum, but no vesicles could be found in the 
deepest layers of the stratum corneum (Bouwstra et al. 2003 ). TEM and freeze-
fracture electron microscopy demonstrated also major morphological changes in the 
intercellular lipid lamellar structure with no changes in the viable epidermis 
ultrastructure, after application of surfactant-based elastic vesicles (van den Bergh et 
al. 1999).  
Given that our previous studies have highlighted that neither the autofluorescence of 
Bleosome or free bleomycin exceeds that of canine skin we determined that to 
effectively image the penetration through the skin of entrapped bleomycin molecules 
within UD liposomes we would need to effectively label Bleosome with a fluorescent 
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marker. In collaboration with Dr. Marc Vandrell’s lab we successfully coupled 
bleomycin with Bodipy-FL prior to encapsulation within UD liposomes.  
Bodipy was selected, from several different available dyes, as it is a relatively non-
polar and non-charged chromophore. These properties tend to minimize dye-induced 
perturbation of the functional properties in the conjugate (Ulrich, Ziessel, and 
Harriman 2008). Bodipy dyes are therefore often the preferred choice for labelling 
nucleotides, amino acids and other low molecular weight ligands. In fact, the green-
fluorescent Bodipy-FL fluorophore has several features that make it potentially 
superior to fluorescein in some applications (Strandberg et al. 1994). These include: 
high extinction coefficient and high fluorescence quantum yield; lack of ionic charge 
and a relative lack of sensitivity to solvent polarity and pH changes; narrow emission 
bandwidth resulting in a higher peak intensity than that of fluorescein; greater 
photostability than fluorescein in some environments and a large two-photon cross-
section for multiphoton excitation (C. Xu et al. 1996). To the best of our knowledge, 
this is the first time that Bodipy-FL has been conjugated to bleomycin, and our main 
concern was that the reactive succinimidyl group of Bodipy-FL could have bound to 
all the three amine groups of the metal binding domain of the bleomycin molecule. 
The metal binding domain contains the ligands (nitrogen atoms) involved in 
octahedral complex formation with the transition metals. The N3- and N4-amino 
groups of the pyrimidine moiety of the metal binding domain of bleomycins are 
proposed to define the sequence specificity of DNA cleavage by binding to the N3- 
and N2-amino groups of the guanine 5’ to the pyrimidine cleavage site. The 
pyrimidine moiety of bleomycin, interacting with the bithiazole tail, is responsible for 
DNA binding (Chen and Stubbe, 2005).  Hence, during the coupling process, we 
wanted to prevent Bodipy-FL from binding to all the three amine groups of bleomycin, 
in order to avoid a diminished DNA binding and an overall decreased efficacy of the 
fluorescent compound. HPLC profile of the final labelled bleomycin confirmed that 
the fluorescent dye bound the bleomycin molecule on just one amine group. Moreover, 
cellular viability assays performed using two different canine cancer cell lines, 
confirmed that F-Bleosome is as cytotoxic as its unlabelled counterpart.  
Confident in the functionality of F-Bleosome, we performed the last step of our study: 
the direct visualisation of the drug through skin explants of different species. Canine, 
equine and human skin sections were treated with fluorescently labelled Bleosome 
over a time course to assess the extent of penetration of bleomycin-encapsulated 
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liposomes within animal and human skin. Furthermore, we compared this innovative 
topical treatment with the standard unencapsulated bleomycin labelled with the same 
fluorophore. Our analysis showed that F-Bleosome penetrated significantly deeper 
through the skin than the free F-bleomycin, and that this was consistent for equine, 
canine and human skin sections. Furthermore, F-Bleosome penetrated significantly 
deeper through cutaneous layers with increasing time of treatment; indeed, after 4 and 
6 h, the drug molecules were found at a significantly greater depth compared to the 
first 10 min of treatment in all the three species. 
In all the three species examined, there was a significant difference in the position of 
F-Bleosome molecules within the skin at each time point of treatment, while this was 
not the case of the F-bleomycin particles, in which there was no significant difference 
in the position of the particles between 10 min, 4 h and 6 h of application. Interestingly, 
after the few min of treatment, the two compounds were found both in the superficial 
layers of the skin. However, after 4 and 6 h, F-Bleosome penetrated significantly 
deeper through skin compared to the free F-bleomycin. These findings indicate that 
the length of time of treatment is closely related to the ability of F-Bleosome in 
crossing several innermost cutaneous layers, rendering the time of treatment a crucial 
aspect to be considered when translating this therapy in the clinical application. 
To confirm the superior ability of F-Bleosome in penetrating through the skin, the 
number of the Bleosome particles in canine and equine skin were analysed. We found 
significantly more drug molecules in skin sections, at each time point, treated with F-
Bleosome compared to the free F-bleomycin, suggesting that liposomes are effective 
carriers for the passage of bleomycin through the skin. 
The penetration experiment using human skin was conducted only once, and the 
number of particles of F-Bleosome and F-bleomcyin within skin was not analysed, as 
there was insufficient data to be statistically reliable. However, our initial results in 
human skin are comparable to those from canine and equine skin, indicating that F-
Bleosome is more efficient at penetrating deeper into human skin that free F-
bleomycin.  
Our findings are compelling regarding the localisation of drug particles within the 
skin. Imaris calculated the position of the targeted drug particles in the canine skin 
treated with F-Bleosome: the maximum distance from the outermost cutaneous layer 
where the F-Bleosome molecule was found was ~300 µm after 4 h of treatment and 
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800 µm after 6 h. The canine skin sections used for this experiment were collected 
from the flank of canine cadavers. Theerawatanasirikul et al. (2012) found that the 
average thickness of the canine epidermis in this area is 40 µm, thus, F-Bleosome can 
cross the stratum corneum and penetrate deeper into the dermis, passing through the 
epidermis layers. In equine skin, after 4 h, the deepest Bleosome particle was found at 
271 µm of depth and at 430 µm after 6 h of treatment. The skin sections used were 
collected from the abdomen of an equine cadaver. Although there is not a consensus 
on the exact thickness of the epidermis of horses, it is well recognised that this differs 
among different regions of the horse body, and Jorgensen et al. (2018), estimated an 
averaged epidermal thickness for this area of approximately 29.36 µm. Therefore, as 
for the canine experiment, F-Bleosome can reach deep regions within the dermis of 
equine skin, crossing the outermost layers of the skin and the epidermis. In human 
skin, we could not establish the exact depth of the F-Bleosome molecules due the 
limited availability of skin samples to conduct technical replicates. However, in the 
single experiment conducted, at 6 h of treatment F-Bleosome molecules were found 
at a depth of about 1 mm within skin explants, indicating that the fluorescent liposomal 
drug had the ability to penetrate through the whole skin section. The epidermal 
thickness of human breast is 76.9 µm (Ince et al. 2015) and thus, after 4 h of a single 
topical application, when encapsulated in liposomes, bleomycin seems to be able to 
penetrate into the dermal layer in human skin. However, these results are preliminary 
findings and an extended study using human skin should be considered.  
In all three species tested F-Bleosome molecules, after 4 and 6 h of treatment, were 
found intercalated in skin structures at the same level of the cellular nuclei. The first 
nucleated layer of the skin, starting from the outermost stratum corneum, is the stratum 
spinosum, which, in human skin, has an approximative thickness of 100 µm 
(Horikoshi et al. 2005). Furthermore, the epidermis is an avascular component of the 
skin (Horikoshi et al. 2005), and in some 3-D images, it is possible to identify some 
F-Bleosome molecules located close to structures that appear similar to small blood 
vessels. This might reinforce the hypothesis that the encapsulated bleomycin is able to 
penetrate beyond not only the hard outermost corneocytes but also the epidermis.  
However, a major issue in the evaluation of the exact z-position of the particles of drug 
was the overall depth of the skin explants themselves examined with MP. During the 
preparation of skin sections, care was taken to process samples with the same 
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dimension and thickness. However, to produce accurate and high-quality images, MP 
needs samples that are as flat as possible. Obviously, dealing with live, intact skin 
sections, rather than histological slides, leads to inherent variation in the final sample; 
however, in order to obtain an even surface, sections were anchored to the bottom of 
a petri dish, kept as flat as possible, embedded in agarose. Nonetheless, some areas of 
some sections were not clearly visible due to naturally occuring irregularity of the skin 
surface. Moreover, the cutaneous sections were visualised with the epidermis side 
facing the bottom of the petri dish and with the lens of the MP directed toward the 
subcutaneous side, because the epidermis is hairy and the keratynocytes themselves 
have a level of high autofluorescence and may prevent the visualisation of other 
structures within that section (data not shown). Hence, these additional factors were 
considered when establishing the exact z-position and depth of the skin section 
examined. 
To gain quantifiable data from the images captured by MP, we used Imaris software; 
however, this program has several limitations and it was not always possible to 
accurately target all the F-Bleosome and F-Bleomycin particles. Hence, in limited 
situations, some particles recognised as cellular nuclei, were manually converted to F-
Bleosome or F-bleomcyin molecules. Reasuringly, the consistency of the results 
between technical and biological replicates (including between different breeds and 
species), was a confirmation that, even with limitations, our methodology was a 
suitable and reliable first step towards accuratly visualising the fate and the mechanism 
of action of drug penetration through animal and human skin.  
Unfortunately, it was not possible to have an accurate measurement of the size of the 
F-Bleosome and F-bleomycin particles, using the Imaris software. However, it is 
certainly possible to note, by the images gained with the MP, that the size of the F-
Bleosome particles tends to increase at the increasing time points. Moreover, their 
shape, which is well demarcated and spheroidal in the early stage of treatment, changes 
at later time points of Bleosome application: molecules, after 6 h of treatment, appear 
without clear margins and with a wider variation among all the drug particles present. 
This is consistent across all the species compared in this study.  These findings, 
together with the results of the TEM experiment, led us to hypothesise that Bleosome 
is able to reach the deeper strata of the epidermis and the underlying dermis, according 
the mechanism number 2 proposed by Verma et al (2003), acting as penetration 
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enhancer. In the electron microscope study, liposomes were found only in the stratum 
corneum, after treating skin explants for more than 6 h. However, having treated the 
skin explants in the same manner, and visualising with the MP, the F-bleomycin 
molecules reached the deeper layers of the skin after 4 h of treatment, and the dermal 
layer 6 h after one single application of Bleosome. Furthermore, the fact that F-
Bleosome molecules tended to increase in size and have less defined margins at 
increasing time of treatment and thus, depth of penetration, it might be a further 
indication that liposomal nanocarriers interact with the hard keratynocytes, finding 
spaces between interlipidic lamellae and being therefore disrupted. Our hypothesis is 
that after 10 min, Bleosome consists of bleomycin still encapsulated in liposomes, and 
is found only at a superficial level. After 4 - 6 h, once Bleosome has passed beyond 
the stratum corneum, liposomes are damaged and the entrapped drug is released and 
free to expand, to aggregate with other molecules and to penetrate deeper into the 
cellular and vascular dermal layer.  
To the best of our knowledge, this is the first study that has investigated the fate of 
bleomycin encapsulated liposomes after topical skin application, through direct 
visualisation of both UD liposomes and the entrapped drug. Our findings support the 
greater ability of Bleosome to penetrate through the skin, when compared to the free 
bleomycin, and explain that UD liposomes, when loaded with bleomycin, act as 
penetration enhancer, interacting with the stratum corneum and releasing the payload 
after 4 h of treatment. 
 
3.6 Conclusions, limitations and future directions 
 
In this study, we sought to assess if and how Bleosome was able to penetrate through 
animal and human skin. To this extent, we optimised an innovative imaging technique 
to directly visualise both the liposomes and the entrapped bleomycin in ex-vivo viable 
skin explants. Firstly, we attempted the direct visualisation of the drug using the 
fluorescent microscope, confident of the intrinsic fluorescence of bleomcyin. 
However, the high level of the autofluorescence of skin structures hampered a clear 
visualisation of the drug; hence, we performed a penetration study using canine skin 
sections treated with Bleosome over several time points. After the treatment, sections 
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were analysed with the TEM. This technology does not allow direct visualisation of 
bleomycin particles, however, liposomes were observed and recognised and they were 
consistently found within the stratum corneum, but were not detected in any of the 
deeper layers of the epidermis after 30 min, 2, 4, 6 and 8 h of treatment. Subsequently, 
we coupled the bleomycin with a fluorophore, Bodipy-FL, to detect F-bleomycin 
using the MP. We successfully visualised F-bleomycin inside liposomes, and detected 
their localisation after different times of treatment. After 6 h of treatment, the deepest 
particle was found at 800 µm in the canine skin, at 430 µm in the equine skin, and at 
approximately 1 mm in human skin. This is significantly deeper than the average 
thickness of the stratum corneum (15/20 µm) (Theerawetanasirikul, et al 2012), and 
the average thickness of the epidermis (40 µm). We therefore propose that liposomes 
allow and improve the penetration of encapsulated bleomycin through animal and 
human skin, acting as penetration enhancers, following the mechanism number 2 
proposed by Verma et al (2003): liposomal vesicles might interact with outermost 
keratinocytes, disrupting intercellular lipid lamellae and allowing the release and 
consequently the penetration of the entrapped bleomcyin through the skin.  
This study has several limitations: The TEM and the MP provided integrative data, 
however, even if the experimental settings used were the same, the studies were 
performed under different conditions and this might cause some variability in the 
outcome. We did not visualise equine and human skin with the TEM, to prove that 
liposomes behave in the same manner in the skin of these species. Images gained with 
MP were analysed with using Imaris software. However, the program did not allow us 
to compensate for variability in depth of single skin explant imaged (which might 
explain the different position of the particles after 4 and 6 h of treatment among the 
different species), nor the exact dimension and size of the drug particles. Furthermore, 
our Imaris protocol generated some controversies in distinguishing exactly all the F-
Bleosome particles from the autofluorescent skin structures, generating the need to 
manually adjust the count in limited circumstances. 
The skin samples used for this study were collected from abdomen and flank of dogs 
and horses, and from breast tissue in human. These anatomical regions were chosen as 
they are easy accessibility from cadavers and we wished to remove the skin 
promptly after the euthanasia of the animals. Moreover, withrowing skin from a large, 
even surface of the body allowed us to perform our study on the penetration of 
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Bleosome through the skin, using samples from the same animal and from the same 
anatomical region, hence, with similar characteristic and thickness. This was an 
important factor in order to assure the reproducibility and consistency of the study and 
allowed us to locate the position of the drug particles according to the depth of 
epidermis of that particular body area.  
The skin explants used for this study were withdrown from cadavers, immediately 
frozen and thawed at the time of the relative experiment. This methodology was used 
according to the OECD guidelines for assessing the permeability and penetration of 
compounds through the skin. These guidelines state that the features of the skin 
processed according to the procedure illustrated within the document and used in our 
study, resemble to a good extent the ones of skin in a living organism. However, 
several studies also claim that the fluxes of transdermal permeation of compounds in 
vitro are generally lower than what found in vivo; this might be due to the dermal 
vasculature and to the hydration gradient present in the skin of living body, which is 
diffuclt to reproduce in the laboratory (Nakadate 1991; Davies, Ward, and Heylings 
2004). Hence, although with some limitations, this type of studies is considered a 
suitable metodology in order to assess the ability of a substance to penetrate through 
the skin (Nakadate 1991; Davies, Ward, and Heylings 2004). 
The next step would be to repeat the TEM study using equine and human skin explants; 
to have at least a duplicate of the MP study using human skin and to improve the 
protocol used with Imaris, designing a bioinformatics script, made ad-hoc for this 
purpose. Furthermore, longer time points and repeated treatment can be employed to 
perform the penetration study with MP. We established a method to fluorescently label 
the bleomycin prior to encapsulation within liposomes, and it would be exciting to 
expand this experiment to include labelling of the liposomal nanoparticles with a 
contrasting fluorescent probe, this would enable a direct comparison of the position of 
the liposomes and the entrapped bleomycin within the skin after treatment with 




























Chapter 4 Cellular uptake and molecular signalling 




Bleomycin is a chemotherapy agent that induces cancer cell death mainly by 
producing double- and single-strand (DSB and SSB) DNA breaks. However, the 
action of bleomcyin is proposed to be cell type dependent and more efficient in certain 
types of tumours indicating that there may be different mechanisms of cellular uptake 
and of cellular resistance to the treatment. To date, these processes are still undefined. 
We are interested in studying the cellular effects of Bleosome, a form of bleomycin 
encapsulated in ultra-deformable (UD) liposomes and aim to determine if liposome-
encapsulation can improve the cellular uptake of the entrapped drug and to elucidate 
the mechanism of resistance to the treatment.  
Here, we showed that Bleosome kills canine, feline and human cancer cell lines, and 
compared its efficacy with free bleomycin. From our data, Bleosome is taken up by 
cells and stored in the cytoplasm more efficiently than free bleomycin. Furthermore, 
a preliminary investigation within two different types of canine cancer cell lines 
revealed that the response to Bleosome treatment is cell type dependent. Focusing on 
canine melanoma cancer cell line (CML10), we found that these cells were unable to 
repair the DNA lesions, produced by Bleosome treatment, through the activation of 
DNA repair pathways and cell cycle checkpoints, while, after initial Bleosome 
treatment, CML10 cells may stimulate the promotion of the tumour 
microenvironment. 
We also investigated the effect of Bleosome on bleomycin hydrolase (BLMH) levels, 
an enzyme previously shown to be induced by bleomycin treatment and to mediate 
inactivation of the drug. We speculated that BLMH may drive cellular resistance to 
bleomycin but found no evidence of a link between the treatment and the level of 
BLMH within cells and tumours.  
Overall, our findings provide novel and compelling information about both the 
mechanism of cellular interaction of liposomal encapsulated bleomycin and the 





Bleomycin (BLM) is a chemotherapeutic drug belonging to the class of glycopeptidic 
antibiotics; it exerts its function against cancer cells by producing DNA single and 
double-strand breaks (SSB and DSB), and, to some extent, RNA damage as well (Chen 
and Stubbe, 2005). Depending on the presence of oxygen, this mechanism generates 
radical intermediates, which can be rearranged to produce different types of DNA 
lesions, closely related to the ones produced by ionizing radiation (Ramotar and Wang 
2003). However, bleomycin is considered more efficient against some types of cancer 
than others, and this may be related to the efficiency of drug uptake and to the 
mechanism of action in specific cancer cell types.  
Bleomycin is a large (molecular weight of 1.5 kDa), hydrophilic molecule that is 
unable to efficiently diffuse across cell membranes. The mechanism of cellular uptake 
has been the focus of several investigations (Roy and Horwitz 1984; Lyman et al. 
1986). However, there is no general consensus regarding the mechanism of uptake, 
efficiency of translocation into the nucleus or annotation of the domains of the 
bleomycin molecule. Some studies using bleomycin labelled with radioactive cobalt 
have identified a potential cellular binding partner on the surface of Chinese hamster 
fibroblasts and human head and neck carcinoma cells. These studies indicated that 
bleomycin binds to a receptor protein on the plasma membrane that is then transferred 
into intracellular endocytotic vesicles by receptor-mediated endocytosis. Furthermore, 
A253 cells are inherently resistant to bleomycin because they have reduced 
bleomycin-membrane binding sites (Pron et al. 1999). The mechanism of transport of 
bleomycin from the endocytotic vesicles to the cytosol has not yet been elucidated. No 
further characterisation of this putative binding protein or the endocytosis pathway has 
been reported. Identification of the plasma-membrane binding protein and its 
expression in different tissues could be the key to the differential toxicity of bleomycin 
to tumour cells and lung cells. (Chen and Stubbe 2005).  
Bleosome is a form of bleomycin encapsulated in ultra-deformable (UD) liposomes. 
This formulation has been created with the aim to enable the passage of bleomycin 
molecules through the skin. However, to what extent liposomes can improve the 
cellular uptake of the entrapped drug is still under investigation. 
Liposomes have been developed as versatile nanocarriers for various pharmacological 
agents. The effect of surface charges on the cellular uptake of the liposomes has been 
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studied by various methods. However, due to limitations of techniques used, the exact 
mechanism of cellular uptake of the liposomal nanocarriers is still poorly understood 
(Kang, Jang, and Ko 2017). Types of liposomal nanocarrier, entrapped drug and target 
cells all contribute to the different pathway of cellular internalisation of liposomes, 
however, endocytosis appears to be the most likely mechanism of cellular penetration 
used by liposomes (Alshehri, Grabowska, and Stolnik 2018). In addition, the 
mechanistic effects at cellular level of bleomycin are not fully understood. Early 
studies in cultured cells indicated that bleomycin did not directly inhibit DNA 
replication, RNA synthesis or protein synthesis. Instead, numerous studies on a range 
of cell lines demonstrated that bleomycin induced global changes in chromosome 
morphology, including chromosome breaks, gaps, and deletion (Hecht 2000; 
Schroeder et al. 2014). More quantitative and molecular analysis of DNA from cells 
treated with bleomycin demonstrated that both SS and DS DNA cleavage resulted. 
Furthermore, the extent of the DNA cleavage was dependent on the bleomycin 
concentration and time of incubation (Chen and Stubbe, 2005). 
Studies in cell culture have given further insight into which stages in DNA biology are 
most susceptible to bleomycin damage. Actively transcribed genes, for example, were 
shown to be more susceptible to bleomycin than silenced genes. Kuo  (1981) examined 
the DNA cleavage of the globin and ovalbumin genes by bleomycin in different tissues 
(Kuo 1981). The globin gene is actively transcribed in erythrocytes and inactive in 
ovocytes, while the ovalbumin gene is actively transcribed in ovocytes and inactive in 
erythrocytes. Kuo (1981) showed that, in both cases, the actively transcribed 
chromatin was more sensitive to bleomycin-induced DNA damage. 
Cell culture studies further revealed that bleomycin-induced DNA damage is cell-
cycle dependent. In synchronized Chinese hamster lung fibroblasts, DNA DSBs 
induced by bleomycin at different stages in the cell cycle were examined. Bleomycin 
caused 2–3 times fewer DNA DSB in S-phase cells than in G1 or G2/M phase cells. 
This observation is consistent with previous studies claiming that bleomycin does not 
directly interfere with DNA replication (Kunimoto, Hori, and Umezawa 1967). 
In summary, in a wide range of experimental cell-culture systems, using numerous 
methods for analysis of DNA cleavage, there is mounting evidence that DNA damage 
is a likely contributor, if not the major contributor, to the cytotoxicity of bleomycin. 
These studies further show that proteins interacting with DNA affect cleavage 
susceptibility in ways that remain to be elucidated (Chen and Stubbe 2005;.Tounekti 
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et al. 2001; Mekid et al. 2003). Further studies where the concentration of bleomycin 
inside the cell was controlled by electric pulses, which temporarily altered cell 
permeability (also known as electroporation), showed that bleomycin induced two 
distinct types of tumour cell death, which were dependent on the bleomycin 
concentration within the cell and consequently, different amounts of DNA DSBs. At 
a low therapeutic dose of bleomycin, cells accumulated in G2/M phase and a slow, 
mitotic cell death was observed. At high doses of bleomycin, the drug itself acted as a 
micro-nuclease, causing extensive DSBs in DNA and rapidly initiating an apoptotic-
like process. The operative pathway was related to the number of DSBs mediated by 
activated bleomycin (Chen and Stubbe 2015). However, there is evidence that the cell 
death pathway induced by bleomycin is cell type dependent (Fulda et al. 2001). The 
reason why this drug seems to be more efficient against some malignancies rather than 
others is currently unknown. A possible reason could reside in the mechanism of drug 
resistance and in the different mechanisms of cellular uptakes (Chen and Stubbe 2005; 
Pron et al. 1999). The DNA-repair pathway is part of a bigger cellular response 
network that has evolved to deal with DNA damage generated by bleomycin, ionising 
radiation and other DNA-damaging agents. Cells detect DNA damage and trigger 
various signal-transduction cascades that ultimately lead to different fates, including 
cell-cycle arrest, DNA repair, mitotic cell death and apoptosis. (Chen and Stubbe 
2005). Bleomycin causes mutational lesions; it is likely that the normal cells of a 
cancer patient exposed to bleomycin rely on mechanisms that lead to repair of the 
drug-induced lesions (Ramotar and Wang 2003). Several studies have identified some 
repair pathways involved in repair of bleomycin-induced lesions; among these, Xu et 
al. (1998) claimed that the single-strand lesions of DNA could be rescued by the base 
excision repair pathway (BER). Moreover, as bleomycin is capable of producing DNA 
DSB, it is likely that specific DS-lesion repair pathways are involved in this process, 
such as non-homologous end joining (NHEJ) and homologous recombination repair 
(HRR) (Chen and Stubbe 2005). Lu et al. (2017) performed a microarray analysis on 
gene expression in response to bleomycin treatment in human fibroblasts. They found 
that fibroblasts respond to Bleomycin-induced DNA damage mainly by activating the 
p53 pathway, but that ATM, cell cycle checkpoint and NHEJ were also implicated in 
the cellular signalling cascade generated by the treatment (Lu et al. 2017). Moreover, 
Forrester et al. (2012) found that lymphoblastoid cells responded to IR in a different 
manner compared to fibroblasts, and that nucleotide excision repair (NER, another 
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DNA repair mechanism), rather that HRR and NHEJ, was the most representative 
activated pathway. 
However, major targets of bleomycin toxicity are lungs and skin; these two tissues 
have a low level of an enzyme called Bleomycin hydrolase (BLMH). This enzyme 
plays a role in the degradation of the bleomycin molecules, rendering the drug inactive 
and unable to exert its function, hence, BLMH might play a key role in the bleomycin 
resistance, although the current literature remains controversial (Chen and Stubbe 
2005). 
In this chapter, our aim was to provide an insight into the molecular mechanisms 
exploited by Bleosome (bleomycin encapsulated within liposomes) to kill different 
types of cancer cells, in comparison with free bleomycin. Here, we investigated the 
cellular uptake of the fluorescently labelled Bleosome by live-cell imaging and FACS 
to quantify the amount of drug taken up over a time course of treatment, and compared 
it with the free bleomycin. Furthermore, we explored the molecular signalling 
cascades activated by Bleosome in two different types of canine cancer cells at the 
cellular level and used RNA Seq to identify global differences in transcriptomic 
profiles after Bleosome treatment. Lastly, we evaluated the role of BLMH in response 
to Bleosome treatment at the cellular and tumour level. 
 
4.3 Material and Methods 
 
4.3.1 Cell culture 
 
For routine cell culture, all cell lines used for the experiments (MCF7, REM134, C2, 
CML10, SMG, SCCF1) were grown using appropriate media (section 2.1) in an 
incubator at 37oC, in a humidified atmosphere with 5 % CO2 under mycoplasma-free 
conditions.  
 




Cells were trypsinised into single cells and seeded at a density of 5x102 cells in the 
media, in triplicate, in opaque 96-well plates (Corning, CA, USA). Serial dilutions of 
Bleosome and free (aqueous cream) bleomycin (containing bleomycin non-
encapsulated within liposomes) (table 4.1) were added to the appropriate cells the 
following day. The control was represented by media and bleomycin dilutions. Dose-
response curves were generated 48 hours after exposure. Cytotoxicity was measured 
using the CellTiterGlo® Luminescent Cell Viability Assay (Promega, Madison, 
USA), which quantifies the number of viable cells in culture based on quantification 
of ATP present. Luminescence was recorded by luminometer (Viktor3, PerkinElmer, 
Massachusetts, USA). Data was averaged and normalized against the average signal 
of untreated/vehicle control treated samples (details in section 2.2). Each experiment 
was performed at least twice: in the first Cell Viability Assay, drug titration showed 
in table 4.1 (A) was used, while the second experiment was performed with the 
concentrations showed in table 4.1 (B), adapted according to the results of the first 
experiment, in order to gain more precise data for establishing IC50. 
For each cell line, two 96 well plates were used at the same time: one with cells treated 
with Bleosome and the other with cells treated with bleomycin aqueous cream. Each 




D1: 100 µM, D2: 60 µM, D3: 30 µM, D4: 10 µM, D5: 1 µM, D6: 0.5 µM, D7: 0.25 
µM, D8: 0.1 µM, D9: 0.05 µM, D10: 0.025 µM 
B  
D1: 20 µM, D2: 10 µM, D3: 7 µM, D4: 5 µM, D5: 4 µM, D6: 3 µM, D7: 2 µM, 
D8: 1 µM, D9: 0.5 µM, D 10: 0.1 µM 
Table 4.1 Drug titrations. (A) dilutions (D) of Bleosome and aqueous cream bleomycin used for treating 
cells during the first experiment, while (B) shows dilutions (D) of Bleosome and aqueous free bleomycin 
used for treating cells during the second experiment 
 
 
IC50 values were obtained using GraphPad Prism7 software, with non-linear 
regression equation. Final IC50 for each cell line was calculated as the average of the 
results of the two viability experiments.  
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4.3.3 Colony formation assay 
 
Cells were trypsinised into single cells and seeded at 1000 cells/10 cm plate (CML10) 
and at 500 cells/10 cm plate (REM134). Experiments were performed twice. During 
the first experiment, cells were treated with doses of Bleosome and aqueous cream 
bleomycin indicated in table 4.2. The second experiment was conducted with drug 
concentrations showed in table 4.3. Each drug titration was performed in triplicate. 
Plates were incubated at 37oC in humidified CO2 incubator within 10-14 days, until 
colonies were visible. Growth media was changed once a week. The colonies were 
fixed by incubating with ice-cold methanol for 5 minutes at room temperature. 
Colonies were stained with Giemsa stain (Invitrogen, Paisley, UK) according to the 
manufacturer’s instruction. The total number of colonies was counted and the average 








Drug  concentration 
Bleosome 
IC50 5.06 µM IC50 3.81 µM 
½ IC50 2.53 µM ½ IC50 1.90 µM 











IC50 0.23 µM IC50 0.68 µM 
½ IC50 0.115 µM ½ IC50 0.34 µM 




Table 4.2 Concentrations of drug corresponding to the relative titrations of Bleosome and free 
bleomycin (aqueous cream solution) IC50  in  REM134 cell lines, (A) and (B) respectively, and in CML10 
cells, (C) and (D) respectively. 
 
Bleosome: 0 µM, 0.25 µM, 0.5 µM, 1 µM 
Aqueous cream bleomycin (free form): 0 µM, 0.25 µM, 0.5 µM, 1 µM 
 
Table 4.3 Titrations of Bleosome and aqueous cream bleomycin used to treat the plates for the second 




To analyse the protein levels, immunoblotting, using a list of primary antibodies, was 
performed, according to section 2.3. Cell lysates were obtained from MCF7, SMG, 
CML10 and C2 cells. Cells were treated for 4 hours with several dilutions of 
Bleosome, or aqueous cream bleomycin for comparison, as following: 0 µM, 0.25 µM, 
0.5 µM, 1 µM, 4 µM, 8 µM, 16 µM. A further immunoblotting was conducted using 
CML10 cells treated with the relative IC50 of Bleosome (3.81 µM) or free bleomcyin 
(0.68 µM), and the double of the IC50 value of Bleosome (7.62 µM) or free bleomycin 
(1.36 µM), over a time course of 2, 4 and 6 hours for each treatment. Untreated cells 
were used as control.  
 
4.3.5 Quantitative Real Time (qRT) PCR  
 
4.3.5.1 Treatment of cells 
 
C2 and CML10 cells were treated in 100 x 17 mm petri dishes (Nunclon™ Delta, 
ThermoFisher), with the relative IC50 concentrations of Bleosome: 1.56 µM and 3.81 
µM respectively over a time-course including 2, 4, 8 and 24 hours of treatment. 
Untreated cells were used as control. At the relative time point of treatment, cells were 




4.3.5.2 RNA extraction and quantitative Real Time PCR 
 
Basic methods for RNA extraction and qRT-PCR are described in section 2.4. Briefly, 
total cellular RNA was extracted using RNeasy® kit (Qiagen, CA, USA) and RNA 
quality was determined by A260 measurement. Total RNA was reverse transcribed 
using the Omniscript TM RT Kit (Qiagen, CA, USA) according to the manufacturer’s 
instruction. Primers were designed using Ensembl.org and Primer3Plus online 
software and tested as detailed in section 2.4. qRT-PCR was performed using the 
Roche LightCycler® 480 instrument with LightCycler® 480 Multiwell Plate 96 
according to the manufacturers protocol. The reactions were performed with 
QuantiNova™ Sybr® Green (Qiagen) master mix. 
All measurements were performed at least in triplicates. Normalisation was made 
using GAPDH gene expression. Relative gene expression levels were obtained by 
normalisation to the expression levels of housekeeping gene (GAPDH). Comparative 
quantification was made using the Delta Delta Ct Method for calculating fold-changes 
in the gene of interest normalised to the untreated samples. Results were statistically 
analysed using MINITAB, fitting data in a general linear model (GLM):  two-way 
ANOVA and Tukey’s post-hoc test. 
 




C2 and CML10 cells were treated with the respective IC50 of Bleosome as detailed in 
4.3.5.1. For this experiment, cells were treated for 8 and 24 hours and cells untreated 
were used as control. For each time point of treatment, three biological replicates were 
used: they corresponded to the same cancer cells treated at a different passage 
numbers. In details, CML10 cells were treated at passages (P) 37, 38 and 40, whereas 





Table 4.4 Samples with sample-associated variables 
 
 RNA isolation, quality control and mRNA sequencing are detailed in section 2.5. 
 
4.3.6.2 Exploratory analysis 
 
Exploratory analysis was conducted by Edinburgh Genomics (Edinburgh, UK). A 
principal component analysis (PCA) was undertaken on normalised and filtered 
expression data to explore observed patterns with respect to experimental factors. The 
cumulative proportion of variance associated with each factor was used to study the 
level of structure in the data, while associations between continuous value ranges in 
principal components and categorical experimental factors was assessed with an 
ANOVA test. 
 
4.3.6.3 Differential gene expression 
 
Differential analysis was performed by Edinburgh Genomics (Edinburgh, UK). 
Briefly, analysis was carried out with edgeR (version 3.20.9). edgeR was chosen for 
this study as it is the only software that can account for biological variability with only 
few replicates per sample. (Robinson et al., 2010). edgeR software was used for the 
identification of differences in gene expression of pairwise comparisons organised as 
follows: (1) CML10 cells treated with Bleosome for 8 hours against CML10 cells 
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untreated; (2) CML10 cells treated for 24 hours with Bleosome against CML10 cells 
untreated; (3) CML10 cells treated with Bleosome for 24 hours against CML10 cells 
treated with Bleosome for 8 hours. Fold changes were estimated as per the default 
behaviour of edgeR, to avoid artefacts, which occur with empirical calculation. 
Specifically, a small prior count is added to each observation before fitting a model, 
in proportion to the library size. Log fold-changes are shrunk towards 0, to a greater 
degree with genes of low count, and infinite fold changes are avoided. Statistical 
assessment of differential expression was carried out with the quasi-likelihood (QL) 
F-test using the contrasts shown in table 4.5. Where specified in this table, 
confounding covariates (for example sample pairing, batch effects) were adjusted for 
by incorporating them as a blocking factor in an additive model. Where comparisons 
were to be compared, comparisons instead of individual sample groups are specified 
in the ‘Group’ columns of Table 4.5 with notation like (Treatment-Control). 
 
 
Table 4.5. Contrasts specified for differential analysis. Any variable specified under ‘blocking’ 
was used as part of an additive model, and accounted for in differential analysis of that contrast. 
 
Genes were considered differentially expressed only at a p-value <0.05 and at FDR < 
0.05. Genes with log2-fold changes of more than 2 or less than 2 were then selected 
to ensure that only robust changes were considered. Differentially expressed genes 
were identified by hierarchical clustering analysis. In hierarchical clustering, each 
cluster is subdivided into smaller clusters, forming a tree-shaped data structure or 
dendrogram. Agglomerative hierarchical clustering starts with the single-gene clusters 
and successively joins the closest clusters until all genes have been joined into the 
supercluster (D’haeseleer, 2005). Heatmaps were generated using the package called 
“pheatmap” in R. 
 
4.3.6.4 Functional Annotation 
 
To examine whether certain pathways are over- or under-represented in the gene list, 
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all genes significantly differentially expressed between the three comparisons were 
introduced into GSEA (GSEA version 4.0.1). GSEA employs the (weighted) 
Kolmogorov-Smirnov (K-S) statistic to test whether genes contributing to the 
phenotype are ‘enriched’ in each gene-set (Boerkamp et al, 2013). Thereby, GSEA 
evaluates how genes in queried pathways are distributed in the fold change ordered 
list generated by the data. This distribution is quantified by using the Enrichment Score 
(ES) that evaluates if the members of the pathway are randomly distributed or found 
at the extremes (top or bottom) of the list (Boerkamp et al, 2013). For each gene set, 
GSEA looks if differentially expressed genes in a pathway rank are enriched at the top 
fold change list (up-regulated genes), then the ES will be close to 1. Conversely, if the 
ES = −1, then genes are enriched at the bottom of our fold change data (down-
regulated genes) (Lowes et al, 2010). Pathways and biological processes with an FDR 
value <0.05 were considered as significantly over- or under-represented. Also, 
Reactome (http://www.reactome.org) and Ingenuity Pathway Analysis (IPA, Qiagen 
Bioniformatics) were performed based on the dysregulated genes that were identified 
in the RNA-seq datasets (data not shown). 
 
4.3.7 Immunohistochemistry (IHC) 
 
Equine sarcoids and equine skin were collected according to section 2.9.2. For this 
study, three sarcoids from patients that underwent surgery, and skin from an equine 
cadaver without any known cutaneous disease were used. All the samples were 
withdrawn from different animals. Sarcoids used derived from patients that were 
presented to the Equine Hospital of the R(D)SVS for the surgical excision of cutaneous 
sarcoids as part of their planned treatment. Due to limited number of sarcoids available 
for our research, all the samples collected at the time of the experiment were used (3 
sarcoids). The first sample was a mixed fibroblastic sarcoid collected from the elbow, 
the second one was a nodular sarcoid excised from the region close to the umbilicus 
and the third mixed sarcoid was excised from the shoulder area. Skin was collected 
from the abdomen. Each sarcoid was cut in two parts: one part was left untreated and 
considered as the control, and cut in small pieces of approximately 0.5 x 0.5 x 0.5 cm, 
and fixed individually in 10% NBF. The second part was treated with Bleosome for 6 
hours, spreading the compound all over the free surfaces of the tumour/skin. At the 
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time point, the sample was cut in small pieces of approximately 0.5 x 0.5 x 0.5 cm and 
fixed individually in 10% NFB. Each sample was processed by the Pathology Unit of 
the Royal (Dick) Veterinary School of the University of Edinburgh, as detailed in 
section 2.6. At least three histological slides were examined from each sample (from 
both treated and untreated part), one from each 0.5 x 0.5 x 0.5 cm section, and positive 
staining was evaluated for each slide. Endogenous negative controls were represented 
by slides of the treated and untreated part of the sample, not stained with the antibody. 
Absolute positive and negative controls was represented by an equine melanoma 
stained and unstained with anti-BLMH antibody ab204584 (Abcam), respectively. 
Each slide was scanned with the slide scanner Nanozoomer XR (Hamamatsu) 
according to the manufacturer’s protocol. Quantitative comparison of 
immunohistochemical staining was measured by image analysis performed by QuPath 
software. QuPath is designed for digital pathology and whole slide images for 
bioimaging analysis. Briefly three areas of 35000 µm2, visualised at 40X 
magnification, were analysed for each slide. Using the appropriate thresholds and 
settings  the software was able to detect the positive stained cells within the area and 
indicated the overall positivity as a percentage. Positivity of the three areas, examined 
within the same slide, were averaged and final value for each sample (treated and 
untreated) was obtained comparing the means of the three slides. 
 
4.3.8 Bleosome cellular up-take evaluation 
 
4.3.8.1 Visualisation by live-cell imaging study 
 
4.3.8.1.1 Sample preparation 
 
C2 and CML10 cells were seeded in 2-well chamber slides (Nunc Lab-Tek II 
Chambered Coverglass, 1.5 borosilicate glass, ThermoFisher) at a density of 3x107 
cells per well, immersed in DMEMs without phenol red (details in table 4.6) When 
near confluency, cells were stained with Hoechst 33342 (ThermoScientific) as per 
manufacturer’s protocol. Subsequently, cells of both cell lines, were treated with the 
158 
 
relative IC50 of F-Bleosome (3.81 µM for CML10 and 1.56 µM for C2) and F-free 
bleomycin (0.68 µM for CML10 and 0.28 µM for C2) for 2 and for 24 hours. Untreated 
CML10 and C2 cells were used as control. At the relative time points, drugs were 
removed and chamber slides were rinsed with 3X PBS, filled with new media and 
visualised under the Zeiss LSM 880 Confocal microscope Airyscan/Fastscan with 32 
sensitive GaAsP detectors, equipped with an incubation chamber, which is maintained 
at 37 °C with controlled CO2 flow, as detailed in section 2.10.3.2. 
Cell Line Media Supplements 
C2  Eagles Dulbecco’s Modified 
Eagle Media( DMEM) low 
glucose, pyruvate, no glutamine, 
no phenol red (11880028) 
(Gibco®, Life Technologies, 
Invitrogen, UK) 
5% Foetal bovine serum 0.1 
mg/ml; 1x Non-essential 
amino acid; 1% Glutamax: 25 
mg Gentamicin 
CML Dulbecco’s Modified Eagle 
Media (DMEM) low glucose, 
pyruvate, no glutamine, no phenol 
red (11054020) (TermoScientific) 




Table 4.6. Media used to grown C2 and CML10 cells for live-cell imaging 
. 
4.3.8.2 Quantification by fluorescence activated cell sorting (FACS) 
 
4.3.8.2.1 Sample treatment 
 
C2 and CML10 cells were seeded in 6-well cell culture plates (ThermoScientific) at a 
density of 3x107 cells per well and let them attaching to the bottom of the wells 
overnight. The day after, cells were stained with Hoechst 33342 (ThermoScientific) 
as per manufacturer’s protocol. Subsequently, cells of both cell lines, were treated with 
the relative IC50 of F-Bleosome (3.81 µM for CML10 and 1.56 µM for C2) and F-free 
bleomycin (0.68 µM for CML10 and 0.28 µM for C2) for 2 and for 24 hours. Untreated 
CML10 and C2 cells were used as control. Contemporarily, other two 6-well plates 
were used as compensation for the FACS analysis. Briefly, two 6-well plates were 
seeded respectively with C2 and CML10 cells and stained as following: in one well, 
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cells were stained with Hoechst 33342, the second well included cells treated for two 
hours with F-Bleosome, the third well included cells treated for two hours with F-free 
bleomycin, another well included cells stained with Zombie Yellow dead cell marker 




At the relative time points, C2 and CML 10 cells were detached by trypsinisation, 
washed with PBS and stained with Zombie Yellow Fixable Viability Kit (BioLegend 
Inc., USA) to detect dead cells. Next, cells were washed again with PBS, re-suspended 
in PBS and analysed using the cytometer BD Fortessa (BD Biosciences, USA) with a 
throughput detection set at 30000 events/second. Analysis post-acquisition were 





4.4.1 Bleosome decreases cell viability and colony forming ability in a 
dose dependent manner in a panel of cancer cell lines  
 
The aim of the experiment was to determine the effectiveness of Bleosome  
(bleomycin encapsulated within liposomes) to reduce the cell viability of a panel of 
cancer cell lines, to establish the IC50 of Bleosome for each cell line, and to compare 
its efficacy with non-encapsulated free bleomycin (bleomycin aqueous cream). The 
following graphs, shown in figure 4.1, illustrate the effect of Bleosome on the viability 
of the indicated cell line, and comparison with the free bleomycin. After each assay, 
IC50 values were calculated using GraphPad Prism software, with the non-linear 




Figure 4.1 Viability curves produced by dose titrations of Bleosome and free bleomycin. The effect of 
Bleosome (blue line) compared with free bleomycin (orange line) 72 hours post-treatment, on cell 
viability of C2 (A), CML10 (B), REM134 (C), MCF7 (D),SCFF1 (E), and SMG (F) cell lines.  
 
In canine mammary carcinoma (REM134) and in canine mast cell tumour (C2) cell 
lines, the free bleomycin produced a steep decrease in cell viability, while Bleosome 
caused a dose-dependent reduction in viability. In canine melanoma cells (CML10), 
the two curves looked similar, but the drug concentration needed to kill all the cells 
was lower for the free bleomycin than Bleosome. In human mammary carcinoma 
(MCF7) and in feline laryngeal squamous cell carcinoma (SCC) (SCCF1) cell lines, 
the free bleomycin produced a steep decrease in cell viability, while Bleosome caused 
a steady fall in viability. In feline oral SCC (SMG) cells, the two curves generated by 
the two treatment had the same trend, but the concentration of Bleosome necessary to 
cause 100% of cell death was higher than the free form. 
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Cell line IC50 Bleosome 
µM 
IC50 free 
 bleomycin µM 
C2 1.56 0.28 
CML10 3.81 0.68 
MCF7 8.96 0.16 
REM134 5.06 0.23 
SCFF1 1.68 0.09 
SMG 3.26 0.12 
 
Table 4.7  IC50 of Bleosome and aqueous cream bleomycin in different cancer cell lines. These values 
were made by the mean of the IC50 obtained by each viability assay per cell line and calculated using 
the GraphPad software. 
 
Both Bleosome and free bleomycin produced a 100% of mortality in all the treated 
cancer cell lines. However, the drug concentration of the aqueous cream with free 
bleomycin, needed to cause cell death, was consistently several-fold lower compared 
to the IC50 of Bleosome as illustrated by the IC50 values in table 4.7. Importantly, these 
results do show that Bleosome is able to kill a range of canine cancer cell lines. 
 
To substantiate the cell viability data, we assessed the effect of Bleosome on colony 
forming ability, focusing on two canine cell lines: REM134 and CML10 cells.   
Cells were treated with a titration of previously calculate IC50 values (table 4.7), and 
the number of colonies assessed after 10 days. In the REM134, Bleosome inhibited 
the formation of all the colonies even at a quarter of IC50 drug concentration, while the 
free form allowed the formation of a small number of colonies at the half and a quarter 
of the respective IC50 value. In the melanoma cell line, CML10, both the compounds 
prevented the formation of colonies at the respective IC50 values, while free bleomycin 
yielded the formation of more colonies at the lower titrations compared to the 






To directly compare the effect of Bleosome and free bleomycin on colony forming 
ability, both cell lines were treated with titrations showed in table 4.3. Figure 4.3 
reveals that free bleomycin was able to inhibit the formation of colonies at each 
concentration used, while Bleosome produced a dose-dependent decrease in the 
formation of colonies.  
 
The results of the first assay suggest that at the previously calculated IC50 value 
Bleosome is more efficient in inhibiting the growth of cancer cells compared to free 
bleomycin compound. However, using the same titrations for both the compounds, 
aqueous cream bleomycin was more effective at killing cells than Bleosome. Although 
of note, Bleosome was effective at inhibiting colony-forming ability in a dose-
dependent manner.  
Figure 4.2 Colonies formed after IC50 – based assay in CML10 and REM134 cells treated with Bleosome or free 
bleomycin.. (a) shows the percentage of colonies found in REM 134 plates after titrations of Bleosome (blue) (0, 
1.26, 2.53 and 5.06 µM), (b) shows the percentage of colonies found in REM 134 after titration of  free bleomycin 
(orange) (0, 0.057, 0.115, 0.23). (c) shows the percentage of colonies found In CML10 plates after titrations of 
Bleosome (blue) (0, 0.95, 1.9 and 3.81 µM) and (d) after free bleomycin (orange) (0, 0.17, 0.34 and 0.68 µM). 


















Figure 4.3 Bleosome inhibits the colony forming ability of canine cancer cells in a dose-dependent 
manner. The colony-forming ability of (a) REM 134 cells  after 0, 0.25, 0.5 and 1 µM of Bleosome (blue 
columns) and (b) after  0, 0.25, 0.5 and 1 µM of free bleomycin treatment (orange coloumns). 
Percentage of colonies found in (c) CML10 cells after 0, 0.25, 0.5 and 1 µM of Bleosome (blue columns) 
and (d) after  0, 0.25, 0.5 and 1 µM of free bleomycin treatment (orange coloumns)  Colonies were 
counted after 10 days of incubation with treatments. 
 
4.4.2 Bleosome is taken up by cancer cells more efficiently than free 
bleomycin 
 
To evaluate the mechanism of Bleosome cellular uptake and to compare it with the 
free bleomycin, we treated two types of different canine cancer cell lines with their 
respective Bleosome IC50. C2 cells and CML10 cells were treated with 1.56 µM and 
3.81 µM of F-Bleosome and F-bleomycin (preparation of fluorescent drugs is detailed 
in section 2.8) respectively, and both compounds were applied for 2 and for 24 hours.  
Untreated cells were used as a control. Cells were visualised using the confocal 
airyscan/fastscan microscope (Figures 4.4 and 4.5).  
In the untreated cells, no green particles were observed within the cytoplasm or the 
nuclear compartment. Whereas, after 2 hours post-treatment with both fluorescent 
compounds, the presence of drug molecules was located within the cytoplasm. In 
particular, there are more F-Bleosome particles within cells, compared to the F-
bleomycin. However, the position of both compounds is evenly distributed within cell 
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cytoplasm, but not within the nucleus, as confirmed also from videos made in time-
lapse, related to this time-points (supplementary data 8.2.5). Interestingly, after 24 
hours of treatment, drug molecules were strongly evident within cells, and the overall 
amount of green particles appeared to be increased compared to the earlier time-point, 
in both C2 and CML10 lines treated with F-Bleosome and F-bleomycin. However, 
some key differences between the two treatments can be observed. In the F-Bleosome 
treatment, the shape of F-Bleosome molecule is spherical and the dimension varied 
from very small particles to larger oval structures (figures 4.4 and 4.5 (b), (c), (d), (e)). 
This finding was consistent between the two different types of cells and can be 
interpreted as the aggregation of liposomal carriers, which fuse together after several 
hours following their cellular uptake, or as the results of the storage of the drug by 
cellular organelles (e.g. lysosomes). Of note, this pattern of fluorescence is typical of 
F-Bleosome treatment, as, in C2 and CML10 cells treated with F-bleomycin after 24 
hours, an overall green background and uniform presence of very small particles could 
be observed within cytoplasm, but without the presence of large spheroid green 
structures or spherical molecules (figures 4.4. and 4.5 (i), (j)). Moreover, in the case 
of F-Bleosome only, few green fluorescent objects were appreciated overlapped to 





Figure 4.4 CLSM appearance of C2 cells treated  with F-Bleosome and F-bleomycin. (a)  are cells 
untreated and represent the control. (b) and (c) indicate cells treated with F-Bleosome for 2 hours, (d) 
and (e) represents cells treated F-Bleosome for 24 hours. (f) are cells untreated and represent the 
control, (g) and (h) represent cells after 2 hours of F-bleomycin treatment, while (i) and (j) illustrate 





Figure 4.5 CLSM appearance of CML10 cells treated  with F-Bleosome and F-bleomycin.( a)  are cells 
untreated and represent the control. (b) and (c) indicate cells treated with F-Bleosome for 2 hours, (d) 
and (e) represents cells treated F-Bleosome for 24 hours. (f) are cells untreated and represent the 
control, (g) and (h) represent cells after 2 hours of F-bleomycin treatment, while (i) and (j) illustrate 
cells treated for 24 hours with F-bleomycin.  
 
Fluorescence-activated cell sorting (FACS) was performed to quantify the green 
fluorescence intensity corresponding to the amount of F-Bleosome and F-bleomycin 
taken up by cells at the indicated time points. Results of cell sorting revealed that the 
level of green intensity within cells treated with F-Bleosome was consistently higher 
compared to the F-bleomycin-treated cells, indicating the greater cellular uptake of 
Bleosome, compared to the free bleomycin, after 2 and 24 hours of treatment in both 
cell types. Figures 4.6 and 4.7 show the results of imaging in tandem with the relative 
FACS quantification of drug included within cells. Confocal images and cell sorting 
analysis were concordant, indicating that the overall cellular uptake of F-Bleosome 
was higher than free F-bleomycin in both C2 and CML10 cell lines. This finding was 




Figure 4.6 Bleosome is taken up more than free bleomycin in C2 cells. Confocal laser scanning images and respective FACS analysis of C2 cells treated with F-Bleosome and F-
bleomycin for 2 and 24 hours.  Pictures of C2 cells captured with the confocal airyscan/fastscan microscope with their respective green fluorescence quantification through FACS 
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are shown. “Untreated” represents C2 cells not treated with drugs (control), “2h and 24h F-bleomycin” indicates cells treated for 2 and 24 h with F-bleomycin, while “2h 
Bleosome and 24h F-Bleosome” represents C2 cells treated with fluorescent Bleosome for 2 and 24 hours. Graphs represents the level of green fluorescent within control cells 





Figure 4.7  Bleosome is taken up more than free bleomycin by CML10 cells. Confocal laser scanning images and respective FACS analysis of CML 10 cells treated with F-
Bleosome and F-bleomycin for 2 and 24 hours. Pictures of CML10 cells captured with the confocal airyscan/fastscan microscope with their respective green fluorescence 
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quantification through FACS are shown. “Untreated” represents CML10 cells not treated with drugs (control), “2h and 24h F-bleomycin” indicates cells treated for 2 and 24 
hours with F-bleomycin, while “2h Bleosome and 24h F-Bleosome” represents C2 cells treated with fluorescent Bleosome for 2 and 24 hours. Graphs represent the level of green 
fluorescent within control cells (pink), cells treated with F-Bleosome (orange) and F-bleomycin (blue) after 2 and 
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Furthermore, the rate of both free and encapsulated drug up-taken by cells increases 
over time. Figure 4.8 shows that the amount of green fluorescence detected within the 
two canine cancer cell lines is much higher after 24 hours of treatment than after 2 
hours, in both F-Bleosome and F-bleomycin treatment, yet confirming the greater 
level of F-Bleosome found within both cell lines, compared to the one of F-bleomycin. 
 
 
Figure 4.8  Comparison of green fluorescence intensity detected through FACS between treatments 
and time points in C2 and CML10 cell lines. (a) represents areas of green fluorescence intensity 
detected within each time points and treatment in C2 cells: pale green and red areas are the green 
intensity of the untreated cells. Blue and dark green areas corresapond to F-bleomycin treated cells 
after 2 and 24 hours respectively; orange and pink areas correspond to F-Bleosome treated cells for 2 
and 24 hours respectively. (b) shows areas of green fluorescence intensity detected within each time 
points and treatment in CML 10 cells: pale green and red areas are the green intensity of the untreated 
cells. Blue and dark green areas corresapond to F-bleomycin treated cells after 2 and 24 hours 
respectively; orange and pink areas correspondo to F-Bleosome treated cells for 2 and 24 hours 
respectively. 
 
4.4.3 Investigation of the cellular response to Bleosome: exploring the 
role of DNA DSB and repair mechanisms 
 
We have previously shown that Bleosome is effectively taken up by cancer cells. To 
further elucidate the cellular response to Bleosome treatment and to investigate the 
hypothesis of a cell type dependent effect of Bleosome, we evaluated the activation 
the DNA damage pathways in several cancer cell lines after Bleosome treatment. 
 Canine, feline and human cell lines were treated with a drug titration of either 
Bleosome or free bleomycin, and harvested after 4 hours. Firstly, the level of 
phosphorylation of the histone H2AX (ɣH2AX), which is a marker of DNA DSB, was 
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evaluated. In all cell lines tested, both Bleosome and free-bleomycin, induced a dose-
dependent increase in ɣH2AX and therefore of DNA DSBs (Figure 4.9)     
 
Figure 4.9 Bleosome and free bleomycin induce DNA DSBs in a dose-dependent manner. Bands relate 
to the level of Histone ɣH2AX as marker of  DNA DSBs Four cancer cell lines: C2 (canine mast cell 
tumour), CML 10 (canine melanoma),, SMG (feline squamous cell carcinoma), MCF7 (human breast 
tumour), were treated for 4 hours with the following concentrations: 0.25 µM, 0.5 µM, 1 µM, 2 µM, 4 
µM, 8 µM, 16 µM  of Bleosome  (a) and aqueous form free bleomycin (b). UT represents the untreated 
control cells. Beta actin band is shown as control. 
 
We focused on the evaluation of C2 and CML10 canine cells by probing for markers 
of key pathways involved in the DNA DSB repair machinery including NHEJ and 
HRR signalling. Key elements in HRR and NHEJ were evaluated at genomic and 
proteomic level. In the qRT PCR study, we treated C2 and CML10 cells with their 
respective IC50 concentrations of Bleosome (1.56 µM and 3.81 µM) for 2, 4, 8 and 24 
hours. Untreated cells were used as control.  All the genes, when compared together 
in statistical analysis, showed a significant difference in their relative expression 
during the time-course, in both C2 and CML10 (p≤0.000, two-way ANOVA). 
Interestingly, figure 4.10 (c) and (d) shows the activation of the HRR pathway in C2, 
with a peak of expression after 8 hours for Rad51 and after 2 hours for BRCA1; at 
subsequent time-points, the expression of both genes appeared to slightly decrease. 
However, the fold changes in the expression level of these two genes in CML10 cells 
is relatively low and decreased with the time after treatment, indicating that this 




The NHEJ pathways was also differentially activated between the two cell lines tested.  
After an initial increase and a slight decrease at 8 hours post-treatment, PRKDC level 
rose in C2 after 24 hours of treatment, while it tended to remain steady in CML10. In 
contrast, expression of XRCC4 was elevated after 8 hours of treatment but reduced 
back to basal level by 24 hours post-treatment in the CML10 cell line, whereas in the 
C2 cell line XRCC4 expression was always low (Figure 4.10 (a) and (b)). Of note, we 
found interesting differences in the activation of these two DNA-damage repair 
signalling between the two different canine cancer cell lines tested, suggesting that the 





Figure 4.10 Cell-type dependent activation of DNA damage repair is affected more by the length rather than by the dose of Bleosome treatment. Differences in gene expression of 
components of NHEJ and HRR evaluated by mean of qRT PCR (a), (b),(c) and (d) and by immunoblotting (e) and (f). (a) and (b) represent graphs of the relative expression of 
PRKDC and XRCC4 (elements of NHEJ pathways) in C2 (blue) and CML10 (orange) at 2, 4, 8 and 24 hours of Bleosome treatment. (c) and (d) represent graphs of the relative 
expression of Rad51 and BRCA1 (elements of HR pathways) at 2, 4, 8 and 24 hours.  in C2 (blue) and CML10 (orange). Statistical analysis was performed by GLM: two-way 
ANOVA and Tukey’s post-hoc test * represent significant differences (p<0.05). (e) Evaluation of activation of HR pathway at protein level in canine mast cell tumour cell line (C2) 
in response to Bleosome (i) and free bleomycin treatment (ii). Cells were treated with seven growing concentration of Bleosome (B) or free bleomycin (FB): 0.25;0.5;1;2;8 and 16 
µM and compared to the untreated cells (UT) as control. BRCA1 indicates the bands corresponding to the BRCA1 protein, Rad51 indicates bands corresponding to Rad51 protein. 
(f) Evaluation of activation of HR pathway at the protein level in canine melanoma cell line (CML10) in response to Bleosome (B) or free bleomycin (FB). Cells were treated with 
Bleosome (i) at two different concentration: IC50 (B IC50):3.81 µM and the double of the IC50 (B 2IC50): 7.62 µM, for 2, 4 and 6 hours respectively (2h, 4h, 6h); UT represent the 
untreated control. Column (ii) shows the treatment with free bleomycin aqueous form (FB) at the IC50 concentration (FB IC50) (0.68 µM) and the double dose (FB 2IC50) (1.36 
µM), for 2, 4, and 6 hours (2h, 4h, 6h). UT represent the untreated control. BRCA1 indicates the bands corresponding to the BRCA1 protein, while Rad51 indicates bands 




To validate our findings, to explore the role of drug concentration and to compare 
Bleosome treatment with the free bleomycin, we treated C2 cells with a drug titration 
of Bleosome or free bleomcyin for a total length of treatment of 4 hours, and 
immunoblotted for key players in the HRR signalling. From PCR analysis, this 
pathway resulted activated in mast cell tumour cell lines but not in the melanoma ones 
(figure 4.10 (a), (b), (c), (d)). For this reason, the protein levels of RAD51and BRCA1 
were evaluated over different concentration of both chemotherapeutics, and C2 cells 
revealed that these proteins were not much affected by the increase of concentration 
of both encapsulated and free bleomycin. Figure 4.10 (e) illustrates how the intensity 
of the bands from RAD51 and BRCA1 slightly increased at the increase of bleomycin 
and Bleosome dose to slightly decrease at higher doses; however, the variation of the 
intensity of the relative bands are minimal, indicating that the timing rather than the 
concentration of treatment is crucial for the activation of the pathway. 
Moreover, to further confirm the non involvement of the HRR pathway in the cellular 
response of CML10 cells to the Bleosome treatment, we treated the canine melanoma 
cell line with two doses of Bleosome corresponding to the IC50 (3.81 µM) and twice 
the IC50 (7.62 µM) as previously determined, or the equivalent of bleomycin (0.68 and 
1.36 µM respectively) and harvested over a time course of 2,4 and 6 hours. This 
allowed assessment of the levels of RAD51 and BRCA1 proteins at both increasing of 
doses and time points of treatment. Figure 4.10 (f) shows that the basal level of both 
proteins was unchanged compared to the untreated cells and over time, irrespective of 
dose or form of the drug. These findings suggest that the overall level of components 
of HRR and NHEJ are not strictly dependent on Bleosome concentration, but rather 
on the timing of treatment and that the cellular response to Bleosome is likely cell-
type dependent. 
 
4.4.4 Exploring the molecular response to Bleosome in CML10 cells 
by RNA sequencing over a time-course 
 
We showed that the DNA repair pathways were differentially activated in two 
different canine cancer cell lines and that the level of proteins was affected more by 
the time of treatment rather than the concentration of the drug. Hence, after having 
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focused on the main pathways underlying DNA repair, our further aim was to have a 
more comprehensive understanding of the molecular mechanisms triggered by the 
Bleosome treatment within these cancer cell lines, to find out whether other signalling 
could play a key role in the treatment response. To this extent, we treated CML10 and 
C2 cell lines with the respective Bleosome IC50 for 8 and 24 hours, and performed 
next generation sequencing (NGS) comparing the relative gene expressions to the 
untreated cells of both cancer cell lines. 
 
4.4.4.1 Quality analysis of RNA-sequencing data 
 
RNA-Sequencing generated a total reads pairs, after trimming, between 74 and 104.3 
million paired-end reads and around 80% of the reads were mapped to the canine 
genome. 
Principal Component Analysis (PCA) was used as a type of clustering to check the 
quality of RNA-seq data in the three pairwise comparisons. PCA represents a plot of 
the RNA samples in which distances correspond to leading log-fold-changes between 
each pair of RNA samples, and it is considered, therefore, the clustering algorithm of 
choice to predict the relatedness of samples based solely on differential gene 
expression (Gerst and Hölzer 2018). PCA analysis of the expression profiles of C2 
cells (untreated vs treated for 8 hours vs treated for 24 hours) revealed that the 
biological replicates did not cluster together according to the time point of treatment, 
but were randomly allocated within the PCA plot (data not shown). This finding 
indicated that C2 cells treated with Bleosome over a time course of treatment were 
highly heterogeneous and not optimal for drowning significant conclusion with this 
genetic study. For this reason, C2 cells were excluded from the analysis. Figure 4.11 
illustrates how the three biological replicates for each group of CML10 cells 
(untreated, cells treated for 8 hours and cells treated for 24 hours) formed a 
homogeneous cluster and were clearly separated from each other in all the three 
components of the PCA plot. For these reasons, following analysis were performed on 







Figure 4.11 Exploratory analysis of CML10 cells. (a) Plots of the first, second and third components 
from principal components analysis (PCA) using all CML10 samples. (b) Heatmap and hierarchical 
clustering dendograms illustrating clustering of samples by filtered and normalised expression values 
for all CML10 samples. Figures were generated with the ‘pheatmap’package. 
 
4.4.4.2 Differential expression gene analysis 
  
In the differential expression gene analysis, genes above a minimum 2-fold change 
difference and below the maximum level of false discovery rate (FDR) of 0.05 were 
considered. These thresholds were set to give statistical robustness to the data and to 
produce significant results. Within the analysis, three contrasts were considered: 1) 
comparison between CML10 cells treated for 8 hours with Bleosome and CML10 cells 
untreated (CML_8H vs CML_UT), here 365 genes were found differentially 
expressed, 221 of which were upregulated and 144 downregulated. 2) Comparison 
between CML10 cells treated with Bleosome for 24 hours and CML10 cells untreated 
(CML_24H vs CML_UT), where the majority of differentially expressed genes were 
found. In this contrast, 766 genes showed to be upregulated, against 1025 genes 
downregulated, for a total of 1791 genes. 3) Comparison between CML10 cells treated 
with Bleosome for 24 hours and 8 hours (CML_24H vs CML_8H), in this group there 





Table 4.8 Table of statistics showing numbers of differentially expressed genes in each contrast 






















Figure 4.12 Differential plots for specified contrasts. Volcano plots illustrate log(2) fold change vs –log(10) false discovery rate (FDR) between groups, with FDR calculation 
adjusted for passage. The horizontal dashed line represents the specified FDR threshold for significance (0.05), dotted lines represent the specified fold change threshold (2) in 
both the positive and negative directions. Point passing both thresholds are colored red. (a) represents volcano plot related to the comparison between cells untreated and treated 
with Bleosome for 8 hours, (b) is the comparison between CML10 cells untreated and treated for 24 hours, (c) is the volcano plot related to the comparison between CML10 cells 





4.4.4.2.1 Different gene expression profile of CML10 cells treated with Bleosome for 
8 hours compared to untreated cells 
 
Within the group including the comparison between cells treated with Bleosome for 8 
hours and untreated cells, a heatmap was generated including the top 50 most 
differential genes according to FDR value (figure 4.13). Hierarchical clustering 
analysis confirmed the distinction in gene profiles between cells treated for 8 hours 
with Bleosome compared to untreated cells. Of note, the heatmap shows that among 
the 50 most differentially expressed genes, 33 genes were upregulated and 17 
downregulated in the melanoma cells treated for 8 hours. Interestingly, when we 
interrogated the details of the differentially expressed genes, many of the genes 
upregulated following the Bleosome treatment, were involved in cellular growth and 
proliferation signalling (RAB20, FOSL1, PLIN2, TNFAIP3, EGR2, JUN, ATF3). 
Moreover, we found also key players in inflammatory response, such as TNF 
induced protein (TNFAIP3) and the early growth response protein 4 (EGR4), which 
is supposed to play a role in the downstream signalling in naïve CD8+ T-cells, or the 
interferon regulatory factor 5 (IRF5).  However, we also found genes involved in anti-
proliferative processes, such as BTG2 or DUSP5, which block the activation of MAP 
kinase pathway, indicating that, after 8 hours of treatment, cells, that survived the 
treatment, may trigger anti-mitotic cellular signalling. Looking at the genes that were 
downregulated following the chemotherapeutic treatment, most of them are involved 
in metabolic (LIPG, MSMO1, INSIG1) and endocytosis processes (LDLR), 





Figure 4.13 Heatmap showing the top 50 most differential genes by false discovery rate (FDR) between 
CML10 cells treated with Bleosome for 8 hours and the untreated cells, with the FDR calculation 
adjusting for passage. Figure was generated with the ‘pheatmap’ package. Factor variables from the 





4.4.4.2.2  Different gene expression profile of CML10 cells treated with Bleosome for 
24 hours compared to untreated cells 
 
The heatmap related to the contrast between cells treated for 24 hours and the 
untreated, including the 50 most differentially expressed genes, revealed again two 
distinct clusters formed by melanoma cells treated for 24 hours and by the untreated 
cells (figure 4.14). 24 hours of Bleosome treatment triggered the upregulation of many 
genes involved in inhibition of cell growth and angiogenesis (DUSP5, DUSP2, 
SPRY2, THBS2), to a greater extent than the 8 hour time point, suggesting that, after 
24 hours of treatment, cells are no longer able to proliferate and divide properly. This 
finding was confirmed also by the overexpression, in the same cluster, of CDKN1A, 
which is supposed to play a main role as a cell cycle inhibitor. Similarly, to the earlier 
time point, in 24 hours-treated cells signals of inflammatory response, such as 
interferon regulatory factor 5 (IRF5), were also found, along with genes responsible 
of remodelling the extracellular matrix (PLAUR), indicating a key role of the tumour 
microenvironment. Interestingly, when the downregulated cluster of genes within the 
treated cells group was interrogated, many regulators of cell cycles and chromosome 
stability were present. NUF2 and ASPM are involved in regulation of cell cycle and 
normal function of mitotic spindle formation, suggesting that Bleosome treatment 







Figure 4.14 Heatmap showing the top 50 most differential genes by false discovery rate (FDR) between 
CML10 cells treated with Bleosome for 24 hours and untreated cells, with the FDR calculation 
adjusting for passage. Figure was generated with the ‘pheatmap’ package. Factor variables from the 
experiments are highlighted above each plots and key genes discussed in the text are highlighted in red. 
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4.4.4.2.3  Different gene expression profile of CML10 cells treated with Bleosome for 
24 hours compared to cells treated for 8 hours 
. 
Figure 4.15 relates to the heatmap generated by the 50 most differentially expressed 
genes in the contrast made by cells treated for 24 and 8 hours. There was a distinct 
separation of genetic profiling between the two time points of treatment, as confirmed 
by the hierarchical clustering analysis. Again, when the fold-change expression was 
evaluated, genes were subdivided in two clusters: one included 22 genes upregulated 
in cells treated with Bleosome for 24 hours compared to the earlier time point of 
treatment, while the second cluster contained 28 genes downregulated in cells 
following 24 hours of treatment compared to 8 hours post-treatment. In the longer time 
point of treatment, signal of chromosome stability (CENPE) and regulator of cellular 
mitosis (NUF2), still present after 8 hours of treatment, were downregulated. Genes 
related to inhibition of cellular proliferation and migration (HYAL1 and ARNT2) and 
transport of cations (SLC6A17, SLC30A3) were upregulated after 24 hours of 
treatment, compared to earlier time point, suggesting that the duration of treatment 





Figure 4.15 Heatmap showing the top 50 most differential genes by false discovery rate (FDR) between 
CML10 cells treated with Bleosome for 24 and 8 hours., with the FDR calculation adjusting for 
passage. Figure was generated with the ‘pheatmap’ package. Factor variables from the experiments 





4.4.4.3 Functional annotation 
 
To further consider the biological significance of these data, GSEA was used to 
identify upregulated and downregulated pathways correlating to the three 
comparisons: CML10 cells treated with Bleosome for 8 hours and CML10 untreated; 
CML10 treated for 24 hours and untreated cells; CML10 cells treated for 24 hours and 
for 8 hours. For accuracy and reproducibility, analysis was repeated using also 
Reactome tool and Ingenuity Pathway Analysis (IPA) (data not shown). Results from 
the three software programs were consistent. Furthermore, GSEA was also used to 
highlight biological processes involved within the differential expressed genes 
between the comparisons. Pathways and biological processes with FDR<0.05 were 
considered as significant. 
 
4.4.4.3.1 Dysregulated pathways between CML10 treated with Bleosome for 8 hours 
compared to untreated control 
 
GSEA revealed 47 upregulated and 81 downregulated pathways in cells treated with 
Bleosome for 8 hours when compared to the untreated cells. Of note, Bleosome 
treatment triggered various immune response signalling within melanoma cancer cells. 
Figure 4.16 (a) illustrates the plethora of toll-like receptors cascade, along with the 
activation of myeloid differentiation primary response pathway (MyD88), which 
activates the transcription factor NF-ĸB and is involved in signalling within immune 
cells. Moreover, mechanisms of recruitment of cytokines and interleukins were also 
upregulated. Interestingly, in cells treated for 8 hours, mitogen activated protein kinase 
(MAPK) and the phosphoinositide 3-kinase (PI3K) signalling were still active. 
Considering the upregulated biological processes, GSEA found 17 upregulated 
processes (supplementary data 8.2.6, figure 8.1), all involved in the inflammatory and 
immune responses, cellular growth and migration. Interestingly, following the 
Bleosome treatment, there was a downregulation of chromosome maintenance and of 
several mechanisms involved in the mitotic process (including cell cycle checkpoint, 
mitotic prometaphase and anaphase, separation of sister chromatids). However, within 
the downregulated pathways, an interesting finding was the presence of mechanisms 
implicated in the arrest of DNA synthesis and replication and in the downregulation 
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of various DNA DSB repair signalling. Moreover, pathways involved in metabolism 
of lipids were also downregulated, suggesting the progressive arrest of cellular activity 
and of their metabolism. Twenty-four biological processes were found downregulated 





Figure 4.16 Top 30 most significant (according to FDR<0.05) upregulated (a) and downregulated (b) pathways between CML10 cells treated with Bleosome for 8 hours and 




4.4.4.3.2 Dysregulated pathways between CML10 treated for with Bleosome for 24 
hours compared to untreated control 
 
Pathway analysis of the contrast between CML10 cells treated for 24 hours and 
untreated highlighted 52 upregulated and 117 downregulated pathways (figure 4.17). 
Incubation of CML10 cells for 24 hours with Bleosome triggered the upregulation of 
signalling pathways similar to the earlier time point. Of note, immune response 
mechanisms were highly represented, with the activation of several types of Toll-Like 
receptor cascades, MyD88 pathway, recruitment of interleukin and cytokines and, 
interestingly, also with the dysregulation of  B-cell receptors. As reported in the 
previous comparison, MAPK pathway was also activated in melanoma cells after 24 
hours of treatment. Here, the expression of genes associated with the autophagy 
process are upregulated, suggesting that autophagy is a potential mechanism of cell-
death induced by the Bleosome treatment. When considering biological processes, 
GSEA found only two positive regulated functions, according to the FDR threshold 
(<0.05). However, ranking the first 30 most significant biological processes according 
to crescent FDR, it was interesting to note how, other than the same signalling 
pathways indicated in the initial pathway analysis, transport of different types of ions 
was a recurrent mechanism, along with the regulation of intracellular pH and the 
response to amyloid beta. These pathways are related to the promotion of tumour 
microenvironment, which appear to have a key role within this type of cancer, 
especially during stress condition caused by the treatment with Bleosome. 
Interestingly, along with the downregulated pathways, gene set enrichment analysis 
revealed also 117 negatively regulated biological processes (supplementary data 8.2.6, 
figure 8.2). According with what found in the earlier time point, also here, both 
pathways and biological processes were concordant and identified the arrest of cell 
division, with the affection of mitotic processes, DNA synthesis and chromosome 
stability, as major elements. Furthermore, from the data, it appeared that cells were 




Figure 4.17 Top 30 most significant (according to FDR<0.05) upregulated (a) and downregulated (b) pathways between CML10 cells treated with Bleosome for 24 hours and 




4.4.4.3.3 Dysregulated pathways between CML10 treated with Bleosome for 24 hours 
compared to cells treated for 8 hours 
 
Here we compared CML10 cells treated with Bleosome for 24 hours to cells treated 
with Bleosome for 8 hours. Differences in gene expression profiles were investigated 
with GSEA and showed that 35 pathways were upregulated and 117 downregulated 
after 24 hours’ time point, compared to the 8 hours’ time point (figure 4.18). 
Interestingly, after 24 hours, cells upregulated mechanisms involved in translational 
initiation and protein phosphorylation (Cap-dependent translation initiation, formation 
of a pool of free 40S subunits, ribosomal scanning and start codon recognition). 
Signals of cell growth and migration were still present (MAPK, m-TORc, EPHB), 
along with upregulation of transport of ions and small molecules. Interestingly, after 
24 hours of treatment, pathways associated with autophagy (microautophagy and 
macroautophagy) were upregulated, similarly to what was observed in the previous 
comparisons (section 4.4.4.3.2). Moreover, pathways associated with the production 
of ROS and RNS were upregulated as a consequence of the Bleosome effect. Just one 
upregulated biological process was found below the FDR threshold (0.05), however, 
if considering the 29 following biological processes, according to FDR values, results 
were concordant with pathway analysis, highlighting also the recruitment of 
macrophages and the involvement of interferon-gamma as part of cellular response to 
the treatment (supplementary data 8.2.6, figure 8.3). The study of the most 
significantly downregulated pathways suggested, according to results of previously 
analysed contrasts (4.4.4.3.1 and 4.4.4.3.2), that cells had impaired cell cycle functions 
after 24 hours of Bleosome treatment. Moreover, again, several mechanisms of DNA 
DSB repair were downregulated, indicating how it is unlikely that cells are able to 
repair the DNA damage produced by the Bleosome treatment. The evaluation of thirty-
one significantly downregulated biological processes revealed results consistent with 




Figure 4.18 Top 30 most significant (according to FDR<0.05) upregulated (a) and downregulated (b) pathways between CML10 cells treated with Bleosome for 24 hours and 
CML10 cells treated with Bleosome for 8 hours, Analysis were performed using gene set enrichment analysis (GSEA) software
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4.4.5 Investigating the role of bleomycin hydrolase (BLMH) after 
Bleosome treatment 
 
A further aim was to focus in particular on the investigation of the role of bleomycin 
hydrolase (BLMH) in response to Bleosome treatment. To this extent, we evaluated 
the presence of the enzyme at the cellular level, treating several cancer cells with either 
Bleosome or free bleomycin and compared results to the untreated cells. Furthermore, 
we explored the role of the enzyme also at the tumour level, analysing 
immunohistochemical slides from equine sarcoids and equine healthy skin treated with 
Bleosome, and we compared them to their respective untreated counterparts.  
 
4.4.5.1 Evaluation of the role of BLMH in the response to Bleosome treatment at 
the cellular level 
 
Canine cancer cells (C2 and CML10), feline squamous cell carcinoma (SMG) and 
human breast cancer cells (MCF7) were treated with either a drug titration of 
Bleosome or free bleomcyin for 4 hours and immunoblotted for BLMH antibody 
(figure 4.19 (a) and (b)). The total basal protein level of the enzyme was comparable 
among the four cancer cell lines from three different species. The band corresponded 
to BLMH, after treatment with either Bleosome or bleomycin, had a steady intensity 
over the drug titrations and when compared to relative untreated cells of each cell 
lines, indicating that the enzyme might not be affected by the drug treatment. Only in 
CML10 cells, there was a slight decrease in the intensity of the relative band, at 
increasing drug dose. However, it is interesting to note that a second close paler band 
was always present at a slightly higher molecular weight of the BLMH protein. We 
speculate that this represents a post-translationally modified version of BLMH, which 
may be biologically active. 
 
We explored the BLMH gene expression by quantitative real-time PCR over a time 
course of Bleosome treatment of 2, 4, 8 and 24 hours. C2 and CML10 canine cancer 
cells were treated with respective IC50 concentrations of Bleosome (1.56 µM and 3.81 
µM). Again, BLMH expression was consistent during the indicated time course and 
there was no significant change in expression compared to the untreated cells. 
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Moreover, statistical analysis (two-way ANOVA and Fishers’s post-hoc test) revealed 
no significant difference in the gene expression between the C2 and CML10 cell lines 
(Fig 4.19 (c)). 
  
 
Figure 4.19 Evaluation of bleomycin hydrolase (BLMH) protein after Bleosome (a) and free bleomycin 
(b) treatments and comparison of BLMH gene expression in C2 and CML10 cells after Bleosome 
treatment (c). C2, CMl10, SMG, MCF7 cells were treated with 0.25, 0.5,1, 2, 4, 8, 16 µM of Bleosome 
(a) and free bleomycin (b) for 4 hours and relative levels of BLMH protein are shown. UT represents 
cells untreated and beta actin bands are shown as control. (c) illustrates the relative expression of 
BLMH gene in C2 (blue columns) and in CML10 (orange columns) after 2, 4, 8 and 24 hours of 
treatment with relative Bleosome IC50s (3.81 and 1.56 µM).Statistical analysis were performed with 
GLM: 2-way ANOVA and post-hoc Fisher’s test.  
 
4.4.5.2 Evaluation of the role of BLMH in the response to Bleosome treatment at 
the tumour level 
 
To further investigate if Bleosome treatment increases the protein level of BLMH  
within the context of a tumour, we performed an immunohistochemistry (IHC) study, 
using an antibody to BLMH on three different types of equine sarcoids and on healthy 
equine skin sections. They aim was to evaluate whether Bleosome treatment induces 
BLMH within tumour models and skin, using live samples. Each sarcoid and skin 
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section were treated with Bleosome for 6 hours and compared to their respective 
untreated counterpart. Evaluation of each tumour/ skin was made averaging three 
technical replicates for statistical robustness and results validation. 
An endogenous negative control for each sample was used and represented by a slide 
of the lesion or the skin not stained with the antibody anti-BLMH. Furthermore, an 
equine melanoma was used as positive control for the antibody staining 
(supplementary data 8.2.7, figure 8.4). This latter was particularly important not only 
to assess the efficacy of the antibody, but it also highlighted the difficulty in 
distinguishing between the melanin pigments and the colour of the antibody staining. 
For this reason, a Vector Red chromogen (Impact Nova Red Vector SK-4805) was 
used to visualise positive antibody-staining in red, rather than in brown, to differentiate 
it clearly from melanin pigments.  Histological slides were visualised and processed 
using QuPath software. The intensity of the staining was weak in each slide examined, 
and slightly weaker compared to the positive control, suggesting either that the overall 
presence of BLMH was not abundant in any of the lesions or that the cross-reaction of 
the antibody was not optimal within samples.   
However, the antibody staining was visible in all the sarcoids examined, either 
whether untreated or treated with Bleosome, and easily distinguishable from melanin. 
The distribution of the staining within single sections did not followed a specific 
pattern and, in some areas, stained structures were over-represented compared to 
others, without a specific tropism for particular features of tumour. However, the 
staining positivity was always found within the cytoplasm of fibroblasts. Of note, first 
layers of epidermis did not express any positivity to the staining, and this might be due 
to the lack of fibroblasts within this outermost stratum. Figure 4.20 illustrates the lack 
of a link between treatment and pattern or presence of antibody staining. In each 
treated sarcoid and in the respective untreated counterpart, the feature of histological 
slides appeared very similar and the software analysis confirmed that there was no 
significant difference in the amount of BLMH within sarcoids treated with Bleosome 
compared to their respective untreated counterparts (figure 4.21). Interestingly, the 
BLMH was not present in healthy skin (either treated with Bleosome or untreated). 
This finding, together with the preliminary molecular data, indicate that the level of 






Figure 4.20 Level of BLMH is not affected by Bleosome treatment at the tumour level. Histological slides stained with the antibody anti-BLMH of three different equine sarcoids 
and healthy skin untreated and treated with Bleosome. Slides were stained with anti-BLMH antibody ab204584 (Abcam), processed and scanned. QuPath software was used to 
detect positivity of stained cells. The showed percentage value of the positivity is the mean values of the positivity detected in nine areas analysed for each lesion (three areas for 
each slide of the same lesion, as described in 4.3.7). (a), (d), (g), (j) represents slides of relative samples not stained with the BLMH antibody and used as negative control. (b), 
(e), (h), (k) represents slides of the first, second, third sarcoid and healthy skin untreated, while (c), (f), (i) and (l) represent their counterpart treated with Bleosome. Red arrows 





Figure 4.21 Box plots related to staining positivity of immunohistochemistry (IHC) confirm the lack of 
connection between Bleosome treatment and levels of BLMH. (a) refers to the untreated (blue) and 
Bleosome treated parts of the firs sarcoid, (b) illustrates the level of antibody staining of the untreated 
part (blue) and Bleosome treated counterpart (orange) of the second sarcoid, (c) shows the positivity 
of staining of the third sarcoid in its untreated (blue) and treated (orange) portion and (d) shows the 
presence of BLMH antibody in the untreated (blue) and Bleosome treated (orange) healthy skin. 
Statistical analysis were performed using GLM: 2-way ANOVA, and Tuckey post-hoc test. * indicates 




4.5.1 Bleosome is efficient in killing a panel of human, canine and 
feline cancer cell lines in vitro 
 
The efficacy of Bleosome in inhibiting the viability of cancer cells has been tested 
using a panel of canine, feline and human cancer cells. However, not all the cell lines 
used in this study derived from cutaneous cancers. The main reason resides in the 
limited access to cell lines derived from skin cancers for all the species tested, due to 
technical and financial restrictions; however, cell lines derived from cancers of interest 
in this study has been used when possible. 
Our further experiments using cell lines were performed using a canine mast cell 
tumour (C2) and a canine melanoma (CML10) cell lines. The rationale behind this 
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choise was to compare the effect of the treatment on a melanoma and a non-melanoma 
tumour, in order to highlight the possible different, cell-type dependent effects of the 
Bleosome treatment at the molecular level, and have a better understanding of its 
mechanism of action within the class of tumours of our interest.  
The results of cytotoxicity assays confirmed that Bleosome, the encapsulated form of 
bleomycin, is able to kill different types of cancer cell lines in vitro at different drug 
concentrations. However, it is less potent than free bleomycin. These findings were 
confirmed when Bleosome was tested for inhibiting cells growth and reproducibility 
using a colony formation assay. Encapsulating bleomycin molecules inside vesicles 
naturally partitions them away from and hinders their presentation to cells. This 
compartmentalisation of the cytotoxin most likely limits the immediate amount of 
drug available to the cells in vitro. This finding is in accordance with the study by Lau 
et al (2005), which compared the efficacy of encapsulated bleomycin with the free 
form in vitro, to target human keratinocytes and a human squamous cell carcinoma 
(SCC) cell line. The authors concluded that IC50 values for immortalised keratinocytes 
(NEB-1) were found to be 30µg/ml for Bleosome and 1µg/ml for free bleomycin 
solution, while the estimated IC50 values for SCC cells were found to be 9 µg/ml for 
Bleosome and 3 µg/ml for free bleomycin solution (Lau et al 2005). These results are 
comparable to our data derived from different types of human, canine and feline cancer 
cells. In particular, in two feline squamous cell carcinoma cell lines, SCFF1 and SMG 
(table 4.1), the free bleomycin showed a stronger cytotoxicity as compared to 
Bleosome, of 19 and 27-fold respectively. The greatest difference in efficacy between 
the two compounds was found in MCF7 cells, where the free bleomycin was 56-fold 
more efficient at killing cancer cells than Bleosome, whereas C2 and CML10 cells had 
the smallest difference of 5.6-fold.  
 
4.5.2. UD liposomes improve the cellular uptake of bleomycin 
 
To better evaluate whether this difference in IC50 values between encapsulated and 
free drug was due to the hindrance of cellular uptake, we treated two canine cancer 
cell lines, at two time points (2 and 24 hours), with either Bleosome or free bleomycin, 
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and compared the rate of cellular uptake using live-cell microscopy in conjunction 
with FACS analysis. 
Previous studies have utilised confocal laser scanning microscopy (CLSM) and flow 
cytometry, in particular FACS, to determine the cellular uptake of liposomal drug 
delivery systems. These techniques provide the potential to localize carriers in cells 
and quantify the amount of liposomal uptake, leading to essential information on the 
interaction between the formulation of the drug and the target cells (Ducat et al. 2011). 
Mechanisms of liposome-cell interaction vary as a consequence of the type and 
composition of the formulation used but also as a function of the type of cell and stage 
of the cell cycle (Ducat et al. 2011). According to the types of liposomal nanocarrier, 
entrapped drug and target cells, several mechanisms of cellular uptake have been 
implicated in the literature, however, endocytosis pathway seems to be the 
predominant one for internalisation of liposome-entrapped compounds. For instance, 
clathrin-mediated endocytosis, macropinocytosis, and cell membrane cholesterol 
dependent processes were all shown to play a role in the internalisation of siRNA-
liposomes (Alshehri, Grabowska, and Stolnik 2018). In another study, the cationic and 
anionic liposomes were mainly taken up via macropinocytosis, while the neutral 
liposomes mainly via caveolae-mediated endocytosis (Kang, Jang, and Ko 2017). 
Our results showed that bleomycin encapsulated in UD liposomes was internalised by 
cells more efficiently than the free bleomycin after 2 hours of treatment, in both types 
of canine cancer cells treated. Moreover, after 24 hours of treatment, imaging and 
FACS analysis confirmed that the gap between the concentration of Bleosome and 
free bleomycin inside cells was even greater compared to earlier time point of 
treatment, with Bleosome being taken up more than free bleomycin. Therefore, the 
length of treatment influences the rate of cellular uptake in both free and encapsulated 
bleomycin. This was confirmed by microscopy and FACS showing a significantly 
higher level of green fluorescence within cells after 24 hours of treatment compared 
to the earlier time point in C2 and CML10 cells treated with both compounds. This 
finding is in accordance with literature; Kang et al. (2017), indeed demonstrated that 
cationic, neutral and anionic liposomes showed time-dependent cellular uptake 
through specific endocytic pathways. Interestingly, we found also a different pattern 
of fluorescence expression within cells between treatments. After 2 hours and, more 
evidently, after 24 hours of treatment, F-Bleosome was found in cell cytoplasm within 
well-defined, round shaped structures of different dimensions, while the fluorescence 
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of free bleomycin was evenly present within cell cytoplasm. This might indicate that 
liposomal bleomycin particles fuse together in particular cytoplasmic area, especially 
after several hours of treatment, or that liposomes accumulate within cellular 
organelles, likely lysosomes, as part of the endocytic pathway for the cellular 
internalisation. To explore this latter hypothesis, during our previous live-cell 
experiment (data not shown), we used a red lysosomal staining (Lysotracker Deep 
Red). However, as this dye has an affinity for the inside of the lysosomal particles 
rather than for their membrane, after the staining procedure, we noticed a marked 
reduction of the presence of the green drug particles and the red lysosomal staining, 
when combined together. We assumed that this phenomenon was due to a possible 
competitive mechanism between F-Bleosome molecule and the red staining to be 
stored inside lysosomes. For this reason, we tried to use another type of lysosomal 
dye, which has a greater affinity for the lysosomal membrane (CellLight Lysosomes 
RFP, BacMam 2.0). However, this dye was previously untested on canine cell lines 
and, after several attempts with the support of the manufacturer, we concluded that 
this product was not suitable for canine samples (data not shown). For these reasons, 
it is difficult to draw definitive conclusions about the molecular mechanism of 
Bleosome cellular uptake. However, our previous live-cell imaging experiment using 
the red lysosomal staining (Lysotracker Deep Red), showed some degree of co-
localisation between the green fluorescence of F-bleomycin and the red staining of the 
lysosomal dye (figure 4.22), suggesting the involvement of the endocytic pathway in 
the storage of bleomycin within cells. 
 
Overall, our results showed that bleomycin, when encapsulated in UD liposomes 
passes through plasma membrane and is internalised by cancer cells more efficiently 
than free bleomycin, in the two different cancer cell lines tested.  However, we 
confirmed the presence of the drug inside the cytoplasm of the cell but we could not 
confirm its location within the nucleus. Also taking into account the results of the 
viability study and the reduced efficacy of the encapsulated drug compared with the 
free form, we speculate that, after the initial passage through plasma membrane, 
liposomes are stored within lysosomal compartments and this might hamper or delay 
the passage of the drug into the nucleus after its release from the liposomes. This is 
consistent with a similar study conducted on Doxil (liposomal encapsulated 
doxorubicin). Here, the authors found that 8 hours after administration of free 
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doxorubicin 26% of the drug translocated to the nucleus and, when reaching a specific 
concentration, killed the cell, whereas only 0.4% of the doxorubicin encapsulated in 
liposomal formulation entered the nucleus and had a cytotoxic effect. Kinetically, they 
observed a build-up of nuclear doxorubicin within minutes of adding free doxorubicin 
whereas translocation of Doxil to the nucleus was slow and accumulated in the 
cytoplasm. The authors concluded that liposomal doxorubicin was sequestered in the 
lysosomal compartment and resulted in limited delivery to the nucleus, therefore the 
bioavailable concentration of Doxil-delivered doxorubicin is significantly lower than 
free doxorubicin (Seynhaeve et al. 2013). 
 
Figure 4.22 Co-localisation of F-bleomycin and lysosomes. (a) shows blue (Hoechst, nuclear staining), 
red (Lysotracker Deep red lysosomal staining) and green (F-bleomycin) channel, (b) shows the same 
picture highlighting only the red and the green channel, (c) is the same picture including blue, red, 
green and phase contrast channel. 
 
4.5.3 Bleosome treatment triggers alternative DNA-repair pathways 
in two different canine cancer cell lines 
 
We established that Bleosome was able to kill several types of human, canine and 
feline cancer cell lines, and provided an insight into its cellular uptake. We 
subsequently aimed to gain a better understanding of the molecular effects underlying 
the mechanism of action of Bleosome at cellular level.  
Bleomycin produces DNA SSB and DSB (Chen and Stubbe 2005). This mechanism 
generates free-radical intermediates, it is dependent on the presence of oxygen, and 
can produce a range of different types of DNA lesions, comparable to those produced 
by ionising radiation (Ramotar and Wang 2003). The sensitivity of cancer cells to 
bleomycin it is reported to be variable and tumour type dependent (Chen and Stubbe 
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2005). It is currently unknown why this drug is more efficient against some 
malignancies rather than others. Studies propose that this variability is related to 
upregulation of alternative DNA damage and repair signalling pathways (Chen and 
Stubbe 2005; Pron, Mahrour et al. 1999). As bleomycin is capable also to produce 
DNA DSB, it is likely that specific DS-lesion repair pathways are involved in this 
sense, such NHEJ and HRR (Chen and Stubbe 2005). Moreover, major targets of 
bleomycin toxicity are lungs and skin, two tissues that have a low level of an enzyme 
called bleomycin hydrolase (BLMH). This enzyme might play a role in the 
degradation of the bleomycin molecules, rendering the drug inactive and unable to 
exert its function; hence, BLMH might play a key role in the bleomycin resistance 
(Chen and Stubbe 2005). For these reasons, our aim was to gain insight into the 
molecular cascades activated by cancer cell lines treated with Bleosome, focusing on 
the HRR and NHEJ as possible pathways affecting its therapeutic efficacy. 
Furthermore, we compared the liposome-encapsulated bleomycin with the free 
bleomycin, treating canine cancer cells with both forms of the drug, to the purpose of 
understanding whether liposomal formulation might modulate the activation of 
specific signalling pathways following the treatment. Canine mast cell tumour (C2) 
and canine melanoma (CML10) cell lines were chosen to prove the cell-type response 
of Bleosome treatment and to compare the efficacy of the compound on cellular model 
of NMSC with a malignant melanoma one. A very early step in the response of 
mammalian cells to DNA DSBs is the phosphorylation of histone H2AX at serine 139 
at the sites of DNA damage (Burma et al. 2001). This newly phosphorylated protein, 
γ-H2AX, is a marker of DNA DSB foci (Kuo and Yang 2008). Firstly, we assessed 
the efficacy of Bleosome in producing DNA DSBs in different species, by treating 
canine, feline and human cell lines with a dose titration of the drug, and compared its 
effects with those generated by the same dose titration of free bleomycin. Both 
encapsulated and free drugs increased the level of the protein γ-H2AX in a dose-
dependent manner, suggesting that Bleosome retains the efficacy of the free bleomycin 
in causing DNA lesions according to the increase of the dose (figure 4.9).  
The DNA damage produced by bleomycin can be considered as radiomimetic; several 
studies claim that the most representative repair pathways for this class of 
chemotherapeutic agent include NHEJ and HRR (Helleday et al. 2008) (figure 4.23). 
Therefore, we have focused our analysis on these two pathways, using CML10 and 





Figure 4.23 DNA DSB repair pathways. (a): Homologous recombination (HR) repair. MRE11-RAD50-
NBS1 (MRN) complex recognizes and senses  DSBs. This complex activates ATM kinase, which in turn 
initiates the full DNA damage response. Then Rad51 nucleoprotein filament is assembled, which, 
performs homology sequence searching, and mediates strand invasion. DSBs are restored by branch 
migration of this joint DNA molecule, DNA synthesis, ligation, and resolution of Holliday junctions; B: 
Non-homologous end joining (NHEJ) repair. The two broken ends are processed and ligated directly 
by the action of the end-binding KU70/80 complex and DNA-PKcs, followed by XRCC4-ligase4. Thus, 
NHEJ is an intrinsically error-prone pathway while HR results in accurate repair (Peng and Lin 2011). 
Elements circled in blue were investigated in this study. 
 
Considering the NHEJ and HRR pathways, our  qRT-PCR results indicated that the 
two cell lines responded to the treatment in differently (figure 4.10 (a),(b),(c),(d)). 
Components of HRR following Bleosome treatment, Rad 51 and BRCA1 were 
differently expressed between the two cancer cell lines during every time point of 
treatment, showing increasing expression and peaking at 8 hours post-treatment in C2. 
In contrast, in CML10 cells, Rad 51 and BRCA1 showed a consistently low level of 
expression and a decreasing trend over the time course. These findings suggest that 
the HRR pathway might be activate in mast cell tumour (C2) cells after Bleosome 
treatment but not in canine melanoma cells (CML10). Interestingly, XRCC4 which is 
associated with NHEJ, was only differentially expressed in the two cancer cell lines 
after 8 hours of Bleosome treatment, peaking at this time-point in CML10 cells. 
XRCC4 is a key player in the repair of DNA DSB in mammalian cells, as part of the 
NHEJ signalling. XRCC4 is also an integral part of the DNA end-joining in V(D)J 
recombination, the mechanism that assembles coding regions for the variable domains 
of immunoglobulin and T cell receptors in developing lymphocytes (Grawunder et al. 
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1998). Level of expression of PRKDC, the gene coding for DNA-PK, a protein 
involved in NHEJ, was slightly, yet significantly, higher in CML10 cells until 8 hours 
of treatment, while, after 24 hours, there was an upregulation of this gene in C2 and a 
downregulation in CML10. However, it is important to say that DNA-PK also 
cooperates with ATR and ATM to phosphorylate proteins involved in the DNA 
damage checkpoint (Arlander et al. 2008) and thus, its activation can be unrelated to 
the NHEJ. These findings exclude the activation of the NHEJ pathway in C2 cells and 
limit the evidence of its involvement in CML10 cellular response to Bleosome. 
To confirm the different role of HRR in the two cell lines, and to explore the possibility 
that drug concentration also affected the activation of this DNA repair signalling, we 
immunoblotted for the Rad51 and BRCA1 proteins in canine cancer cell lines (figure 
4.10 (e) and (f)). To rule out the activation of the pathway in CML10 cells, we used 
two different concentrations of Bleosome or free bleomycin, and evaluated cells after 
0, 2, 4 and 6 hours of treatment. Protein levels of Rad51 and BRCA1 were found 
steady when compared to the untreated cells, regardless of type, dosage and timing of 
treatment, confirming that HRR is not the route of DNA repair in CML10 canine 
melanoma cells. C2 cells were treated with Bleosome and free bleomcyin for 4 hours, 
using a drug titration. The dose kinetics of the DNA repair proteins showed slightly 
increased level at the lower doses, but commonly reached a maximum level before 
reaching the maximal dose, to decrease at the highest drug concetration, indicating a 
plateau effect. This is an interesting finding, especially if compared to the parallel 
study conducted by Forrester et al. (2012), where they treated lymphoblastoid cell 
lines and primary fibroblasts with increasing dose of ionising radiation (IR). Authors 
tested the expression of the major DNA damage repair pathways genes, and they 
reached similar conclusion on the plateau effect happening at increasing doses. In the 
same study, a subsequent time-course experiment showed, similarly to our results, that 
the expression of most genes associated with DNA damage repair peaked at 8 hours 
after treatment. In our qRT PCR data all the genes tested, resulted in differential 
expression levels between C2 and CML10 cells, 8 hours after treatment indicating that 
signalling pathways are initially activated at this time point.  
These findings confirm the hypothesis of a cell-type dependent response to bleomycin, 
in its free and encapsulated form. Interestingly, HRR seems to be activated in C2 but 
not in CML10 cell line. However, CML10 has a higher IC50 than C2; this might 
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indicate that there are some other mechanisms implicated in the drug resistance, and 
that more than one pathway might be activated within the same cell line. 
 
4.5.4 Bleosome treatment of CML10 cells may produce unrepairable 
DNA damage and increase the expression of factors that 
stimulate the tumour microenvironment  
 
Subsequently, we aimed to have a better understanding of the cellular mechanisms 
triggered by Bleosome treatment, by performing NGS on C2 and CML10 cells that 
have been treated with either Bleosome or free bleomycin at the respective Bleosome 
IC50 concentration at 0 hr, 8 hr and 24 hours. These time points were chosen based on 
our previous qRT PCR data, showing that the most significant variations in gene 
expression were found at 8 and 24 hours post-treatment. Exploratory analysis of the 
data generated by RNA seq revealed that C2 cells did not form homogeneous groups 
according to the time points of treatment; moreover, when considering cell passages, 
we found a significant variation of gene expression in samples derived from cells from 
different passages. This finding suggested that this cancer cell line is highly 
heterogeneous, hampering, functional analysis and the production of significant 
results. The transcriptomic analysis therefore, focused on CML10 cells only. PCA 
clustering of the RNA seq data separated the CML10 cells according to time point of 
treatment (CML10_UT vs  CML_8H vs CML10_24H) thus suggesting a good quality 
of our data. Using edgeR, we (with the help of Edinburgh Genomics) evaluated the 
expression levels of genes in the different pairwise comparisons. edgeR was used as it 
has the advantage of implementing the method based on negative binominal 
distribution, and model over dispersion for digital gene expression data even with 
small replicates (Robinson, McCarthy, and Smyth 2010). 
Our data showed that the majority of differentially expressed genes (1791 genes) 
(|log(FC)| > 2 and FDR <0.05) were found in the comparison between the 24 hour and 
0 hr time point, suggesting that the majority of changes in gene expression occurred 
after 24 hours of treatment compared to 8 hours. 
We generated heatmaps containing the top 50 most significantly differentially 
expressed, according to the FDR value (<0.05), genes for each contrast, in order to 
highlight the genes underlying the most representative molecular variations. Of note, 
in each of the pairwise comparison, time points of treatment were grouped in two 
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distinct hierarchical clusters, with opposite trend of gene expression, highlighting the 
different gene signatures produced by the treatment. 
When cells were treated with Bleosome for 8 hours, a plethora of growth factors and 
oncogenes were found overexpressed. Notably, among them, RAB20 was present and 
similarly upregulated after 24 hours of treatment. This gene is a member of RAS 
oncogene family; it is well-established in literature that activated RAS pathway, 
anchored by oncogenic BRAF, appears to be the central motor driving melanoma 
proliferation (Ji, Flaherty, and Tsao 2013).  When treated for 8 hours, cells 
overexpressed JUN, the gene encoding for the c-Jun protein, which is reported to plays 
a crucial role in the development and progression of malignant melanoma via direct 
regulation of cancer-relevant target genes (Schummer et al. 2016).  EGR4 was also 
overexpressed after 8 hours of treatment, and, of note, it was found that the early 
growth factor 4 (EGR4), a DNA-binding, zinc-finger transcription factor, plays a 
critical role in cell proliferation and metastasis in small cell lung cancer (Matsuo et al. 
2014).  Interestingly, after 24 hours of treatment with Bleosome, the most 
representative upregulated genes compared with untreated cells, were involved in the 
regulation of extracellular matrix and maintenance of tumour microenvironment, such 
as IRF5 and PLAUR, rather than proper transcription factors directly related to cell 
division and motility. Indeed, we also found the upregulation of ARNT2, which is the 
gene encoding for the hydrocarbon receptor nuclear translocator 2. This gene is 
associated with inhibition of proliferation and tumour aggressiveness in gastric 
carcinoma and in non-small cell lung cancer (Yang et al. 2015; Jia et al. 2019)  
This is an interesting finding as it may indicate that after prolonged time of treatment, 
melanoma cancer cells are no longer able to rapidly divide and grown; however, to 
sustain their vitality, they could stimulate the tumour microenvironment, which could 
play a major role in the cellular response to Bleosome, and may represent a valuable 
target to consider for combined treatments. In further support of this hypothesis, when 
we compared differentially expressed genes between cells treated for 24 and 8 hours, 
we found that after 24 hours hyaluronidase-1 (HYAL1) was overexpressed. 
Hyaluronidases intracellularly degrade hyaluronan, one of the major 
glycosaminoglycans of the extracellular matrix and involved in cell proliferation, 
migration and differentiation (Weber et al. 2019). Thus HYAL1 is considered as a 
tumour suppressor (Lokeshwar et al. 2005).  
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When compared the two time points of treatment to the untreated canine melanoma 
cells, another important finding was that the cells, after both 8 and 24 hours 
overexpressed genes responsible for inflammation and modulation of immune 
response. Experimental evidence links inflammatory and immune cells to cancer 
development. Tumour infiltrating myeloid and lymphoid cells can either promote or 
inhibit cancer development, depending on the nature of the immune-cancer interaction 
(Tang and Wang 2016). Through the production of cytokines, chemokines and 
extracellular enzymes, tumour infiltrating immune cells may serve as tumour promoter 
by supporting tumour cell proliferation and inhibiting programmed cell death. In 
addition to the direct tumour-immune interaction, different branches of immune cells 
also crosstalk within the tumour microenvironment and regulate their counterparts’ 
recruitment and activity, regulating, for instance, also oxygen and nutrient supply to 
tumour cells (Tang and Wang 2016). The eventual outcome of this complicated 
network of regulation is the formation of a unique tumour microenvironment that has 
profound impacts on the development, progression, and metastatic spread of cancers 
(Tang and Wang 2016) 
Furthermore, in the cells treated for 8 hours, TNFAIP3 was found upregulated. This 
gene encodes for the A20 protein and was identified as a gene whose expression is 
rapidly induced by the tumour necrosis factor (TNF). The encoded protein, which has 
both ubiquitin ligase and de-ubiquitinase activities, is involved in the cytokine-
mediated immune and inflammatory responses (Yu et al. 2019). However, 
interestingly, a recent study identifies the ubiquitin-editing enzyme A20 as a key factor 
in mediating cancer cell resistance to DNA-damaging therapy (Yang et al. 2018). 
Hence, further studies aimed to target this gene are needed to observe whether the 
response to Bleosome could be improved. 
Interestingly, in cells treated with Bleosome for 24 hours there is an increase in the 
expression of IL11 and IRF5 compared to untreated control. These genes are 
associated with inflammation. IRF5 is a member of the interferon regulatory 
factor (IRF) family, a group of transcription factors with diverse roles, including 
virus-mediated activation of interferon, and modulation of cell growth, differentiation, 
apoptosis, and immune system activity. IRF5 acts as a molecular switch that controls 
whether macrophages will promote or inhibit inflammation. We speculate that in this 
context, IRF5 can play an important role in the stimulating tumour associated 
macrophages, contributing to the promotion of tumour microenvironment (Thompson, 
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Matta, and Barnes 2018). However, after 8 and 24 hours of Bleosome treatment, cells 
expressed also genetic elements regulating tumour suppression. Among those, 
DUSP2, DUSP5 and DUSP6 were present. In particular, dual-specificity phosphatase 
5 (DUSP5) is one of four mammalian inducible, nuclear mitogen-activated protein 
kinase (MAPK) phosphatases (MKPs). However, DUSP5 is unique within this group, 
targeting only the classical extracellular signal-regulated kinases 1 and 2 (referred to 
hereafter as ERK). This, coupled with the finding that ERK activation is required for 
inducible DUSP5 expression, indicates that it acts as a negative feedback regulator of 
nuclear Ras/ERK signaling (Rushworth et al. 2014). Ectopic expression of DUSP5 in 
lung and colon cancer cells lowers ERK activity and suppresses growth. Furthermore, 
in stomach cancer, low DUSP5 expression correlates with poor prognosis and its re-
expression reduces both cell growth and colony-forming ability in vitro. Taken 
together, these observations suggest that DUSP5 may act as a tumour suppressor 
(Rushworth et al. 2014). This finding might confirm the impaired cellular growth and 
division and the activation of tumour suppressive elements triggered by Bleosome 
treatment in CML10 cells. 
Considering the downregulated elements after Bleosome administration at 8 hours 
post-treatment, the majority of genes were involved in cellular metabolism of 
lipoprotein and endocytosis (LIPG, LDLR, MSMO1), while after 24 hours, key 
regulator of mitosis and chromosome stability were lost. Notably,  NUF2 is 
responsible for the attachment of mitotic spindle microtubules to kinetochore, cell 
division, kinetochore organization, meiotic chromosome segregation and mitotic 
spindle organization (Xu et al. 2019). We speculate that its downregulation may 
contribute to the arrest of mitotic division after 24 hours of Bleosome treatment. 
Interestingly, the ASPM gene was also found downregulated. The ASPM gene 
provides instructions for making a protein that is involved in cell division. ASPM  is 
upregulated in several types of cancer. In particular, upregulation of the ASPM gene 
has been studied in brain tumours and liver tumours. Studies suggest that unusually 
high activity of the ASPM gene is related to cancer progression, spread to other parts 
of the body (metastasis), and recurrence (Pai et al. 2019). Its downregulation following 
Bleosome treatment, therefore, confirms the compelling role of the drug in hampering 
cell division and growth in the treated cells. When looking at the genes downregulated 
after 24 hours compared with earlier time of treatment, we found key elements for 
cellular division, as CENPE and NUF2. CENPE encodes for a kinesin-like motor 
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protein that accumulates in the G2 phase of the cell cycle. This protein is required for 
stable spindle microtubule capture at kinetochores, which is a necessary step in 
chromosome alignment during prometaphase. Hence, we speculate that its 
downregulation can affect the cell mitosis and replication. Furthermore, recently, a 
study found that its overexpression was a negative prognostic indicator for overall 
survival in oesophageal carcinoma (Zhu et al. 2019). 
These findings indicate that the Bleosome treatment triggers the activation of tumour 
suppressor elements and signals that block mitosis and cell cycle progression 
following the DNA damage caused by the treatment. 
Genome analysis provides a large quantity of information concerning molecules that 
are involved in disease pathogenesis and may be used to interpret health disorders 
(Soneson and Delorenzi 2013). While it is not difficult to obtain the gene expression 
profiles, the extraction of biological insight from such information remains a major 
challenge. 
Pathway analysis is a frequently used analytical tool for a better detection of biological 
processes related to a wide distribution throughout the whole network of genes 
(Suarez-Farinas et al. 2010). GSEA compared to single-gene methods gives a better 
overview of the complex biological altered hubs such as metabolic pathways and 
transcriptional programmes. GSEA can capture the subtle but coordinated changes in 
a gene-set and has been commonly used to find important pathways or functions in 
various diseases (Yoon, Kim, and Nam 2016). Reactome is a peer-reviewed pathway 
database of human pathways that have additional types of annotations to support 
pathway curation including a variety of biological processes such as signalling, 
metabolism, transcriptional regulation, apoptosis and synaptic transmission (Croft et 
al. 2011). Ingenuity pathway analysis (IPA) is a web-based software application for 
the analysis, integration, and interpretation of data derived from ‘omics’ experiments, 
such as RNA seq, small RNA seq and microarrays. Data analysis and interpretation 
with IPA builds on the comprehensive, manually curated content of the Ingenuity 
Knowledge Base. Powerful algorithms identify regulators, relationships, mechanisms, 
functions, and pathways relevant to changes observed in an analyzed dataset. 
In this project, combined analysis with GSEA, Reactome and IPA tools revealed a set 
of mechanisms dysregulated in untreated and CML10 cells treated for 8 and 24 hours 
with Bleosome. For instance, when cells treated with Bleosome in both considered 
time points where compared to the untreated, we identified that the majority of the 
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upregulated pathways were involved in inflammation, immune response and growth 
factor. Among those, a plethora of toll-like receptor (TLR) signalling were found to 
be upregulated. TLRs serve as signalling molecules that are usually expressed on 
sentinel cells, such as macrophages and dendritic cells, and recognise pathogen-
associated molecular patterns (PAMPs) as well as damage-associated molecular 
patterns (DAMPs) (Burns and Yusuf 2014). However, studies argued that several 
kinds of toll-like receptors, such as TLR3 and TLR4, are strongly expressed on cells 
isolated from human cutaneous melanoma biopsies. Chronic inflammation is a risk 
factor for the development and progression of cancer. Infiltration of tumours with 
specific T-cell subsets can be beneficial to control the tumour; however, overabundant 
innate immune cells and chronic inflammation can also relate to angiogenesis and poor 
prognosis (Goto et al. 2008). Activation of TLR triggers a cascade of intracellular 
events, including innate immune responses, through NF-κB–dependent and interferon 
regulating factor (IRF)-dependent signalling pathways. This is known to recruit and 
activate leukocytes to sites. Moreover, MyD88 pathway (also found upregulated in 
our pathway analysis), which is the canonical adaptor for inflammatory signalling 
pathways, was found significantly stimulated by activation of TLR2, TLR3, and TLR4 
in melanoma cells, similarly to our study. MyD88 is considered a central node in 
inflammation and can cause also chemo resistance (Deguine and Barton 2014). NF-
κB plays a key role in regulating the immune response and controls many genes 
involved in inflammation, such as growth factors, cytokines, and chemokines. 
Moreover, activation of the NF-κB and IRF family members may play a significant 
role in regulating cytokine and chemokine production and recruiting immune cells in 
the tumour microenvironment.  TLR activation of tumour cells has been suggested to 
be a factor promoting tumour progression in carcinomas (Goto et al. 2008). 
The molecular pathogenesis of cutaneous melanoma is strongly correlated with a 
constitutive activation of the mitogen-activated protein kinase (MAPK) signalling 
pathway (Acosta and Kadkol 2016), which, together with PI3K, was found as 
upregulated pathway after Bleosome treatment. The MAPK pathway plays a key role 
in modulating melanoma survival, proliferation, invasion and angiogenesis. In normal 
cells, this pathway is tightly regulated by extracellular signals from the cell membrane 
to the nucleus, mediated by a cascade of phosphorylation events. Frequent somatic 
point mutations have been found in the BRAF (66%) and N-RAS (15%) genes, two 
key elements of this pathway. The activity of the PI3K pathway is also increased in 
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melanomas, due to the loss of function of the phosphatase and tensin homolog (PTEN), 
either through mutation, deletion or methylation (Daphu et al. 2014). Interestingly, 
when interrogating the pathways differentially regulated after 24 hours of treatment 
compared to the earlier time point, we found that autophagy was upregulated. 
Autophagy is induced by starvation to capture and degrade intracellular proteins and 
organelles in lysosomes, which recycles intracellular components to sustain 
metabolism and survival. Autophagy also plays a major homeostatic role in controlling 
protein and organelle quality and quantity. The role of autophagy in cancer is still 
controversial; it can be neutral, tumour-suppressive, or tumour promoting in different 
contexts (Amaravadi, Kimmelman, and White 2016). Moreover, autophagy influences 
the interaction between the tumour and the host by promoting stress adaptation and 
suppressing activation of innate and adaptive immune responses. Additionally, 
autophagy can promote a cross-talk between the tumour and the stroma, which can 
support tumour growth, particularly in a nutrient-limited microenvironment. Thus, the 
role of autophagy in cancer is determined by nutrient availability, microenvironment 
stress, and the presence of an immune system (Amaravadi, Kimmelman, and White 
2016). Recent studies revealed that the consequence of defective autophagy in the 
context of melanoma is fundamentally contingent upon the stage of cancer 
development (Ndoye and Weeraratna 2016). 
Notably, a number of downregulated pathways were mostly related to DNA synthesis, 
DNA damage repair and mitotic checkpoints. DSBs are extremely hazardous lesions 
for all DNA‐bearing organisms and the mechanisms of DSB repair are highly 
conserved. The DSBs are mainly repaired by HRR, which utilises an intact DNA 
molecule as the repair template. Mitotic HRR is managed by checkpoints that inhibit 
cell division until DSB repair is complete. The mitotic cycle is managed by a 
checkpoint mechanism that acts to delay cell division when DSBs are present at the 
end of G2, during the G2/M checkpoint (Burgoyne, Mahadevaiah, and Turner 2007). 
Although the exact fate of the cell cycle following the DNA damage is still poorly 
elucidated (Thompson, Gatenby, and Sidi 2019),  some authors consider the process 
of HRR as having three components: (1) the process of HRR itself that achieves the 
re-joining of the broken DNA duplex, (2) the process by which the cycle is prevented 
from proceeding to cell division, and (3) the management and coordination of these 
two processes, such that only when DSB repair is completed, the cell division occur  
(Burgoyne, Mahadevaiah, and Turner 2007).  The latter two components are strictly 
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dependent on mitotic checkpoints, while, among other factor, ATR plays a key role in 
the third one. Interestingly, in our pathway analysis, G2/M checkpoint, ATR, mitosis, 
the cell cycle and HRR were all downregulated in cells treated for 8 and 24 hours, 
indicating that cells after Bleosome treatment are not able to repair the impaired 
genetic material. This is a compelling finding as it can open novel perspectives on the 
putative mechanism of resistance to the treatment, which, to date, is still lacking of 
consensus.  
So far, it has been reported that extended cell-cycle arrest/senescence, apoptosis and 
mitotic cell death are the most common cellular responses to bleomycin treatment and 
that bleomycin was found to induce G2/M cell cycle arrest in cancer cell lines (Wang 
et al. 2013). Previously, it has been speculated that this may be because of a G2/M 
checkpoint response to DNA damage. The G2/M checkpoint is important for genomic 
stability; it ensures that chromosomes are intact and ready for separation before cells 
enter mitosis. Thus, authors of the study concluded that although the mechanism of 
bleomycin-resistance is unclear, the ability for bleomycin-induced DNA damage to be 
repaired is the most likely one (Wang et al. 2013).  
Our results open novel perspectives on the putative mechanism of action and of 
resistance to bleomycin treatment, as we have evidence that the DSBs induced by 
Bleosome are not repaired in canine melanoma cells, by activating cell cycle 
checkpoint, and HRR. Taken together, we speculate that after Bleosome treatment 
melanoma cancer cells are still metabolically active and produce signals of cell 
growth. However, importantly, the DNA damage produced by Bleosome is not 
repaired in CML10 cells, as the cell cycle progression is arrested, cell cycle and mitotic 
checkpoints are inhibited along with DNA synthesis and DNA DSB repair 
mechanisms. We also speculate that cells can respond to the stress of the Bleosome 
treatment by undergoing autophagy. We assessed by viability assays the efficacy of 
Bleosome in killing CML10 cells, however, in this study, we did not identify clear 
markers of cellular apoptosis or other processes directly related to cellular death; thus 
we hypothesise that autophagy might be the mechanism leading to cellular death after 
Bleosome treatment. Moreover, in order to survive after the treatment, cells may rely 
on tumour microenvironment, by triggering inflammatory processes and dysregulating 
immune system, and thus, creating a protective environment that might represent a 




4.5.5 BLMH is not a key player in the response to the Bleosome 
treatment 
 
In regards to the possible mechanism of resistance to Bleosome treatment, results of 
RNA sequencing did not reveal any significant variation in the expression of BLMH 
after the Bleosome treatment.  
Several papers identified BLMH, a neutral cysteine protease, as another key factor in 
bleomycin resistance. It is supposed to inactivate bleomycin in normal and cancer 
tissues (Umezawa et al. 1974). It also plays an important role in antigen presentation, 
hydrolysis of homocysteine-thiolactone, and breakdown of deaminated filaggrin into 
amino acids N-terminal proteolysis of huntingtin (Y. Chen et al. 2013). To better 
understand the role of BLMH, using a specific thiol protease inhibitor (E64) that 
blocks BLMH activity, it was shown that mammalian cells exposed to E64 become 
more sensitive to bleomycin (Sebti et al. 1991). However, a more recent study in the 
yeast orthologue gene, BLH1, showed that this enzyme does not affect cytotoxicity of 
bleomycin in the organism when deleted or overexpressed. Thus, the role of BLMH 
in producing tumour resistance is controversial (Ramotar and Wang 2003). On the 
basis of the foregoing studies, it would appear that BLMH has a more general role in 
cells to degrade proteins, or perhaps to regulate gene expression by degrading certain 
transcription factors (Koldamova et al. 1999). In the scenario of bleomycin cellular 
response, we aimed to investigate the role of this enzyme at cellular and tumour level. 
We treated canine (C2 and CML10), feline (SMG) and human (MCF7) cancer cell 
lines for 4 hours with crescent doses of Bleosome or free bleomycin as comparison, 
and immunoblotted for the BLMH protein. Band intensities in C2 and in SMG did not 
show significant differences between increasing doses of the drug. In CML10 cells 
treated with Bleosome, the level of BLMH appeared to decrease with increasing doses 
of the drug, while it was overall very low at every drug dose of the free bleomycin. 
Human breast cancer cells, when treated with Bleosome, revealed a slight increase in 
the intensity of the BLMH related bands at the increase of the drug concentration, 
suggesting a possible activation of the enzyme within this cell line, after the Bleosome 
treatment. However, the intensity of this variation is very weak, without giving 
sufficient evidences about its modification following the treatment. Furthermore, our 
results on the BLMH gene, by mean of qRT PCR, did not show significant changes in 
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the expression of the enzyme in response to a time-course of Bleosome treatment in 
two canine cell lines (figure 4.19).  
However, the western blot analysis revealed the constant presence of a second band at 
a slightly higher molecular weight of the BLMH protein. This might indicate that 
BLMH is activated post-translationally after the Bleosome treatment. Further studies 
are needed to better investigate these possibilities. To validate these results and explore 
further the possible involvement of BLMH in response to Bleosome treatment, we 
decided to use also a tumour model, treating cutaneous sarcoids excised from equine 
patients. As control, we used also healthy equine skin. Three different pathological 
types of sarcoids, excised from different patients, were cut in two parts, one was left 
untreated and represented the control, and the other part was treated with Bleosome 
for 6 hours, spreading the cream on all over the free surfaces of the lesions. We choose 
6 hours as length of treatment because from our previous skin penetration studies 
(section 3) we observed that Bleosome penetrates deeper in the skin after 6 hours than 
earlier times of treatment. Moreover, according to our qRT PCR findings in this 
chapter (section 4.4.5), we observed that the activation of pathways implicated in DNA 
damage repair might occur after 6\8 hours of bleomycin administration. 
Subsequently, histological slides generated from each sample were stained with an 
antibody anti-BLMH, to observe whether the level of the enzyme in sarcoids and 
healthy skin was affected by the Bleosome treatment. Equine melanoma was used as 
control, to assess the efficacy of the antibody in staining cell cytoplasm 
(supplementary data 8.2.7). Moreover, the adding of Vector red enabled clear 
distinction between the melanin pigment and area of positive antibody staining. As 
reported in figure 4.20, the presence of BLMH was constantly low in all the sarcoids 
examined; this might be due to the small amount of the enzyme present within the 
slides or to the poor efficacy of this particular antibody in equine samples. Due to 
technical and financial restrictions, it was not possible to test further the quality of the 
antibody; however, an accurate optimisation of the staining procedure was performed 
by the pathology unit of the R(D)SVS to the best of their possibility, in light of the 
described limitations. The staining appeared in the cytoplasm of fibroblastic cells, 
without a specific tropism for elements or layers of the cancer lesion. However, as 
statistical analysis confirmed, the amount of BLMH within sarcoids was not affected 
by Bleosome treatment, as there was no difference in the amount of staining, in the 
treated and the untreated portion of every lesion considered. We are confident in the 
216 
 
reliability of these results as the starting samples (excised sarcoids) were processed 
and treated according to OECD guidelines (Davies, Ward, and Heylings 2004) to 
maintain them vital over the chemotherapeutic treatment. Importantly, we analysed 
every portion of each considered sarcoid, obtaining at least three histological slides 
withdrawn from every area of the lesions. Moreover, we performed at least three 
technical replicates, to produce statistically significant results. Of note, the use of 
NanoZoomer XR (Hamamatsu) to scan single histological slides enabled us to analyse 
the whole section, avoiding the possibility of missing area of BLMH accumulation. 
Interestingly, the enzyme was not present in equine healthy skin, regardless of whether 
it was treated with Bleosome or not. This finding is in accordance with literature as 
skin is one of the targets of bleomycin toxicity and several authors claim that this is 
due to its lack or low level of BLMH, which exert in other organs, protection against 
the effect of the drug (Reinert et al. 2013). It is interesting however, that equine 
sarcoids of different pathological types and excised from different patients manifested 
the presence of the enzyme. The involvement of BLMH in cutaneous disorder is 
preliminary investigated in some studies, although there is still a lack of consensus in 
literature about its role in different cutaneous pathologies (Kamata et al. 2011; Kamata 
et al. 2007). However, our finding might open novel routes to explore the actual role 
of BLMH, not only in response to the bleomycin treatment, but also in pathological 
and cancerous skin conditions.   
These results, together with the molecular data, suggest that the level of bleomycin 





In this study, we found that Bleomycin encapsulated in UD liposomes can kill several 
types of human, canine and feline cancer cell lines, although its efficacy is slightly 
reduced compared to the free form of drug, in vitro. We determined that the cellular 
uptake of Bleosome is time-dependent and that it can more effectively cross the plasma 
membrane and penetrate into cells than the free drug. Given these counterintuitive 
findings we determined that the encapsulated form of bleomycin is less efficient at 
killing cancer cells than the free form because the drug is sequestered in the cytoplasm 
217 
 
and unable to penetrate the nucleus and cause DNA damage. Further live-cell imaging 
studies, including optimising the labelling of cellular organelles within canine cells, 
could further elucidate the mechanism of cellular uptake of Bleosome. This was the 
first study to examine the global changes in gene expression induced by Bleosome 
treatment. We found that Bleosome treatment generated DNA DSBs and that, 
interestingly, canine CML10 melanoma cells were unable to repair the DNA damage 
through cell cycle arrest and HRR. Interestingly, CML10 cells overexpressed genes 
responsible of inflammation and organisation of extracellular matrix, suggesting that 
Bleosome treated cancer cells stimulate the tumour microenvironment and that cellular 
components of the tumour microenvironment may mediate the patient’s response to 
treatment. Further work is required to establish if the cytotoxic effects of Bleosome 
can be enhanced by dual targeting of components of the tumour microenvironment, 



















Chapter 5 Evaluation of Bleosome as part of a 





In veterinary medicine, sarcoids are neoplasms belonging to the non-melanoma skin 
cancer (NMSC) class of tumours and are the most common skin tumours in equids. 
This class of tumours are not fatal in most cases, in both human and veterinary patients, 
but their treatment still represents a challenge as it includes disfiguring and highly 
invasive treatments in both species. For this reason, there is growing interest in 
Bleosome, a topical compound made by encapsulating the bleomycin in ultra-
deformable (UD) liposomes, as a novel, non-invasive treatment option. To date, there 
have been limited pilot studies conducted on the safety and efficacy of Bleosome as a 
topical treatment in the management of NMSCs, including one study using Bleosome 
alone to treat human NMSC, and a second study in horses using Bleosome in 
combination protocol to treat equine sarcoids. Both studies showed promising results 
and highlighted the non-invasive nature and lack of side effects of the treatment. 
Here, we aimed to assess the ability of Bleosome to penetrate through equine 
cutaneous sarcoids in vitro, and to conduct a preliminary investigation of the clinical 
application of Bleosome administered topically to equine patients bearing sarcoids.   
To this extent, we treated patient-derived sarcoids with F-Bleosome for 6 hours and 
visualised the living-samples by using the CLSM. We found the presence of drug 
particles within the whole depth of the lesion and concluded that Bleosome is able to 
penetrate through sarcoids, accumulating within the superficial layers, but also to 
reach inner parts of the lesions, until the bottom of the tumour model after a 6-hour 
long single application of the compound.  
Subsequently, we treated 12 horses bearing different types of cutaneous sarcoids with 
Bleosome, following CO2 laser excision, at the Dick Vet Equine Hospital of the 
University of Edinburgh. To date, we found that 5 patients (41.6%) were in complete 
remission, 4 patients (33.3%) experienced relapsed lesion(s), and 3 (25%) were failed 
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to follow-up. Sarcoids that recurred were previously reported to be at higher risk of 
relapse because of their pathological types, multiple lesions or location in anatomical 
areas where it is difficult to achieve clean margins by surgery. Overall, Bleosome 




Sarcoids are the most common type of equine skin neoplasm on a worldwide basis 
(Bergvall 2013). Approximately 1% to 11.5% of all horses have sarcoids, and this type 
of tumour is reported to account for up to 90% (35%–90%) of all skin neoplasms in 
horses (Bergvall 2013). Sarcoids are non-metastatic, fibroblastic neoplasms that rarely 
regress spontaneously; they can remain static or become very aggressive locally. 
Although the condition is not lethal itself, size and distribution of the tumour can 
severely compromise the use and value of the horse, and lead to a decision of 
euthanasia (Bergvall 2013). 
Equine sarcoids are proposed to have a multifactorial aetiology. An association with 
infectious agents in the form of bovine papillomavirus (BPV) types 1 and 2, as well 
as genetic risk factors, have been documented  (Angelos et al. 1991). Sarcoids are 
generally first noticed in horses aged 1 to 7 years old and there is no reported colour 
or gender predisposition (Brostrom 1995). 
The macroscopic presentation of sarcoids can be highly variable. A clinically based 
classification of sarcoids has been suggested by Knottenbelt (2005), which includes 
occult, verrucous, nodular, fibroblastic, mixed, and malignant/malevolent types of 
tumours. 
Occult sarcoids are focal areas with alopecia, scaling, skin thickening, hyperkeratosis, 
and hyperpigmentation. Common locations include the neck, face, sheath, medial 
thigh, and shoulder (Knottenbelt 2005). 
Verrucous sarcoids have a rough, alopecic, raised surface, which can be verrucous and 
irregular. This type is usually found on the head and neck and in the axillae and groin.  
Nodular sarcoids can be divided into types A and B, whereby type A are spherical 
subcutaneous masses and type B have dermal involvement, which precludes the 
independent movement of the overlying skin. The overlying skin is often haired, but 
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can become alopecic and ulcerated. These types are often seen in the eyelid region and 
groin, and on the prepuce. Fibroblastic sarcoids are fleshy, ulcerated masses; type 1 is 
pedunculated and type 2 has a broad, locally invasive base. Common locations include 
the axillae, groin, legs, and the periocular region. Tumours can resemble granulation 
tissue or infectious processes, such as habronemiasis. Another differential is squamous 
cell carcinoma. Non-fibroblastic tumours can become fibroblastic after being 
traumatised. Mixed forms (two or more types) of tumours are common. 
Malignant/malevolent sarcoids are aggressive and locally invasive. These tumours 
extend widely into adjacent skin and subcutis, are invasive, and infiltrate lymphatic 
vessels. The occult and verrucous type can remain static for years if not traumatised. 
Nodular tumours can also remain unchanged, although less often. Any type of sarcoid 
lesions can develop into an aggressive fibroblastic or malignant/malevolent tumour if 
traumatised (Knottenbelt 2005; Bergvall 2013). 
A high proportion of affected horses (14%–84%) have multiple tumours, and all types 
of sarcoids can be present in the same horse. Sarcoids often develop at the site of 
previous trauma or where the skin is thin. Exposure to trauma can induce a worsening 
of the lesion and a more aggressive development of the tumour (Knottenbelt 2005). 
An early age of onset, time, and number of lesions are associated with larger tumour 
size (Bergvall 2013). 
Sarcoids are diagnosed based on clinical signs and histopathology, as other conditions 
can macroscopically be difficult to differentiate from sarcoids (Bergvall 2013). For 
instance, alopecia areata, bacterial folliculitis, and dermatophytosis can mimic occult 
sarcoids. Moreover, all types of nodular conditions (eosinophilic granulomas, 
melanomas, schwannomas, and so forth) can be mistaken for nodular sarcoids. One 
important differential diagnosis for fibroblastic sarcoids is exuberant granulation 
tissue. A biopsy should include deep dermal tissue and be at least 6 mm in diameter if 
a biopsy punch is used to harvest the sample (Bergvall 2013). Before verifying the 
diagnosis by biopsy, serious consideration should be given to the fact that traumatised 
sarcoids can potentially transform into a more aggressive type of tumour. It has been 
recommended that traumatic intervention should not be performed on a presumed 
sarcoid unless a treatment plan has been established after the diagnosis is confirmed. 
Fine-needle aspiration (FNA) for cytology is usually unrewarding and carries the same 
risk of exacerbating tumour growth. FNA is not recommended for the diagnosis of 
sarcoids (Bergvall 2013). 
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Despite being so widespread, there is no a universal consensus of treatment for 
sarcoids, which has been suggested to be related to their diverse phenotypic 
appearance (Compston et al. 2016). A range of treatment modalities, including various 
topical applications, immunotherapy, radiation therapy, chemotherapy, cryosurgery, 
‘traditional’ sharp surgery and laser surgery, have all been reported in the veterinary 
literature and an even wider variety of non-prescription treatments are used by the 
horse-owning public (Compston et al. 2016). Success rates with respect to recurrence 
vary widely; however, no single treatment has been shown to be suitable for all 
sarcoids in all locations (Compston et al. 2016). 
If complete surgical removal with wide margins is achievable, it may be an optimal 
choice for therapy. The presence of BPV DNA has been demonstrated up to 16 mm 
outside the macroscopic lesion, and local recurrence has been correlated to DNA-
positive surgical margins (Martens et al. 2001). The probability of local recurrence 
after sharp surgery or carbon dioxide laser is significantly higher for large sarcoids 
and sarcoids that had previously failed to respond to treatment (Martens et al. 2001). 
Sharp surgery has been reported to result in 50% to 64% recurrence of the tumour 
within six months. With non-touch techniques that avoid autoinoculation and wide 
surgical margins, the result improved to 82% complete remission without recurrence 
(Martens et al. 2001). In a retrospective study of 28 periorbital verrucous and nodular 
sarcoids without extensive involvement of the eyelid, 23 had recurrence (82%) and 
39% grew additional tumours after surgery (Knottenbelt and Kelly 2000). 
Furthermore, recurrence was associated with a more aggressive behaviour. 
Combination of sharp surgery and other therapies, for example, cisplatin injection, has 
been reported to improve success rates. In one case report, surgery was combined with 
photodynamic treatment in a horse with multiple lesions, some, but not all sarcoids, 
went into remission (Reschke 2012). 
Carbon dioxide laser treatment was reported by Carstanjen et al. ( 1997) to result in 
remission without recurrence in 62% of sarcoids from 60 equids, of which 45 were 
horses. Follow-up was longer than 6 months. Animals with multiple sarcoids had a 
higher risk of recurrence. In another study, 20 of 28 sarcoids (71%) resolved after laser 
treatment (Martens et al. 2001), while in the study by Compston et al. (2016), 82 (83%) 
out of 99 horses treated with CO2 laser surgery had no recurrence of the sarcoid 
removed. Advantages over conventional surgery are reduced risks of postoperative 
swelling, pain, and hypergranulation.  
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Cryotherapy has achieved up to 42% to 100% success with no recurrence, with an 
average healing time of 2 to 4 months (Taylor and Haldorson 2013). A successful 
outcome was obtained in 11 of 14 (79%) horses treated by cryosurgery (Martens et al. 
2001). However, when small (<2 cm2), occult, or verrucous periocular sarcoids were 
treated with liquid nitrogen, 91% had aggressive, rapid-growing relapses within 12 
weeks of treatment (Knottenbelt and Kelly 2000). Side-effects reported included post-
treatment alopecia or regrowth of white hair and, if used on the face or periocular area, 
facial nerve paralysis and loss of the upper eyelid function. Caution is also warranted 
when lesions are located close to joints, as septic arthritis has also been reported.  
Hyperthermia through heating the sarcoid with a thermo-probe has been used alone or 
in combination with chemotherapy, radiotherapy, or immune modulation. Only a 
small number of cases resolved and stayed in remission for 6 months to 1 year 
(Knottenbelt and Kelly 2000).  
Radiotherapy, also known as interstitial brachytherapy (implants of, eg, iridium-192, 
cobalt-60, radium-226, radon-222, or gold-198) was effective in 50% to 100% of 
cases, with a low (5%) recurrence rate. By use of ionizing-radiation brachytherapy 
(iridium-192), 8 of 8 and 13 of 15 periocular and  non ocular sarcoids, respectively, 
went into remission (Theon and Pascoe 1995). In another study, 66 nodular, 
fibroblastic, and mixed tumours were treated with brachytherapy with platinum-
sheathed iridium. Of the 53 cases that were followed up, 98% were resolved 
(Knottenbelt and Kelly 2000).  
Chemotherapy can be effective, either by intralesional injections (cisplatin powder 
emulsion in sesame oil or almond oil, or aqueous formulation of fluorouracil) or 
topical application (fluorouracil, thiouracil). Mixing cisplatin with oil increases the 
local concentration and prolongs the retention time of the drug, and reduces the risk 
of cisplatin-induced nephrotoxicity and hepatotoxicity. Cisplatin is usually 
recommended at a dose of 1 mg/cm3 and is deposited intralesionally using sedation 
and analgesia 4 times at 2-week intervals. The treatment can be combined with 
debulking surgery (Bergvall 2013).  
The intralesional administration of 5-fluorouracil (5-FU) into 13 sarcoids at the dose 
of 50 mg/cm3 given every 2 weeks for up to 7 treatments resulted in complete 
regression in 61.5% of cases. Follow-up time was 3 years. Lesions larger than 13.5 
cm3 responded less favourably (Stewart, Rush, and Davis 2006). Topical 5% 5-FU 
was used twice daily for 5 days then once daily for 5 days, followed by 5 applications 
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on an every-other-day schedule in 9 periocular, occult, and verrucous lesions. Six 
sarcoids resolved, and 3 improved but later developed into fibroblastic tumours 
(Knottenbelt and Kelly 2000). 
AW4(5)-LUDES, a combination of topical fluorouracil, thiouracil, and heavy metals, 
has been reported to result in 35% to 80% complete regression (Knottenbelt and Kelly 
2000). When used in 159 periocular small occult or verrucous sarcoids, 35% resolved. 
Significant scarring and a detrimental effect on eyelid function were recorded in 6 
cases. Because of the risk of side effects, this treatment is not recommended for 
periocular regions, distal limbs, and coronary bands (Knottenbelt and Kelly 2000). 
With all chemotherapy protocols, consideration must be given to the risk of exposing 
health care personnel, owners, and others who handle the treated horses. 
Despite the implementation of safety precautions (eg, double gloves, mask, safety 
bench), surface contamination with antineoplastic drugs including 5-FU was detected 
in 65% to 75% of samples taken from 6 cancer treatment centres in the United States 
and Canada (Connor et al. 1999). Furthermore, one study detected cytotoxic drugs or 
metabolites in urine samples from nurses not directly involved in drug preparation or 
administration (Sessink et al. 1992). These findings stress the importance of 
establishing strict safety precautions for both health care workers and owners who 
handle the horses. 
Other reported treatments for equine sarcoids include the use of antiviral agents. 
Acyclovir, used in human herpesvirus infections, is metabolised to the active form 
acyclovir triphosphate in virally infected cells. It inhibits viral DNA replication, but is 
not known to eradicate latent virus (Bergvall 2013). Topical daily application of 
acyclovir 5% was used in 47 sarcoids, in a few of which after surgical debulking. 32 
of 47 (68%) lesions went into remission, whereas incomplete resolution was observed 
in the remaining 15 (32%). Tumour thickness was associated with a less favourable 
response (Stadler et al. 2011). Other antiviral agents, such as Cidofovir and Xanthates 
have been reported as treatments for sarcoids, although the reported outcomes 
achieved were doubtful (Scagliarini et al. 2012). 
As BPV might be one of the key players involved in the aetiology of sarcoids, few 
immune-modulating agents have been experimented as possible therapeutic strategy. 
Among them, bacillus Calmette-Guerin (BCG) from Mycobacterium bovis is an 
immune modulator that stimulates host lymphocytes and natural-killer cells. With this 
therapy, only sarcoid cells undergo necrosis, as has been shown histologically. 
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Inflammatory reactions to BCG frequently require nonsteroidal anti-inflammatory (eg, 
flunixin) and/ or corticosteroid treatment. The best results have been seen with 
periocular sarcoids, where, in one study, 18 of 27 (67%) lesions treated with BCG 
vaccination resolved (Knottelbelt and Kelly 2000). 
Imiquimod is an immune-modulating agent used to treat human genital warts, actinic 
keratosis, and superficial basaliomas. Imiquimod has potent antiviral and antitumor 
activity. It stimulates both the innate and acquired immune system via toll-like 
receptor 7, thereby inducing a T-helper–1 cytokine response as well as an increase of 
TNF-a, IL-1, IL-6, and IL-8 (Bergvall 2013). A 5% cream (Aldara) was used in one 
study, applied topically 3 times weekly for up to 32 weeks. 56 % of treated sarcoids 
went into complete remission and 20% had partial remission. Overall, 80% had a 
greater than 75% reduction in tumour size (Pettersson, Bergvall, and Humblot 2011). 
However, few side effects were reported within this therapy. Pain, erythema, 
exudation, and erosion of the area of the application were reported following Aldara 
treatment (Pettersson, Bergvall, and Humblot 2011). 
Retinoid drugs such as tazarotene have been trialled on over 500 cases. It could be 
considered a useful adjunctive treatment in some forms of sarcoids (especially 
verrucous and occult lesions) but it seldom results in a cure. Furthermore, in one study, 
treatment with a retinoid (0.1% tazarotene gel) resulted in high recurrence (60%) and 
variable outcomes (Knottenbelt et al. 2018). 
 
In conclusion, although there is a plethora of therapeutic options, there is a lack of 
consensus on the best treatment option for equine sarcoids; furthermore, most of these 
treatments produce several side effects. Therefore, our aim was to test the efficacy of 
Bleosome as topical non-invasive treatment for equine sarcoids in an adjuvant setting.  
Bleosome has previously been applied, in a preliminary study, on human patients 
bearing NMSC, showing promising outcomes without adverse reactions reported 
(Chopra, S. unpublished data). Furthermore, a pilot study on the efficacy of Bleosome 
in combination with other topical agents, as a treatment for equine sarcoids, was 
conducted by Knottenbelt et al. (2018). The authors showed that when applied alone, 
tazarotene and 5-FU achieved only 17% and 27% of completely resolved sarcoids 
respectively, by 12 months, whereas the combinations of either 5-FU and Bleosome, 
or tazarotene and Bleosome, resulted in resolution of 77% and 78% of the lesions, 
respectively. Combination treatment was significantly superior to sole treatments with 
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tazarotene or 5-FU, however, this study was limited by the number of horses treated 
with Bleosome alone to reach a meaningful conclusion regarding the synergy of 
Bleosome and other treatment options. 
Moreover, in that study, all horses treated using tazarotene showed pain and skin 
exudation. Pain and discomfort were also noted with application of 5-FU. Throughout 
the duration of treatment with Bleosome, no pain or discomfort, or any overt 
inflammatory effects, were noted and no apparent systemic effects of the treatment 
were encountered in any of the horses (Knottenbelt et al. 2018). 
 
In this study, we conducted a preliminary experiment to test the ability of Bleosome 
to penetrate through sarcoids in vitro. We used sarcoids surgically excised from 
patients as part of their standard therapeutic protocol, we treated them with Bleosome 
and assessed the degree of Bleosome penetration, using the confocal laser scanning 
microscope. To the best of our knowledge, this was the first study that explored the 
ability of penetration of a chemotherapeutic through a tumour by directly visualising 
with microscopy the Bleosome particles within a living sarcoid tissue, following its 
topical application. 
Subsequently, we treated equine patients, presented to the Dick Vet Equine Hospital 
(The University of Edinburgh), bearing single or multiple cutaneous sarcoids, with 
topical application of Bleosome to the tumour excision site, following surgical 
excision with a CO2 laser. Our aim was to observe whether the topical compound 
improved the outcome of the surgical treatment, lessening the rate of re-occurrence of 
the neoplasms, compared to previously reported case studies. Furthermore, we aimed 
to confirm, in a wider cohort of patients, the safety and lack of side effects of the 
treatment. This study was still on going at the time of the writing and therefore, data 
shown should be considered as preliminary results. 
 
5.3 Materials and Methods 
 





Two sarcoids, excised from two different equine patients, were used in this study. 
They were of different clinical type and located in different anatomical regions: one 
was a fibroblastic sarcoid excised from the elbow of a patient and the other lesion was 
a mixed sarcoid excised from the neck of a different horse.  
Pathological samples were provided by the surgical team of the Equine Veterinary 
Hospital at the Royal (Dick) Veterinary School of the University of Edinburgh, as part 
of the study on the Bleosome efficacy on equines sarcoids (VERC reference number 
6.19.). Straight after the collection, sarcoids were wrapped in aluminium foil, stored 
in sealed plastic bags and snap frozen in dry-ice, and stored at -70◦C or -20◦C.  
At the time of the experiment, each sarcoid was thawed in 3x PBS at RT and then cut 
into two sections: one section was used as the untreated control, and the other was 
treated with F-Bleosome. Both sections were stained with Hoechst 33342 
(ThermoFisher Scientific) diluted in PBS at concentration of 0.02 mg/ml, for 1 hour 
at RT. Subsequently, F-Bleosome was applied to the outermost surface of the tumour, 
in an amount sufficient to completely cover the external area of the lesion, and 
incubated for 6 hours at RT. 
At the indicated time point, F-Bleosome was gently removed and the sarcoid was 
washed with PBS; subsequently, the tumour (both treated and untreated parts) was cut 
into 1 mm thick slices including the whole thickness of the lesion, using an acrylic 
mouse brain matrix (RBMA 600C, repeatable sections, coronal slices, 1 mm spacing, 
World Precision Instruments). The section was oriented with the outermost surface 
(the part where F-Bleosome was applied), facing the right of the glass slide and the 
innermost part of the sarcoid facing left (figure 5.1). 
 
 
Figure 5.1 Orientation of the sample on the slide. The section is cut horizontally, from the outermost 
to the innermost part of the lesion. The blue arrow indicates the outermost surface of the sarcoid, where 




Three sections from the F-Bleosome treated part of the sarcoid and three from the 
untreated control were analysed. Slices were put on a glass slide and kept flat by 
positioning another glass on the top. Slides were visualised using the Zeiss LSM 710 
AxioObserver Confocal Microscope equipped with EC Plan-Neofluar 20x/0.50 M27 
objective lens (details on microscope settings in section 2.10.3.1). 
 
5.3.1.1 Image analysis 
 
Images captured with the confocal laser scanning microscope (CLSM) were analysed 
using the software Zen lite 3.0 (Blue edition, Zeiss). This software has dedicated tools 
that allowed the measurement of the fluorescence intensity of the green (F-Bleosome) 
and blue (Hoechst) channel. Thanks to this software, we were able to assess the overall 
fluorescence intensity of a selected slide as well as the fluorescence intensity level for 
every pixel detected within the whole slide analysed. The fluorescence intensities 
relative to the length of the section were plotted (from the outermost surface, where 
F-Bleosome was applied, to the opposite innermost surface), in order to obtain 
information about the level of fluorescence relative to every distance (in µm) from the 
outermost external surface of the sarcoid (depth). The relative graphs were generated 
using the software ‘R’, with the help of Dr Gianluigi Rossi (The Roslin Institute).  The 
position of F-Bleosome molecules (green objects) were calculated by Zen lite, in 
relation to their distance from the outermost surface of the sarcoid.  
Statistical analysis was performed using the ‘Minitab’ software. 
 
5.3.2 Preliminary evaluation of the efficacy of Bleosome on equine 
sarcoids in vivo 
 
This study was conducted in collaboration with the staff of the Dick Vet Equine 
Hospital of the University of Edinburgh (in particular with Dr Richard Reardon) and 
was considered as a preliminary case-observation study. It was conducted to gain 
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information about the efficacy in vivo of the Bleosome, as an adjuvant treatment for 
horses bearing cutaneous sarcoids. The study was on-going at the time of writing and 




This was a prospective study using clinical cases presented to the Royal (Dick) 
Veterinary Equine Hospital of The University of Edinburgh between 2018 and 2020. 
Owners were informed of all the procedures and provided with a dedicated 
information leaflet (supplementary data 8.2.8) before consenting to include their 
horses in this study by signing a consent form. This study received the approval of the 
Veterinary Ethical Review Committee (VERC) with the VERC reference number 
6.19. 
Horses with different clinical type (fibroblastic, nodular, verrucous, occult and mixed 
according to clinical classification; Knottenbelt 2005), size, number and location of 
cutaneous sarcoids were treated. Cases in which previous therapy had been 
unsuccessful were included, with these tumours classified as recurrent. Twelve 
animals met the criteria for inclusion in the study (Table 5.1). There were four Irish 
Sports Horses, one Welsh Cob, one Appaloosa, one Warmblood, one Clydesdale, one 
Icelandic Horse, and three Racehorses. The cases ranged in age from 3- to 16-years-
old with a mean of 7.7 years. There were seven geldings and five mares, in the study. 
Sarcoids were measured and evaluated by clinicians prior to therapy. Serial 
photographs were obtained and clinical records were kept of the sarcoid(s) size on 
presentation, location, and previous treatments. Owners were asked to provide 
photographic, telephonic and/or written updates of the lesions every two weeks and 
feedbacks about the general health status of their animals. Over serial evaluations, the 
response to treatment, side effects and the length of Bleosome treatment were 
recorded. 
 




In all but two patients, Bleosome was administered in an adjuvant setting, after the 
surgical excision of the sarcoid(s) by means of CO2 laser. Among the two exceptions: 
one patient received cisplatin beads implant concomitant to CO2 laser excision, 
followed by Bleosome treatment, and the other one received combined Bleosome and 
tazarotene as the only treatment, without surgical excision. Prior to surgical excision, 
each patient received anti-inflammatory (1.1 mg/kg flunixin meglumine 
intravenously) and antibacterial (20 mg/kg penicillin procaine intramuscularly) 
treatments. Some of the cases underwent the surgical procedure under standing 
sedation and local anaesthesia, while other patients received general anaesthesia 
according to clinician preference (predominantly based on lesion location). Procedures 
for proper handling and disposal of Bleosome followed the Occupational Safety and 
Health Administration guidelines. 
Following surgical procedures, owners were given guidelines for safely and correctly 
applying Bleosome. Briefly, they were asked to wear two pairs of nitrile gloves before 
coming into contact with the Bleosome, to clean the lesion, removing any loose scale 
and crust. Subsequently, they were advised to apply Bleosome cream, wearing gloves, 
in an amount sufficient to cover the whole surface of the lesion, and to massage it 
gently over the target area, until the lesion dried out, and to repeat the procedure every 
12 hours (twice per day). The overall length of treatment suggested ranged between 4 
and 6 weeks, according to the response to the treatment, side effects and tolerance of 
the patient. Owners were asked to bring their horses to the Equine Hospital of the 
R(D)SVS for regular post-operative checks every 2 weeks, or, where not possible, to 
provide photographic and/or telephonic updates. Particular emphasis was put in 
requesting description of the surgical site and in reporting any signs of bleeding, 
inflammation, swelling or poor healing of the scar. Owners were also asked to provide 
accurate information about any signs of stress, discomfort, pain or behavioural 
abnormalities of their horses during the course of application of Bleosome. 
 
5.3.2.3 Classification of response 
 
The responses to treatment were classified according to the following outcomes. A 
case was classified as ‘resolved’ if the tumour was not visible at the time of evaluation 
by clinicians or by owners after the course of Bleosome treatment. A case was 
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considered to be ‘persistent’ if the tumour was grossly visible at inspection following 
the treatment. A case was considered to be ‘recurrent’ if the tumour had disappeared 
at inspection at any point during Bleosome therapy, but was reported to be present in 
the same site any time after the completion of the Bleosome therapy or after the initial 




5.4.1 Bleosome penetrates through equine sarcoids in vitro 
 
We used patient excised sarcoids as a model to test the efficacy of Bleosome to 
penetrate through cutaneous neoplastic lesions. Sarcoids were treated with Bleosome 
for 6 hours, observed at the CLSM and compared to their untreated counterparts. The 
same experiment was performed twice, using two different types of sarcoids excised 
from two different patients (section 5.3). We obtained comparable results and will 
focus on the results from one experiment in more detail. 
Three sections from the F-Bleosome treated part of the sarcoid and three sections from 
the untreated control were visualised using the CLSM. This type of visualisation 
allowed us to explore the whole depth of the sarcoid section and to detect the position 
of the drug particles within this area using the Zen lite software. As shown in section 
3, Hoechst staining highlighted cellular nuclei and other background skin structures 
containing DNA. As skin has intrinsic autofluorescence, when the image was analysed 
with Zen lite, in the control section a very low level of green background was detected, 
as shown in figure 5.2 (c). 
The section of the sarcoid treated with F-Bleosome showed an overall high level of 
green fluorescence. When the fluorescence level was plotted against the length of the 
section, the maximum intensity of the green fluorescence was detected within 0.4 cm 
depth, indicating that the majority of the F-Bleosome compound is in the superficial 
layers of the tumour. However, some F-Bleosome molecules were observed at a much 
greater depth, up to 1.6 cm from the top surface of the sample (figure 5.3 (b)), 
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suggesting that after 6 hours of treatment, with a single application, F-Bleosome is 
able to penetrate through almost the whole of the tumour section.  
We compared the overall green (F-Bleosome) fluorescence intensity within the treated 
and untreated sections and we found that this was significantly higher (p <0.05) in the 
F-Bleosome treated part than the very low green fluorescence detected within the 






Figure 5.2 Image and fluorescence intensity plots of the untreated  sarcoid (control). (a) Image of the whole depth of the untreated section of the sarcoid captured with the CLSM, 
the outermost surface is facing left (as indicated by the blue arrow). (b) Represents the intensity of Hoechst blue fluorescence (blue lines) compared to green fluorescence (green 
lines) detected along the whole section. “Distance” in the histogram indicates the position related to the outermost surface (0 - 16000 µm). (c) Indicates the green fluorescence 




Figure 5.3 Images and fluorescence intensity of the F-Bleosome treated sarcoid. (a) Image of the whole depth of the F-Bleosome treated section of the sarcoid captured with the 
CLSM, the outermost surface is facing left (as indicated by the blue arrow). (b) Highlights the indicated position (distance from the top surface) of selected F-Bleosome particles 
(11018.995 and 15929.894 µm depth). (c) Represents the intensity of Hoechst blue fluorescence (blue lines) compared to green fluorescence (green lines) detected along the whole 





Figure 5.4 Box-plots comparing the blue and the green fluorescence intensity between the treated and 
untreated part of the sarcoid. (a) Hoechst blue fluorescence intensity of the control (untreated sample, 
blue plot) and the F-Bleosome treated portion of sarcoid (green plot). The difference between the two 
is not statistically significant (p: 0.083, Student T-test). (b) Comparison of the green fluorescent 
intensity of the control (untreated sample, blue plot) and the F-Bleosome treated portion of the sarcoid 
(green plot); they are statistically different (p<0.05), as the treated sarcoid has a significantly higher 
green fluorescence intensity (p: 0.003, Student T-Test).  
 
Subsequently, we compared the overall green fluorescent intensity, detected along the 
whole depth of the section, of each of the three examined slides of the F-Bleosome 
treated part of the sarcoid, and the untreated control. All of the F-Bleosome-treated 
sections showed a high intensity of green fluorescence up to 0.4 cm distance from the 
outermost surface of the sarcoid (figure 5.5 (b)). Deeper than 0.5 cm, the green 
fluorescence gradually decreased and followed a steady pattern, remaining close to the 
average green intensity of the three sections; however, there were some notable peaks 
at deeper depth. As confirmed from imaging, these peaks indicate single F-Bleosome 
particles detected in the innermost part of the sarcoid. Whereas the green intensity of 
the untreated sections was consistently very low and evenly close to the average 
(figure 5.5 (a)).  This indicates that the green fluorescence detected in the control 
represents the autofluorescence background of the skin, a feature already confirmed 
in section 3, with the experiments on penetration of F-Bleosome on healthy animal 
and human skin using the MP. Rare peaks noted in the histogram (figure 5.5 (a)) 
probably represent cutaneous structures, such as hair follicles, which naturally auto-





Figure 5.5 Histograms of green fluorescence intensity of the three slides of the treated and untreated 
part of the sarcoid.(a) compares the green fluorescence intensity of the three slides analysed of the 
untreated part of the sarcoid (control). Profile of the first slide is the grey line, profile of the second 
slide is the blue line and the third slide has red line. The green line represents the mean value of the 
green fluorescence intensity within the three slides (b) compares the green fluorescence intensity of the 
three slides analysed for the F-Bleosome treated part of the sarcoid. Profile of the first slide is the grey 
line, profile of the second slide is the blue line and the third slide has red line. The green line represents 
the mean value of the green fluorescence intensity within the three slides. 
 
These significant findings demonstrate that F-Bleosome can penetrate through 
cutaneous sarcoids and reach some of the innermost structures of the lesion with a 
single administration in vitro, and that after 6 hours, F-Bleosome mainly concentrates 
at a depth of 0.4 cm but can penetrate as far as 1.6 cm. 
 
5.4.2 Bleosome shows potential as an adjuvant therapy in the 
treatment of equine sarcoids in vivo 
 
To date, 12 horses fulfilled the inclusion criteria for this study (table 5.1). There were 
7 males and 5 females, and the mean age was 7.7 years. To date, 5 patients were in 
remission (41.6%), 4 experienced recurrences (33.3%), and 3 failed to follow up 
(25%). Overall mean of follow-up was 12 months. 
Within the horses in remission, 3 horses had sarcoids in multiple sites and some of 
them were recurrent lesions at the time of the initial presentation at the Dick Vet 
Equine Hospital. The remaining 2 patients had 1 primary lesion each: 1 had a 
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verrucous sarcoid on the neck and the other one had a fibroblastic sarcoid on the 
abdomen. The mean follow up for this group was 14.8 months. 
The relapse group includes 1 horse with multiple lesions classified as recurrent at the 
time of the initial presentation; in particular, this patient had multiple nodular, mixed 
and occult sarcoids in the abdomen, legs and chest areas. This horse experienced 
recurrent lesions (reappearance of a nodular lesion on the left radius and 2 occult 
plaques in the left inguinal area) after 5 months from the laser surgery, however, due 
to initial intolerance to the treatment Bleosome was applied only for 2 weeks. At the 
re-check, another course of Bleosome was prescribed to cure the recurrent sarcoid, the 
compound was applied for 4 weeks, it was well tolerated, and after 3 months from the 
end of the treatment, the horse experienced a remission, however after 7 months from 
the end of the second course of Bleosome, clinicians noted another single recurrent 
lesion, which is currently being treated with Bleosome. Of the other 3 patients 
experiencing recurrence following the treatment, 2 had multiple verrucous, nodular 
and occult sarcoids in the face and abdomen, and in multiple locations respectively. 
The first horse experienced a recurrence of the verrucous lesion close to medial cantus 
of the eye. Neither of the patients had any previous treatments. However, the latter 
received cisplatin beads within the laser surgery as part of the treatment and 
experienced a recurrence 4 months following surgery. The last horse within this group 
had a primary fibroblastic sarcoid in the abdominal area, which recurred after 1 year 
post-surgery. The mean time of recurrence was 9.25 months after surgery. 
At the time of writing, 3 patients failed to follow up; 1 of them had multiple recurrent 
occult and nodular sarcoids on the thighs and on the penile sheath, and was reported 
to be free from disease 3 months after the surgery. The other 2 had multiple nodular, 
ulcerated, and nodular and occult primary sarcoids. The first was reported to be free 
from disease 6 months after the surgery. Owners of this horse reported a minor 
swelling and bleeding on one of the surgery sites at the time of Bleosome 
administration, however it was unclear whether this was due to delayed healing of the 
surgical wound or to the Bleosome treatment. The other surgical sites treated with 
Bleosome did not manifested any of these side-effects and, after some topical 
symptomatic medications, the swollen site recovered and the Bleosome course was 
completed. The second horse had an occult and a nodular primary sarcoids in the groin 
area and was treated with Bleosome and Tazarotene, without surgical excision. 6 
238 
 
months following the topical application of both medications, the owner reported that 
the horse was in remission; subsequently, the animal was sold and failed to be followed 
up. 
Overall, follow-ups ranged from 3 to 20 months after surgical excision, the treatment 
was well tolerated, and none of the horses experienced topical and systemic side-
effects, except for one and the cause was doubtful. 
Fig. 5.6 and 5.7 show as an example, the appearance of three excised sarcoids on the 
same patient, immediately after the surgery (fig. 5.6) and two months after the end of 




Figure 5.6 Appearance of three sarcoids after surgical excision prior to Bleosome application. (a) The scar of a 






Figure 5.7 Appearance of scars 2 months after the Bleosome application. There is no evidence of recurrence, 







Table 5.1 List of patients enrolled in the study. Signalment including breed, age and sex (F: female, 
CM: castrated male), is reported. Types of sarcoids, location and whether they were primary or 
recurrent lesions at the time of the first presentation at the Dick Vet Equine Hospital is given. Type of 
treatment, length of Bleosome application, type and length of follow-up are illustrated. Outcome is 
showed: ‘yes’ represents the presence of recurrent lesion after the treatment; ‘no’ represents the 





In this section, we aimed to investigate the ability of Bleosome in penetrating through 
equine cutaneous sarcoids and its efficacy as non-invasive treatment in the 
management of the disease. We addressed our aims by assessing the penetration of 
Bleosome through excised, living sarcoid tissues and by applying the compound on 
equine patients bearing sarcoids, as adjuvant treatment. 
Skin is the external barrier of the body and its main function is to provide protection 
against the surrounding environment, and to limit the absorption of exogenous 
molecules (Fleury and Vianna Lopez 2011). UD liposomes are nanocarriers designed 
to carry entrapped drugs through the hardest layers of the skin and delivery their 
payload directly to the target lesion.  However, the mechanism exploited by UDs to 
penetrate through the skin is still poorly elucidated (Romero and Morilla 2013). In 
section 3, we proposed that UD liposomes allow the penetration of encapsulated 
bleomycin through animal and human skin, acting as penetration enhancers, following 
the mechanism number 2 proposed by Verma et al. (2003): liposomal vesicles might 
interact with outermost keratinocytes, disrupting intercellular lipid lamellae and 
allowing the release and consequently the penetration of the entrapped bleomycin 
through the skin. Furthermore, we showed that after 6 hours of skin treatment, F-
Bleosome particles can be found at 430 µm of depth within healthy equine skin. This 
depth is significantly greater than the average thickness of the stratum corneum 
(Theerawatanasirikul et al. 2012), and the average thickness of the epidermis. Hence, 
we concluded that, with a single administration on healthy equine skin, Bleosome 
penetrates through the skin and enables the encapsulated bleomycin to reach the 
deeper cutaneous structures after only 6 hours of topical application. These findings 
were reproducible in a tumour model, where we interrogated the penetration of F-
Bleosome through equine sarcoids in vitro. In this study, we treated patient-derived 
equine sarcoids with Bleosome for 6 hours. We choose this length of treatment as, in 
our previous experiment on the efficacy of Bleosome in passing across healthy equine 
skin (section 3), we observed the deepest penetration of F-Bleosome molecules at 6 
hours post application. In the previous penetration study (section 3), we used the MP 
to visually explore the position of F-Bleosome within the live cutaneous tissue. Here, 
we cut the sarcoid into thin slices (1 mm) after the application of the chemotherapy, 
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and we visualised the treated lesion by means of CLSM. MP holds inherent 
advantages for imaging living tissues by improving depth penetration and reducing 
photodamage (Larson 2011). However, its imaging penetration power does not 
exceed 700-800 µm depth (Durr et al. 2011). As the thickness of the sarcoid lesions 
was greater than 1.5 cm, we concluded that it was not optimal to visualise a whole 
section of the sarcoid with the MP, as performed previously with healthy equine skin. 
Furthermore, MP does not produce images with higher resolution than CLSM 
(Jonkman and Brown 2015). The illumination in a CLSM is achieved by a collimated 
laser beam across the specimen (Jonkman and Brown 2015); just the light in-focus 
can pass through the pinhole, reach the detector, and then form the image with more 
details because the blurring from out-of-focus has vanished. By using CLSM, it is 
possible to obtain high-resolution images from the samples, which increase to 
accuracy of the microscopic images (Rossetti 2013). 
As performed for healthy skin, we still aimed to visualise the treated sarcoids without 
fixing them, in order to avoid possible artefacts and alteration of the structure and 
position of F-Bleosome molecules within the lesion. For these reasons, we cut the 
sarcoids horizontally, including the whole depth of the lesion, in order to investigate 
the penetration of F-Bleosome throughout the entire neoplasm. To this extent, after 
having tried several techniques for cutting live sarcoids in even and thin slices without 
damaging the tissue, a mouse brain matrix was used. This tool, thanks to repeated 
grooves with 1 mm distance gaps, enabled the sarcoid to be sectioned in thin and 
homogeneous slices, suitable for evaluation with the CLSM. Analysis of obtained 
images revealed, in the F-Bleosome treated section of the sarcoid, an abundant 
presence of the fluorescence compound within the first 0.4 cm from the outermost 
surface of the lesion, indicating that the majority of the applied compound, after a 
single application, resides within the superficial layers of the neoplasm. However, it 
was interesting to observe the presence of several F-Bleosome particles within the 
whole depth of each section examined of the treated sarcoid, with the deepest drug 
particle found very close to the bottom of the lesion (1.6 cm depth). This is a 
compelling finding that further confirms our previous data on the efficacy of 
Bleosome in penetrating through healthy animal and human skin. Moreover, it 
provides evidence on how just a single application of Bleosome in a tumour model 
leads the chemotherapy to pass the superficial layers of the neoplasm and to reach the 
bottom of the lesion. This information might have important repercussions in the 
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application of the Bleosome on equine patients in clinics, not only because it supports 
the penetration power of the chemotherapy compound, but also because it suggests 
that multiple topical applications could be of a great benefit, as Bleosome may spread 
within the area of the target lesion. Furthermore, this is an optimised, novel technique 
to directly visualise the fate of Bleosome through living tumour explants and can open 
innovative ways of exploring the concentration and the pattern of accumulation of a 
chemotherapeutic drug within target tumours. 
We confirmed that the green fluorescence detected was due to the presence of F-
Bleosome particles rather than background autofluorescence of skin structures by 
comparing to the untreated control. Within  the control section some peaks could be 
observed and likely correspond to some specific structures of the skin, such as hair 
follicles, with a higher basal level of autofluorescence as previously discussed (section 
3). The overall level of the green fluorescence was significantly higher in the F-
Bleosome-treated sarcoid compared to the control. However, there was no statistically 
significant difference between the level of Hoechst signal indicating that the intensity 
of the nuclear staining was comparable between the F-Bleosome treated and control. 
These findings indicate that Bleosome can effectively penetrate through sarcoids after 
a single topical application.  
NMSC are a group of cutaneous tumours, which include basal cell carcinoma (BCC) 
and squamous cell carcinoma (SCC) in men, dogs and cats (Simonetti et al. 2009). 
Within this class of neoplasms, in horses, sarcoids are locally invasive, fibroblastic 
skin tumours and represent the most common tumours in equids worldwide (Bergvall 
2013). Despite the high frequency of this class of malignancies, their therapeutic 
management it is still challenging in both human and veterinary medicine. Therefore, 
the topical administration of Bleosome has begun to be investigated. This is an 
interesting alternative for reducing side effects and for increasing drug targeting. In a 
preliminary study conducted on human patients, 0.1% liposome-encapsulated 
bleomycin was used successfully in named patient to treat a variety of skin 
malignancies including BCC, SCC, actinic keratosis and keratoacanthoma, as well as 
benign growths such as warts and verrucae (S. Chopra, personal communication). 
Standard care for these conditions included localised tissue ablation through 
cryotherapy, chemical ablation or surgical excision, all aggressive and potentially 
disfiguring treatments, particularly if the lesion involve the facial area. The face is 
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one of the most common locations for BCC and actinic keratosis in people. In the 
study of Dr Chopra, involving 60 named patients, Bleosome gave 100% responses 
and 97% clearance rates, including large, deep or multiple BCC lesions. The patients 
treated were unfit for, or had refused, surgery due to concerns about physical trauma 
or facial disfigurement. The topical formulation of liposomal bleomycin resulted easy 
to apply, well-tolerated, painless, and cost-effective and resulted in excellent cosmetic 
outcomes (S. Chopra, unpublished data). These features appeared to suggest that 
liposome-encapsulated bleomycin would be potentially useful in treating skin 
malignancies in the veterinary species. In the pilot study of Knottenbelt et al (2018), 
there were 118 horses of mixed age and breed. Authors compared the efficacy of 
tazarotene and 5-FU alone and in combination with Bleosome as topical treatment for 
equine cutaneous sarcoids. They found that the therapeutic benefit of the novel 
formulation of topically applied liposome-encapsulated bleomycin (0.1%) in 
combination with 5-FU or tazarotene was shown to be effective at 12 months in 
treating 77 and 78%, respectively, of periocular, facial verrucous or occult sarcoids 
(Knottenbelt et al. 2018). The success of this twice daily treatment over a period of 
up to 60 days indicates it is a potential new approach to the treatment of certain types 
of sarcoid in the horse. Importantly, they also found that Bleosome was easily applied 
by horse owners and remarkably free of side effects in the patients, especially when 
compared to alternative standard treatments. These findings support preliminary 
results in human studies (Knottenbelt et al. 2018). 
We conducted a case observation study on the Bleosome efficacy as adjuvant 
treatment, administered after the CO2 laser surgical excision, in the management of 
equine cutaneous sarcoids. Here, the main difference compared to the previously 
mentioned studies was the application of Bleosome to surgical scars and not on gross 
lesions. In the majority of the cases, the surgical wound was left healing by secondary 
intention. Healing by secondary intention occurs when the sides of the wound are not 
opposed, therefore healing must occur from the bottom of the wound upwards. It 
occurs in the same four stages as primary intention, including: haemostasis, where a 
large fibrin mesh forms, which fills the wound; inflammation, where an inflammatory 
response acts to remove any cell debris and pathogens present; proliferation, where a 
granulation tissue forms at the bottom of the wound. This is an important step, as the 
epithelia can only proliferate and regenerate once granulation tissue fills the wound 
to the level of the original epithelium, and once the granulation tissue reaches this 
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level, the epithelia can completely cover the wound; and lastly, the remodelling phase 
occurs, where the inflammatory response begins to resolve, and wound contraction 
can occur. Myofibroblasts are vital cells in secondary intention. They are modified 
smooth muscle cells that contain actin and myosin, and act to contract the wound; 
decreasing the space between the dermal edges. They also can deposit collagen for 
scar healing (Chhabra et al. 2017). We speculated that as granulation tissue, collagen 
and myofibroblasts during the healing process are not organised in thightly structure, 
such as the one of the stratum corneum, the efficacy of penetration of Bleosome 
through the surgical site could be greater compared to what we found in section 3 in 
intact skin. Moreover, in this section, we observed that Bleosome is able to penetrate 
through the inner layers of a sarcoids in vitro. Hence, we assumed that the 
disorganised architecture proper of the granulation tissue might be an easy barrier for 
Bleosome to trepass and reach the residual cancer cells, compared to the densely 
compacted aggregation of fibroblasts proper of the sarcoid. 
To date, 12 patients fulfilled the inclusion criteria; there were 7 males and 5 females 
and the mean age of the horses was 7.7 years. 5 patients experienced a complete 
remission at the time of writing, with an mean follow-up of  14.8 months. 3 patients 
failed to follow up; however, all of them were reported to be free of recurrence during 
the last updates, which occurred after 3 months in 1 and 6 months in 2 cases. 4 patients 
experienced recurrences. Of those, 1 had recurrent lesions at the time of the first 
treatment at the Dick Vet Equine Hospital and 3 had multiple sarcoids at the initial 
presentation. Previously, horses affected with multiple sarcoids and with recurrent 
lesions have been shown to have a poorer prognosis following treatment (Lane 1977). 
Types of recurrent lesions were fibroblastic in 1 cases, mixed and occult in 1 case, 
verrucous and verrucous and nodular in the last 2 patients. The presence of verrucous 
sarcoids was significantly associated with a higher rate of sarcoid recurrence in the 
study of Compston et al. (2016). Previously poor results have been reported for 
periocular verrucous sarcoids. The reasons for this are unclear. Histological 
examination of verrucous sarcoids has shown increased levels of hyperkeratosis, rete 
pegs and ‘picket fence’ appearance at the dermoepidermal junction compared with 
other types of sarcoid except for mixed varieties. These histological characteristics 
may indicate that verrucous sarcoids extend further into the dermal layer than other 
types of sarcoid, which could have an influence on excisional margins (Compston et 
al. 2016). Sites of recurrence varied among all the horses. Follow-ups were conducted 
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by photos sent by owners, phone, e-mail or clinical re-check. Length of Bleosome 
treatment was 4 weeks, 2 patients received the topical application for longer (6 weeks) 
according to the clinician’s instructions. One patient, who experienced a recurrence, 
only received Bleosome treatment for 2 weeks, as the horse was reluctant to being 
handled and having the cream applied. However, following the recurrence of 3 
lesions, she received a course of 4 weeks of Bleosome and she seemed to tolerate the 
treatment well during the second administration. 
The treatment was well tolerated in all the patients, according to the lack of clinical 
signs associated with pain or discomfort reported by the owners and to the lack of 
adverse cutaneous reactions at the site of the surgical excision following the Bleosome 
application. One patient experienced some swelling on the site of the surgical excision 
during the first week post-surgery. However, it was unlikely due to the Bleosome 
administration, as the lesion appeared as a minor complication following the surgical 
procedure and was treated accordingly. Furthermore, this horse had other sarcoids 
removed in other areas of the body that were treated with Bleosome without showing 
any side effects. All the other patients treated with Bleosome did not show any pain 
or adverse reactions to the treatment. 
The clinical study we conducted was still on-going at the time of the writing and thus, 
data shown should be considered as a preliminary insight into the efficacy of the 
Bleosome as adjuvant treatment in the management of equine cutaneous sarcoids. 
However, the major limitations so far, include the low number of patients enrolled, 
that prevents any significant statistical analysis at this stage of the study. Additional 
bias will occur when long-term follow-up cannot be obtained for all animals, and 
recall bias is unavoidable when using telephone and mailing communication. Owner-
reported data on follow-up were used to obtain information on recurrence. Although 
it was expected that most owners would be capable of identifying evident lesions, 
some occult sarcoid types may have been missed in particular locations, such as the 
inguinal region. Furthermore, at this stage, this was a one-harm study, without a 
‘control’ group of horses treated with CO2 laser surgical excision only, used as 
comparison. However, this has the advantage to be a prospective study and in our 
future plans there are the recruitment of more patients, the inclusion of a ‘control’ 
arm, represented by horses treated at the Dick Vet Equine Hospital with the surgical 
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excision without the Bleosome treatment, and the on-going follow-ups of the patients 
already treated. 
However, to date, our results showed that Bleosome was very well tolerated by the 
patients and was effective in maintaining the disease-free status in some patients who 
bore recurrent and/ or multiple sarcoids, sometimes located in area of the body where 
it is difficult to achieve clear margins with surgery due to anatomical restrictions. 
Furthermore, the cases who experienced recurrences had lesions that were previously 
treated at the time of the first check and types of sarcoids and location which are 
reported in literature to be difficult to treat and more prone to relapse. 
 
5.6 Conclusions, limitations and future directions 
 
This study was aimed to evaluate the ability of Bleosome in penetrating through equine 
sarcoids and to investigate the efficacy and safety of the treatment as adjuvant therapy 
in the management of equine cutaneous sarcoids, as part of the comparative study on 
the potential of Bleosome against NMSC in human and veterinary species. 
We treated living sarcoids explants, excised from patients as part of their therapeutic 
protocol, with F-Bleosome, and assessed that the fluorescent liposomal bleomycin was 
able to penetrate through the lesion, reaching the bottom of the tumour, after a single 
administration lasted 6 hours.  We established a method to detect the fluorescence 
intensity within every distance from the outermost surface of the analysed section, 
calculating the depth at which F-Bleosome particles were visualised. However, the 
next step would be enriching the tumour-penetration analysis by adding further 
sarcoids excised and treated in the same manner, of other pathological types, in order 
to strengthen and confirm our findings. 
Subsequently, we conducted a case observation study in order to evaluate the efficacy 
and safety of Bleosome as adjuvant treatment for equine sarcoids. We treated 11 
patients with Bleosome after the CO2 laser surgical excision and 1 patient received 
concomitant Bleosome and tazarotene treatment without surgical excision. To date, 
we observed that 5 patients (41.6%) were in complete remission, 4 patients (33.3%) 
experienced recurrences and 3 (25%) were lost of follow up. The number of patients 
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evaluated so far was too low to yield statistically significant conclusions and a 
complete analysis will be performed at the end of the case study. However, there were 
no adverse reactions reported and the treatment was overall well tolerated. 
Overall, we showed the ability of Bleosome in penetrating deep through sarcoids in 
vitro and obtained promising outcomes in the application of Bleosome in vivo to date, 
suggesting the safety and non-invasiveness of the treatment as adjuvant agent for the 




















Chapter 6 General conclusions 
 
6.1 Summary of findings 
 
Bleomycin is a chemotherapeutic agent which produces cancer cell death mainly by 
generating DNA single and double-strand breaks (SSB and DSB), and, to some extent, 
RNA damage as well (J. Chen and Stubbe 2005b). However, current knowledge in 
the literature indicates that its mechanism of action may be cell-type dependent (Chen 
and Stubbe 2005). Moreover, as bleomycin is a large and hydrophilic molecule, it 
cannot easily diffuse across the plasma membrane from the extracellular compartment 
to the inside of cancer cells, and its passage through the external cutaneous body 
barrier is restricted (Roy and Horwitz 1984; Lyman et al. 1986).  Moreover, when 
administer systemically, bleomycin has severe intrinsic toxicity (Sleijfer 2001). 
However, there is evidence suggesting that this drug is highly valued in the treatment 
of a range of malignancies in human and veterinary medicine, and the target class of 
tumours, shared between men and animals, are non-melanoma skin cancers (NMSC). 
To avoid the unwanted side effects following systemic treatment with bleomycin, it 
has been used as a topical agent for the management of NMSC in human and 
veterinary species, administering this drug by means of electrochemotherapy (ECT) 
(Glass et al. 1997; Rodrıguez-Cuevas et al. 2001; Spugnini and Baldi 2019; Tozon, 
Tamzali, and Cemažar 2017). This therapeutic strategy achieved promising outcomes; 
however, it can be invasive and painful, and usually requires the patients to undergo 
general anaesthesia (Impellizeri et al. 2016).  
 
To overcome these issues liposomes loaded with a chemotherapy payload have been 
proposed as a novel minimally invasive approach to directly and effectively target 
cancer cells  (Utku 2011).  
The theoretical benefit of nanocarrier-mediated drugs include greater solubility, 
longer duration of exposure, selective delivery of entrapped drug to the site of action, 
superior therapeutic index and the potential to overcome resistance associated with 
the regular anticancer agent (Zamboni 2008). Within the different types of liposomes, 
ultra-deformable (UD) or flexible liposomes demonstrated to be the optimal carriers 
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for the delivery of entrapped active principles through the skin (Cevc and Blume 
1992). However, there is still a lack of consensus about the mechanism exploited by 
these nanoparticles in passing through the several layers of the skin (Honeywell-
Nguyen and Bouwstra 2003(B)). For all these reasons, the idea behind the Bleosome 
was that entrapping of bleomycin within UDs would allow the encapsulated drug to 
penetrate through the skin, reaching the topical cutaneous tumour, skipping the blood 
stream and thus, reducing systemic toxicological risks. Moreover, UD liposomes, as 
small, lipophilic particles, would enable the cellular uptake of the entrapped 
bleomycin, being potentially effective in penetrating the plasma membrane. 
This study focused on the evaluation of the efficacy and safety of the Bleosome as 
novel, non-invasive treatment for NMSC in veterinary cancer medicine, using 
companion animals as both target and model for human medicine. 
Our first aim was to investigate the ability of Bleosome to penetrate through human, 
canine and equine skin; to determine the mechanism exploited by UD liposomes to 
improve the passage of bleomycin through cutaneous layers; and to investigate 
whether liposomes enable the cellular uptake of the entrapped drug. 
 
Therefore, we sought to explore the mechanism of skin penetration of Bleosome by 
treating canine, equine and human skin explants with our compound of interest and 
visualising directly both the liposomes and the entrapped bleomycin within skin 
layers. In order to perform this study, transmission electron microscope (TEM) and 
multiphoton microscope (MP) were both used as complimentary techniques: the 
former allowed the direct visualisation of liposomes, whereas the latter allowed the 
direct visualisation of encapsulated bleomycin particles within skin samples. Firstly, 
we treated canine skin sections with Bleosome over a time course, and we sought to 
visualise the UD liposomes within skin using the TEM, comparing the final images 
with those from the untreated skin explants, used as control. In doing so, we found the 
presence of the UD nanoparticles through the stratum corneum in the treated samples 
only. Our results suggested that the nanoparticles are able to penetrate through the 
stratum corneum and reside between corneocytes, but they could not reach layers 
deeper than this outermost stratum, even after several hours of application of the 
compound (up to 8 hours of treatment). We performed several replicates of this 
experiment, optimising the experimental settings in terms of time and modality of skin 
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treatment. To explore the possibility that the amount of applied compound played the 
main role in enhancing the penetration of liposomes deeper through the skin, we 
treated skin explants with repeated application of the compound every 60 minutes, 
passing from 0.1 ml to 0.4 ml of Bleosome per skin section. Again, we found that UDs 
were confined in the stratum corneum and not in the deeper underlying cellular layers. 
Therefore, we concluded that UD liposomes within Bleosome, are able to penetrate 
through the first outermost layer of the skin; crossing and intercalating between the 
keratinocytes of the stratum corneum, but they are not able to pass beyond this layer. 
Other studies in literature were concordant with this finding. Bouwstra et al. (2003) 
conducted a similar experiment using the electron microscopy, and demonstrated that 
after topical application, flexible liposomes were found intercalated between the 
outermost skin layers, but no vesicles could be found in  layers deeper than the stratum 
corneum (Bouwstra et al. 2003 ). Authors claimed that, according to Cevc and Blume 
(2002), the osmotic force resulting from the hydration gradient in the skin is the 
dominant force for partitioning of vesicles into the stratum corneum. However, same 
authors have noticed that even in a fully hydrated state the water content in the lowest 
stratum corneum layers close to the viable epidermis is much lower than in the central 
regions of the stratum corneum. Therefore, it is expected that as a result of the osmotic 
force, the vesicle ingredients will not penetrate beyond the level of the lowest layers 
in the stratum corneum (Bouwstra et al. 2003 ).  
Having established the fate of UD liposomes after cutaneous application of Bleosome, 
we moved to the visualisation of the entrapped bleomycin molecules through the skin. 
Hence, we treated skin explants from different species according to the same 
experimental settings of the previous study, but we utilised a different imaging 
technique. Our preliminary penetration study visualising treated skin explants with the 
fluorescent microscope demonstrated that the fluorescence of the drug itself was not 
sufficient to allow a proper visualisation of bleomycin. Thus, we coupled the 
bleomycin to Bodipy-FL, a green fluorescent fluorophore. To the best of our 
knowledge, this is the first time that Bodipy-FL has been conjugated to bleomycin, 
and our main concern was that binding the fluorophore to the bleomcyin molecule, 
could produce a reduction of its overall efficacy. Therefore, we conducted a viability 
assays, comparing the efficacy of fluorescently labelled Bleosome (F-Bleosome) with 
the unlabelled compound and we proved that the F-Bleosome retained the same 
252 
 
efficacy of the non-fluorescent counterpart. Confident in the functionality of F-
Bleosome, we directly visualised the penetration of the drug through skin explants of 
different species. 
Canine, equine and human skin sections were treated with F-Bleosome over a time 
course to assess the extent of penetration of bleomycin-encapsulated liposomes within 
animal skin. Furthermore, we compared this innovative topical treatment with the 
standard non-encapsulated bleomycin, labelled with the same fluorophore (F-
bleomycin). Our analysis showed that F-Bleosome penetrated significantly deeper 
through the skin than the free F-bleomycin, and that this was consistent within equine, 
canine and human skin sections. Furthermore, F-Bleosome penetrated significantly 
deeper through cutaneous layers over time of treatment; following 4 and 6 hours of 
administration, the drug molecules were found at a significant greater depth compared 
to the first 10 minutes of treatment in all the three species. 
In all the three species examined, there was a significant difference in the position of 
F-Bleosome molecules within the skin at each time point of treatment, while this was 
not the case of the F-bleomycin particles. These findings indicate that the length of 
treatment is closely related to the ability of F-Bleosome to cross several innermost 
cutaneous layers, hence, this is an important aspect to be considered when translating 
this therapy into clinical application. 
Moreover, image analysis revealed that, within the canine and equine skin sections 
treated with F-Bleosome, the deepest drug particles were found at ~300  and 271 µm 
after 4 hours of treatment and  at 800 and 430 µm  respectively after 6 hours, which is 
definitely deeper than the average thickness of the epidermis of both species as 
previously reported (Theerawatanasirikul et al. 2012; Jorgensen et al. 2018).  
To further confirm these findings, examining the images after 4 and 6 hours of 
treatment, in equine, canine and human sections, F-Bleosome molecules were found 
intercalated in skin structures at the same level of the cellular nuclei. The first 
nucleated layer of the skin, starting from the outermost stratum corneum, is the stratum 
spinosum, which, in human skin, has an approximate thickness of 100 µm (Horikoshi 
et al. 2005). Furthermore, the epidermis is an avascular component of the skin 
(Horikoshi et al. 2005); and in some 3-D images, it is possible to identify few F-
Bleosome molecules, located close to structures that appear to be small blood vessels. 
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This might reinforce the hypothesis that the encapsulated bleomycin is able to 
penetrate beyond not only the hard outermost corneocytes but also the epidermis. 
Integrating the findings of the MP and the TEM, we concluded that Bleosome is able 
to reach the deeper layers of the epidermis and the underlying dermis, according to 
mechanism number 2 proposed by Verma et al. (2003) acting as penetration enhancer. 
Of note, liposomes might interact with the hard external keratinocytes, finding their 
way between lipidic extracellular matrix and lastly being disrupted. This would enable 
the release of the entrapped bleomycin, rendering the drug free to diffuse across the 
deeper layers of the dermis and beyond. Our hypothesis is that after 10 minutes, 
Bleosome consists of bleomycin still encapsulated in liposomes, and this is the main 
reason why drug molecules are found only in a superficial level, at a depth similar to 
the one of the free drug, in well-defined, small, round-shaped particles, hence, likely 
still engulfed in UD nanoparticles. After 4 and 6 hours, once passed beyond the 
stratum corneum the entrapped drug is released out of liposomes and free to expand, 
to aggregate with other molecules and penetrate in the cellular and vascular deeper 
dermal layer.  
To the best of our knowledge, this is the first study that has investigated the fate of 
bleomcycin encapsulated within liposomes after topical skin application, through 
direct visualisation of both UD liposomes and the entrapped drug in live-tissue 
samples. Our findings support the greater ability of Bleosome to penetrate through the 
skin, when compared to the free bleomycin, and speculate that UD liposomes, when 
loaded with bleomycin, act as penetration enhancer, interacting with the stratum 
corneum and releasing the payload after 4 hours of treatment. 
 
To evaluate whether liposomes improve the cellular uptake of bleomycin, we treated 
two different types of canine cancer cell lines, for short and long time of treatment, 
with F-Bleosome and F-free bleomycicn, as comparison, and we visualised them in 
live-cell imaging setting, using the confocal laser scanning microscope (CLSM) and 
quantified the amount of drug taken-up by fluorescence activated cell sorting (FACS). 
Our findings showed that bleomycin encapsulated in UD liposomes was internalised 
by cells more efficiently than the free bleomycin after 2 and 24 hours of treatment, in 
both types of canine cancer cells treated. Moreover, after 24 hours of treatment, 
imaging and FACS analysis confirmed that the difference in concentration of 
Bleosome and free bleomycin inside cells was even greater compared to earlier time 
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point of treatment, with Bleosome being taken-up more than free-bleomycin. 
Furthermore, the cellular uptake was dependent on the length of treatment for both 
free and encapsulated bleomycin; images and FACS confirmed the significantly 
higher level of green fluorescence within cells after 24 hours of treatment compared 
to the earlier time point in C2 and CML10 cells treated with both compounds. Of note, 
the different pattern of fluorescent signal from F-Bleosome between the two time 
points, led us to hypothesise that liposomal bleomycin particles fuse together in 
particular cytoplasmic areas, especially after several hours of treatment, or that 
liposomes accumulate within cellular organelles, such as lysosomes, as part of the 
endocytic pathway for the cellular internalisation. To further explore this latter 
hypothesis, we investigated the role of lysosomes within Bleosome treatment, 
however, due to technical limitations, we could not obtain conclusive results about the 
involvement of this pathway. However, our observations led us to assume a possible 
involvement of lysosomes in the Bleosome cellular uptake, and, as this finding has 
been already speculated in literature, further studies should be conducted to validate 
this hypothesis. Overall, our results showed that bleomycin, when encapsulated in UD 
liposomes passes through plasma membrane and is internalised by cancer cells more 
efficiently than its free counterpart, in two different cancer cell lines. Further studies 
are required to establish the fate of Bleosome after the cellular internalisation and its 
translocation to the cellular nucleus, the target of its toxicity. 
In literature, there are in vivo and in vitro evidence about the efficacy of bleomycin as 
an effective treatment in a range of tumours in human medicine. Therefore, our second 
major aim was to compare the efficacy of Bleosome in achieving the same outcomes 
in a range of human and animal neoplasms. To this extend we performed viability and 
colony formation assays in vitro using human, canine and feline cancer cell lines.  
The results of cytotoxicity and colony formation assays confirmed that Bleosome is 
able to kill different types of cancer cell lines in vitro at different drug concentrations. 
However, when its efficacy was compared with the free bleomycin, it appeared that 
the encapsulated drug was less potent than the free form. The same findings were 
confirmed when Bleosome was tested for inhibiting cells growth and reproducibility. 
This finding is in accordance with the literature. Studies demonstrated that 
encapsulating bleomycin molecules inside vesicles naturally partitioned them away 
from as well as hindered their presentation to keratinocytes. The compartmentalisation 
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of the cytotoxin in UDs most likely limits the amount of drug available to the cells in 
vitro (Lau et al. 2005). However, given our results on improved Bleosome cellular 
uptake, these findings can be refuted treating for instance, cancer cells for longer time. 
The encapsulated form of bleomycin is internalised in the cell cytoplasm better than 
the free counterpart, however, it is stored in particular areas (likely lysosomes) and its 
releasing out from these structures might be delayed, leading to a delayed nuclear 
uptake and thus, a delayed killing effect. Hence, further studies over longer time of 
treatment are worth to be conducted, to better elucidate the effective potential of 
liposomal bleomycin compared to its free form. 
We established that Bleosome was able to kill several types of human, canine and 
feline cancer cell lines and had an insight into its cellular uptake. Hence, subsequently, 
we aimed to have a better understanding of the molecular effects underlying the 
mechanism of action of Bleosome at cellular level. Bleomycin produces SSB and DSB 
(Chen and Stubbe 2005). The sensitivity of cancer cells to bleomycin is reported to be 
variable and tumour-type dependent (Chen and Stubbe 2005). It is currently unknown 
why this drug is more efficient against some malignancies rather than others. Studies 
propose that this variability is related to upregulation of alternative DNA damage and 
repair signalling pathways (Chen and Stubbe 2005; Pron et al. 1999). As bleomycin 
main toxicity is achieved by the production of DSB, it is likely that specific DS-lesion 
repair pathways are involved in this, such as non-homologous end joining (NHEJ) and 
homologous recombination repair (HRR) (Chen and Stubbe 2005). To this extent, we 
explored the activation of these two main pathways by means of western blot and qRT 
PCR, treating with Bleosome canine mast cell tumour (C2) and canine metastatic 
melanoma (CML10) cell lines, over a time course. We found that all the genes tested 
resulted in differential expression levels between the two cell lines, following 8 hours 
of treatment.  In particular, we observed an upregulation of HRR in C2 cells, whereas 
the response of CML10 did not include the activation of any of the tested signalling. 
However, CML10 has a higher IC50 than C2; this suggested that some other 
mechanisms might be involved in the drug resistance, and that more than one pathway 
might be activated within the same cell line. However, these preliminary findings 
confirm the hypothesis of a cell-type dependent response to bleomycin, in its free and 
encapsulated form and that the activation of the molecular response to the treatment 
might be activated after 8 hours. 
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All these reasons led us to investigate the whole transcriptome modification following 
Bleosome treatment, in order to have a better understanding of the cellular 
mechanisms triggered by the drug. Hence, we performed next-generation sequencing 
(NGS) on C2 and CML10 cells. After having proven that cellular response to the 
treatment was affected more by the timing of treatment rather than by the 
concentration of the drug, cells were treated with relative Bleosome IC50 
concentrations for 8 and 24 hours. These time points were chosen based on our 
previous finding with qRT-PCR, where the most significant variations in gene 
expressions was found after 8 and 24 hours. Due to technical issues with C2, we 
excluded this cell lines from the analysis and our results focused on CML10 cells only.  
In this study, data showed that the majority of differentially expressed genes were 
found in the contrast between cells treated with Bleosome for 24 hours and untreated 
cells, suggesting that the major changes in gene expression occurred after prolonged 
length of treatment. 
When cells were treated with Bleosome for 8 hours, the most upregulated genes 
included growth factors and oncogenes (such as RAB20 and EGR4). Interestingly, 
after 24 hours of treatment with Bleosome, the most representative upregulated genes 
compared with untreated cells, were involved in the regulation of extracellular matrix 
and maintenance of tumour microenvironment, such as IRF5 and PLAUR, but also in 
the inhibition of cell proliferation and in tumour suppression (HYAL1, ARNT2 and 
DUSP5). This is an interesting finding as it may indicate that after prolonged time of 
treatment, melanoma cancer cells are no longer able to rapidly divide and grown; 
however, to sustain their vitality, they could rely on their tumour microenvironment, 
which could play a major role in the resistance to the Bleosome, and a valuable target 
to consider for combined treatments. When the two time points of treatment were 
compared to the untreated canine melanoma cells, another important finding was that 
the in cells, after both 24 and 8 hours, overexpressed genes responsible for 
inflammation and modulation of immune response were found. This supported the 
hypothesis of the formation of a unique tumour microenvironment, which, after 
Bleosome application, might be the key element in the resistance to the treatment.  
(Tang and Wang 2016). Current literature supports the role of the tumour 
microenvironment in the resistance to chemotherapy. Classic cytotoxic chemotherapy 
targets rapidly proliferating cells. Stromal secretion of ligands promoting proliferation 
is one of the reasons why cancer cells proliferate rapidly. Chemotherapy cannot 
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eliminate 100% of cancer cells partially owing to the presence of intrinsic resistant 
phenotypes within the cancer cell population. Moreover, the tumour 
microenvironment can promote cancer cell survival and proliferation in a treatment-
naive setting and in response to treatment, which does not eliminate nonproliferating 
stromal cells (Valkenburg, De Groot, and Pienta 2018). Looking at the downregulated 
elements after Bleosome administration, in the group of cells treated for 8 hours, the 
majority of genes were involved in cellular metabolism of lipoprotein and endocytosis 
(LIPG, LDLR, MSMO1), while after 24 hours, key regulator of mitosis and 
chromosome stability were lost. These findings indicate that following Bleosome 
treatment, cells have impaired functions in cell cycle progression and cellular division 
but they can notably promoted by the tumour microenvironment. Chemotherapy-
induced DNA damage in the tumour microenvironment causes a stress response in 
stromal cells, which then secrete many factors that promote cancer cell survival, 
proliferation, invasion, and metastasis (Valkenburg, De Groot, and Pienta 2018). For 
example, in a prostate cancer model, DNA damage induced by docetaxel or 
mitoxantrone caused increased expression of GDNF in stromal cells, which promoted 
tumour cell proliferation, invasion, and chemotherapy resistance in a paracrine fashion 
(Huber et al. 2015). Docetaxel and mitoxantrone also caused increased stromal 
secretion of WNT16, which promotes prostate cancer cell survival in the presence of 
chemotherapeutic agents (Sun et al. 2012). Similarly, in a lymphoma model, 
doxorubicin led stromal cells to secrete IL-6 and TIMP1, both of which supported 
cancer cell survival in the thymus (Gilbert and Hemann 2010). However, mechanisms 
inhibiting mitosis and cell cycle progression were notably present, indicating an 
impaired ability in cellular division, confirming that Bleosome treatment affect the 
ability of this cells to divide, proliferate and exert their function. 
To better evaluate the functional significance of these data, we performed pathway 
analysis using GSEA, Reactome and IPA tools. Our results revealed a set of 
mechanisms dysregulated in untreated and CML10 cells treated with Bleosome for 8 
and 24 hours. For instance, when cells were treated with Bleosome, at both, time points 
and compared to the untreated, we found that the majority of the upregulated pathways 
were involved in inflammation and immune response. Among those, a plethora of toll-
like receptor (TLR) signalling pathways were found along with processes involved in 
inflammation and immune response. Interestingly, when interrogating the pathways 
differentially regulated after 24 hours of treatment compared to the 8 hour time point, 
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we found that autophagy was also upregulated. We also noted that downregulated 
pathways were mostly related to DNA synthesis, DNA damage repair and mitotic 
checkpoints. 
The main mechanism of action of bleomycin is to generate DNA DSBs (Chen and 
Stubbe 2005). DSBs are extremely hazardous lesions for all DNA‐bearing organisms 
and the mechanisms of DSB repair are highly conserved. So far, other authors reported 
that extended cell-cycle arrest/senescence, apoptosis and mitotic cell death are the 
most common cellular responses to bleomycin treatment and that bleomycin was 
found to induce G2/M cell cycle arrest in cancer cell lines (Wang et al. 2013). Thus, 
they concluded that although the mechanism of bleomycin resistance is unclear, the 
ability for bleomycin-induced DNA damage to be repaired is the most likely one 
(Wang et al. 2013).  
Our results can open novel perspectives on the putative mechanism of action and of 
resistance to the treatment, as we have evidence that the DSBs induced by Bleosome 
are not repaired in canine melanoma cells, and that cell cycle checkpoint and HRR are 
inhibited. 
Taking our findings together, we speculate that after Bleosome treatment, melanoma 
cancer cells are still metabolically active and produce signals of cell growth. However, 
importantly, the DNA damage produced by Bleosome cannot be repaired, as the cell 
cycle progression is arrested, mitotic check points are inhibited along with DNA 
synthesis and DNA DSB repair mechanisms. We also speculate that cells can respond 
to the stress of the Bleosome treatment with autophagy. We assessed by viability 
assays the efficacy of Bleosome in killing CML10 cells, however, in the proteomic 
study, we did not identify clear markers of cellular apoptosis or other processes 
directly related to cellular death; thus we hypothesise that autophagy can be a 
mechanism leading to cellular death after Bleosome treatment. Moreover, in order to 
survive after the treatment, cells may rely on tumour microenvironment, triggering 
mostly inflammatory processes and dysregulating immune system, and thus, creating 
a protective tumour microenvironment. This finding open novel compelling insights 
into the molecular resistance of Bleosome and bleomycin, highlighting the important 
role of the tumour stroma in supporting cancer cell survival and recurrence, upon 
exposure to therapies that target these cells. To combat this resistance, therefore, 
combining the Bleosome treatment with drugs that target stromal components could 
be a fundamental next step to consider within preclinical and clinical development. 
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Bleomycin hydrolase (BLMH), also, has been reported in literature as a possible 
mechanism of resistance to the bleomycin, although this remains controversial (Chen 
and Stubbe 2005). Our RNA sequencing results did not reveal any significant 
difference in the expression of BLMH after Bleosome treatment.  To expand on this, 
we evaluated the expression and protein level of BLMH in cells treated with increasing 
doses and at various time points after treatment with Bleosomes. We found that either 
western blot and qRT PCR did not reveal any significant differences in the amount of 
the enzyme expressed by several cancer cell lines. Moreover, the level of BLMH 
remained steady not only within the dose titration, but also when compared to the basal 
level within the  respective cells untreated. Furthermore, we evaluated this enzyme at 
the tumour level by treating equine sarcoids and healthy skin with Bleosome and 
investigating by IHC differences in the protein levels of BLMH. We showed that the 
level of BLMH did not changes significantly in the tumour before and after treatment. 
These results, together with the transcriptomic data, suggest that the level of BLMH 
does not increase after Bleosome treatment. Although BLMH it is supposed to be 
involved in the bleomycin resistance, its role is still controversial according to the 
literature. Blocking its activity, some studies showed that mammalian cells became 
more sensitive to the bleomycin (Sebti et al. 1991), although others found a lack of 
connection between this enzyme and the outcome of the treatment (Ramotar and Wang 
2003). Our results at both molecular at tumour level did not find any connection 
between the treatment and the level of BLMH, however, the western blot analysis 
revealed, in all the cell lines tested, the presence of a second band at a slightly higher 
molecular weight of the BLMH protein. This might indicate that BLMH is activated 
post-translationally after the Bleosome treatment.  
Hence, further studies are needed to better understand its role in relation to bleomycin 
and Bleosome treatment, and for future investigation, it would be interesting exploring 
more in detail the activity more than just the level of this enzyme. 
 
Lastly, we aimed to investigate Bleosome as a non-invasive treatment for NMSC in 
veterinary species, in vivo. Previously, we assessed the efficacy of Bleosome to 
penetrate through healthy skin; here we utilised similar technique to establish if 
Bleosome was also able to penetrate through cutaneous sarcoids of horses. With the 
help of the confocal laser scanning microscope (CLSM) and the F-Bleosome we 
optimised an innovative technique to visualise the presence of the drug within a living 
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tumour tissue, excised from patients. We showed that the majority of F-Bleosome, 
after a single application, resides within the superficial layers of the neoplasm but 
some F-Bleosome particles were found within the whole depth of each section with 
the deepest drug particles found very close to the bottom of the lesion (1.6 cm depth). 
We speculated that after a single application, the majority of the compound reaches 
mostly the outermost cellular layer of the lesion, leading the Bleosome to be more 
effective in killing the superficial cells. Hence, this can lead to shrink the tumour in a 
centripetal manner, decreasing its mass thanks to sequentially repeated application. 
Further studies can be performed treating the lesion for longer time and/or with 
repeated application of the compound, visualising the treated lesion over a time 
course, to gain better understanding of the timing and action of Bleosome within the 
sarcoid. However, at this preliminary stage, we performed the experiment treating the 
tumour with an amount sufficient to cover completely external surface, without 
exploring the optimal therapeutical dose. Moreover, we treated the lesion only once, 
for a length of 6 hours, and observed that few particles of F-Bleosome were able to 
reach the bottom layer of the tumour. This information might have important 
repercussions in the application of the Bleosome on equine patients in clinics, not only 
because it supports the penetration power of the chemotherapy compound, but also 
because it suggests that multiple topical applications could be of a great benefit, 
increasing the number of Bleosome particles within deeper layers of the tumour. This 
is an important preliminary assessment that enables further studies focused on finding 
the optimal therapeutic dose of Bleosome to apply on patients in vivo. Furthermore, 
to the best of our knowledge, this was the first time that the topical penetration of a 
chemotherapeutic was assessed by its direct visualisation within a live-tumour model. 
This compelling finding not only further confirms our previous data on the efficacy 
of Bleosome in penetrating through healthy animal and human skin, but may also 
drive to the development of other innovative similar studies on drug discovery. 
A part of this PhD project involved also a case observation study on the efficacy and 
safety of the Bleosome administration, in combination with other treatment, as part of 
the therapeutic protocol for equine sarcoids, which was conducted in collaboration 
with the clinicians of the Dick Vet Equine Hospital of the University of Edinburgh, 
in particular with Dr Richard Reardon. This study is still on going and results 
presented in this thesis are preliminary data collected until the time of writing, and 
should, therefore, be considered as preliminary observations. 
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The aim of this case observation series was to investigate whether Bleosome could 
extend the length of remission or achieve long-term cure of equine sarcoids after CO2 
laser excision. To date, 12 patients bearing single or multiple cutaneous sarcoids 
underwent surgical excision of the tumours by CO2 laser, followed by 4 or 6 weeks 
course of Bleosome topical application on the site of the scar, twice a day. Within the 
group of patients, there were 7 males and 5 females and the mean age of the horses 
was 7.7 years. Types, location and number of sarcoids treated varied among animals 
and about half of the patients were presented with lesions that recurred or failed any 
other previous treatment. 5 patients (41.6%) experienced a complete remission at the 
time of writing, with a mean follow-up of  14.8 months. 3 patients (25%) failed to 
follow up; however, all of them were reported to be free of recurrence during the latest 
updates, which occurred after 3 months in 1 and 6 months in 2 cases. 4 patients 
(33.3%) experienced recurrence. Overall, the mean follow-up was 12 months. Of note, 
most of the lesions that recurred after the treatment were types of sarcoids considered 
at high risk of relapse according to previous studies. None of the patients experienced 
any adverse effects and, overall, the treatment was very well tolerated.  
 
6.2 Limitations of the study and potential future studies 
 
This study has several limitations. Animal and human skin samples used in this project 
were collected immediately after the euthanasia, in the case of dogs and horses, and at 
the time of surgical excision for the human samples. Subcutaneous fat was removed,  
to facilitate handling later, and the skin samples were stored at -20 ◦C or, in some cases 
at - 70 ◦C, according to the guidance documents for the conduct of the skin absorption 
studies (Nakadate 1991; Davies, Ward, and Heylings 2004). These guidance 
documents claim that animal and human skin can be stored for several months at -
20°C. No changes in human skin permeability have been reported in frozen skin stored 
for up to 466 days. This documents advice to test the viability of the skin before 
performing a test on permeation/penetration of a compound through the skin. 
However, the suggested tests to control the quality of the skin have shown to produce 
different results when applied on the same skin samples in literature, generating doubts 
on the optimal test to adopt in order to exclude damaged skin (Zhang et al. 2018). 
Furthermore, several studies have now shown that freezing skin samples does not alter 
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the skin permeability compared to fresh samples (Barbero and Frasch 2016). 
Publications involving skin penetration and permeation experiments routinely do not 
assess the viability of skin sections frozen at -20°C before performing the tests (Mills, 
Magnusson, and Cross 2003; Cross, Anderson, and Roberts 1998; Yousef et al. 2019; 
de Oliveira et al. 2020). Therefore, there is established precedence to support our 
methodology. Furthermore, well preserved frozen biospecimens are reported to be 
ideal for evaluating the genome, transcriptome, and proteome. Frozen biospecimen 
degradation can be influenced by factors independent of the collection methodology 
including tissue type, premortem agonal changes, and warm ischemia time during 
surgery. Rapid stabilization of tissues by snap freezing immediately can mitigate 
artifactually altered gene expression and protein phosphorylation profiles. If data is 
not available for a particular tissue type, a practical goal is snap freezing within 20 
minutes. Tissue storage at -70°C can preserve DNA and protein for years but RNA 
can show degradation at 5 years, and it is reported to decrease the risk of proteins 
cross-linking when compared to paraffin embedded tissues (Shabinkhani et al. 2014). 
Of note, this literature support the rationale of using skin explants, immediately snap-
frozen following the collection and stored at -20°C and -70°C, as suitable tool to test 
the ability of Bleosome to penetrate to skin, resembling an in vivo model. 
In the first part of the study, we optimised a method to directly visualise liposomes 
and the entrapped bleomycin through skin and sarcoid tumours in live-tissue explants. 
To this extent, the TEM and the MP provided integrative data, however the TEM 
analysis was only applied to canine skin.  In future, the fate of nanoparticles through 
equine and human skin should be assessed by TEM. Images obtained with MP were 
analysed using Imaris software. This program has pre-set tools for analysing images, 
and we optimised these settings to assess the degree of penetration of F-Bleosome. 
However, many issues arose including compensation for variability in depth of single 
skin explants imaged, and the exact dimension and size of the drug particles. We 
developed a novel Imaris protocol to overcome some of these experimental hurdles. 
The program successfully identified the majority of F-Bleosome particles but in a 
minority of cases was unable to differentiate F-Bleosome particles from the 
autofluorescent structures of the skin, producing the need to manually adjust the count 
in limited circumstances. Thus, an important improvement could be achieved by 
designing a personalised script in MATLAB (the programming language used by 
Imaris), which will allow to meet the remained pending questions and help in 
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differentiating better the F-Bleosome molecules from the autofluorescent structures of 
the skin. However, this is the first study, to the best of our knowledge, that successfully 
visualised directly both the entrapped drug and liposomes within skin, using live-
tissues, and we obtained innovative and important information about not only the 
efficacy of the drug and the mechanism of penetration of Bleosome but also on the 
methodology to be employed to answer these important research questions. Therefore, 
new and exciting trials can be conducted to gain more detailed information about the 
skin penetration of this and other compounds. For instance, liposomal nanoparticles 
could be labelled with an alternative fluorescent probe to that of the entrapped drug, 
to enable a direct comparison of the position of the liposomes and the encapsulated 
bleomycin in the skin using MP. 
Subsequently, we observed that the cellular uptake of Bleosome is time-dependent and 
proved that the ability of Bleosome to cross the plasma membrane and to reach the 
inside of the cells is superior to that of the free drug. However, during our cytotoxicity 
assay, we observed that Bleosome is slightly less efficient at killing cancer cells 
compared to the free drug. We speculated that the encapsulated form of bleomycin 
may be hindered in its ability to translocate into the nucleus. Further live-cell imaging 
studies, optimising the labelling of cellular organelles, could further the mechanism of 
cellular uptake, confirming the involvement of the endocytic pathways, and can enable 
a better evaluation of the nuclear passage of the drug. Moreover, labelling also the 
liposomal membrane can elucidate the timing and mechanism of release of the 
entrapped bleomycin. 
The second part of this study was focused on assessing the molecular response to the 
Bleosome treatment on cancer cell lines, with a particular emphasis on the molecular 
basis of the mechanism of resistance to the treatment and on exploring the hypothesis 
of a cell-type dependant response. In this study we used the C2 cells and the CML10 
cells, as they showed, by western blotting and qRT-PCR that HRR was the dominant 
response to bleomycin-induced DNA damage in C2 but not in CML10, confirming the 
different molecular mechanisms activated in different cell types. To improve the 
biological significance of the data we used biological replicates at different passages 
rather than technical replicates. Unfortunately, analysis of the data generated by RNA 
Seq revealed that C2 cells did not form homogeneous groups according to the time 
points of treatment; moreover, when considering the number of cell passages, we 
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found a significant variation in gene expression in samples derived from cells from 
different passages. This may indicate that the C2 cell line has a mutational load. A 
recent study about the whole genome sequencing of canine cancer cell lines shows 
that these cells have a mutated TP53, the gene encoding for p53; hence, this  
accelerates accumulation of mutations over time leading to the high variance of these 
cells at different passage number (Das et al. 2020). This should be taken into account 
for future studies within this cell line, and noted that C2 cells should be used with a 
given cell passage number window, to avoid significant heterogeneity derived by 
mutations. However, we did obtain important and novel findings from the sequencing 
of CML10 cells. Hence, we are confident that performing replicates of the experiment 
using other canine cancer cell lines, derived from other types of NMSC, would be 
compelling in order to compare the cellular effects of Bleosome on different cell lines, 
and to evaluate whether there would be significant differences. Furthermore, the ideal 
condition for a further transcriptomic profiling of Bleosome-treated samples, would 
be to utilise skin tumours excised from patients, rather than cell lines. One part of the 
tumour can be used as the untreated control, and another part can be treated with 
Bleosome, in order to observe the modification in molecular signalling at the tumour 
level. 
Lastly, our preliminary investigation on the efficacy and safety of Bleosome as 
adjuvant treatment in the management of equine sarcoids showed promising outcomes 
to date; however, it is not possible to drawn any conclusion from our data so far, as 
this study is still under completion and we aim to fully analyse results at the end of 
case observation study. To date, one of the major shortcomings of this case observation 
series is the low number of patients involved. Furthermore, as the Dick Vet Equine 
Hospital is a referral centre, many owners live far away and regular visits for follow-
ups can be very difficult in most cases. This led to photographic and telephone updates 
conducted by referring veterinarians or by the owners. This naturally creates a bias in 
establishing the exact response to the treatment, as it is influenced by different 
personal point of views and by personal feelings of the owners. Moreover, one patient 
did not undergo surgical excision of the sarcoid, like all the others, but received 
Bleosome as part of a topical treatment. Lastly, this study was not stratified according 
to the type, location and number of tumours. This can generate variable results, as 
some types of sarcoids naturally carry worse prognosis than others. However, the 
study was on going at the time of the writing, and more patients were recruited and 
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follow-ups are still being collected. Therefore, these results should be considered as 
preliminary observations and as a first stage of a study on the efficacy and safety of 
the Bleosome treatment as part of the therapeutic protocol for equine cutaneous 
sarcoids. The planned next steps in the future are to continue recruiting patients to be 
treated with Bleosome as adjuvant post-operative treatment, to improve the statistical 
power of the study and to confirm the lack of side effects of the treatment. Moreover, 
at this stage, we conducted an observational study. Observational studies and 
randomised controlled trials are the main types of studies used to evaluate treatments. 
In the latter, patients are assigned to active or control group by chance (through 
randomization) in order to reduce errors or bias and to remark only the differences due 
to the treatment. On the contrary, observational studies do not require randomization: 
differences in outcomes are only observed after a particular therapy has been opted 
for. Although randomized controlled trials are considered to be more reliable than 
observational studies when evaluating treatment effectiveness, meta-analyses that 
confronted the results on different interventions typologies from both types of studies 
did not systematically show significant differences in the estimates of the effects 
(Concato et al. 2000). However, more often observational studies (compared to 
randomized controlled trials) tend to overestimate the effects of the treatment and 
show more variability in the estimates of the effects because of residual confounding 
(Concato et al. 2000). Therefore, we are planning to compare the results of the 
Bleosome treatment with a ‘control arm’, represented by horses treated with CO2 laser 
excision without post-operative Bleosome treatment, to better evaluate whether the 
Bleosome treatment is effective at prolonging the disease-free interval, and in 
achieving long lasting clinical remission. 
 
6.3 Conclusions and future perspectives 
 
NMSC are a class of tumour that share similar behaviour and outcome in some cases 
in both humans and animals. Advances in cancer research are focusing on precise and 
minimal invasive approach-based medicine. In this study, we evaluated the efficacy 
and safety of Bleosome as topical treatment for cutaneous neoplasms, conducting a 
transversal in vitro, ex vivo and in vivo study, using animals as target and model for 
human medicine. We have preliminary evidence on the efficacy of the penetration of 
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Bleosome through healthy skin and cutaneous tumour models, as well as the improved 
cellular uptake of bleomycin when encapsulated in UD liposomes. We showed how 
the DNA damage generated by the Bleosome at the cellular level is not repaired in a 
canine metastatic melanoma cell line, and speculate that the tumour microenvironment 
may play a significant role in the resistance to the treatment in this particular cell line. 
We also have evidence indicating that the cellular response to Bleosome is cell-type 
dependent and that the use of Bleosome as part of the treatment for equine sarcoids 
has the potential to improve the outcome and well-being of patients, without producing 
any painful or systemic consequences. 
These findings support advanced research on the ability of Bleosome to target a wider 
range of neoplasms in vitro. Similarly, understanding of the cellular mechanisms 
leading to the acquisition of resistance to Bleosome treatment, would allow the 
evaluation of combination therapies to use alongside the non-invasive form of 
liposomal bleomycin. Of note, we conducted a translational study, from in vitro 
experiments to the application of the Bleosome in vivo, using human and animal 
samples. In doing so, we supported the preliminary findings on the safety of Bleosome 
in human medicine with our case observation study on horses, highlighting the 
benefits of comparative research between human and veterinary medicine. Within this 
‘one-health’ approach, future studies on the molecular mechanisms of the action of 
Bleosome and emergence of resistance can improve the formulation and drive the 
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Chapter 8 Supplementary data 
 
8.1 Appendix 1 Buffers and Solution 
 
Urea lysis buffer: 7 M urea, 0.1 M DTT, 0.01% Triton X-100, 25 mM NaCl, 20 
mM HEPES-KOH pH 7.6. 
1.5 M Tris-HCl, pH 8.8: 45.43g Tris base in 200 ml H2O adjusted to pH 8.8 with 12 
 M HCl. Made up to 250 ml with dH2O. 
 
10x SDS-Page Running Buffer (1l): 30.3g Tris base, 144g glycine, 10g SDS in 1l 
 H2O (dissolved on heat stirrer). 
 
10x Tris-Glycine Buffer (Transfer buffer 1L): 30g Tris base, 144g glycine in 1l 
 dH2O. 
 
10% SDS: 5g SDS dissolved in 40 mL dH2O with gentle heated stirring. Bring to 50 
 ml with dH2O. 
 
10% APS (Ammonium persulphate): 5g APS dissolved in 40 ml dH2O with 
 gentle stirring. Bring to 50 ml with dH2O. 
 
1M DTT (dithiothreitol): 1.5g DTT dissolved in 10 ml dH2O. 
 
4x SDS (sodium dodecyl sulfate) sample buffer (16 mL): 4 mL 20% SDS, 4 ml 1 
M Tris pH 6.8, 5 ml 80% glycerol, 2 ml 0.1 M EDTA and 1 ml 1%  bromophenol 
blue. 1 M DTT is added immediately prior to sample preparation in a 1:4 
(DTT:Sample buffer) ratio. 
 
Freezing media: FBS (fetal bovine serum) + 10 % DMSO. 
 
PBS (phosphate buffered saline): Provided by the Central Services Unit (CSU) at 
The Roslin Institute. 
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PBS Tween (0.1%): 1 ml of Tween 2000 (Scientific Laboratory Supplies) in 1 L of 
PBS. 
5% milk: 5g of skimmed milk powder (Sigma Aldrich) dissolved on 100 ml PBS 
Tween (0.1%). 
BSA (bovine serum albumin) standard solutions: 10mg/mL BSA stock solution 
(>99% pure grade, A-7638 Sigma) in dH2O serially diluted to 0.125mg/ml, 
0.25mg/ml, 0.5mg/ml, 1mg/ml, 2mg/ml and 4mg/ml. 
 
8.2 Appendix 2 Supplementary material 
 
8.2.1 Staining program for IHC in material and methods (2.6)  
1. Rinse buffer                2 minutes 
2. Primary antibody              30 minutes 
3. Rinse buffer                2 minutes 
4. Rinse buffer                2 minutes 
5. Endogenous block (peroxidase) 10 minutes 
6. Rinse buffer                 2 minutes 
7. Rinse buffer                 2 minutes 
8. Labelled polymer              40 minutes 
9. Rinse buffer                2 minutes 
10. Rinse buffer                2 minutes 
11. Chromogen (dab or vector red) 15 minutes 
12. Rinse buffer                2 minutes 
13. Dist. Water rinse               5 minutes 
 
Solutions required: 
Tris Buffered Saline + Tween 20 (100 ml in 2 l of dH2O) (TA-999-TT) 
Peroxidase Block (Dako K4007) 
Red Vector SK-4805 chromagen (Impact Nova) 




8.2.2 Information leaflet for donation of human skin as part of the 
study on the Bleosome penetration through the skin (2.9.1.2) 
 
PARTICIPANT INFORMATION SHEET 
 
“Investigation of the penetration potential of a novel formulation of a drug to 
treat skin cancer” 
We'd like to invite you to take part in our research study. Before you decide, it is 
important that you understand why the research is being done and what it will 
involve for you. Please take time to read this information, and discuss it with others 
if you wish. If there is anything that is not clear, or if you would like more 
information, please ask us. 
What is the purpose of the study? 
We are testing the efficacy of Bleosome, a novel cream designed for the treatment of 
skin tumours. Bleosome is made by encapsulating bleomycin, a chemotherapy agent, 
into small particles that enhance the penetration of the drug through the skin. Our 
research is focused on determining how far through the skin Bleosome penetrates 
and this will give us an indication as to how successful it will be in reaching the 
deeper layers of the tumour. We have completed this work with dog and horse skin 
and would now like to do this work with human skin. We are inviting you to be part 
of this research by donating the excess skin that will be removed during your 
surgery. In the lab, we will apply Bleosome cream to the skin section and look at it 
under the microscope to see how far through the skin the drug has travelled. 
Why have I been invited? 
You are invited because you have planned plastic surgery, which involves the 
removal of a portion of skin. This surplus of skin is required to enable us to study 
how effective this treatment is on human skin. We will apply Bleosome cream to the 
top of the skin explant, and at different time points we will look at the skin section 
under the microscope to see how far through the skin the drug has travelled. At the 
end of the experiment, the skin will be destroyed. 
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Do I have to take part? 
Your participation to this study is entirely voluntary.  
What will happen to me if I decide to take part? 
Beyond agreeing to donate the skin removed during your planned surgery, this study 
does not require anything further from you. Your therapeutic plan will not be 
affected.  
What should I consider? 
If you have known skin problem, please let us know about them.  
Are there any possible disadvantages or risks from taking part? 
There are no side effects or risks for you associated with your participation in the 
study; we will collect only skin that is the by-product of your planned surgery.   
What are the possible benefits of taking part? 
There are no financial benefits in being part of the study. 
Will my General Practitioner/family doctor (GP) be informed of my 
participation? 
We will contact your GP and let her/him know about your involvement in the study. 
Will my taking part in the study be kept confidential? 
All your personal data will be kept strictly confidential, your samples will be stored 
only fully anonymised and identified by a code rather than by your name. 
What will happen to the samples I give? 
After the collection, your skin donation will be frozen and transported to our labs. It 
will be then thawed and treated with Bleosome for several hours, subsequently, the 
skin will be processed to be observed under the microscope to see how far through 




All skin explants will be used for this purpose only and any unused samples will be 
disposed of six months after collection.  
What will happen to the results of this study?  
This study has scientific relevance; hence, the results may be shared in the scientific 
community through publications and/or conferences, this can involve also images 
taken from your biological samples, before and after the study. However, your 
personal information will be kept strictly confidential and you will be identified by a 
number. 
Some of the research being undertaken will also contribute to the fulfilment of an 
educational requirement (e.g. doctoral thesis and academic presentations). 
Who is organising and funding the study? 
All work will be carried out at The Roslin Institute, the University of Edinburgh. 
This work is funded by SPS Animal Care Company Ltd. 
Further information and contact details: 
Please contact  by e-mail:  
Thank you for considering taking part. 
 
8.2.3 Consent form for donors of human skin as part of the study on 
the Bleosome penetration through the skin (2.9.1.2) 
 
Consent form for the donation of skin to study the penetration of a novel 
formulation of a drug to treat skin cancer 
This Informed Consent Form (ICF) is for patients undergoing plastic surgery 
involving skin reduction to donate the skin removed during surgery to be used in a 
study to determine the penetration of Bleosome cream through the layers of the skin. 
This product has previously been tested on explants of dog and horse skin and we 
would like to compare these results to human skin.  
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The title of our research project is “Investigation of the penetration potential of a 
novel formulation of a drug to treat skin cancer”. 
The Principal Investigator of this project is Prof. David J. Argyle. All work will be 
carried out at The Roslin Institute. This work is funded by SPS Animal Care 
Company Ltd.    
Part I: Information sheet 
I am Giulia Ferrari, and I work for The Roslin Institute. We are doing research on a 
new drug called Bleosome that we hope will be used to successfully treat skin 
cancer. Bleosome is a cream that is applied to the tumour. Our research is focused on 
determining how far through the skin Bleosome penetrates and this will give us an 
indication as to how successful it will be in reaching the deeper layers of the tumour. 
We have completed this work with dog and horse skin and would now like to do this 
work with human skin. We are inviting you to be part of this research by donating 
the excess skin that will be removed during your surgery. In the lab we will apply 
Bleosome cream to the skin section and look at it under the microscope to see how 
far through the skin the drug has travelled.   
Purpose of the research 
Skin cancer is the most common cancer in the UK, and rates continue to rise. Drugs 
that could be applied directly to the skin tumour are poorly absorbed and have 
limited effect. Here we are testing novel formulation of a drug called Bleosome. 
Bleosome is an established chemotherapy drug, bleomycin, packaged inside a bubble 
composed of tiny fat molecules, which aid absorption through the skin. The skin is 
made up of many different layers and our research is focused on determining how far 
through the skin Bleosome can travel. This is preliminary work to show that the 
Bleosome cream can penetrate through the skin layers, we will then use this 
information to find out how well Bleosome penetrates through a tumour, with the 
aim of establishing a new treatment to fight skin cancer.   
Type of Research Intervention 
This research will not involve any additional procedures. We will use the excess skin 




We are inviting all adults, without known skin issues, undergoing skin removal 
surgery to donate skin explants for our study.  
Voluntary participation 
 Your participation is voluntary. Skin removed during your surgery will be disposed 
of, as is general practise, if you choose not to participate in this study.  
Procedures and protocol 
Skin removed during your surgery will be frozen. In the laboratory we will cut the 
skin explant into 2 x 2 x 1 cm dimensions and apply Bleosome cream to the top of 
the skin; at different time points we will look at the skin section under the 
microscope to see how far through the skin the drug has travelled. At the end of the 
experiment, the skin will be destroyed.  
All skin explants will be used for this purpose only and any unused samples will be 
disposed of six months after collection.  
Beyond the initial donation patient participation is not required.    
Side-effects and risks 
There are no side-effects or risks. We will only use skin that is the by-product of 
your planned surgery.   
Confidentiality 
Information collected about you will be confidential. Any information about you will 
have a number on it instead of your name.  
Sharing the results 
This research is of significant scientific value and we will share the results with the 
scientific community through publications and conferences. All patient information 
will be confidential.   
Part II: Certificate of consent  
304 
 
I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions that I have asked have been 
answered to my satisfaction. I consent voluntarily to participate as a participant in this 
research and that any data generated may be used for scientific publication.  
 
Print Name of Participant__________________ 
      
Signature of Participant ___________________ 
 
Date ___________________________ 
 Day/month/year    
 
Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to 
the best of my ability made sure that the participant understands. I confirm that the 
participant was given an opportunity to ask questions about the study, and all 
the questions asked by the participant have been answered correctly and to the best of 
my ability. I confirm that the individual has not been coerced into giving consent, and 
the consent has been given freely and voluntarily.    
A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent________________________
     
Signature of Researcher /person taking the 
consent__________________________ 
 
Date ___________________________    
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                 Day/month/year 
 
 
8.2.4 Optimised protocol for IMARIS 9.1.2. (3.3.5.4) 
 
 3-D images, captured with the multiphoton and automatically stored as ZEN 
files (AIMApplication documents) are converted into IMARIS FILE.IMS 
 Pictures appear in the “Arena” in Imaris software; 
 “Groups” are created to compared groups of files; 
 “SPOTS” tool is used to identify F-Bleosome and F-free bleomycin 
molecules and structure emitting high intensity of green fluorescence (such as 
some nuclei, co-emitting Hoechst staining); within this command, the 
following settings are used as default for all the file analysed, to customize 
the function to the purpose of this study:  
o Algorithm Settings: tick “Different Spot Sizes (Region Growing)” 
o Source Channel: Channel 2 – NDD R4 
o Spot Detection: Estimated XY Diameter: 8.30 um, tick “Model PSF-
elongation along Z-axys”, Estimated  Z Diameter: 16.6um, tick 
Background Subctraction” 
o Filter Type: “Quality”, Upper and Lower threshold: The value is 
automatically set (depending on images. Between 1 and 10%) 
o Spot Regions from: Local Contrast 
o Region Treshold: 0, Diamter from: Region Volume 
 
 “SURFACES” tool is used to identify Hoechst staining objects (mainly 
nuclei) and autofluorescent skin structures (structures emitting low level of 
Hoechst staining and  low level of green autofluorescence concomitantly; e.g. 
hair follicles, glands, connective tissue); within this command, the following 
settings are used as default for all the file analysed, to customize the function 
to the purpose of this study: 
o Algorithm settings: all unticked 
o Source Channel: Channel 1 – NDD R3, tick “Smooth”, Surfaces 
details: 1.66 um; Thresholding: tick “Background subtraction (local 
Contrast), Diameter of largest Sphere which fits into the object: 6.23 
um 
o Threshold: Lower threshold: 0, Upper threshold: 166 
o Filter Type: Number of Voxels Img=1: Lower threshold: 10, Upper 
threshold: 65508 (the maximum for each file) 
 
 On “Matlab”: “Distance Transformation”, tick “Outside Surface Object” 
 On “Edit”:“Change Data Type”,tick“32 bit float”; 
 On“Matlab”:“Find Spot Close to The Surfaces”: threshold: “0.5” ; 
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 “Spots Close to The Surfaces” are the nuclei identified as “spots” (close to 
other “surfaces”) and autofluorescent green structure. They are turned in 
MAGENTA colour for ease of observation; 
 “Spots Far From the Surfaces” are the objects emitting green fluorescence, 
far from autoflurescence structure (the majority of F-Bleosome and F-free 
bleomycin molecules). They are turned in GREEN for ease of observation; 
 “Stats” command gives the Area, Volume and Position of the Spots. 
Highlight “spots far from the surface” and click on STATS----export AREA, 
VOLUME and POSITION. 
 
8.2.5 Link for the access to the live cell imaging videos of  the 
cellular uptake of F-Bleosome and F-bleomcyin in C2 and 







 ‘C2 2h F-Bleosome’: video corresponding to C2 cells treated for 2 hours with 
F-Bleosome 
 ‘C2 2h F-Bleomycin’: video corresponding to C2 cells treated for 2 hours 
with F-Bleomycin 
 ‘C2 24h F-Bleosome’: video corresponding to C2 cells treated for 24 hours 
with F-Bleosome 
 ‘C2 24h F-Bleosome’: video corresponding to C2 cells treated for 24 hours 
with F-Bleomycin 
 ‘CML10 2h F-Bleosome’: video corresponding to C2 cells treated for 2 hours 
with F-Bleosome 
 ‘CML10 2h F-Bleomycin’: video corresponding to C2 cells treated for 2 
hours with F-Bleomycin 
 ‘CML10 24h F-Bleosome’: video corresponding to C2 cells treated for 24 
hours with F-Bleosome 
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 ‘CMl10 24h F-Bleomycin’: video corresponding to C2 cells treated for 24 








8.2.6 Dysregulated biological processes assessed by GSEA as part of the functional annotation analysis within the 
NGS of CML10 cells treated with a time course of Bleosome (4.4.4.3) 
 
 
Figure 8.1 Top most significant (according to FDR<0.05) upregulated (a) and downregulated (b) Biological processes between CML10 cells treated with Bleosome for 8 




Figure 8.2 Top most significant (according to FDR<0.05) upregulated (a) and downregulated (b) Biological processes  between CML10 cells treated with Bleosome for 24 




Figure 8.3 Top most significant (according to FDR<0.05) upregulated (a) and downregulated (b) Biological processes between CML10 cells treated with Bleosome for 24 
hours and CML10 cells treated for 8 hours. Analysis were performed using gene set enrichment analysis (GSEA) software.
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8.2.7 Equine melanoma as positive control for IHC slides of equine sarcoids stained with anti-BLMH antibody 
(4.4.5.2) 
 
Figure 8.4 IHC slides of equine melanoma used as positive control for the staining of the anti-BLMH antibody ab204584 (Abcam). (a), (b), (c) are three different area of the 
lesion stained with the anti-BLMH hydrolase. (d), (e), (f) correspond to the same lesion unstained with the antibody. Red arrows indicate relevant area of antibody staining 
(Vector Red) and black circles highlight melanin pigments 
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8.2.8 Disclosure form and protocol for Bleosome application for equine patients (5.3.2.1) 
 
Figure 8.5 Discharge form and protocol for Bleosome application with safe handlings guidelines for owners of equine patients enrolled in the Bleosome case observation 
series
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